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A B S T R A C T
Background
Liver transplantation is an established treatment option for end-stage liver failure. Now that newer, more potent immunosuppressants
have been developed, glucocorticosteroids may no longer be needed and their removal may prevent adverse effects.
Objectives
To assess the benefits and harms of glucocorticosteroid avoidance (excluding intra-operative use) or withdrawal versus glucocorticos-
teroid-containing immunosuppression following liver transplantation.
Search methods
We searched the Cochrane Hepato-Biliary Group Controlled Trials Register, Cochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, EMBASE, Science Citation Index Expanded and Social Sciences Citation Index, The Transplant Library, and the
World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) until September 2014.
Selection criteria
Randomised clinical trials assessing glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression for liver-transplanted people. Our inclusion criteria stated that participants should have received the same co-interventions. We
included trials that assessed complete glucocorticosteroid avoidance (excluding the perioperative period and excluding the occurrence
of acute rejection) versus short-term glucocorticosteroids, as well as trials that assessed short-term glucocorticosteroids versus long-term
glucocorticosteroids.
Data collection and analysis
We used RevMan to conduct meta-analyses, calculating risk ratio (RR) for dichotomous variables and mean difference (MD) for
continuous variables, both with 95% confidence intervals (CIs). We used a random-effects model and a fixed-effect model and reported
both results where a discrepancy existed. We assessed the risk of systematic errors using risk of bias domains. We controlled for random
errors by performing Trial Sequential Analysis. We presented our results in a ’Summary of findings’ table.
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Main results
We included 16 completed randomised clinical trials with a total of 1347 participants. We found 10 trials that assessed complete postop-
erative glucocorticosteroid avoidance (excluding intra-operative use and treatment of rejection) versus short-term glucocorticosteroids
(782 participants) and six trials that assessed short-term glucocorticosteroids versus long-term glucocorticosteroids (565 participants).
We found one ongoing trial assessing complete postoperative glucocorticosteroid avoidance versus short-term glucocorticosteroids,
which is expected to enrol 300 participants. All trials were at high risk of bias. Overall, we found no statistically significant difference for
mortality (RR 1.15, 95% CI 0.93 to 1.44; low-quality evidence), graft loss including death (RR 1.16, 95% CI 0.91 to 1.48; low-quality
evidence), or infection (RR 0.88, 95% CI 0.73 to 1.05; low-quality evidence) when glucocorticosteroid avoidance or withdrawal was
compared with glucocorticosteroid-containing immunosuppression. Acute rejection and glucocorticosteroid-resistant rejection were
statistically significantly more frequent when glucocorticosteroid avoidance or withdrawal was compared with glucocorticosteroid-
containing immunosuppression (RR 1.33, 95% CI 1.08 to 1.64; moderate-quality evidence; and RR 2.14, 95% CI 1.13 to 4.02;
very low-quality evidence). Diabetes mellitus and hypertension were statistically significantly less frequent when glucocorticosteroid
avoidance or withdrawal was compared with glucocorticosteroid-containing immunosuppression (RR 0.81, 95% CI 0.66 to 0.99; low-
quality evidence; and RR 0.76, 95% CI 0.65 to 0.90; low-quality evidence). We performed Trial Sequential Analysis for all outcomes.
None of the outcomes crossed the monitoring boundaries or reached the required information size. Hence, we cannot exclude random
errors from the results of the conventional meta-analyses.
Authors’ conclusions
Many of the benefits and harms of glucocorticosteroid avoidance or withdrawal remain uncertain because of the limited number of
published randomised clinical trials, limitednumbers of participants andoutcomes, andhigh risk of bias in the trials.Glucocorticosteroid
avoidance or withdrawal appears to reduce diabetes mellitus and hypertension whilst increasing acute rejection, glucocorticosteroid-
resistant rejection, and renal impairment. We could identify no other benefits or harms of glucocorticosteroid avoidance or withdrawal.
Glucocorticosteroid avoidance or withdrawal may be of benefit in selected patients, especially those at low risk of rejection and high risk
of hypertension or diabetes mellitus. The optimal duration of glucocorticosteroid administration remains unclear. More randomised
clinical trials assessing glucocorticosteroid avoidance or withdrawal are needed. These should be large, high-quality trials that minimise
the risk of random and systematic error.
P L A I N L A N G U A G E S U M M A R Y
Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Review question
We assessed whether avoiding or withdrawing glucocorticosteroids was better or worse than continuing to use glucocorticosteroids for
immunosuppression after liver transplantation.
Background
Glucocorticosteroids are used to prevent rejection of the liver after transplantation by suppressing the immune system. Some centres use
glucocorticosteroids indefinitely after liver transplantation whilst others slowly reduce them, and others do not use glucocorticosteroids
at all. Glucocorticosteroids have a number of important adverse effects, which may lead to illness and sometimes death in liver
transplantation. These adverse effects include diabetes mellitus, high blood pressure, and infection.
With recent developments in immunosuppression, glucocorticosteroids no longer feature as the main immunosuppressant used follow-
ing transplantation. The use of new immunosuppressant medication may mean that glucocorticosteroids may no longer be necessary
after transplantation. Rather than helping to prevent rejection of the liver graft theymight cause adverse effects. The benefits of avoiding
glucocorticosteroids or withdrawing them after a short while remain unclear.
Study characteristics
We searched for trials comparing glucocorticosteroid avoidance or withdrawal to continuing glucocorticosteroids and we found 16
randomised clinical trials including 1347 participants. All of the studies assessed adults who had received a liver transplant. We found
one more trial that was not completed when our review was completed, so it could not be assessed in our review. Of the 16 randomised
clinical trials, 10 trials assessed avoidance of glucocorticosteroids compared with slowly reducing glucocorticosteroids (782 participants)
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and six trials assessed withdrawal of glucocorticosteroids following a slow reduction compared with a longer reduction or long-term
use of glucocorticosteroids (565 participants). The evidence is current to September 2014.
Key results
Rejection, severe rejection, and kidney failure may be increased by avoiding or withdrawing glucocorticosteroids compared with contin-
uing glucocorticosteroids. Diabetes mellitus and high blood pressure may be reduced by avoiding or withdrawing glucocorticosteroids
compared with continuing glucocorticosteroids. We did not find any difference in survival of the patients, survival of the liver, other
adverse effects, or health-related quality of life.
Quality of the evidence
We assessed all of the trials we included as being at high risk of bias, which means that they may overestimate the benefits and
underestimate the harms of avoiding or withdrawing glucocorticosteroids. The evidence for glucocorticosteroid avoidance or withdrawal
increasing acute rejection was of moderate quality. The evidence for the remainder of the effects was either low quality or very low
quality.
Conclusion
There is still some uncertainty about the benefits and harms of avoiding or withdrawing glucocorticosteroids after transplantation.
Avoiding or withdrawing glucocorticosteroids appears to increase rejection, severe rejection, and kidney failure but seems to reduce
diabetesmellitus and high blood pressure.We found no other obvious benefits or harms of avoiding or withdrawing glucocorticosteroids.
More randomised clinical trials are needed to assess avoidance and withdrawal of glucocorticosteroids for liver transplanted patients.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Glucocorticosteroid avoidance or withdrawal compared to glucocorticosteroid-based immunosuppression for liver transplanted patients
Patient or population: liver transplanted patients
Setting: inpatient and outpatient
Intervention: glucocorticosteroid avoidance or withdrawal
Comparison: glucocorticosteroid-based immunosuppression
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with glucocorticos-
teroid-based immuno-
suppression
Risk with Glucocorticos-
teroid avoidance orwith-
drawal
Mortality Study population RR 1.15
(0.93 to 1.44)
1323
(15 RCTs)
⊕⊕©©
LOW 124
The quality of the ev-
idence was considered
low for both glucocorti-
costeroid avoidance and
glucocorticosteroid with-
drawal
166 per 1000 191 per 1000
(154 to 239)
Moderate
204 per 1000 234 per 1000
(189 to 293)
Graft loss including death Study population RR 1.16
(0.91 to 1.48)
1002
(11 RCTs)
⊕⊕©©
LOW 124
The quality of the ev-
idence was considered
low for both glucocorti-
costeroid avoidance and
glucocorticosteroid with-
drawal
175 per 1000 203 per 1000
(159 to 259)
Moderate
218 per 1000 253 per 1000
(198 to 322)
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Acute rejection Study population RR 1.33
(1.08 to 1.64)
1347
(16 RCTs)
⊕⊕⊕©
MODERATE 14
The quality of the ev-
idence was considered
moderate for glucocorti-
costeroid avoidance but
low for glucocorticos-
teroid withdrawal
173 per 1000 230 per 1000
(187 to 283)
Moderate
194 per 1000 257 per 1000
(209 to 317)
Infection Study population RR 0.88
(0.73 to 1.05)
778
(8 RCTs)
⊕⊕©©
LOW 134
The quality of the ev-
idence was considered
low for both glucocorti-
costeroid avoidance and
glucocorticosteroid with-
drawal
359 per 1000 316 per 1000
(262 to 377)
Moderate
402 per 1000 354 per 1000
(293 to 422)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; OR: odds ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1We assessed all studies as having high risk of bias using the Cochrane ’Risk of bias’ tool.
295% CI includes both benefit and harm.
3Significant heterogeneity identified between subgroups (avoidance versus withdrawal).
4We assessed all outcomes at latest follow-up (range 13 to 108 months).
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B A C K G R O U N D
Liver transplantation is an established treatment option for end-
stage liver failure in selected patients and results in improved qual-
ity and quantity of life (Pillai 2009; Dienstag 2012). Currently,
liver transplant recipients have a one-year survival of over 90%
and a five-year survival of over 75% (Perera 2009).
Description of the condition
Over 1800 liver transplantations per year (whole liver or split liver)
were performed from post-mortem and living donors in the Eu-
rotransplant region from 2008 to 2012 (Eurotransplant 2012).
However, at the end of 2011 there were 2406 people in need of
liver transplantation (Eurotransplant 2012). In the UK, 784 liver
transplantations were carried out in 2012 through 2013, but 494
patients remained on the waiting list as of 31 March 2013 (NHS
Blood and Transplant 2013). In the United States, 6445 livers
were transplanted in 2013 including 252 living donor liver trans-
plants (OPTN 2014). In 2012, in the UK, the indications for
liver transplantation fromdeceased donors included alcoholic liver
disease (18.5%), hepatitis C virus cirrhosis (8.1%), hepatocellular
carcinoma (17.1%), primary sclerosing cholangitis (8.2%), pri-
mary biliary cirrhosis (7.6%), and metabolic diseases (8.1%). Of
the deceased donor transplants, 88% were elective procedures and
12% for fulminant hepatic failure (Johnson 2014).
Description of the intervention
Liver transplant recipients have to take life-long immunosup-
pressive medication in order to achieve an effective prophy-
laxis against allograft rejection. The most commonly used im-
munosuppressive agents are calcineurin inhibitors (e.g., cy-
closporine, tacrolimus), antiproliferative agents (e.g., azathioprine,
mycophenolate mofetil), and glucocorticosteroids (e.g., methyl-
prednisolone). In addition, mammalian target of rapamycin in-
hibitors (e.g., sirolimus, everolimus) are used to prevent rejection.
Glucocorticosteroids decrease interleukin 1, 2, and 6 activity and
non-specifically inhibit T-cell activation. Adverse effects due to
glucocorticosteroids such as hypertension, hyperglycaemia, hyper-
cholesterolaemia, and obesity are well known. In some cases, hy-
pertension is reported in over 50% of patients (Neal 2005; Llado
2006), but a glucocorticosteroid bolus is still given at time of trans-
plantation and tapered after a while (Fernandez 1998; Hatz 1998;
Renoult 2005; Hirose 2006). Cyclosporin A and tacrolimus are
both calcineurin inhibitors. Calcineurin normally activates nu-
clear factor of activated T cells, which leads to production of in-
terleukin 2 and 4 that stimulate growth and differentiation of the
T-cell response. Tacrolimus is used more widely than cyclosporin
due to reduced acute rejection and increased graft survival, but
tacrolimus carries a higher risk of new-onset diabetes after trans-
plant (NODAT) (Ho 1996; Ojo 2003; Haddad 2006). Despite
the favourable profile of tacrolimus compared with cyclosporine,
tacrolimus still carries a significant risk of renal failure and many
trials investigate the replacement of tacrolimus with other drugs,
usually sirolimus or everolimus (Penninga 2012; Sterneck 2014).
Mycophenolate mofetil (MMF; also known as mycophenolic acid;
MPA) inhibits inosinemonophosphate dehydrogenase (IMPDH).
This enzyme is responsible for de novo synthesis of guanosine nu-
cleotides. The inhibition byMMF has cytostatic effects on T- and
B-lymphocytes. MMF is still preferred to azathioprine (Allison
2000; Knight 2009).
How the intervention might work
Through the use of calcineurin inhibitors, liver transplantation
has become a standard procedure with good long-term results
(Haddad 2006). However, the burden of life-long immunosup-
pressive treatment in liver transplant recipients causes increased
morbidity and mortality. Optimal long-term immunosuppressive
treatment to reduce morbidity and mortality without leading to
graft loss has become of major importance. Treatment with gluco-
corticosteroids induces bone loss and may lead to cardiovascular
risk factors (e.g., hypertension, hyperlipidaemia, obesity, glucose
intolerance) (Hatz 1998). Avoidance of glucocorticosteroids may
reduce this excess morbidity without having an effect on graft loss
(Knight 2011). In addition, use of glucocorticosteroids after trans-
plantationmight reduce physical andmental health-related quality
of life, and increase symptoms of anxiety (Zaydfudim 2012). Fur-
thermore, glucocorticosteroids might increase the risk and severity
of hepatitis C recurrence in patients transplanted for hepatitis C.
Hence, glucocorticosteroid avoidance and reduction regimens for
liver transplant recipients have been developed and studied, but it
is still uncertain whether these regimens offer clear benefits (Segev
2008). These long-term adverse events and the development of
relatively new immunosuppressive medication (e.g., basiliximab)
may potentially enable the reduction or withdrawal of glucocor-
ticosteroids as an immunosuppressive treatment (Vanrenterghem
1999; Ganschow 2005; Penninga 2014).
There is some evidence that glucocorticosteroid avoidance or with-
drawal could be beneficial (Adams 2001; Kato 2005; Cintorino
2006; Llado 2006; Moench 2007; Penninga 2014a), but the over-
all effect still remains unclear. Four reviews with meta-analyses on
glucocorticosteroid avoidance or withdrawal for liver-transplanted
people have been published, showing a possible advantage in car-
diovascular risk factors (e.g., diabetes mellitus, hypertension), and
a possible benefit for people transplanted for hepatitis C virus in-
duced liver disease (Segev 2008; Sgourakis 2009; Knight 2011;
Gu 2014).
Why it is important to do this review
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It is possible that glucocorticosteroids could be withdrawn follow-
ing liver transplantation or completely avoided without any nega-
tive effects whilst reducing the adverse effects associated with glu-
cocorticosteroids. However, people may face more adverse events
due to increased use of other immunosuppressants.
O B J E C T I V E S
To assess the benefits and harms of glucocorticosteroid avoidance
(excluding intra-operative use) or withdrawal versus glucocorticos-
teroid-containing immunosuppression following liver transplan-
tation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised clinical trials evaluating the benefits and
harms of complete glucocorticosteroid avoidance (excluding the
perioperative period) or withdrawal versus glucocorticosteroid-
containing immunosuppression for liver-transplanted people. We
did not include non-randomised clinical trials or trials that re-
ported per-treatment analysis rather than intention-to-treat anal-
ysis. For evaluation of harms, we included quasi-randomised clin-
ical trials and observational trials that we identified during our
searches for randomised clinical trials.
We did not apply any restrictions on date of publication, language,
or publication status (published or unpublished work).
Types of participants
We included people of any age, sex, and ethnic group during
and after liver transplantation, in any care setting, irrespective of
diagnosis and disease stage, type of graft (live donor, cadaveric,
split, whole, domino), and prescribed medication. We did not
include participants with other transplanted organs or those with
a previous liver transplant.
Types of interventions
We included randomised clinical trials that investigated weaning
off, versus not weaning off, glucocorticosteroids, as well as trials
that compared standard immunosuppression without glucocorti-
costeroids versus standard immunosuppression including gluco-
corticosteroids directly following transplantation.
We allowed co-interventions (e.g., induction with basiliximab,
co-administration of an antiproliferative such as mycophenolate
mofetil) if received equally by all intervention groups of the trial.
Types of outcome measures
Outcome measures did not form part of the eligibility criteria for
including trials in this review. We assessed all outcome measures
at latest follow-up.
Primary outcomes
• All-cause mortality.
• Graft loss including death.
• Acute rejection. This is diagnosed by the combination of
abnormal liver biochemical variables (e.g., bilirubin, aspartate
transaminase, alanine transaminase, alkaline phosphatases,
gamma glutamyl transpeptidase), clinical signs such as fever, and
liver histological changes including mononuclear portal
inflammation, bile duct damage, and subendothelial
inflammation of portal or terminal hepatic veins (IWP 1995; IP
2000).
• Infection.
We have not included serious adverse events as an outcome as fol-
lowing organ transplantation the number of serious adverse events
is extremely high. As a result of this, very few trials in transplanta-
tion report serious adverse events as an outcome and instead report
outcomes individually (e.g., diabetes mellitus, infection, hyper-
tension). As well as this, most transplant recipients experience one
or more serious adverse events following transplantation, meaning
that the number of adverse events may be 100% in both groups.
This means neither complete nor consistent serious adverse event
reporting can be guaranteed. We instead analysed selected out-
comes individually.
Secondary outcomes
• Other adverse events. Adverse events were defined as any
untoward medical occurrence not necessarily having a causal
relationship with the treatment but resulting in a dose reduction
or discontinuation of treatment (ICH-GCP 1997).
• Chronic rejection. Chronic rejection was characterised by
liver histological changes including the progressive loss of
interlobular bile ducts and arteriopathy characterised by foam
cell infiltration of the arterial intima.
• Glucocorticosteroid-resistant rejection.
• Diabetes mellitus (de novo diabetes mellitus as described in
the study or total number of people with diabetes mellitus).
• Cytomegalovirus (CMV) infection (infection requiring
treatment).
• Hepatitis C virus recurrence.
• Malignancy.
• Post-transplantation lymphoproliferative disorder (PTLD).
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• Renal function (renal failure requiring dialysis, renal
insufficiency, estimated glomerular filtration rate, and serum
creatinine).
• De novo autoimmune hepatitis.
• Hypertension.
• Hyperlipidaemia.
• Cholesterol (serum cholesterol and hypercholesterolaemia).
• Health-related quality of life.
Search methods for identification of studies
We searched for eligible trials for the earliest entrance date possible
until the latest search date.
We managed all references with Refworks©.
Electronic searches
We searched the Cochrane Hepato-Biliary Group Controlled Tri-
als Register (Gluud 2015), Cochrane Central Register of Con-
trolled Trials (CENTRAL), MEDLINE, EMBASE, Science Cita-
tion Index Expanded, and Social Sciences Citation Index (Royle
2003). We have given the search strategies with the time spans of
the searches in Appendix 1. As the review progressed, we did not
need to improve the search strategies.
We also searched the World Health Organization (WHO)
International Clinical Trials Registry Platform (apps.who.int/
trialsearch/), ClinicalTrials.gov (https://clinicaltrials.gov/), and
The Transplant Library (Pengel 2011).
Searching other resources
Wecontacted experts in the field, such as scientific societies for liver
transplantation, and we asked whether they have been involved in
any further trials or are aware of recent or ongoing trials on the
effects of glucocorticosteroids for liver-transplanted patients. We
tried to identify unpublished trials by contacting manufacturers of
glucocorticosteroids (i.e., Ratiopharm, Astellas, Aventis, Novartis,
Merck, Hexal, Pfizer, Roche).
We searched the reference lists of identified trials, non-randomised
trials, and other systematic reviews for additional publications of
interest.
Data collection and analysis
Selection of studies
Four review authors (CF, EH, JP, SW) independently assessed the
retrieved references for eligibility and resolved disagreement by
discussion with another author (LP). The excluded studies and the
reasons for their exclusion are listed in the table Characteristics of
excluded studies.
Data extraction and management
We extracted data on source, inclusion and exclusion criteria, de-
scription of participants and setting, interventions and co-inter-
ventions, outcomes, and sample size calculation using a data ex-
traction sheet. We did not identify any cross-over trials. We ex-
tracted data using the intention-to-treat principle. We translated
all trials reported in non-English language journals before assess-
ment.Wheremultiple publications of a trial exist we have grouped
the publications together and we extracted data from the most
complete publication and any relevant outcomes that are only re-
ported in one of the other publications. Where further informa-
tion was required we wrote to the original authors requesting this.
Assessment of risk of bias in included studies
Four review authors (CF, JP, EH, SW) independently assessed the
risk of bias of the trials, without masking them. We followed the
instructions given in the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011), and the Cochrane Hepato-
Biliary Group Module (Gluud 2015). Due to the risk of biased
overestimation of beneficial intervention effects (or underestimat-
ing of harmful effects) in randomised trials (Schulz 1995; Moher
1998; Kjaergard 2001; Wood 2008; Lundh 2012; Savovi 2012;
Savovi 2012a), we assessed the following bias risk domains with
definitions below. If information was not available in the pub-
lished trial, we contacted the authors in order to assess the trials
correctly.
Allocation sequence generation
• Low risk of bias: sequence generation was achieved using
computer random number generation or a random number
table. Drawing lots, tossing a coin, shuffling cards, and throwing
dice are adequate if performed by an independent person not
otherwise involved in the trial.
• Uncertain risk of bias: the method of sequence generation
was not specified.
• High risk of bias: the sequence generation method was not
random.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. Allocation
was controlled by a central and independent randomisation unit.
The allocation sequence was unknown to the investigators (e.g.,
if the allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Uncertain risk of bias: the method used to conceal the
allocation was not described so that intervention allocations may
have been foreseen in advance of, or during, enrolment.
• High risk of bias: the allocation sequence was likely to be
known to the investigators who assigned the participants.
8Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Blinding of participants and personnel
• Low risk of bias: it was mentioned that both participants
and personnel providing the interventions were blinded, and the
method of blinding was described, so that knowledge of
allocation was prevented during the trial.
• Unclear risk of bias: it was not mentioned if the trial was
blinded, or the trial was described as blinded, but the method or
extent of blinding was not described, so that knowledge of
allocation was possible during the trial.
• High risk of bias: the trial was not blinded, so that the
allocation was known during the trial.
Blinded outcome assessment
• Low risk of bias: it was mentioned that both participants
and personnel providing the interventions were blinded, and the
method of blinding was described, so that knowledge of
allocation was prevented during the trial.
• Unclear risk of bias: it was not mentioned if the trial was
blinded, or the trial was described as blinded, but the method or
extent of blinding was not described, so that knowledge of
allocation was possible during the trial.
• High risk of bias: the trial was not blinded, so that the
allocation was known during the trial.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. Sufficient
methods, such as multiple imputation, have been employed to
handle missing data.
• Uncertain risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias in the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk: the trial reported the following pre-defined
outcomes: all-cause mortality, graft loss including death, acute
rejection, and infection. If the original trial protocol was
available, the outcomes should be those called for in that
protocol. If the trial protocol was obtained from a trial registry
(e.g., www.clinicaltrials.gov), the outcomes sought should have
been those enumerated in the original protocol if the trial
protocol was registered before or at the time that the trial was
begun. If the trial protocol was registered after the trial was
begun, we did not consider those outcomes to be reliable.
• Unclear risk: not all pre-defined outcomes were reported
fully, or it was unclear whether data on these outcomes were
recorded or not.
• High risk: one or more pre-defined outcomes were not
reported.
For-profit bias
• Low risk of bias: the trial appears to be free of industry
sponsorship or other type of for-profit support that may
manipulate the trial design, conduct, or results of the trial.
• Uncertain risk of bias: the trial may or may not be free of
for-profit bias as no information on clinical trial support or
sponsorship was provided.
• High risk of bias: the trial was sponsored by industry or
received another type of for-profit support.
Other risk of bias
• Low risk of bias: the trial appears to be free of other
components that could put it at risk of bias.
• Uncertain risk of bias: the trial may or may not be free of
other components that could put it at risk of bias.
• High risk of bias: there are other factors in the trial that
could put it at risk of bias.
We considered trials assessed as having ’low risk of bias’ in all of
the specified individual domains as trials with ’low risk of bias’. We
considered trials assessed as having ’uncertain risk of bias’ or ’high
risk of bias’ in one or more of the specified individual domains as
trials with ’high risk of bias’.
Dealing with missing data
Where possible we contacted the original authors of articles with
missing outcomes, missing summary data, or missing individual
data to request the missing data.
We included all participants irrespective of compliance or follow-
up. We analysed all available data and performed best-worst and
worst-best case scenario analyses in the event of missing data.
Assessment of reporting biases
We used a funnel plot to explore publication bias (Egger 1997;
Macaskill 2001), as we identified more than 10 randomised trials.
We used the linear regression approach described by Egger et al to
determine the funnel plot asymmetry (Egger 1997).
Data synthesis
We performed the meta-analyses according to the recommenda-
tions of Cochrane (Higgins 2011), and the Cochrane Hepato-Bil-
iary Group Module (Gluud 2015). We used the software package
Review Manager 5.3 to conduct meta-analyses when there were
two or more eligible trials (RevMan 2014). For dichotomous vari-
ables, we calculated the risk ratio (RR) with 95% confidence in-
terval. For continuous variables, we calculated themean difference
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(MD) with 95% confidence interval. We used a random-effects
model (DerSimonian 1986), and a fixed-effect model (DeMets
1987). In case of discrepancy between the twomodels, we reported
both results; otherwise we reported only the results from the fixed-
effect model. We explored heterogeneity by Chi2 test with signif-
icance set at P value 0.01, and we measured the quantity of het-
erogeneity with the I2 statistic (Higgins 2002). We grouped trials
investigating complete avoidance of glucocorticosteroids together
with trials investigating a rapid taper of glucocorticosteroids as
’glucocorticosteroid avoidance and withdrawal’ (Gluc avoid) pro-
tocols. We presented both avoidance and rapid tapers as separate
subtotals and where a discrepancy exists between the two protocols
we reported both results separately.
Trial Sequential Analysis
We applied Trial Sequential Analysis, as cumulative meta-analyses
are at risk of producing random errors because of sparse data and
repetitive testing on accumulating data (Thorlund 2011b; TSA
2011). To minimise random errors, we calculated the diversity-ad-
justed required information size (i.e., the number of participants
needed in a meta-analysis to detect or reject a certain intervention
effect) (Wetterslev 2008;Wetterslev 2009). The diversity-adjusted
information size calculation accounts for the heterogeneity present
in the meta-analysis. In our meta-analysis, the diversity-adjusted
required information size was based on the assumption of a plau-
sible RR reduction of 20% (Wetterslev 2008). The underlying as-
sumption of Trial Sequential Analysis is that significance testing
may be performed each time a new trial is added to the meta-
analysis. We added the trials according to the year of publication,
and if more than one trial was published in a year, we added trials
alphabetically according to the family name of the first author.
On the basis of the risk for type I (5%) and type II (20%) errors,
the chosen RR, the proportion with the outcome in the control
group, and the observed heterogeneity, we calculated the diversity-
adjusted required information size and we constructed the trial
sequential monitoring boundaries for benefits and harms (Brok
2008; Wetterslev 2008; Brok 2009; Thorlund 2009; Wetterslev
2009; Thorlund 2010). These boundaries determine the statistical
inference one may draw regarding the cumulative meta-analysis
that has not reached the required information size. If the cumula-
tive Z-curve crosses the trial sequential monitoring boundary for
benefit or harm before the required information size is reached in
a cumulative meta-analysis, firm evidence may have been estab-
lished and further trials may be superfluous. On the other hand,
if the sequential monitoring boundaries are not surpassed and the
trial monitoring boundaries for futility are not crossed, it is most
probably necessary to continue doing trials in order to detect or
reject a certain intervention effect. We used as default a type I er-
ror of 5%, type II error of 20%, and a diversity-adjusted required
information size as found in the conventional meta-analysis unless
otherwise stated (Wetterslev 2008; Thorlund 2011a).
Subgroup analysis and investigation of heterogeneity
We performed the following pre-defined subgroup analyses:
• Different immunosuppressive agents.
• Co-interventions: comparing the intervention effect of
trials with one, two, or three co-interventions.
• Duration of treatment with glucocorticosteroids.
• Trials before the year 2000 compared to trials in and after
the year 2000 (since immunosuppression protocols have changed
notably since 2000).
We were unable to perform the following pre-defined subgroup
analyses due to lack of evidence:
• Trials with low risk of bias compared to trials with high risk
of bias.
• Paediatric compared to adult liver transplantation.
• Time between transplantation and start of
glucocorticosteroid administration, determined by the median
time.
• Different indications for transplant.
Sensitivity analysis
We determined potential sensitivity analyses when we assessed our
results to examine the robustness of our findings.
Zero event trials
Review Manager 5 software is unable to handle trials with zero
events in both intervention groups when meta-analyses are per-
formed as risk ratios or odds ratios. It seems unjustified and unrea-
sonable to exclude zero event trials (Keus 2009), and potentially
create the risk of inflating the magnitude of the pooled treatment
effects. Therefore, we also performed a random-effects meta-anal-
ysis with empirical continuity correction of 0.01 in zero event tri-
als (Sweeting 2004; Keus 2009), using the R software (R 2013).
’Summary of findings’ tables
We constructed ’Summary of findings’ tables for the comparison
glucocorticoid-free versus glucocorticoid-containing immunosup-
pression following liver transplantation, presenting data on all pri-
mary outcomes and assessing the quality of the evidence based on
risk of bias, imprecision, indirectness, heterogeneity, and risk of
publication bias.We used the softwareGRADEpro© (GRADEpro
2008) to create Summary of findings for the main comparison.
R E S U L T S
Description of studies
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Results of the search
Our search identified 2529 references (Figure 1). Searching of bib-
liographies found 111 additional references. Exclusion of dupli-
cates and irrelevant references left 16 completed randomised clin-
ical trials published in a total of 67 publications (31 peer-reviewed
journal articles and 36 conference abstracts) (see Characteristics of
included studies; Characteristics of excluded studies). Four of the
trials were published only in peer-reviewed journals (Belli 1998;
Chen 2007; Hu 2008; Ju 2012). Eleven of the trials were pub-
lished as both peer-reviewed journal articles and conference ab-
stracts (Tisone 1999; Belli 2001; Pageaux 2004; Margarit 2005;
Reggiani 2005; Llado 2006; Moench 2007; Vivarelli 2007; Lerut
2008; Pelletier 2013; Ramirez 2013), and one was published only
as a conference abstract (Studenik 2005). We also identified one
ongoing trial that has been published in a conference abstract
(Zhong 2010).
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Figure 1. Flow chart to show studies included and excluded. RCT - randomised clinical trial; PP - per
protocol; ITT - intention-to-treat; HBG - Hepato-Biliary Group.
12Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
We included 16 randomised clinical trials, of which 15 trials were
two-armed trials and one was a three-armed trial (Belli 2001).
The 16 trials included a total of 1347 participants in whom glu-
cocorticosteroids were compared as follows: complete glucocorti-
costeroid avoidance (excluding the perioperative period or treat-
ment of acute rejection) versus short-term glucocorticosteroids
was compared in 10 trials with a total of 782 participants (Tisone
1999; Belli 2001; Margarit 2005; Reggiani 2005; Studenik 2005;
Llado 2006; Lerut 2008; Ju 2012; Pelletier 2013; Ramirez 2013);
and short-term glucocorticosteroids versus long-term glucocorti-
costeroids were compared in six trials with a total of 565 par-
ticipants (Belli 1998; Pageaux 2004; Chen 2007; Moench 2007;
Vivarelli 2007; Hu 2008). The ongoing trial Zhong 2010 com-
pares complete glucocorticosteroid avoidance (excluding the peri-
operative period) versus short-term glucocorticosteroids and plans
to include 300 participants. The preliminary findings of this trial
were presented in an abstract, but it is not possible to extract accu-
rate numeric data from the abstract as the trial reports percentages
of outcomes and not the exact number of participants receiving
each intervention.
As stated, complete glucocorticosteroid avoidance (excluding the
perioperative period or treatment of acute rejection) was used in
the experimental group in 10 trials (Tisone 1999; Belli 2001;
Margarit 2005; Reggiani 2005; Studenik 2005; Llado 2006; Lerut
2008; Ju 2012; Pelletier 2013; Ramirez 2013). These trials of com-
plete post-transplant glucocorticosteroid avoidance allowed glu-
cocorticosteroids during the perioperative period and for treat-
ment of acute rejection. Seven trials used no glucocorticosteroids
in the perioperative period (Tisone 1999; Belli 2001; Margarit
2005; Reggiani 2005; Llado 2006; Pelletier 2013; Ramirez 2013),
two trials used 500 mg glucocorticosteroids in the perioperative
period (Ju 2012; Studenik 2005), and one trial used 100 mg glu-
cocorticosteroids in the perioperative period (Lerut 2008).
For the full details of glucocorticosteroid regimes (including doses,
frequencies, durations, and tapers) for each arm in all 16 trials see
Characteristics of included studies.
Characteristics of the studies
Fifteen of the trials are published in English. One of the trials is
published only in Mandarin (Hu 2008). Two of the trials have
additional publications in languages other than English: one ab-
stract is published in German (Moench 2007), and one article in
Mandarin (Ju 2012).
Mean follow-up time was reported in 12 trials and varied from
13 months to 108 months (Belli 1998; Tisone 1999; Belli 2001;
Margarit 2005; Reggiani 2005; Studenik 2005; Moench 2007;
Vivarelli 2007; Lerut 2008; Ju 2012; Pelletier 2013; Ramirez
2013).
Three of the 16 trialsweremulticentre (Pageaux 2004; Llado 2006;
Vivarelli 2007), and the remaining 13 were single centre (Belli
1998; Tisone 1999; Belli 2001; Margarit 2005; Reggiani 2005;
Studenik 2005; Chen 2007;Moench 2007;Hu 2008; Lerut 2008;
Ju 2012; Pelletier 2013; Ramirez 2013).
All 16 of the trials consisted of exclusively adult populations.
Mean age of the intervention groups was reported in 14 trials
(Belli 1998; Tisone 1999; Pageaux 2004;Margarit 2005; Reggiani
2005; Llado 2006; Chen 2007; Moench 2007; Vivarelli 2007;
Hu 2008; Lerut 2008; Ju 2012; Pelletier 2013; Ramirez 2013).
Mean age of the participants ranged from 42 to 58 years. Sex ratio
of the participants was reported in 12 trials (Belli 1998; Tisone
1999; Pageaux 2004; Margarit 2005; Reggiani 2005; Llado 2006;
Chen 2007; Moench 2007; Lerut 2008; Ju 2012; Pelletier 2013;
Ramirez 2013). The total number of male participants in the 12
trials was 845 (73.0%) and the total number of female participants
was 312 (27.0%).
All of the trials report the primary indications for transplantation.
In 11 trials there were a variety of indications (Belli 1998; Tisone
1999; Pageaux 2004; Margarit 2005; Reggiani 2005; Studenik
2005; Llado 2006; Moench 2007; Lerut 2008; Ju 2012; Pelletier
2013; Ramirez 2013). Two trials exclusively included participants
with hepatitis C virus (HCV) cirrhosis as the primary indication
for transplantation, with a total of 71 participants (Belli 2001;
Vivarelli 2007). Two trials exclusively included participants with
hepatocellular carcinoma as the primary indication for transplan-
tation (Chen 2007; Hu 2008). A total of 258 participants are
reported as having HCV cirrhosis as the primary indication for
transplantation, although there may be more participants who
have an alternative primary indication but are also HCV positive.
Two trials publish separate articles dealing with a cohort of HCV
positive participants including a total of 124 participants (Llado
2006; Lerut 2008). One trial describes the outcomes of HCV-
positive participants as a separate cohort within the main article,
including a total of 35 participants (Margarit 2005).
Eight trials report on the type of donor used. In six of the trials the
grafts were obtained exclusively from deceased (cadaveric) donors
(Pageaux 2004; Llado 2006; Vivarelli 2007; Hu 2008; Ju 2012;
Ramirez 2013). In two of the trials the grafts were obtained from
both deceased (cadaveric) and living donors (Moench 2007; Lerut
2008), but in one of these trials the deceased donors were exclu-
sively donors after brain death (Moench 2007). The remaining
trials did not report on type of donor used (Belli 1998; Tisone
1999; Belli 2001; Margarit 2005; Reggiani 2005; Studenik 2005;
Chen 2007; Pelletier 2013).
Fifteen trials reported on the duration of glucocorticosteroid ad-
ministration in the glucocorticosteroid-containing arm. One trial
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administered glucocorticosteroids for 64 days in the glucocor-
ticosteroid-containing arm (Lerut 2008). Seven trials adminis-
tered glucocorticosteroids for three months in the glucocorticos-
teroid-containing arm (Tisone 1999; Belli 2001; Margarit 2005;
Reggiani 2005; Llado 2006; Hu 2008; Ju 2012). One trial admin-
istered glucocorticosteroids for three to six months in the gluco-
corticosteroid-containing arm (Pelletier 2013). Two trials admin-
istered glucocorticosteroids for six months in the glucocorticos-
teroid-containing arm (Moench 2007; Ramirez 2013). One trial
administered glucocorticosteroids for nine months in the gluco-
corticosteroid-containing arm (Studenik 2005). One trial admin-
istered glucocorticosteroids for 25 months in the glucocorticos-
teroid-containing arm (Vivarelli 2007). Two trials administered
glucocorticosteroids indefinitely in the glucocorticosteroid-con-
taining arm (Belli 1998; Chen 2007). One trial did not report the
duration of glucocorticosteroid administration in the glucocorti-
costeroid-containing arm (Pageaux 2004). For the subgroup analy-
ses on duration of glucocorticosteroid administration, we grouped
the trials together as ’less than or equal to three months’, ’greater
than three and up to six months’, and ’greater than six months’.
Five trials were commenced before 2000 (Belli 1998; Tisone 1999;
Belli 2001; Pageaux 2004; Margarit 2005), and the remaining
11 trials were commenced from 2000 onwards (Reggiani 2005;
Studenik 2005; Llado 2006; Chen 2007; Moench 2007; Vivarelli
2007; Hu 2008; Lerut 2008; Ju 2012; Pelletier 2013; Ramirez
2013).
Three trials report no missing data at latest follow-up (Moench
2007; Lerut 2008; Ramirez 2013). Eight trials do not report num-
ber of drop-outs adequately (Tisone 1999; Belli 2001; Reggiani
2005; Studenik 2005; Llado 2006; Chen 2007; Ju 2012; Pelletier
2013). Five trials report at least one participant lost to follow-
up, with a total of 25/642 participants in the glucocorticosteroid
avoidance or withdrawal group lost to follow-up and 21/651 par-
ticipants in the glucocorticosteroid-containing group lost to fol-
low-up. One trial reported two drop-outs in each group (Belli
1998). One trial reported three drop-outs in the glucocorticos-
teroid withdrawal group and four drop-outs in the glucocorticos-
teroid-containing group (Hu 2008). One trial reported one drop-
out in the glucocorticosteroid withdrawal group and no drop-
outs in the glucocorticosteroid-containing group (Margarit 2005).
One trial reported 19 drop-outs in the glucocorticosteroid with-
drawal group and 12 drop-outs in the glucocorticosteroid-con-
taining group (Pageaux 2004). One trial reported no drop-outs
in the glucocorticosteroid withdrawal group and three drop-outs
in the glucocorticosteroid-containing group (Vivarelli 2007). One
trial excluded 16 participants from the reported acute rejection
rate due to treatment failure (Belli 1998). Our protocol states that
all available data should be analysed using the intention-to-treat
principle (Fairfield 2014).We therefore included the three partici-
pants in the glucocorticosteroid withdrawal group and 13 partici-
pants in the long-term glucocorticosteroid group as ’lost to follow-
up’ for the outcome ’acute rejection’.
Concomitant immunosuppression
All trials reported on concomitant immunosuppression but this
varied between trials. Of the 16 trials all used a calcineurin in-
hibitor with 11 using tacrolimus (Margarit 2005; Reggiani 2005;
Studenik 2005; Chen 2007; Moench 2007; Vivarelli 2007; Hu
2008; Lerut 2008; Ju 2012; Pelletier 2013; Ramirez 2013), and
five used cyclosporine A (Belli 1998; Tisone 1999; Belli 2001;
Pageaux 2004; Llado 2006). One trial replaced tacrolimus with
sirolimus when clinically indicated (Ju 2012). Of the 11 trials in
which tacrolimuswas used, five of the trials usednoother concomi-
tant immunosuppression as described in the intervention groups
(Margarit 2005; Moench 2007; Vivarelli 2007; Hu 2008; Lerut
2008) (see Characteristics of included studies).
Seven of the 16 trials used an antiproliferative agent, with six trials
using mycophenolate mofetil (Reggiani 2005; Studenik 2005;
Chen 2007; Ju 2012; Pelletier 2013; Ramirez 2013), and one
trial using azathioprine (Tisone 1999). All of the trials that used
mycophenolate mofetil also used tacrolimus and the one trial that
used azathioprine used cyclosporine A.
Induction therapy with a non-glucocorticosteroid agent was used
in eight of the trials. Two trials used rabbit antithymocyte globulin
(RATG) (Belli 1998; Belli 2001); five trials used basiliximab (
Pageaux 2004; Llado 2006; Ju 2012; Pelletier 2013; Ramirez
2013); and one trial used daclizumab (Studenik 2005).
Concomitant immunosuppression consisted of a calcineurin in-
hibitor used in combination with an antiproliferative agent in
three trials (Tisone 1999; Reggiani 2005; Chen 2007). Concomi-
tant immunosuppression consisted of a calcineurin inhibitor used
in combination with induction therapy in four trials (Belli 1998;
Belli 2001; Pageaux 2004; Llado 2006). Concomitant immuno-
suppression consisted of triple therapywith a calcineurin inhibitor,
an antiproliferative agent, and induction therapy in four trials
(Studenik 2005; Ju 2012; Pelletier 2013; Ramirez 2013).
Excluded studies
We excluded 26 trials after reading the full text of the articles.
These articles all related to randomised clinical trials but did not
assess glucocorticosteroid-containing versus glucocorticosteroid-
free immunosuppression. We explained the reasons for their ex-
clusion in Characteristics of excluded studies.
Risk of bias in included studies
Trial methodology was only adequately reported in two of the
trials (Moench 2007; Lerut 2008) (see Figure 2; Figure 3). We
considered all 16 of the trials to be at high risk of bias as we
considered one ormore of the bias components of each trial to be at
unclear risk of bias due to inadequately reported methodology or
at high risk of bias (Belli 1998; Tisone 1999; Belli 2001; Pageaux
2004;Margarit 2005; Reggiani 2005; Studenik 2005; Llado 2006;
Chen 2007;Moench 2007; Vivarelli 2007; Hu 2008; Lerut 2008;
Ju 2012; Pelletier 2013; Ramirez 2013).
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Generation of the allocation sequence was adequately reported
in three trials (Tisone 1999; Ju 2012; Ramirez 2013), and in-
adequately reported in 13 trials (Belli 1998; Belli 2001; Pageaux
2004;Margarit 2005; Reggiani 2005; Studenik 2005; Llado 2006;
Chen 2007;Moench 2007; Vivarelli 2007; Hu 2008; Lerut 2008;
Pelletier 2013).
Allocation concealment was adequate in four trials (Margarit
2005; Moench 2007; Lerut 2008; Pelletier 2013), and inade-
quately reported in 12 trials (Belli 1998; Tisone 1999; Belli 2001;
Pageaux 2004; Reggiani 2005; Studenik 2005; Llado 2006; Chen
2007; Vivarelli 2007; Hu 2008; Ju 2012; Ramirez 2013).
Blinding
Three trials reported accurately and applied adequate methods for
blinding (Pageaux 2004;Moench 2007; Lerut 2008). Six trials did
not report on blinding (Belli 1998; Belli 2001; Studenik 2005;
Chen 2007; Hu 2008; Ju 2012), and seven trials did not perform
blinding (Tisone 1999; Margarit 2005; Reggiani 2005; Llado
2006; Vivarelli 2007; Pelletier 2013; Ramirez 2013).
Incomplete outcome data
In five trials, either no data were missing or missing data were
adequately reported and unlikely to have influenced outcome re-
sults (Margarit 2005; Moench 2007; Vivarelli 2007; Lerut 2008;
Ramirez 2013). In the remaining 11 trials missing data were inad-
equately addressed (Belli 1998; Tisone 1999; Belli 2001; Pageaux
2004;Reggiani 2005; Studenik 2005; Llado2006;Chen2007;Hu
2008; Ju 2012; Pelletier 2013). In one trial, a participant was ex-
cluded following a re-transplant and death 10 days later (Ramirez
2013); as this occurred after randomisation, we have re-entered the
participant into the analysis for inclusion in the meta-analysis. In
one trial, three participants were excluded due to early death (two
participants) and positive cross-match (one participant) (Margarit
2005); as this occurred after randomisation, we have re-entered
the participants into the analysis for inclusion in the meta-analy-
sis: one case of mortality has been added to each group and one
case of missing data has been added to the glucocorticosteroid-
free group as well as the totals adjusted accordingly. One trial ex-
cluded nine participants due to early death (five participants) and
ABO-blood group incompatibility (four participants) (Ju 2012),
reporting on the original allocated groups of the deaths but not the
ABO-blood group incompatibility; as this occurred after randomi-
sation, we have re-entered the participants who suffered from early
mortality into the analysis for inclusion in the meta-analysis. One
trial excluded eight participants due to early death (three partici-
pants), graft loss (two participants), change to alternative primary
immunosuppressant (two participants), and de novo hepatitis B
virus (HBV) infection (one participant) (Vivarelli 2007); as this
occurred after randomisation, we have re-entered the participants
into the analysis for inclusion in the meta-analysis: the cases of
mortality and graft loss have been added to the intervention groups
accordingly and the change in immunosuppressant and HBV in-
fection counted as loss to follow-up. As some of these participants
were randomised but excluded from the analysis, they may not
be included in the demographic data except where authors have
provided relevant details.
Missing summary data
One trial reported mean arterial pressure, serum cholesterol, and
fasting blood glucose, but it did not provide a standard deviation or
range (Ramirez 2013). Furthermore, in this trial, no exact P values
are reported, but P values are described as “NS” (not significant) (
Ramirez 2013). These results have not been included in this review.
Selective reporting
We had no access to the protocols for any of the trials. One trial
was published only in an abstract, so no comment on selective
reporting can be made (Studenik 2005). Of the 15 remaining
trials, 12 report expected clinical outcomemeasures or outcomes as
specified in themethods section of the article (Belli 1998; Pageaux
2004; Margarit 2005; Llado 2006; Chen 2007; Moench 2007;
Vivarelli 2007; Hu 2008; Lerut 2008; Ju 2012; Pelletier 2013;
Ramirez 2013). Two trials appear not to report expected outcomes
or outcomes described in themethods section of the article (Tisone
1999; Reggiani 2005). In the three-armed trial, six participants
died and one developed portal vein thrombosis (Belli 2001). The
participants are split between the three arms (two in the standard
therapy arm; three in the glucocorticosteroid-free arm; and two in
the glucocorticosteroid-free and ribavirin arm), but which group
the participant with portal vein thrombosis was in and which
groups the deaths occurred in is not reported.We couldnot include
the outcome of mortality in this trial in the main analysis, but
it was possible to include it in the best-worst worst-best analysis:
the number of participants suffering from mortality is either one
or two in the standard therapy arm and either two or three in
the glucocorticosteroid-free arm, and we used these values in the
analysis.
Other potential sources of bias
Seven trials reported part or full industry sponsorship (Pageaux
2004; Llado 2006; Moench 2007; Vivarelli 2007; Lerut 2008;
Pelletier 2013; Ramirez 2013). Three trials report sponsorship
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exclusively fromother sources (Margarit 2005;Hu2008; Ju 2012).
The remaining six trials do not report on sponsorship (Belli 1998;
Tisone 1999; Belli 2001; Reggiani 2005; Studenik 2005; Chen
2007).
Three of the 16 trials report a required sample size calculation
(Llado 2006;Moench 2007; Lerut 2008), whilst the remainder do
not (Belli 1998; Tisone 1999; Belli 2001; Pageaux 2004;Margarit
2005; Reggiani 2005; Studenik 2005; Chen 2007; Vivarelli 2007;
Hu 2008; Ju 2012; Pelletier 2013; Ramirez 2013).
All but one of the trials appear to be free from early stopping. One
of the trials was stopped early following an interim analysis. The
stopping criteria are not described in the trial that was stopped
early (Reggiani 2005).
Ten of the 16 trials are free from baseline imbalance (Tisone 1999;
Pageaux 2004; Studenik 2005; Llado 2006; Chen 2007; Moench
2007; Vivarelli 2007; Hu 2008; Pelletier 2013; Ramirez 2013).
Three trials report on significant baseline imbalance (Margarit
2005;Reggiani 2005; Lerut 2008). In three of the trials the baseline
characteristics are inadequately reported to allow comparison (
Belli 1998; Belli 2001; Ju 2012).
Effects of interventions
See: Summary of findings for the main comparison
Glucocorticosteroid avoidance or withdrawal compared
to glucocorticosteroid-based immunosuppression for liver
transplanted patients
See Summary of findings for the main comparison for the effects
of glucocorticosteroid avoidance or withdrawal versus glucocor-
ticosteroid-containing immunosuppression for liver transplanted
patients.
Glucocorticosteroid avoidance or withdrawal versus
glucocorticosteroid-containing immunosuppression
All-cause mortality
Fifteen trials with 1323 participants reported adequately on mor-
tality, and overall we found no statistically significant difference
when glucocorticosteroid avoidance or withdrawal was compared
with glucocorticosteroid-containing immunosuppression (128/
659 (19%) versus 110/664 (17%); risk ratio (RR) 1.15, 95% con-
fidence interval (CI) 0.93 to 1.44; low-quality evidence) (Analysis
1.1). One trial reports the total number of deaths and a portal vein
thrombosis as a composite outcome for the entire trial but does
not adequately describe to which group the portal vein thrombo-
sis and the deaths belong (Belli 2001). As a result of this the trial
cannot be included for this outcome except in the best-worst and
worst-best analyses (Analysis 8.1; Analysis 9.1). Trial Sequential
Analysis showed that trial sequential monitoring boundaries were
not broken by the cumulative Z-curve and the required informa-
tion size of 3520 participants was not obtained (Figure 4).
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Figure 4. Mortality: glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid containing
immunosuppression. Trial Sequential Analysis of the effect of glucocorticosteroid avoidance or withdrawal
versus glucocorticosteroid-containing immunosuppression on mortality based on 15 trials with 1323
participants. The diversity adjusted required information size (DARIS) of 3520 participants was calculated on
the basis of type I error of 5%, type II error of 20% and risk reduction of 20%, and information size was adjusted
for diversity (0%). The cumulative Z-curve does not cross trial sequential monitoring boundaries, and the
required information size was not reached.
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Graft loss including death
Eleven trials with 1002 participants reported on graft loss includ-
ing death, and overall we found no statistically significant dif-
ference when glucocorticosteroid avoidance or withdrawal was
compared with glucocorticosteroid-containing immunosuppres-
sion (118/631 (19%) versus 96/638 (15%); RR 1.16, 95% CI
0.91 to 1.48; low-quality evidence) (Analysis 1.2). Trial Sequential
Analysis showed that trial sequential monitoring boundaries were
not broken by the cumulative Z-curve and the required informa-
tion size of 3289 participants was not obtained (Figure 5).
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Figure 5. Graft loss including death: glucocorticosteroid avoidance or withdrawal versus
glucocorticosteroid containing immunosuppression. Trial Sequential Analysis of the effect of
glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression on
graft loss including death based on 11 trials with 1002 participants. The diversity adjusted required information
size (DARIS) was calculated on the basis of type I error of 5%, type II error of 20% and risk reduction of 20%,
and information size was adjusted for diversity (0%). The cumulative Z-curve does not cross trial sequential
monitoring boundaries, and the required information size was not reached.
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Acute rejection
Acute rejection was defined as the total number of participants
who experienced one or more rejection episodes. Sixteen trials
with 1347 participants reported on acute rejection, and acute re-
jectionwas statistically significantlymore frequent when glucocor-
ticosteroid avoidance or withdrawal was compared with glucocor-
ticosteroid-containing immunosuppression (150/670 (22%) ver-
sus 117/677 (17%); RR 1.33, 95% CI 1.08 to 1.64; moderate-
quality evidence) (Analysis 1.3). However, Trial Sequential Anal-
ysis showed that trial sequential monitoring boundaries were not
broken by the cumulative Z-curve and the required information
size of 3520 participants was not obtained (Figure 6).
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Figure 6. Acute rejection: glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid
containing immunosuppression. Trial Sequential Analysis of the effect of glucocorticosteroid avoidance or
withdrawal versus glucocorticosteroid-containing immunosuppression on acute rejection based on 16 trials
with 1347 participants. The diversity adjusted required information size (DARIS) was calculated on the basis of
type I error of 5%, type II error of 20% and risk reduction of 20%, and information size was adjusted for
diversity (0%). The cumulative Z-curve does not cross trial sequential monitoring boundaries, and the required
information size was not reached.
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Infection
Eight trials with 778 participants reported adequately on infec-
tion, and overall we found no statistically significant difference
when glucocorticosteroid avoidance or withdrawal was compared
with glucocorticosteroid-containing immunosuppression (120/
382 (31%) versus 142/396 (36%); RR 0.88, 95%CI 0.73 to 1.05;
low-quality evidence) (Analysis 1.4). Infection was defined in each
of the eight trials as the number of participants who experienced
one or more infection. Two other trials reported the total num-
ber of cases of infection including those with multiple episodes of
infection (Margarit 2005; Lerut 2008). Trial Sequential Analysis
showed that trial sequential monitoring boundaries were not bro-
ken by the cumulative Z-curve and the required information size
of 3222 participants was not obtained.
Other adverse events
No trials reported on adverse events. A number of trials reported
“deaths due to an adverse event” or separate adverse events such
as the development of de novo diabetes mellitus but none of the
trials reported the total number of adverse events.
Chronic rejection
Nine trials with 974 participants reported on chronic rejec-
tion, and overall we found no statistically significant difference
when glucocorticosteroid avoidance or withdrawal was compared
with glucocorticosteroid containing immunosuppression (15/482
(3%) versus 15/492 (3%); RR 1.02, 95% CI 0.52 to 2.00; very
low-quality evidence) (Analysis 1.5). Trial Sequential Analysis
showed that trial sequential monitoring boundaries were not bro-
ken by the cumulative Z-curve and the required information size
of 22,911 participants was not obtained.
Glucocorticosteroid-resistant rejection
Glucocorticosteroid-resistant rejection was defined as the total
number of participants who experienced one or more glucocor-
ticosteroid-resistant rejections. Ten trials with 1020 participants
reported on glucocorticosteroid-resistant rejection, and glucocor-
ticosteroid-resistant rejection was statistically significantly more
frequent when glucocorticosteroid avoidance or withdrawal was
compared with glucocorticosteroid-containing immunosuppres-
sion (27/505 (5%) versus 13/515 (3%); RR 2.14, 95% CI 1.13
to 4.02; very low-quality evidence) (Analysis 1.6). Trial Sequential
Analysis showed that trial sequential monitoring boundaries were
not broken by the cumulative Z-curve and the required informa-
tion size of 2190 participants was not obtained.
Diabetes mellitus
Twelve trials with 1185 participants reported on diabetes mellitus,
and diabetes mellitus was not significantly different when gluco-
corticosteroid avoidance or withdrawal was compared with gluco-
corticosteroid-containing immunosuppression (125/588 (21%)
versus 156/597 (26%); RR 0.82, 95% CI 0.64 to 1.07; low-qual-
ity evidence) when we applied the random-effects model. How-
ever, when we applied the fixed-effect model, diabetes mellitus
was statistically significantly less frequent when glucocorticos-
teroid avoidance or withdrawal was compared with glucocorticos-
teroid-containing immunosuppression (RR 0.81, 95% CI 0.66 to
0.99; low-quality evidence) (Analysis 1.7). Trial Sequential Anal-
ysis showed that trial sequential monitoring boundaries were not
broken by the cumulative Z-curve and the required information
size of 3348 participants was not obtained.
Cytomegalovirus (CMV) infection
CMV infection was defined as the development of CMV disease
requiring treatment. Seven trials with 786 participants reported
on CMV infection, and overall we found no statistically signifi-
cant difference when glucocorticosteroid avoidance or withdrawal
was compared with glucocorticosteroid-containing immunosup-
pression (28/387 (7%) versus 38/399 (10%); RR 0.74, 95% CI
0.48 to 1.16; low-quality evidence) (Analysis 1.8). Trial Sequential
Analysis showed that trial sequential monitoring boundaries were
not broken by the cumulative Z-curve and the required informa-
tion size of 6429 participants was not obtained.
Hepatitis C virus (HCV) recurrence
Ten trials with 477 participants reported on HCV recurrence, and
overall we found no statistically significant difference when gluco-
corticosteroid avoidance or withdrawal was compared with gluco-
corticosteroid-containing immunosuppression (159/232 (69%)
versus 162/245 (66%); RR 1.03, 95% CI 0.92 to 1.15; very low-
quality evidence) (Analysis 1.9). Trial Sequential Analysis showed
that trial sequential monitoring boundaries were not broken by
the cumulative Z-curve but the required information size of 435
participants was obtained, meaning that we can exclude a relative
risk reduction of 20% or more.
Malignancy
Three trials with 528 participants reported on de novomalignancy,
and overall we found no statistically significant difference when
glucocorticosteroid avoidance or withdrawal was compared with
glucocorticosteroid-containing immunosuppression (3/258 (1%)
versus 7/270 (3%); RR 0.52, 95% CI 0.16 to 1.74; very low-
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quality evidence) (Analysis 1.10). Trial Sequential Analysis showed
that trial sequential monitoring boundaries were not broken by the
cumulative Z-curve and the required information size of 22,911
participants was not obtained.
Post-transplant lymphoproliferative disorder
Two trials with 330 participants reported on post-transplant lym-
phoproliferative disorder, and overall we found no statistically sig-
nificant difference when glucocorticosteroid avoidance or with-
drawal was compared with glucocorticosteroid-containing im-
munosuppression (3/162 (2%) versus 1/168 (1%); RR 2.39, 95%
CI 0.36 to 15.95; very low-quality evidence) (Analysis 1.11).
Trial Sequential Analysis showed that trial sequential monitoring
boundaries were not broken by the cumulative Z-curve and the
required information size of 70,005 participants was not obtained.
Renal function
No trials reported on renal failure requiring dialysis.
Four trials with 447 participants reported on renal insufficiency,
and overall we found no statistically significant difference when
glucocorticosteroid avoidance was compared with glucocorticos-
teroid-containing immunosuppression (67/216 (31%) versus 77/
231 (33%); RR 0.93, 95% CI 0.73 to 1.19; very low-quality evi-
dence) (Analysis 1.12). Trial Sequential Analysis showed that trial
sequential monitoring boundaries were not broken by the cumu-
lative Z-curve and the required information size of 3735 partici-
pants was not obtained.
No trials reported on estimated glomerular filtration rate.
Four trials with 309 participants reported on creatinine (mg/dL),
and creatinine was not significantly different when glucocorticos-
teroid avoidance or withdrawal was compared with glucocorticos-
teroid-containing immunosuppression (MD 0.01 mg/dL, 95%
CI -0.21 to 0.23; very low-quality evidence) when we applied the
random-effects model. However, when we applied the fixed-effect
model, creatinine was statistically significantly raised when gluco-
corticosteroid avoidance or withdrawal was compared with gluco-
corticosteroid-containing immunosuppression (MD 0.11 mg/dL,
95% CI 0.07 to 0.16; very low-quality evidence) (Analysis 1.13).
De novo autoimmune hepatitis
No trials reported on de novo autoimmune hepatitis.
Hypertension
Ten trials with 1098 participants reported on hypertension,
and hypertension was statistically significantly less frequent
when glucocorticosteroid avoidance or withdrawal was compared
with glucocorticosteroid-containing immunosuppression (157/
543 (29%) versus 210/555 (38%); RR 0.76, 95%CI 0.65 to 0.90;
low-quality evidence) (Analysis 1.14). Trial Sequential Analysis
showed that trial sequential monitoring boundaries were not bro-
ken by the cumulative Z-curve and the required information size
of 3409 participants was not obtained.
Hyperlipidaemia
Four trials with 400 participants reported on hyperlipidaemia,
and overall we found no statistically significant difference when
glucocorticosteroid avoidance was compared with glucocorticos-
teroid-containing immunosuppression (13/197 (7%) versus 18/
203 (9%); RR 0.75, 95% CI 0.38 to 1.48; very low-quality evi-
dence) (Analysis 1.15). Trial Sequential Analysis showed that trial
sequential monitoring boundaries were not broken by the cumu-
lative Z-curve and the required information size of 7214 partici-
pants was not obtained.
Cholesterol
Five trials with 556 participants reported on serum cholesterol
(mg/dL), and serum cholesterol was statistically significantly re-
duced when glucocorticosteroid avoidance or withdrawal was
compared with glucocorticosteroid-containing immunosuppres-
sion (mean difference (MD) -18.49 mg/dL, 95% CI -22.02 to
14.96; very low-quality evidence) (Analysis 1.16).
Two trials with 266 participants reported on hypercholestero-
laemia, and hypercholesterolaemia was not significantly different
when glucocorticosteroid avoidance or withdrawal was compared
with glucocorticosteroid-containing immunosuppression (16/134
(12%) versus 28/132 (21%); RR 0.56, 95% CI 0.32 to 1.00; very
low-quality evidence) (Analysis 1.17). Trial Sequential Analysis
showed that trial sequential monitoring boundaries were not bro-
ken by the cumulative Z-curve and the required information size
of 20,334 participants was not obtained.
Health-related quality of life
No trials reported on health-related quality of life.
Zero event trial correction
Trials with zero events in both intervention groups were found in
several of the analyses. For all of these analyses, we applied a ran-
dom-effects meta-analysis with empirical continuity correction of
0.01 using the R software (R 2013). This correction of zero event
trials resulted in none of the analyses yielding statistically signifi-
cantly different results (i.e., all statistically significant differences
in results between the groups remained statistically significantly
different after zero event trial correction, and all non-statistically
significant differences in results between the groups remained non-
statistically significantly different after zero event trial correction).
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Subgroup analyses
We were not able to perform our predefined subgroup analysis on
trials with low risk of bias compared with trials to high risk of bias,
as we considered none of the trials included in the review to be at
low risk of bias.
We were not able to perform our predefined subgroup analysis
on trials with paediatric participants compared to trials with adult
participants, as all of the trials included in the review recruited
exclusively adult participants.
We were not able to perform our predefined subgroup analysis
on the median time between transplantation and the commence-
ment of glucocorticosteroid administration, as none of the trials
included in the review reported this in their methodology.
We performed subgroup analyses on glucocorticosteroid avoid-
ance compared to glucocorticosteroid withdrawal (Analysis 1.1
through Analysis 1.17). Tests for subgroup differences between
glucocorticosteroid avoidance and glucocorticosteroid withdrawal
were not statistically significantly different for most outcomes, ex-
cept for the outcomes ’Infection’, ’Creatinine’ and ’Hypercholes-
terolaemia’. We found a statistically significant interaction for in-
fection (P value = 0.04). This difference between glucocorticos-
teroid avoidance and glucocorticosteroid withdrawal is caused by
one trial using glucocorticosteroid withdrawal that caused sig-
nificantly fewer infections in the glucocorticosteroid avoidance
or withdrawal group compared to trials in which glucocorticos-
teroid avoidance was used (RR 0.12, 95% CI 0.02 to 0.89). We
found a statistically significant interaction for creatinine (P value
= 0.0004). This difference between glucocorticosteroid avoidance
and glucocorticosteroid withdrawal is caused by two trials using
glucocorticosteroid withdrawal that caused significantly lower cre-
atinine in the glucocorticosteroid avoidance or withdrawal group
compared to trials in which glucocorticosteroid avoidance was
used (MD -0.06 mg/dL, 95% CI -0.16 to 0.05). We found a sta-
tistically significant interaction for hypercholesterolaemia (P value
= 0.008). This difference is caused by one trial reporting no sta-
tistically significant difference and one trial reporting statistically
significantly lower rates of hypercholesterolaemia in the glucocor-
ticosteroid avoidance and withdrawal arm. There are only a small
number of studies reporting on infection, creatinine and hyper-
cholesterolaemia.The difference observed between subgroups for
these outcomes may therefore be due to a factor other than gluco-
corticosteroid use.
We performed subgroup analyses on type of calcineurin inhibitor
used (tacrolimus or cyclosporine A) (Analysis 2.1 through Analysis
2.16). Tests for subgroup differences between type of calcineurin
inhibitor used as a co-intervention were not statistically signifi-
cantly different for most outcomes, except for the outcome ’Cre-
atinine’ for which we found a statistically significant interaction
(P value < 0.00001). This difference between type of calcineurin
inhibitor used as co-intervention is caused by one trial using the
calcineurin inhibitor tacrolimus, which caused significantly higher
serum creatinine levels in the glucocorticosteroid avoidance or
withdrawal group compared to trials in which cyclosporine A was
used (MD 0.25 mg/dL, 95% CI 0.19 to 0.31).
We performed subgroup analyses on type of antiproliferative agent
(azathioprine or mycophenolate mofetil) compared to no antipro-
liferative agent (Analysis 3.1 through Analysis 3.14). Tests for sub-
group differences between the type of antiproliferative agent used
as a co-intervention when compared to no antiproliferative agent
were not statistically significantly different for most outcomes, ex-
cept for the outcome ’Creatinine’ for which we found a statistically
significant interaction (P value < 0.00001). This difference be-
tween the type of antiproliferative agent used as a co-intervention
is caused by one trial using the antiproliferative agent mycopheno-
late mofetil, which caused significantly higher serum creatinine in
the glucocorticosteroid avoidance or withdrawal group compared
to trials in which azathioprine or no antiproliferative agent were
used (MD 0.25 mg/dL, 95% CI 0.19 to 0.31).
Weperformed subgroup analyses on type of induction agent (basil-
iximab, daclizumab, or rabbit antithymocyte globulin) compared
to no induction agent (Analysis 4.1 through Analysis 4.16). Tests
for subgroup differences between the type of induction therapy
used as a co-intervention when compared to no induction agent
were not statistically significantly different for most outcomes,
except for the outcomes ’Infection’, ’Creatinine’, ’Hypertension’
and ’Cholesterol’. We found a statistically significant difference
for infection (P value = 0.04). This difference between the type
of induction therapy used as a co-intervention is caused by the
induction agent rabbit antithymocyte globulin, which caused sig-
nificantly fewer infections in the glucocorticosteroid avoidance or
withdrawal group compared to trials in which basiliximab or no
induction agents were used (RR 0.12, 95% CI 0.02 to 0.89). We
found a statistically significant interaction for serum creatinine (P
value < 0.00001). This difference between the type of induction
therapy used as a co-intervention is caused by the induction agent
basiliximab, which caused significantly higher serum creatinine in
the glucocorticosteroid avoidance or withdrawal group compared
to trials in which no induction agent was used (MD 0.25 mg/dL,
95% CI 0.19 to 0.31). We found a statistically significant interac-
tion for hypertension (P value = 0.03). This difference between the
type of induction therapy used as a co-intervention is caused by
the induction agent rabbit antithymocyte globulin, which caused
significantly lower rates of hypertension in the glucocorticosteroid
avoidance or withdrawal group compared to trials in which basil-
iximab or no induction agent were used (RR 0.30, 95% CI 0.16
to 0.57). We found a statistically significant interaction for serum
cholesterol (P value = 0.0001). This difference between the type
of induction therapy used as a co-intervention is caused in part by
the induction agent rabbit antithymocyte globulin, which caused
significantly lower serum cholesterol in the glucocorticosteroid
avoidance or withdrawal group compared to trials in which basil-
iximab was used (MD -70.00 mg/dL, 95% CI -101.17 to -39.83)
and in part by one trial that did not use an induction agent, which
caused significantly lower serum cholesterol in the glucocorticos-
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teroid avoidance or withdrawal group compared to trials in which
basiliximab was used (MD -146.00 mg/dL, 95% CI -192.16 to -
99.84).
We performed subgroup analyses on the number of co-inter-
ventions given (monotherapy, dual therapy, or triple therapy)
(Analysis 5.1 through Analysis 5.16). Tests for subgroup differ-
ences between the number of co-interventions given were not sta-
tistically significantly different for most outcomes, except for the
outcomes ’Creatinine’ and ’Cholesterol’. We found a statistically
significant interaction for serum creatinine (P value < 0.00001).
This difference between the number of co-interventions given is
caused by the use of triple therapy in one trial, which caused signif-
icantly higher serum creatinine in the glucocorticosteroid avoid-
ance or withdrawal group compared to monotherapy or triple
therapy (MD 0.25 mg/dL, 95% CI 0.19 to 0.31). We found a
statistically significant difference for serum cholesterol (P value
< 0.00001). This difference between the number of co-interven-
tions given is caused by the use of monotherapy in one trial, which
caused significantly higher serum cholesterol in the glucocorticos-
teroid avoidance or withdrawal group compared to dual therapy
or triple therapy (MD 35.00 mg/dL, 95% CI 12.31 to 57.69).
We performed subgroup analyses on the duration of glucocorti-
costeroid use in the longer glucocorticosteroid taper arm or the
long-term glucocorticosteroid arm (up to three months of gluco-
corticosteroids; greater than three months and up to six months
of glucocorticosteroids; or greater than six months of glucocorti-
costeroids) (Analysis 6.1 through Analysis 6.13). One trial did not
report on the duration of glucocorticosteroid use in the glucocorti-
costeroid-containing arm andwas not included in this sub-analysis
(Pageaux 2004). Tests for subgroup differences between duration
of glucocorticosteroid use in the glucocorticosteroid-containing
armwere not statistically significantly different formost outcomes,
except for the outcomes ’Creatinine’, ’Hypertension’, ’Cholesterol’
and ’Hypercholesterolaemia’. We found a statistically significant
difference for serum creatinine (P value = 0.00001). This differ-
ence between the duration of glucocorticosteroid use is caused by
one trial using three to six months of glucocorticosteroids in the
glucocorticosteroid-containing group, which caused significantly
higher serum creatinine in the glucocorticosteroid avoidance or
withdrawal group compared to trials using two to three months
of glucocorticosteroids and more than six months of glucocorti-
costeroids in the glucocorticosteroid-containing arm (MD 0.25
mg/dL, 95% CI 0.19 to 0.31). We found a statistically signifi-
cant difference for hypertension (P value = 0.001). This difference
between duration of glucocorticosteroid use in the glucocorticos-
teroid-containing arm is caused, in part, by one trial which used
long-term glucocorticosteroid in the glucocorticosteroid-contain-
ing arm, which caused significantly lower rates of hypertension in
the glucocorticosteroid avoidance or withdrawal group compared
to trials using two to three months or three to six months of glu-
cocorticosteroids in the glucocorticosteroid-containing arm (RR
0.30, 95%CI 0.16 to 0.57).We found a statistically significant dif-
ference for cholesterol (P value = 0.002). This difference between
durationof glucocorticosteroid use in the glucocorticosteroid-con-
taining arm is caused by two trials using long-term glucocorticos-
teroids in the glucocorticosteroid-containing arm, which caused
significantly lower serum cholesterol in the glucocorticosteroid
avoidance or withdrawal group compared to trials using two to
three months or three to six months of glucocorticosteroids in the
glucocorticosteroid-containing arm (MD -92.75 mg/dL, 95% CI
-118.01 to -67.50). We found a statistically significant interac-
tion for hypercholesterolaemia (P value = 0.008). This difference
between duration of glucocorticosteroid use in the glucocorticos-
teroid-containing is due to the small number of trials reporting
on hypercholesterolaemia, with one trial reporting no statistically
significant difference and one trial reporting statistically signifi-
cantly lower rates of hypercholesterolaemia in the glucocorticos-
teroid avoidance and withdrawal arm. The difference observed be-
tween subgroups for hypercholesterolaemia may therefore be due
to a factor other than duration of glucocorticosteroid use.
We performed subgroup analyses on trials commenced before the
year 2000 and trials commenced from 2000 onwards (Analysis 7.1
through Analysis 7.16). Tests for subgroup differences between
trials commenced before 2000 and trials commenced from 2000
onwards were not statistically significantly different for most out-
comes, except for the outcomes ’Creatinine’, ’Hypertension’, and
’Cholesterol’. We found a statistically significant interaction for
creatinine (P value < 0.00001). This difference between trials com-
menced before 2000 and trials commenced from 2000 onwards is
caused by one trial started after 2000, which caused significantly
higher serum creatinine in the glucocorticosteroid avoidance or
withdrawal group compared to a trial started before 2000 (MD
0.25 mg/dL, 95% CI 0.19 to 0.31). We found a statistically sig-
nificant difference for hypertension (P value = 0.03). This dif-
ference between trials commenced before 2000 and trials com-
menced from 2000 onwards is caused by one trial started before
2000, which caused significantly lower rates of hypertension in
the glucocorticosteroid avoidance or withdrawal group compared
to trials started after 2000 (RR 0.30, 95% CI 0.16 to 0.57). We
found a statistically significant difference for cholesterol (P value =
0.03). This difference between trials commenced before 2000 and
trials commenced from2000 onwards is caused by one trial started
before 2000, which caused significantly lower serum cholesterol in
the glucocorticosteroid avoidance or withdrawal group compared
to trials started after 2000 (MD -70.00 mg/dL, 95% CI -101.17
to -39.83).
The statistically significant interactions in serum creatinine and
serum cholesterol between many of the subgroups are unlikely to
reflect actual differences between the subgroups. Instead they are
likely to reflect the relatively small number of trials that report
on these outcomes and the considerable heterogeneity influencing
these outcomes.
27Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Best-worst and worst-best analyses
We found trials with missing data in several of the analyses. For
each of these analyses, we applied a best-worst analysis and a worst-
best analysis.
Best-worst analyses
The best-worst analyses (best results possible for glucocorticos-
teroid avoidance or withdrawal) did not yield statistically signif-
icantly different results from the conventional meta-analysis ex-
cept for acute rejection, infection, glucocorticosteroid-resistant
rejection, CMV infection, malignancy, post-transplant lympho-
proliferative disorder, and hyperlipidaemia (Analysis 8.1 through
Analysis 8.12). We observed no statistically significant difference
in the best-worst analyses for acute rejection (RR 1.04, 95%
CI 0.85 to 1.26) or glucocorticosteroid-resistant rejection (RR
1.00, 95% CI 0.61 to 1.65) when glucocorticosteroid avoidance
or withdrawal was compared with glucocorticosteroid-containing
immunosuppression. We found statistically significant reductions
in the best-worst analyses for infection (RR 0.80, 95% CI 0.67
to 0.96), CMV infection (RR 0.57, 95% CI 0.37 to 0.87), ma-
lignancy (RR 0.21, 95% CI 0.07 to 0.61), post-transplant lym-
phoproliferative disorder (RR 0.24, 95% CI 0.07 to 0.85), and
hyperlipidaemia (RR 0.40, 95% CI 0.21 to 0.73) when gluco-
corticosteroid avoidance or withdrawal was compared with glu-
cocorticosteroid-containing immunosuppression. However, it is
unlikely that all 12 participants lost to follow-up in the glucocor-
ticosteroid-containing immunosuppression arm of Pageaux 2004
suffered from malignancy and post-transplant lymphoprolifera-
tive disorder. We found no statistically significant differences be-
tween the best-worst analyses and the conventional meta-analy-
sis for mortality, graft loss including death, chronic rejection, di-
abetes mellitus, or hypertension when glucocorticosteroid avoid-
ance or withdrawal was compared with glucocorticosteroid-con-
taining immunosuppression.
Worst-best analyses
The worst-best analyses (worst results possible for glucocorticos-
teroid avoidance or withdrawal) did not yield statistically signif-
icantly different results from the conventional meta-analysis ex-
cept for mortality, graft loss including death, chronic rejection, di-
abetes mellitus, malignancy, post-transplant lymphoproliferative
disorder, hypertension, and hyperlipidaemia (Analysis 9.1 through
Analysis 9.13). We observed no statistically significant difference
in the worst-best analyses for diabetes mellitus (RR 0.95, 95%
CI 0.79 to 1.15) or hypertension (RR 0.87, 95% CI 0.75 to
1.02) when glucocorticosteroid avoidance or withdrawal was com-
pared with glucocorticosteroid-containing immunosuppression.
We found statistically significant increases in the worst-best analy-
ses formortality (RR1.35, 95%CI 1.10 to 1.67), graft loss includ-
ing death (RR 1.39, 95% CI 1.10 to 1.76), chronic rejection (RR
2.39, 95% CI 1.36 to 4.21), malignancy (RR 3.05, 95% CI 1.38
to 6.73), post-transplant lymphoproliferative disorder (RR 15.64,
95% CI 3.08 to 79.56), and hyperlipidaemia (RR 1.92, 95% CI
1.12 to 3.28) when glucocorticosteroid avoidance or withdrawal
was compared with glucocorticosteroid-containing immunosup-
pression. However, it is unlikely that all 19 participants lost to
follow-up in the glucocorticosteroid withdrawal arm of Pageaux
2004 suffered from malignancy and post-transplant lymphopro-
liferative disorder. We found no statistically significant differences
between the best-worst analyses and the conventional meta-anal-
ysis for acute rejection, infection, glucocorticosteroid-resistant re-
jection, CMV infection, or renal insufficiency when glucocorti-
costeroid avoidance or withdrawal was compared with glucocor-
ticosteroid-containing immunosuppression.
Adverse events reported in non-randomised studies
Our search was primarily to identify randomised clinical trials and
systematic reviews. However, the search returned multiple cita-
tions from quasi-randomised or non-randomised studies. In these
studies, we searched for adverse events that were different to those
reported in the randomised clinical studies in terms of number or
type of adverse event. We were unable to find any unique adverse
events in the non-randomised studies and we found no significant
discrepancy in the rates of the adverse events reported in the ran-
domised trials of this systematic review.
Publication bias
We performed a linear regression test to explore funnel plot asym-
metry for any outcomes reported in 10 ormore trials (Egger 1997).
We found no asymmetry for mortality, graft loss including death,
acute rejection, glucocorticosteroid-resistant rejection, or hepatitis
C virus recurrence. We identified tendencies towards significant
asymmetry for diabetes mellitus (P value = 0.06) and hypertension
(P value = 0.07). This asymmetry may be due to heterogeneity
introduced by one study (Belli 1998); when this study is removed,
no asymmetry is detected.
D I S C U S S I O N
Summary of main results
We identified 16 completed randomised clinical trials includ-
ing 1347 participants and one ongoing trial. Ten of these com-
pleted trials compared glucocorticosteroid avoidance with short-
term glucocorticosteroids and the remaining six compared rapid
glucocorticosteroid tapers with longer tapers or long-term glu-
cocorticosteroids. All of the trials were two-armed parallel-group
trials. We aimed to assess mortality, graft loss including death,
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acute rejection, infection, adverse events, chronic rejection, glu-
cocorticosteroid-resistant rejection, diabetes mellitus, CMV in-
fection, hepatitis C virus recurrence, malignancy, post-transplant
lymphoproliferative disorder, renal failure requiring dialysis, renal
insufficiency, eGFR, serum creatinine, de novo autoimmune hep-
atitis, hypertension, hyperlipidaemia, serum cholesterol, hyperc-
holesterolaemia, and health-related quality of life. Adverse events,
renal failure requiring dialysis, eGFR, de novo autoimmune hep-
atitis, and health-related quality of life were not reported in any
of the trials. We assessed all other outcomes in the meta-analysis.
Acute rejection appeared to be increased when glucocorticosteroid
avoidance or withdrawal were compared with glucocorticosteroid-
containing immunosuppression. Glucocorticosteroid-resistant re-
jection appeared to be increased when glucocorticosteroid avoid-
ance or withdrawal were compared with glucocorticosteroid-con-
taining immunosuppression. Diabetes mellitus appeared to be in-
creased when glucocorticosteroid avoidance or withdrawal were
compared with glucocorticosteroid-containing immunosuppres-
sion, when we applied the fixed-effect, but not the random-effects
model. Serum creatinine appeared to be increased when glucocor-
ticosteroid avoidance or withdrawal were compared with gluco-
corticosteroid-containing immunosuppression, when we applied
the fixed-effect, but not the random-effects model. Hypertension
appeared to be reduced when glucocorticosteroid avoidance or
withdrawal were compared with glucocorticosteroid-containing
immunosuppression. Serum cholesterol appeared to be reduced
when glucocorticosteroid avoidance or withdrawal were compared
with glucocorticosteroid-containing immunosuppression.
We found no evidence for an increase or decrease inmortality, graft
loss including death, infection, chronic rejection, CMV infection,
hepatitis C virus recurrence, malignancy, post-transplant lympho-
proliferative disorder, renal insufficiency, hyperlipidaemia, or hy-
percholesterolaemia when comparing glucocorticosteroid avoid-
ance or withdrawal with glucocorticosteroid-containing immuno-
suppression. We performed Trial Sequential Analysis for all out-
comes, and for none of the outcomes were the monitoring bound-
aries crossed or the required information size reached. Hence, we
cannot exclude random errors for the results of the conventional
meta-analyses.
We identified five trials exclusively composed of or reporting co-
horts of hepatitis C virus-infected participants, including 231 par-
ticipants. Whilst these participants have been included in this re-
view, they will also be considered separately in an additional sys-
tematic review. This will allow more detailed assessment of the
effects of glucocorticosteroid avoidance on hepatitis-C infected
participants.
Overall completeness and applicability of
evidence
We included 16 completed trials in our meta-analysis, which com-
pared glucocorticosteroid avoidance or withdrawal with gluco-
corticosteroid-containing immunosuppression. We could not per-
form meta-analyses on each of our predefined outcomes as the
trials we identified did not report on all of them.
All of the trials reported on acute rejection. Almost all of the tri-
als reported on mortality, graft loss including death, and diabetes
mellitus. Most trials reported on infection, chronic rejection, glu-
cocorticosteroid-resistant rejection, hepatitis C virus recurrence,
and hypertension. Few trials report on cytomegalovirus (CMV)
infection, malignancy, post-transplant lymphoproliferative disor-
der, renal insufficiency, serum creatinine, hyperlipidaemia, serum
cholesterol, and hypercholesterolaemia.None of the trials reported
on adverse events, renal failure requiring dialysis, eGFR, de novo
autoimmune hepatitis, or health-related quality of life.Of the out-
comes for which few trials reported results, many had conflicting
results, as demonstrated by the moderate or significant level of
heterogeneity identified in the analyses.
Our meta-analyses include a variety of immunosuppressive
regimes including different combinations and types of calcineurin
inhibitor, antiproliferative agent, and induction agent and include
the majority of the agents in common use. One induction agent
in common use, alemtuzumab, was not used in any of the trials.
Follow-up in the included trials ranged from six months to 10
years. Our review has very limited evidence for long-term out-
comes for glucocorticosteroid avoidance or withdrawal versus glu-
cocorticosteroid-containing immunosuppression. Long-term ef-
fects are particularly relevant for mortality, graft loss, malignancy,
and post-transplant lymphoproliferative disorder.
The participants included in each of the trials do not fully reflect
the characteristics of the general liver transplant population. None
of the trials included in our review included paediatric participants
and only a limited number included living donors. There is, how-
ever, a variety of concomitant immunosuppressants reflecting the
majority of immunosuppressants in current use as well as a variety
of indications for transplantation.
Quality of the evidence
The quality of our review findings and interpretations is limited
by the number of trials included in the review and the low quality
of certain aspects within the trials. For several of the comparisons
only a very small number of trials could be included, with limited
reporting on the rarer outcomes of interest. These factors are re-
sponsible for the broad confidence intervals representing impreci-
sion in many of our analyses.
Our review is limited by indirectness as it does not include paedi-
atric participants or multiple organ transplant recipients. As well
as this, many of the included studies listed living donors in their
exclusion criteria. For this reason our results cannot be directly
related to these patients.
We explored statistical heterogeneity with the Chi2 test and quan-
tified heterogeneity using the I2 statistic (Higgins 2002). The Chi
2 test is not as effective for situations where few trials with few
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participants are included in a meta-analysis, such as is the case for
our review. This means that many of the outcomes for which we
found a statistically significant difference indicate a moderate or
significant level of heterogeneity. It also means that in situations in
which a non-statistically significant result was shown, it could still
have been influenced by heterogeneity. To overcome this uncer-
tainty, we applied both fixed-effect and random-effects meta-anal-
ysis models, and reported both models whenwe found differences.
In our review, the fixed-effect model identified several statistically
significant differences, which were not identified by the random-
effects model. We considered six outcomes (infection, chronic re-
jection, diabetes mellitus, malignancy, renal insufficiency, and hy-
pertension) to have moderate levels of heterogeneity. We consid-
ered three outcomes (creatinine, cholesterol, and hypercholestero-
laemia) to have significant levels of heterogeneity. The outcomes
with the highest levels of heterogeneity were reported in only a
small number of the included trials. Two of these outcomes were
also continuous outcomes and demonstrated considerable incon-
sistency between the small number of studies in which they were
reported. The heterogeneity identified in the outcomes ’Diabetes
mellitus’ and ’Hypertension’ is due to one trial in the glucocor-
ticosteroid withdrawal sub-analysis (Belli 2001). This trial, with
over 100 participants, which uses rabbit antithymocyte globulin,
also uses the highest cumulative glucocorticosteroid dose in the
glucocorticosteroid-containing group. As glucocorticosteroids are
known to increase the rates of hypertension and diabetes mellitus
(Hatz 1998), we believe that this comparatively high glucocorti-
costeroid dose may be responsible for the inconsistency in these
outcomes. Following the sensitivity analyses, we found that this
trial is also responsible for several of the identified subgroup dif-
ferences.
We detected possible publication bias for hypertension and dia-
betes mellitus. This, however, may be due to the heterogeneity
introduced by one study and when this study is removed from the
analysis, no possibility of publication bias is detected.
Risk of bias is known to be responsible for overestimation of in-
tervention benefits and underestimation of intervention harms in
randomised trials with inadequate methodological quality (Schulz
1995; Moher 1998; Kjaergard 2001; Wood 2008; Lundh 2012;
Savovi 2012; Savovi 2012a). Of the 16 included trials, three
trials (18%) reported adequate generation of the randomisation
sequence, four (24%) reported adequate allocation concealment,
four (24%) reported adequate blinding of participants, four (24%)
reported adequate blinding of outcome assessors, four (24%) ap-
pear to be uninfluenced by incomplete outcome data, 12 (71%)
appear to be free from selective reporting, and we could consider
none to be free from ’other bias’, with reasons being industry spon-
sorship and lack of reporting of required sample size calculation.
Thirteen (76%) appear to be free from early stopping, and ten
(59%) appear to be free from baseline imbalance. We considered
all trials to be at high risk of bias.
Potential biases in the review process
Weperformed a systematic review andmeta-analysis in accordance
with the methodology described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
We followed our peer-reviewed and prepublished protocol with
predefined participants, interventions, comparisons, and out-
comes to avoid biases in the review preparation (Fairfield 2014).
We performed a comprehensive and extensive literature search for
both published and unpublished data from a variety of sources
that met our predefined inclusion criteria. We extracted all avail-
able data and based our meta-analysis on the intention-to-treat
principle. We performed several sub-analyses and sensitivity anal-
yses when appropriate to assess the robustness of our data. We
performed empirical continuity correction for zero event trials.
Our meta-analysis includes larger numbers of randomised clinical
trials on glucocorticosteroid avoidance or withdrawal than other
meta-analyses published on this topic (Segev 2008; Sgourakis
2009; Knight 2011; Gu 2014), improving the quality of the com-
prehensiveness and reducing the risks of imprecision.
Althoughwe contacted various experts in the field and pharmaceu-
tical companies, our search might have missed unpublished data
including trials with negative results. This bias remains difficult to
avoid. We performed linear regression tests to identify asymmetry
in funnel plots in order to identify any possible publication bias.
In addition, we conducted Trial Sequential Analyses for all out-
comes (Wetterslev 2008; Thorlund 2011b; TSA 2011), to test the
robustness of our results. We calculated the diversity-adjusted re-
quired information size (DARIS) on the basis of type I error of
5%, type II error of 20%, and risk reduction of 20%, and adjusted
the information size for diversity (Wetterslev 2009). For all the
Trial Sequential Analyses, the cumulative Z-curve did not cross
trial sequential monitoring boundaries, and the required informa-
tion size was not reached; hence, we cannot exclude random er-
rors regarding our results (play of chance). Except for the outcome
hepatitis C virus (HCV) recurrence, trial sequential monitoring
boundaries were not broken by the cumulative Z-curve, but the
required information size of 435 participants was obtained, mean-
ing that we can exclude a relative risk reduction of 20% or more
regarding HCV recurrence.
Our search was conducted in September 2014 and it is possible
that more recent studies may have been published, which are not
considered in our review.
Agreements and disagreements with other
studies or reviews
Four non-Cochrane meta-analyses on glucocorticosteroid avoid-
ance or withdrawal for liver transplanted patients have been pub-
lished (Segev 2008; Sgourakis 2009; Knight 2011; Gu 2014).
Three of these meta-analyses also include trials in which glucocor-
ticosteroids have been compared with another agent (Segev 2008;
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Sgourakis 2009; Gu 2014), but have reported these as sub-anal-
yses allowing for comparisons with our review. Our review deals
more extensively with risk of bias (systematic errors) and risk of
random errors (play of chance) in the randomised clinical trials
we identified. We have also performed a much larger number of
sub-analyses, and performed Trial Sequential Analyses for all out-
comes.
Overall, the meta-analysis in Segev 2008 found a decrease in
cholesterol, CMV infection, and hepatitis C virus recurrence but
an increase in acute rejectionwith glucocorticosteroid avoidance or
withdrawal, although no difference in mortality, graft loss, hyper-
tension, diabetes mellitus, glucocorticosteroid-resistant rejection,
or infection was observed. Segev 2008 reports statistically signifi-
cantly decreased rates of acute rejection, glucocorticosteroid-resis-
tant rejection, and diabetes mellitus when glucocorticosteroids are
replaced with an alternative immunosuppressive agent. This also
means that overall the rates of acute rejection are decreased when
these trials are assessed in combination with trials where gluco-
corticosteroids are not replaced. One possible reason behind the
comparatively lower rates of diabetes mellitus when glucocorti-
costeroids were replaced rather than withdrawn or avoided is that
the majority of the trials in the review treated acute rejection with
glucocorticosteroids and the higher rates of acute rejection in the
trials where glucocorticosteroids were avoided or withdrawn re-
sults in glucocorticosteroids being administered for rejection treat-
ment. These pulses of glucocorticosteroids may have increased the
rates of diabetes mellitus, masking any benefit gained from not
using them (Hatz 1998). This may also explain why Segev 2008
identified statistically significant reductions in hepatitis C virus re-
currence with glucocorticosteroid avoidance or withdrawal whilst
our review did not. This is because glucocorticosteroid pulses are
known to promote hepatitis C virus recurrence and the higher
rates of acute rejection identified in our review resulted in higher
rates of glucocorticosteroid pulses (Sheiner 1995; Singh 1996).
Overall themeta-analysis in Sgourakis 2009 found a decrease in di-
abetes mellitus, CMV infection, and cholesterol and an increase in
acute rejection with glucocorticosteroid avoidance or withdrawal,
although no difference inmortality, graft loss, glucocorticosteroid-
resistant rejection, chronic rejection, infection, hypertension, re-
nal insufficiency, and mortality in HCV-infected participants was
observed. Sgourakis 2009 also found a decrease in acute rejection
for trials where glucocorticosteroids were replaced by an alterna-
tive immunosuppressive agent.
Overall the meta-analysis in Knight 2011 found a decrease in
diabetes mellitus and no significant increases or decreases in any
other outcomes includingmortality, graft loss, hypertension, acute
rejection, and cholesterol with glucocorticosteroid avoidance or
withdrawal. Knight 2011 contains only seven trials and many
of the analyses have significant levels of heterogeneity. A non-
significant trend was identified in many of the outcomes, but the
low number of trials is likely to have caused wider confidence
intervals, preventing genuine effects from being identified.
Overall, the meta-analysis in Gu 2014 found a decrease in dia-
betes mellitus and CMV infection and no significant increases or
decreases in any other outcomes including mortality, graft loss,
acute rejection, chronic rejection, HCV recurrence, infection, and
hypertension with glucocorticosteroid avoidance or withdrawal.
In accordance with these meta-analyses, we found statistically sig-
nificant decreases in diabetes mellitus and cholesterol as well as a
statistically significant increase in acute rejection with glucocor-
ticosteroid avoidance or withdrawal when applying conventional
meta-analyses. Similarly to the other meta-analyses, we found no
statistically significant changes in mortality, graft loss, chronic re-
jection, and infection. We also found a statistically significant
increase in glucocorticosteroid-resistant rejection and a statisti-
cally significant decrease in hypertension with glucocorticosteroid
avoidance or withdrawal. Reduction in CMV infection and HCV
recurrence was not shown in our review.
A similar meta-analysis has been performed for kidney transplan-
tation (Knight 2010). The review contained 34 trials with a to-
tal of 5637 participants and assessed the benefits and harms of
glucocorticosteroid avoidance or withdrawal in kidney transplant
recipients. Knight 2010 found statistically significant reductions
in hypertension (risk ratio (RR) 0.90, 95% confidence interval
(CI) 0.85 to 0.94), hypercholesterolaemia (RR 0.76, 95%CI 0.67
to 0.87), diabetes mellitus (RR 0.64, 95% CI 0.50 to 0.83), and
creatinine clearance (weightedmean difference (WMD) -3.06 ml/
min, 95% CI -4.66 to -1.45), as well as statistically significant in-
creases in acute rejection (RR 1.56, 95%CI 1.31 to 1.87) and cre-
atinine (WMD 4.24 µmol/L, 95% CI 2.08 to 6.40) with gluco-
corticosteroid avoidance or withdrawal. Knight 2010 observed no
statistically significant differences in mortality, graft loss, or gluco-
corticosteroid-resistant rejection. These findings are very similar
to the findings of our review. The differences observed in Knight
2010 in creatinine in kidney transplant recipients were not found
in our review for liver transplant recipients; this may be due to the
small number of trials included in our review that reported the
serum creatinine.
Knight 2011 also reports the outcomes with glucocorticosteroid
avoidance or withdrawal for heart and pancreas transplantation
although only one trial was identified in each. Esmore 1989 re-
ports statistically significant reductions in the number of antihy-
pertensives required (0.8 ± 0.6 antihypertensives versus 1.3 ± 0.7
antihypertensives) and serum cholesterol (5.4 ± 1.2 mmol/L ver-
sus 6.2 ± 0.9 mmol/L), as well as statistically significant increases
in rejection rates within the first three months from transplanta-
tion (2.3 ± 0.23 episodes per 100 patient days versus 1.5 ± 0.18
episodes per 100 patient days) and glucocorticosteroid-resistant
rejection (26.4% versus 10.2%) with glucocorticosteroid avoid-
ance or withdrawal for heart transplant recipients. Esmore 1989
reports no statistically significant differences in mortality or graft
loss with glucocorticosteroid avoidance or withdrawal. Gruessner
2001 reports a statistically significant reduction in cholesterol and
triglyceride levels in simultaneous pancreas and kidney transplant
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recipients with glucocorticosteroid avoidance or withdrawal (rates
not given). Gruessner 2001 reports no statistically significant dif-
ferences in mortality or graft loss with glucocorticosteroid avoid-
ance or withdrawal.
Possible benefits of glucocorticosteroid avoidance and withdrawal,
including reductions in cardiovascular risk factors, were identified
in this review. However, possible increases in acute rejection and
glucocorticosteroid-resistant rejection were also identified. These
findings are similar to reviews of glucocorticosteroid avoidance
and withdrawal for heart and kidney transplant recipients. Unfor-
tunately the benefits and harms found in the conventional meta-
analysis could not be confirmedbyTrial Sequential Analysesmean-
ing that we cannot exclude random errors.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our review has a low to moderate quality of evidence for the ef-
fects of glucocorticosteroid avoidance or withdrawal. The effects
of glucocorticosteroid avoidance or withdrawal remain uncertain.
Our review showed no clear benefits or harms for mortality, graft
loss including death, infection, chronic rejection, cytomegalovirus
(CMV) infection, hepatitis C virus (HCV) recurrence, malig-
nancy, post-transplant lymphoproliferative disorder, renal insuf-
ficiency, creatinine, hyperlipidaemia, cholesterol, or hypercholes-
terolaemia. Hypertension and diabetes mellitus may be reduced,
but acute rejection and glucocorticosteroid-resistant rejectionmay
be increased with glucocorticosteroid avoidance or withdrawal.
Glucocorticosteroid-free immunosuppression may provide a safe
alternative for liver transplanted patients who are intolerant of glu-
cocorticosteroids. Although we found no statistically significant
difference for mortality or graft loss, these findings should be in-
terpreted with caution.
Implications for research
Given the results of our analysis, it appears that appropriately sized
randomised clinical trials comparing glucocorticosteroid avoid-
ance or withdrawal with glucocorticosteroid-containing immuno-
suppression in liver transplant participants using contemporar-
ily adjunctive immunosuppression are warranted. As episodes of
acute rejection following liver transplantation tend to occur more
frequently in the initial weeks following transplantation (Wiesner
1998), trials investigatingwhether short-termglucocorticosteroids
(first few weeks) reduce the rates of acute rejection without ex-
posing liver transplant recipients to cardiovascular risk factors for
long periods of time appear to be warranted. We feel it may be
of benefit to construct a high-quality three-arm trial comparing
complete postoperative glucocorticosteroid avoidance, short-term
glucocorticosteroids, and long-term glucocorticosteroids.
Our review did not identify any statistically significant increase
or decrease in HCV recurrence with glucocorticosteroid-free im-
munosuppression despite reports that glucocorticosteroids in-
crease the severity of HCV hepatitis (Sheiner 1995; Singh 1996;
Segev 2008; Sgourakis 2009). One possible reason for this is the
higher rate of acute rejection in the glucocorticosteroid-free arm,
which was treated with glucocorticosteroid pulses. Our review
identified a number of studies published between 2009 and 2014
inwhich glucocorticosteroidswere replacedwith an alternative im-
munosuppressant. An updated systematic review and meta-analy-
sis of these studies is merited and may provide additional evidence
for HCV recurrence.
These trials should be conducted with low risk of systematic error
(bias) and low risk of random error (play of chance), and should
follow the ’SPIRIT’ guidelines (SPIRIT 2013a; SPIRIT 2013b)
and ’CONSORT’ guidelines (www.consort-statement.org).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Belli 1998
Methods Trial design: randomised, single-centre clinical trial
Mean follow-up: total: 41 ± 16 months, range 4 to 68 months
Study duration: date of randomisation to last follow-up before 28 February 1997, or
patient death or re-transplantation
Language: English
Type of information: journal article
Judgement on quality: unclear risk of bias
Participants Setting: Ospedale Niguarda Ca’ Granda, Milan, Italy
Allocation of participants: 104 participants, 50 allocated to long-term glucocorticos-
teroids, 54 allocated to short-term glucocorticosteroids
Sex ratio: total: 74 (71%) males, 30 (29%) females
Intervention A: 37 (74%) males, 13 (26%) females
Intervention B: 37 (68.5%) males, 17 (31.5%) females
Mean age: total: not reported
Intervention A: 45 ± 14
Intervention B: 42 ± 16
Indication (no. (%)): (indications reported for whole study population but not inter-
vention groups)
HCV: 42 (40.4%)
HBV: 24 (23.1%)
HBV and HCV: 8 (7.7%)
Alcoholic cirrhosis: 9 (8.7%)
Primary biliary cirrhosis: 6 (5.8%)
Cryptogenic cirrhosis: 8 (7.7%)
Others: 7 (6.7%)
Type of donor: not reported
Inclusion criteria: adult liver transplant recipients
Exclusion criteria: previous liver transplant, previous other organ transplant, multiorgan
transplant
Other: rejection before randomisation (n (%)):
Intervention A: 15 (30%)
Intervention B: 22 (41%)
Interventions Intervention A: methylprednisolone: from day 90, 20 mg per day with 5 mg reductions
every 2 weeks until stopped
Intervention B: methylprednisolone: from day 90, 20 mg per day with 5 mg reductions
every 2 weeks until maintenance dose of 0.1 mg/kg/day continued for duration of study
Concomitant immunosuppression:
Rabbit antithymocyte globulins: 2 mg/kg/day for 5 to 7 days from day 0
Cyclosporine A: 200 to 300 ng/ml (from day 90 for “first months”) and 150 to 250 ng/
ml thereafter
Methylprednisolone: 1000 mg intraoperatively; 200 mg at day 1; 160 mg at day 2; 120
mg at day 3; 80 mg at day 4; 40 mg at day 5; 20 mg at day 6; then continued at the
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Belli 1998 (Continued)
same dose until day 90
Outcomes Patient survival, acute rejection, chronic rejection, hypertension, diabetes, severe bone
complications, infections, serum cholesterol, recurrent hepatitis B, recurrent hepatitis C
and treatment failure
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of randomisation sequence not
described
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants and medical staff
not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors not de-
scribed
Incomplete outcome data (attrition bias) Unclear risk Number of withdrawals and reasons for
withdrawal not reported
Selective reporting (reporting bias) Low risk All relevant outcomes in protocol reported
Other bias Unclear risk No sample size calculation reported
Free of early stopping? Low risk Study not stopped early
Free of baseline imbalance? Unclear risk Baseline characteristics not adequately re-
ported
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Belli 2001
Methods Trial design: randomised, single-centre clinical trial
Mean follow-up: not reported
Intervention A: 22 months
Intervention B: 21 months
Study duration: randomisation fromNovember 1997 toNovember 1999, duration from
randomisation not reported
Language: English
Type of information: journal article
Judgement on quality: high risk of bias
Participants Setting: Ospedale Niguarda Ca’ Granda, Milan, Italy
Allocation of participants: 24 participants, 13 allocated to glucocorticosteroids, 11 allo-
cated to no intervention
Sex ratio: total: not reported
Intervention A: not reported
Intervention B: not reported
Mean age: total: not reported
Intervention A: not reported
Intervention B: not reported
Indication (no. (%)):
HCV cirrhosis: total: 24 (100%), Intervention A: 13 (100%), Intervention B: 11 (100%)
Type of donor: not reported
Inclusion criteria: adult liver transplant recipients with HCV cirrhosis
Exclusion criteria: not reported
Interventions Intervention A: no intervention
Intervention B: glucocorticosteroids for 3 months, doses not reported
Concomitant immunosuppression:
Rabbit antithymocyte globulin: dose not reported, given for 5 days
Azathioprine: dose not reported, given for 1 month
Cyclosporine A: dose not reported
Outcomes Acute rejection, chronic rejection, recurrent hepatitis C, severe cholestasis, ALT, mortal-
ity, portal vein thrombosis
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: not reported
One intervention group was excluded from the meta-analysis as differences between
hepatitis C virus prophylaxis (ribavirin) were noted
Although the overall data for mortality and portal vein thrombosis have been reported,
the exact number of participants in each group with these outcomes is not reported,
therefore these results are not included in the meta-analysis but are included in the best-
worst worst-best analysis
Risk of bias
Bias Authors’ judgement Support for judgement
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Belli 2001 (Continued)
Random sequence generation (selection
bias)
Unclear risk Generation of randomisation sequence not
described
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants and medical staff
not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors not de-
scribed
Incomplete outcome data (attrition bias) Unclear risk Number of withdrawals and reasons for
withdrawal not reported
Selective reporting (reporting bias) High risk Mortality and portal vein thrombosis not
reported fully, outcomes not included in
meta-analysis but included in the best-
worst worst-best analysis
Other bias Unclear risk No sample size calculation reported
Free of early stopping? Low risk Study not stopped early
Free of baseline imbalance? Unclear risk Baseline characteristics not reported
Chen 2007
Methods Trial design: randomised, single-centre clinical trial
Mean follow-up: not reported
Intervention A: not reported
Intervention B: not reported
Study duration: not reported
Language: English
Type of information: journal article
Judgement on quality: unclear risk of bias
Participants Setting: Tongji Hospital, Wuha, Hubei Province, China
Allocation of participants: 54 participants, 28 allocated to Intervention A, 26 allocated
to Intervention B
Sex ratio: total: 53 (98%) males, 1 (2%) female
Intervention A: 27 (96%) males, 1 (4%) female
Intervention B: 26 (100%) males, 0 (0%) female
Mean age: total: not reported
Intervention A: 45.7 ± 3.5
Intervention B: 47.4 ± 6.3
Indication (no. (%)):
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Chen 2007 (Continued)
Hepatocellular carcinoma: total: 54 (100%), Intervention A: 28 (100%), Intervention
B: 26 (100%)
Type of donor: not reported
Inclusion criteria: not reported
Exclusion criteria: not reported
Other:
Cold ischaemia time (minutes): total: not reported, Intervention A: 486.1 ± 97.0, Inter-
vention B: 462.1 ± 88.0
Warm ischaemia time (minutes): total: not reported. Intervention A: 51.5 ± 3.4, Inter-
vention B: 50.8 ± 3.1
Interventions Intervention A: glucocorticosteroids: 3 months rapid taper to stop at 3 months, type of
glucocorticosteroid and doses not reported
Intervention B: glucocorticosteroids: 3 months slow taper with 10 mg/day maintenance
long-term, type of glucocorticosteroid and doses during taper not reported
Concomitant immunosuppression:
Methylprednisolone: 500 mg/day for 3 days
Tacrolimus: aiming for trough doses of 6 to 8 micrograms/ml for 1 year and then 4 to
6 micrograms/ml thereafter
Mycophenolate mofetil: 0.5 to 1 g/day for 1 year and then stopped at 1 year
Outcomes Mortality, acute rejection, creatinine, HCC recurrence, ALT, cholesterol, fasting blood
sugar
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of randomisation sequence not
described
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants and medical staff
not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors not de-
scribed
Incomplete outcome data (attrition bias) Unclear risk Number of withdrawals and reasons for
withdrawal not reported
Selective reporting (reporting bias) Low risk All outcomes appear to be fully reported
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Chen 2007 (Continued)
Other bias Unclear risk No sample size calculation reported
Free of early stopping? Unclear risk Study does not appear to be stopped early
Free of baseline imbalance? Low risk No baseline imbalance
Hu 2008
Methods Trial design: randomised, single-centre clinical trial
Mean follow-up: not reported
Study duration: 6 months from randomisation, randomisation from September 2006 to
March 2008
Language: Mandarin
Type of information: journal article
Judgement on quality: unclear risk of bias
Participants Setting: Organ Transplantation Center, the First Affiliated Hospital of Sun Yat-Sen
University, Guangzhou, China
Allocation of participants: 76 participants, 36 allocated to Intervention A, 40 allocated
to Intervention B
Sex ratio: total: not reported
Intervention A: 5:1 (numbers and % not reported)
Intervention B: 4:1 (numbers and % not reported)
Mean age: total: not reported
Intervention A: 47.6+/-5.8
Intervention B: 45.2+/-6.5
Indication (no. (%)): not reported
Type of donor: deceased donor
Inclusion criteria: first liver transplantation, hepatocellular carcinoma, aged 18 to 65,
deceased donor transplantation and informed consent given
Exclusion criteria: previous liver transplant, multi-organ transplantation, living donor
transplantation, ABO-incompatible transplantation. Primary disease: primary sclerosing
cholangitis or autoimmune hepatitis. Preoperative psychiatric symptoms, gastric ulcer,
use of hormones, diabetes mellitus, hypertension, hyperlipidaemia or malignancy other
than primary hepatocellular carcinoma. Participation in other trials
Interventions Intervention A: no intervention
Intervention B: prednisone from day 8, commencing at 48 mg reduced by 8 mg every 3
days to a maintenance dose of 4 mg by day 26, stopped after 3 months
Concomitant immunosuppression:
Tacrolimus: 3 mg intraoperatively then adjusted postoperatively to 8 to 12 micrograms/
ml
Methylprednisolone: 1000 mg intraoperatively, then 500 mg on day 1, 240 mg on day
2, 200 mg on day 3, 160 mg on day 4, 80 mg on day 5, 40 mg on day 6 and 20 mg on
day 7
Outcomes Mortality, infection, hepatic artery thrombosis, hypertension, diabetes mellitus, hyper-
lipidaemia, neurotoxicity, gastrointestinal complications, other adverse events
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Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: National Nature foundation, China Medical Board in New York,
Nature foundation of Guangzhou province
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of randomisation sequence not
described
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants and medical staff
not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors not de-
scribed
Incomplete outcome data (attrition bias) Unclear risk Number of withdrawals and reasons for
withdrawal not reported
Selective reporting (reporting bias) Low risk All outcomes appear to be fully reported
Other bias Unclear risk No sample size calculation reported
Free of early stopping? Low risk Study not stopped early
Free of baseline imbalance? Low risk Study free from baseline imbalance
Ju 2012
Methods Trial design: randomised, single-centre clinical trial
Mean follow-up: total: not reported; InterventionA: 23months (range: 12 to 36months)
; Intervention B: 21 months (range: 12 to 36 months)
Study duration: 3 years from randomisation, randomisation from September 2006 to
September 2008
Language: English
Type of information: journal article
Judgement on quality: unclear risk of bias
Participants Setting: Organ Transplantation Center, the First Affiliated Hospital of Sun Yat-Sen
University, Guangzhou, China
Allocation of participants: 87 participants, 44 allocated to Intervention A, 43 allocated
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to Intervention B
Sex ratio: total: 64 (78.0%) males, 18 (22.0%) females
Intervention A: not reported
Intervention B: not reported
Mean age: total: 45.7 (range: 26 to 68)
Intervention A: not reported
Intervention B: not reported
Indication (no. (%)): (indications reported for whole study population but not inter-
vention groups)
Hepatocellular carcinoma: total: 36 (43.9%)
HBV cirrhosis: total: 33 (40.2%)
HCV cirrhosis: total: 3 (3.7%)
Alcoholic cirrhosis: total: 3 (3.7%)
Severe hepatitis: total: 6 (7.3%)
Polycystic liver: total: 1 (1.2%)
Type of donor: deceased donor
Inclusion criteria: adult liver transplant recipients
Exclusion criteria: pretransplant infection (except HBV, HCV), marginal grafts (donors
with moderate to severe NAFLD, HBV infection, age > 60, cold ischaemia > 14 hours),
multiorgan transplants, retransplant, partial liver transplant including living donor, lack
of consent, ABO incompatibility
Interventions Intervention A: no intervention
Intervention B: methylprednisolone at 240 mg on day 1 tapered by 10 mg/day for 8
days. Prednisone at 48 mg on day 9 with 8 mg tapered until 4 mg/day by day 26 before
stopping at 3 months
Concomitant immunosuppression:
Methylprednisolone: 500 mg intraoperatively
Basiliximab: 20 mg perioperatively
Tacrolimus: commenced on day 4 at 0.04 mg/kg/day aiming for trough levels of 8 to 12
ng/ml, tapered to 6 to 10 ng/ml by 3 months and 5 to 8 ng/ml by 6 months
Mycophenolate mofetil: as required
Sirolimus: as required
Outcomes Mortality, acute rejection, CMV infection, hypertension, hyperlipidaemia, hypergly-
caemia, infection
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: National High Technology Research and Development Program of
China, the Key Clinical Project from the Ministry of Health, National Natural Science
Foundation of China, special fund for science research by Ministry of Health, the China
Medical Board in New York, the Key Projects in the National Science & Technology
Pillar Program during the Eleventh Five-Year Plan Period of China and Science and
Technology Planning Project of Guangdong Province
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants and medical staff
not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors not de-
scribed
Incomplete outcome data (attrition bias) Unclear risk Number of withdrawals and reasons for
withdrawal not reported
Selective reporting (reporting bias) Low risk All outcomes appear to be fully reported
Other bias Unclear risk No sample size calculation reported
Free of early stopping? Low risk Study not stopped early
Free of baseline imbalance? Unclear risk Baseline characteristics not adequately re-
ported
Lerut 2008
Methods Trial design: randomised, double-blinded, placebo-controlled, single-centre clinical trial
Mean follow-up: total: 48 months (range: 12 to 84 months)
Study duration: 5 years from randomisation
Language: English
Type of information: journal article
Judgement on quality: high risk of bias
Participants Setting: Université Catholique de Louvain Cliniques, Universitaires Saint-Luc, Brussels,
Belgium
Allocation of participants: 156 participants, 78 allocated to Intervention A, 78 allocated
to Intervention B
Sex ratio: total: 98 (62.8%) males, 58 (37.2%) females
Intervention A: 50 (64.1%) males, 28 (35.9%) females
Intervention B: 48 (61.5%) males, 30 (38.5%) females
Mean age: total: not reported
Intervention A: 52.1 ± 13.0
Intervention B: 49.0 ± 12.7
Indication (no. (%)):
HCV cirrhosis: total: 35 (22.4%), Intervention A: 21 (26.9%), Intervention B: 14 (17.
9%)
Cholestatic disease: total: 18 (11.5%), Intervention A: 10 (12.8%), Intervention B: 8
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(10.3%)
Vascular disease: total: 3 (1.9%), Intervention A: 3 (3.8%), Intervention B: 0 (0%)
Metabolic disease: total: 9 (5.8%), Intervention A: 2 (2.6%), Intervention B: 7 (9.0%)
Benign tumour: total: 9 (5.8%), Intervention A: 4 (5.1%), Intervention B: 5 (6.4%)
Hepatocellular carcinoma: total: 37 (23.7%), Intervention A: 19 (24.4%), Intervention
B: 18 (23.1%)
Fulminant failure: total: 22 (14.1%), Intervention A: 9 (11.5%), Intervention B: 13 (16.
7%)
Type of donor: living and deceased donors
Inclusion criteria: adult liver transplant recipient
Exclusion criteria: unfavourable oncological diagnosis, already included in another RCT
Other:
Ischaemia time: Intervention A: 603+/-231 minutes, Intervention B: 682+/-204 minutes
Artificial organ support: total: 11 (7.1%), Intervention A: 10 (12.8%), Intervention B:
1 (1.3%)
Right liver living liver transplantation: total: 9 (5.8%), Intervention A: 0 (0%), Inter-
vention B: 9 (11.5%)
Baseline imbalance: the intervention groups differ significantly in relation to ischaemia
time, living donor liver transplantation and artificial organ support
Interventions Intervention A: matched placebo
Intervention B: methylprednisolone started at 16 mg then tapered every 14 days by 4
mg from day 21 to stop at day 64
Concomitant immunosuppression:
Tacrolimus: aiming for trough level of 5 to 8 ng/ml
Hydrocortisone: 1000 mg intraoperatively
Outcomes Mortality, graft loss, acute rejection, glucocorticosteroid-resistant rejection, chronic re-
jection, infection, bacterial infection, viral infection, fungal infection, CMV infection,
bilirubin, ALT, GGT, post-transplant lymphoproliferative disorder (PTLD), renal insuf-
ficiency, diabetes mellitus, new-onset diabetes after transplantation (NODAT), hyper-
uricaemia, hypercholesterolaemia, hypertension, de novo hypertension, osseo-muscular
pain or fractures, cataract, Karnofsky index, recurrent hepatitis C, intrahepatic biliary
problems
Notes Cross-over between intervention arms: no
Sample size calculation: yes
Sources of funding: the Belgian FRSM, Astellas Pharma, Munchen, Germany
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of randomisation sequence not
described
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded trial, both participants
and medical staff blinded to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All outcome assessors including patholo-
gists blinded
Incomplete outcome data (attrition bias) Low risk No missing outcome data, no withdrawals
Selective reporting (reporting bias) Low risk All outcomes appear to be fully reported
Other bias High risk Study is industry sponsored
Free of early stopping? Low risk Study not stopped early
Free of baseline imbalance? High risk Study not free from baseline imbalance
Llado 2006
Methods Trial design: randomised, multicentre, open-label clinical trial
Mean follow-up: not reported
Study duration: randomisation between April 2001 and September 2004, 6 months
from randomisation (longer for HCV-positive patients)
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: 7 transplantation centres in Spain
Allocation of participants: 198 participants, 102 allocated to Intervention A, 96 allocated
to Intervention B
Sex ratio: total: 155 (78.3%) males, 43 (21.7%) females
Intervention A: 80 (78.4%) males, 22 (21.6%) females
Intervention B: 75 (78.1%) males, 21 (21.9%) females
Mean age: total: not reported
Intervention A: 55.4 ± 8.9
Intervention B: 52.9 ± 9.5
Indication (no. (%)):
HCC: total: 63 (31.8%), Intervention A: 34 (33.3%), Intervention B: 29 (30.2%)
HCV cirrhosis: total: 46 (23.2%), Intervention A: 20 (19.6%), Intervention B: 26 (27.
1%)
HBV cirrhosis: total: 14 (7.1%), Intervention A: 8 (7.8%), Intervention B: 6 (6.3%)
Alcoholic cirrhosis: total: 55 (27.8%), Intervention A: 29 (28.4%), Intervention B: 26
(27.1%)
Other: total: 20 (10.1%), Intervention A: 11 (10.8%), Intervention B: 9 (9.4%)
Type of donor: deceased donor
Inclusion criteria: liver transplant recipients from cadaveric donors aged > 18
Exclusion criteria: exclusion criteria: transplant for fulminant liver disease, retransplant,
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previous or concurrent other organ transplant, autoimmune hepatitis, primary biliary
cirrhosis, HIV infection, likely poor compliance
Other:
Disease status:
HCV-positive recipient: total: 88 (44.4%), Intervention A: 45 (44.1%), Intervention B:
43 (44.8%)
CMV-positive recipient: total: 165 (83.3%), Intervention A: 83 (81.3%), Intervention
B: 82 (85.4%)
Diabetes mellitus pretransplant: total: 49 (24.7%), Intervention A: 28 (27.5%), Inter-
vention B: 21 (21.9%)
Glycated haemoglobin pretransplant: total: not reported, Intervention A: 4.9 ± 1.5,
Intervention B: 4.6 ± 0.9
Hypertension pretransplant: total: 17 (8.6%), Intervention A: 11 (10.8%), Intervention
B: 6 (6.3%)
Serum cholesterol pretransplant: total: not reported, Intervention A: 3.8 ± 1.2, Inter-
vention B: 4.0 ± 1.3 (%)
Interventions Intervention A: no intervention
Intervention B: hydrocortisone: 500 mg intraoperatively, then 0.5 mg/kg/day for days 1
to 5, 0.25 mg/kg/day for days 6 to 30, 0.15 mg/kg/day for days 31 to 90, no intervention
from day 91
Concomitant immunosuppression:
Basiliximab: 20 mg intraoperatively
Cyclosporine A: started at 10 mg/kg/day aiming for trough levels of 800 to 1200 ng/ml
Outcomes Mortality, graft loss, acute rejection, glucocorticosteroid-resistant rejection, chronic re-
jection, adverse events, infections, bacterial infection, viral infection, fungal infection,
CMV infection, HSV infection, metabolic decompensations, diabetes mellitus, hyper-
tension, recurrent hepatitis C, treatment failure, renal failure, neurological deficit, gin-
gival hypertrophy, de novo malignancy, cholesterol, triglyceride, days until rejection
Notes Cross-over between intervention arms: no
Sample size calculation: yes
Sources of funding: Novartis Pharma, TV3 Marathon Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of randomisation sequence not
described
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and medical staff
not performed
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding of outcome assessors not per-
formed
Incomplete outcome data (attrition bias) Unclear risk Number of withdrawals and reasons for
withdrawal not reported
Selective reporting (reporting bias) Low risk All outcomes appear to be fully reported
Other bias High risk Study is partly industry sponsored
Free of early stopping? Low risk Study not stopped early
Free of baseline imbalance? Low risk Study free from baseline imbalance
Margarit 2005
Methods Trial design: randomised, single-centre clinical trial
Mean follow-up: 44 months (range: 3 to 60)
Study duration: randomisation from October 1998 to September 2000, 5 years from
randomisation
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: Liver Transplantation Unit, Hospital General Vall Hebron, Barcelona, Spain
Allocation of participants: 63 participants, 33 allocated to Intervention A, 30 allocated
to Intervention B
Sex ratio: total: 43 (71.7%) males, 17 (28.3%) females
Intervention A: 25 (78.1%) males, 7 (21.9%) females
Intervention B: 18 (64.3%) males, 10 (35.7%) females
Mean age: total: not reported
Intervention A: 56 ± 8
Intervention B: 57 ± 7
Indication (no. (%)):
HCV cirrhosis: total: 35 (58.3%), Intervention A: 15 (46.9%), Intervention B: 20 (71.
4%)
Alcoholic cirrhosis: total: 16 (26.7%), Intervention A: 11 (34.4%), Intervention B: 5
(17.9%)
HBV cirrhosis: total: 5 (8.3%), Intervention A: 2 (6.3%), Intervention B: 3 (10.7%)
Cryptogenic cirrhosis: total: 2 (3.3%), Intervention A: 2 (6.3%), Intervention B: 0 (0%)
Haemochromatosis: total: 2 (3.3%), Intervention A: 2 (6.3%), Intervention B: 0 (0%)
Type of donor: not reported
Inclusion criteria: first elective liver transplant, informed consent
Exclusion criteria: renal failure, preoperative steroid consumption
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Interventions Intervention A: no intervention
Intervention B: methylprednisolone: 100 mg twice daily tapered to 20 mg/day by day 6
and tapered to complete stop at 3 months if possible
Concomitant immunosuppression:
Tacrolimus: 0.05 mg/kg twice daily aiming for trough levels of 10 to 15 ng/ml for “a
few weeks” and 8 to 12 ng/ml thereafter
Outcomes Mortality, infection, bacterial infection, viral infection, fungal infection, toxicity, HCV
recurrence, severity of recurrent hepatitis C, renal insufficiency, de novo hypertension,
de novo diabetes mellitus, dyslipidaemia, neurological complications, diarrhoea
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: Fujisawa GM
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of randomisation sequence not
described
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and medical staff
not performed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding of pathologists performed; blind-
ing of all other outcome assessors not per-
formed
Incomplete outcome data (attrition bias) High risk 3 patients removed from analysis follow-
ing randomisation following data-depen-
dent processes not described in exclusion
criteria
Selective reporting (reporting bias) Low risk All outcomes appear to have been reported
Other bias Unclear risk No sample size calculation reported
Free of early stopping? Low risk Study not stopped early
Free of baseline imbalance? High risk Baseline imbalance observed in recipient
HCV cirrhosis and donor graft steatosis
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Methods Trial design: randomised, double-blinded, placebo-controlled, single-centre clinical trial
Mean follow-up: not reported as all patients followed up at 5 years, except deaths
Study duration: 5 years from randomisation, randomisation from February 2000 to July
2004
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: Johannes Gutenberg University Mainz Hospital, Langenbeckstrasse 1, Mainz,
Germany
Allocation of participants: 110 participants, 54 allocated to Intervention A, 56 allocated
to Intervention B
Sex ratio: total: 74 (67.3%) males, 36 (32.7%) females
Intervention A: 36 (66.7%) males, 18 (33.3%) females
Intervention B: 38 (67.9%) males, 18 (32.1%) females
Mean age: total: not reported
Intervention A: 53.5 ± 8.3
Intervention B: 53.6 ± 10.4
Indication (no. (%)):
Hepatocellular carcinoma: total: 40 (36.4%), Intervention A: 19 (35.2%), Intervention
B: 21 (37.5%)
HBV cirrhosis: total: 19 (17.3%), Intervention A: 7 (13.0%), Intervention B: 12 (21.
4%)
HCV cirrhosis: total: 31 (28.2%), Intervention A: 15 (27.8%), Intervention B: 16 (28.
6%)
Alcoholic cirrhosis: total: 37 (33.6%), Intervention A: 21 (38.9%), Intervention B: 16
(28.6%)
Primary biliary cirrhosis or primary sclerosing cholangitis: total: 8 (7.3%), Intervention
A: 5 (9.3%), Intervention B: 3 (5.4%)
Type of donor: deceased donor after brain death (DBD) or living-related donor
Inclusion criteria: orthotopic liver transplant recipients aged > 18 receiving transplant
for any indication, recipients of whole or partial liver grafts from brain dead donors as
well as living-related donors, oral informed consent
Exclusion criteria: previous organ transplants including liver retransplantation; initial,
sequential or parallel therapy with other immunosuppressive drugs besides the study
protocol; corticosteroid therapy within 6 months before transplantation; HIV infection;
pregnancy and breast feeding; allergy to or intolerance of study medication; participation
in another clinical study
Other:
Partial graft: total: 6 (5.5%), Intervention A: 3 (5.6%), Intervention B: 3 (5.4%)
Deceased donor: total: 100 (90.9%), Intervention A: 50 (92.6%), Intervention B: 50
(89.3%)
Living donor: total: 10 (9.1%), Intervention A: 4 (7.4%), Intervention B: 6 (10.7%)
Interventions Intervention A: matched placebo
Intervention B: methylprednisolone: 12 mg/day from day 15 to 60, 8 mg/day from day
61 to 180 then tapered to stop over 2 weeks
Concomitant immunosuppression:
Tacrolimus: initial dose of 0.01 mg/kg/day with target trough levels 10 to 15 ng/ml for
days 0 to 42 and 5 to 10 ng/ml thereafter
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Methylprednisolone: 1000 mg before reperfusion, 100 mg on day 1, 75 mg on day 2,
48 mg on day 3 and 4, 36 mg on day 5 and 6, 24 mg on day 7 and 8, 16 mg on days 9
to 13 and 12 mg on day 14
Outcomes Mortality, graft loss, acute rejection, time to first rejection, severity of rejection, recurrent
acute rejection, glucocorticosteroid-resistant rejection, chronic rejection, hypertension,
diabetes mellitus, infection, CMV infection, post-transplant lymphoproliferative dis-
order, hypercholesterolaemia, hypertriglyceridaemia, osteoporosis, cholesterol, triglyc-
eride, creatinine, HDL cholesterol, LDL cholesterol, fasting blood glucose, neurological
toxicity, abnormal liver function, abnormal renal function
Notes Cross-over between intervention arms: no
Sample size calculation: yes
Sources of funding: Astellas Pharma Munich, Germany
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of randomisation sequence not
described
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded trial, both participants
and medical staff blinded to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All outcome assessors including patholo-
gists blinded
Incomplete outcome data (attrition bias) Low risk No missing outcome data, no withdrawals
Selective reporting (reporting bias) Low risk All outcomes appear to be fully reported
Other bias High risk Study is industry sponsored
Free of early stopping? Low risk Study not stopped early
Free of baseline imbalance? Low risk Study free from baseline imbalance
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Methods Trial design: randomised, multicentre, double-blinded, placebo-controlled clinical trial
Mean follow-up: not reported
Study duration: 1 year from randomisation, randomisation from December 1999 to
August 2001
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: 7 transplantation centres in France
Allocation of participants: 174 participants, 90 allocated to Intervention A, 84 allocated
to Intervention B
Sex ratio: total: 124 (71.3%) males, 50 (28.7%) females
Intervention A: 68 (75.6%) males, 22 (24.4%) females
Intervention B: 56 (66.7%) males, 28 (33.3%) females
Mean age: total: not reported
Intervention A: 52 ± 10.4
Intervention B: 52.7 ± 8.8
Indication (no. (%)):
Alcoholic cirrhosis: total: 84 (48.3%), Intervention A: 45 (50.0%), Intervention B: 39
(46.4%)
HCV cirrhosis: total: 26 (14.9%), Intervention A: 12 (13.3%), Intervention B: 14 (16.
7%)
HBV cirrhosis: total: 12 (6.9%), Intervention A: 8 (8.9%), Intervention B: 4 (4.8%)
Primary biliary cirrhosis: total: 11 (6.3%), Intervention A: 6 (6.7%), Intervention B: 5
(6.0%)
Hepatocellular carcinoma: total: 11 (6.3%), Intervention A: 5 (5.6%), Intervention B:
6 (7.1%)
Primary sclerosing cholangitis: total: 4 (2.3%), Intervention A: 1 (1.1%), Intervention
B: 3 (3.6%)
Other: total: 26 (14.9%), Intervention A: 13 (14.4%), Intervention B: 13 (15.5%)
Type of donor: deceased donor
Inclusion criteria: adult liver transplant recipients undergoing first cadaveric liver trans-
plant
Exclusion criteria: primary graft dysfunction, early retransplantation (before randomisa-
tion), renal insufficiency (creatinine > 200 ìmol/L), uncontrolled infection, multiorgan
failure, cardiac arrest and presence of adenocarcinoma
Interventions Intervention A: equivalent placebo
Intervention B: prednisone: started on day 8 (dose and duration not reported)
Concomitant immunosuppression:
Basiliximab: 20 mg on day 0 and day 4
Cyclosporine A: started within 24 hours of transplant aiming for trough levels of 200 to
400 ng/ml from day 0 to 3 months and tapered to 150 to 300 ng/ml
Methylprednisolone: 500 mg intraoperatively, 200 mg on day 1, which was tapered to
reach 20 mg on day 7
Outcomes Mortality, graft loss, acute rejection, diabetes mellitus, recurrent hepatitis C, multiorgan
failure, sepsis, intraabdominal haemorrhage, unsatisfactory therapeutic effect, hypertri-
chosis, surgical complications, renal failure, adverse events, CMV infection, CMV dis-
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ease, infections, de novo malignancy, neurological complications, psychiatric complica-
tions, gastrointestinal disorders
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: Novartis Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of randomisation sequence not
described
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded trial, both participants
and medical staff blinded to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All outcome assessors including patholo-
gists blinded
Incomplete outcome data (attrition bias) Unclear risk Number of withdrawals and reasons for
withdrawal not reported
Selective reporting (reporting bias) Low risk All outcomes appear to be fully reported
Other bias High risk Study is industry sponsored
Free of early stopping? Low risk Study not stopped early
Free of baseline imbalance? Low risk Study is free from baseline imbalance
Pelletier 2013
Methods Trial design: randomised, single-centre, open-label clinical trial
Mean follow-up: 2095 days ± 117
Study duration: 7 years, randomisation from June 2002 to May 2005
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: Section of Transplant Surgery, University of Michigan, Michigan, USA
Allocation of participants: 100 participants, 50 allocated to Intervention A, 50 allocated
to Intervention B
Sex ratio: total: 76 (76%) males, 24 (24%) females
61Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pelletier 2013 (Continued)
Intervention A: 38 (76%) males, 12 (24%) females
Intervention B: 38 (76%) males, 12 (24%) females
Mean age: total: not reported
Intervention A: 54 ± 1
Intervention B: 56 ± 1
Indication (no. (%)): (some patients reported as having multiple indications)
HCV cirrhosis: total: 54 (54%), Intervention A: 31 (62%), Intervention B: 23 (46%)
Alcoholic cirrhosis: total: 42 (42%), Intervention A: 19 (38%), Intervention B: 23 (46%)
Hepatocellular carcinoma: total: 20 (20%), Intervention A: 9 (18%), Intervention B: 11
(22%)
Primary biliary cirrhosis or primary sclerosing cholangitis: total: 6 (6%), Intervention
A: 1 (2%), Intervention B: 5 (10%)
Cryptogenic cirrhosis: total: 15 (15%), InterventionA: 8 (16%), InterventionB: 7 (14%)
Type of donor: not reported
Inclusion criteria: all consecutive, consenting participants undergoing liver transplanta-
tion at the University of Michigan between June 2002 and May 2005
Exclusion criteria: participants aged < 18 years, multiple organ recipients and participants
who required post-transplant steroid therapy for an indication other than prevention of
rejection, such as autoimmune hepatitis or inflammatory bowel disease
Other:
BMI (kg/m2): total: not reported, Intervention A: 30 ± 1, Intervention B: 29 ± 1
Pretransplant antihypertensive: total: 73 (73%), Intervention A: 36 (72%), Intervention
B: 37 (74%)
Pretransplant diabetes mellitus: total: 32 (32%), Intervention A: 20 (40%), Intervention
B: 12 (24%)
Pretransplant coronary artery disease: total: 8 (8%), Intervention A: 5 (10%), Interven-
tion B: 3 (6%)
Pretransplant haemodialysis: total: 4 (4%), Intervention A: 3 (6%), Intervention B: 1
(2%)
MELD score: total: not reported, Intervention A: 16 ± 1, Intervention B: 18 ± 1
Warm ischaemia time (minutes): total: not reported, Intervention A: 64 ± 7, Intervention
B: 54 ± 3
Cold ischaemia time (minutes): total: not reported, Intervention A: 518 ± 34, Interven-
tion B: 518 ± 24
Donor age: total: Intervention A: 38 ± 3, Intervention B: 37 ± 2
Donor sex ratio: total: 68 (68%) males, 32 (32%) females; Intervention A: 31 (62%)
males, 19 (38%) females; Intervention B: 37 (74%) males, 13 (26%) females
Donor ethnicity: total: 80 (80%) white, 20 (20%) non-white; Intervention A: 39 (78%)
white, 11 (22%) non-white; Intervention B: 41 (82%) white, 9 (18%) non-white
Donor death from stroke: total: 50 (50%), Intervention A: 25 (50%), Intervention B:
25 (50%)
Donor CMV positive: total: 67 (67%), Intervention A: 35 (70%), Intervention B: 32
(64%)
Interventions Intervention A: no intervention
Intervention B:
Dexamethasone: 50 mg intraoperatively
Prednisone: 3- to 6-month taper (dose not reported)
Concomitant immunosuppression:
Tacrolimus: started within 24 hours aiming for trough levels of 10 to 15 ng/ml for days
62Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pelletier 2013 (Continued)
0 to 30, 8 to 12 ng/ml days 31 to 60, 4 to 8 ng/ml from day 61 (tacrolimus withheld
until day 4 in patients who received basiliximab induction)
MMF: dose and timings not reported
Basiliximab: intraoperatively and day 4 (dose not reported) given to 12 (24%) patients
receiving Intervention A and 13 (26%) patients receiving Intervention B
Outcomes Mortality, graft loss, acute rejection, time to first rejection, chronic rejection, recurrent
hepatitis C, primary non-function, hepatic artery thrombosis, hepatic vein or IVC steno-
sis, biliary complications, postoperative acute renal failure, postoperative chronic renal
failure, duration of high dependency stay, reoperation for bleeding, retransplantation,
infections, surgical site infection, pneumonia, urinary tract infection, septicaemia, peri-
tonitis, BMI, cholesterol, HDL, LDL, triglycerides, creatinine, diabetes mellitus, hyper-
tension
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: Astellas Pharma Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of randomisation sequence not
described
Allocation concealment (selection bias) Low risk Study used “closed envelope system”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and medical staff
not performed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding of outcome assessors not per-
formed
Incomplete outcome data (attrition bias) Unclear risk Number of withdrawals and reasons for
withdrawal not reported
Selective reporting (reporting bias) Low risk All outcomes appear to be fully reported
Other bias High risk No sample size calculation reported, study
is industry sponsored
Free of early stopping? Low risk Study not stopped early
Free of baseline imbalance? Low risk Study is free from baseline imbalance
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Methods Trial design: randomised, single-centre, open-label clinical trial
Mean follow-up: 64.4 months (range: 10.6 to 79.6)
Study duration: randomisation from February 2006 and November 2007
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: Division of Transplantation, Department of Surgery, Thomas Jefferson Univer-
sity, Philadelphia, USA
Allocation of participants: 40 participants, 20 allocated to Intervention A, 20 allocated
to Intervention B
Sex ratio: total: 25 (62.5%) males, 15 (37.5%) females
Intervention A: 12 (60%) males, 8 (40%) females
Intervention B: 13 (65%) males, 7 (35%) females
Mean age: total: not reported
Intervention A: 48.1 ± 4.3
Intervention B: 45.5 ± 3.5
Indication (no. (%)):
HCV cirrhosis: total: 25 (62.5%), Intervention A: 11 (55.0%), Intervention B: 14 (70.
0%)
HBV cirrhosis: total: 4 (10.0%), Intervention A: 2 (10.0%), Intervention B: 2 (10.0%)
Primary sclerosing cholangitis: total: 2 (5.0%), Intervention A: 2 (10.0%), Intervention
B: 0 (0%)
Hepatocellular carcinoma: total: 21 (52.5%), Intervention A: 10 (50.0%), Intervention
B: 11 (55.0%)
Alcoholic cirrhosis: total: 9 (22.5%), Intervention A: 3 (15.0%), Intervention B: 6 (30.
0%)
Non-alcoholic steatohepatitis: total: 1 (2.5%), Intervention A: 1 (5.0%), Intervention
B: 0 (0%)
Budd-Chiari syndrome: total: 1 (2.5%), Intervention A: 0 (0%), Intervention B: 1 (5.
0%)
Cryptogenic cirrhosis: total: 3 (7.5%), Intervention A: 2 (10.0%), Intervention B: 1 (5.
0%)
Type of donor: deceased donors
Inclusion criteria: first adult liver transplant, age 18 to 72, cold ischaemic time < 20
hours
Exclusion criteria: positive pregnancy test, previous organ transplant, multiple organ
transplant recipients, women of childbearing potential not using the prescribed contra-
ceptive methods, known sensitivity to basiliximab or class of basiliximab, participants
with severe medical condition(s) that in the view of the investigator prohibits partici-
pation in the study, and use of any other investigational agent within 30 days prior to
enrolment
Other:
Pretransplant MELD: total: not reported, Intervention A: 23.2 ± 1.5, Intervention B:
24.4 ± 2.0
Interventions Intervention A: no intervention
Intervention B: methylprednisolone: 1000 mg intraoperatively, then tapered to 50 mg
6-hourly on day 1, 40 mg 6-hourly on day 2, 30 mg 6-hourly on day 3, 20 mg 6-hourly
on day 4, 20 mg 12-hourly on day 5 and then 20 mg once daily, tapered until stop at 6
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months
Concomitant immunosuppression:
Tacrolimus: started at 0.1 mg/kg aiming for 8 to 12 ng/ml for 1 month and then 5 to 8
ng/ml thereafter
Mycophenolate mofetil: 1000 mg every 12 hours via nasogastric tube until tolerating
oral medication after which 720 mg enteric-coated mycophenolate sodium twice daily
orally for 3 months
Basiliximab: 20 mg intraoperatively and on day 4
Prophylaxis:
Ganciclovir or valganciclovir: 450 mg once daily for at least 3 months
Trimethoprim sulfa: 3 times per week, dose and duration not reported
Nystatin swish and swallow: 3 times daily, dose and duration not reported
Outcomes Mortality, graft loss, acute rejection, infection, CMV infection, recurrent hepatitis C,
severity of HCV recurrence, diabetes mellitus, hypertension, weight, cholesterol, mean
arterial pressure, fasting blood glucose, ALT, AST, bilirubin
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: Novartis Corporation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and medical staff
not performed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding of outcome assessors not per-
formed
Incomplete outcome data (attrition bias) Low risk No withdrawals
Selective reporting (reporting bias) Low risk All outcomes appear to be fully reported
Other bias High risk No sample size calculation reported; study
is industry sponsored
Free of early stopping? Low risk Study not stopped early
Free of baseline imbalance? Low risk Study is free from baseline imbalance
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Methods Trial design: randomised, single-centre, open-label clinical trial
Mean follow-up: 31 ± 7 months
Study duration: not reported
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: IRCCS Ospedale Maggiore, Milan, Italy
Allocation of participants: 30 participants, 18 allocated to Intervention A, 12 allocated
to Intervention B
Sex ratio: total: 21 (70%) males, 9 (30%) females
Intervention A: 13 (72.2%) males, 5 (27.8%) females
Intervention B: 8 (66.7%) males, 4 (33.3%) females
Mean age: total: not reported
Intervention A: 50.4 ± 8.9
Intervention B: 49.7 ± 4.6
Indication (no. (%)):
HCV or HBV cirrhosis: total: 21 (70.0%), Intervention A: 14 (77.8%), Intervention B:
7 (58.3%)
Alcoholic cirrhosis: total: 3 (10.0%), Intervention A: 1 (5.6%), Intervention B: 2 (16.
7%)
Haemochromatosis: total: 2 (6.7%), Intervention A: 1 (5.6%), Intervention B: 1 (8.3%)
Primary biliary cirrhosis: total: 1 (3.3%), Intervention A: 1 (5.6%), Intervention B: 0
(0.0%)
Acute liver failure: total: 1 (3.3%), Intervention A: 1 (5.6%), Intervention B: 0 (0.0%)
Cryptogenic cirrhosis: total: 1 (3.3%), Intervention A: 0 (0.0%), Intervention B: 1 (8.
3%)
Polycystic liver disease: total: 1 (3.3%), Intervention A: 0 (0.0%), Intervention B: 1 (8.
3%)
Type of donor: not reported
Inclusion criteria: not reported
Exclusion criteria: not reported
Other:
Hepatocellular carcinoma: total: 14 (46.7%), Intervention A: 12 (66.7%), Intervention
B: 2 (16.7%)
Interventions Intervention A: methylprednisolone: no intervention
Intervention B: 1000 mg intraoperatively then 200 mg/day tapered to 40 mg/day at day
5, 20 mg on day 6 then tapered to stop at 3 months
Concomitant immunosuppression:
Tacrolimus: started at 0.1 mg/kg aiming for trough levels of 10 to 15 ng/ml for 2 weeks
then 8 to 10 ng/ml thereafter
Mycophenolate mofetil: 750 mg twice daily for 1 month, 500 mg twice daily thereafter
Outcomes Mortality, surgical complications, tacrolimus levels, MMF levels, acute rejection, graft
loss, infections, diarrhoea, “peptic symptoms”, impaired renal function, leukopenia,
thrombocytopenia, anaemia, neurotoxicity, diabetes mellitus, hypertension
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Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of randomisation sequence not
described
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and medical staff
not performed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding of outcome assessors not per-
formed
Incomplete outcome data (attrition bias) Unclear risk Number of withdrawals and reasons for
withdrawal not reported
Selective reporting (reporting bias) High risk Not all specified outcomes appear to be re-
ported
Other bias Unclear risk No sample size calculation reported
Free of early stopping? High risk Study stopped early due to data dependent
process (interim analysis)
Free of baseline imbalance? High risk Significantly increased rates of pretrans-
plant hepatocellular carcinoma in Interven-
tion A
Studenik 2005
Methods Trial design: randomised, single-centre clinical trial
Mean follow-up: 13 months (range: 2 to 23)
Study duration: not reported
Language: English
Type of information: abstract
Judgement on quality: unclear risk
Participants Setting: Brno, Czech Republic
Allocation of participants: 39 participants, 19 allocated to Intervention A, 20 allocated
to Intervention B
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Sex ratio: total: not reported
Intervention A: not reported
Intervention B: not reported
Mean age: total: not reported
Intervention A: not reported
Intervention B: not reported
Indication (no. (%)): not reported
Type of donor: not reported
Inclusion criteria: not reported
Exclusion criteria: not reported
Other: baseline characteristics reported as comparable
Interventions Intervention A: no intervention
Intervention B: 9-month glucocorticosteroid taper (dose, duration and type of gluco-
corticosteroid medication not reported)
Concomitant immunosuppression:
Tacrolimus: dose and duration not reported
Mycophenolate mofetil: dose and duration not reported
Hydrocortisone: 500 mg intraoperatively
Daclizumab: 1 mg/kg intraoperatively then 1 mg/kg 2 to 7 days later depending on
initial dose effect on CD25 expression on peripheral T-lymphocytes
Outcomes Mortality, graft loss, acute rejection, hypertension, diabetes mellitus, CMV infection,
leucopenia and CD25 expression on peripheral T lymphocytes
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of randomisation sequence not
described
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants and medical staff
not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors not de-
scribed
Incomplete outcome data (attrition bias) Unclear risk Number of withdrawals and reasons for
withdrawal not reported
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Selective reporting (reporting bias) Unclear risk Study protocol not available and results
only published in abstract
Other bias Unclear risk No sample size calculation reported
Free of early stopping? Unclear risk Study only published in abstract
Free of baseline imbalance? Low risk Study is reported as being free frombaseline
imbalance
Tisone 1999
Methods Trial design: randomised, single-centre, open-label clinical trial
Mean follow-up: 108 ± 4 months
Study duration: 10 years from randomisation
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: Ospedale S. Eugenio, Piazzale dell’Umanesimo, Rome, Italy
Allocation of participants: 45 participants, 22 allocated to Intervention A, 23 allocated
to Intervention B
Sex ratio: total: 34 (75.6%) males, 11 (24.4%) females
Intervention A: 16 (72.7%) males, 6 (26.1%) females
Intervention B: 18 (72%) males, 5 (21.7%) females
Mean age: total: not reported
Intervention A: 49.0 ± 9.8
Intervention B: 50.5 ± 6.2
Indication (no. (%)):
HCV cirrhosis: total: 15 (33.3%), Intervention A: 8 (36.4%), Intervention B: 7 (30.
4%)
HBV cirrhosis: total: 13 (28.9%), Intervention A: 7 (31.8%), Intervention B: 6 (26.1%)
Alcoholic cirrhosis: total: 6 (13.3%), Intervention A: 2 (9.1%), Intervention B: 4 (17.
4%)
Cryptogenic cirrhosis and others: total: 11 (24.4%), Intervention A: 5 (22.7%), Inter-
vention B: 6 (26.1%)
Type of donor: not reported
Inclusion criteria: adult liver transplant recipients (> 20 years of age and < 62), HBsAg-
positive participants were only considered for inclusion if repeatedlyHBV-DNAnegative
Exclusion criteria: positive HIV serology, positive for IgM anti-cytomegalovirus, HBV-
DNA-positive participants
Other:
Donor age: total: not reported, Intervention A: 38.3 ± 14, Intervention B: 35.3 ± 16
Donor sex ratio: total: 30 (66.7%) male, 15 (33.3%) female; Intervention A: 13 (59.
1%) males, 9 (39.1%) females; Intervention A: 17 (73.9%) males, 6 (26.1%) females
Cold ischaemia time (hours): total: not reported, Intervention A: 6.2+/-2.8, Intervention
B: 6.4+/-1.8
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Possible selective outcome reporting: hypertension is not reported in any of the relevant
publications
Interventions Intervention A:
No intervention
Intervention B:
Methylprednisolone: 20 mg/day (duration not reported)
Prednisone: (starting from withdrawal of methylprednisolone) 20 mg/day until day 30
then tapered “gradually” to 5 mg/day and stopped at 3 months
Concomitant immunosuppression:
Cyclosporine A: aiming for trough levels of 350 to 450 ng/ml for “the first few months”
then 250 to 350 ng/ml thereafter
Azathioprine: 1 to 1.5 mg/day (duration not reported)
Outcomes Mortality, graft loss, acute rejection, primary non-function, poor initial function, normal
function, chronic rejection, infection, CMV infection, recurrent hepatitis C, renal failure
(requiring dialysis), AST, bilirubin, alkaline phosphatase, GGT, creatinine, cyclosporine
serum levels, time in intensive treatment unit, time in hospital, glucose, cholesterol
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and medical staff
not performed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding of outcome assessors not per-
formed
Incomplete outcome data (attrition bias) Unclear risk Number of withdrawals and reasons for
withdrawal not reported
Selective reporting (reporting bias) Unclear risk Study does not report hypertension
Other bias Unclear risk No sample size calculation reported
Free of early stopping? Low risk Study not stopped early
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Free of baseline imbalance? Low risk Study free from baseline imbalance
Vivarelli 2007
Methods Trial design: randomised, multicentre, open-label clinical trial
Mean follow-up: 841 days (range: 130 to 1376)
Study duration: not reported
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: 2 transplantation centres in Italy
Allocation of participants: 47 participants, 22 allocated to Intervention A, 25 allocated
to Intervention B
Sex ratio: total: not reported
Intervention A: not reported
Intervention B: not reported
Mean age: total: not reported
Intervention A: 58.9 (range: 43 to 66)
Intervention B: 57.2 (range: 41 to 67)
Indication (no. (%)):
HCV cirrhosis: total: 47 (100.0%), Intervention A: 22 (100.0%), Intervention B: 25
(100.0%)
Type of donor: deceased donors
Inclusion criteria: HCV positive first-time whole liver recipients from deceased donors
Exclusion criteria: HBsAg-positive, previous transplant, partial grafts, living donors
Other:
HCV-RNA titres (Meq/ml): total: not reported, Intervention A: 0.755 (range: < 0.003
to 4.3), Intervention B: 0.765 (< 0.003 to 8.04)
MELD score: total: not reported, Intervention A: 16 (range: 8 to 25), Intervention B:
15 (range: 7 to 28)
Pretransplant diabetes mellitus: total: 11 (23.4%), Intervention A: 5 (22.7%), Interven-
tion B: 6 (24.0%)
Interventions Intervention A: prednisone: tapered from 25 mg/day to 15 mg/day from days 6 to day
30, 15 mg/day on days 31 to 45, 10 mg/day on days 46 to 60, 5 mg/day on days 61 to
75, 2.5 mg/day on days 76 to 90) and stopped at day 91
Intervention B: prednisone: 25 mg/day on day 6 tapered to 15 mg/day by day 31, 15
mg/day on days 31 to 90, 10 mg/day on days 91 to day 180, 7.5 mg/day on days 181
to 270, 5 mg/day from day 271 to the end of the first postoperative year, 2.5 mg for the
second postoperative year and stopped at the end of the second postoperative year
Concomitant immunosuppression:
Methylprednisolone: intraoperatively and on days 1 to 5 (dose not reported)
Tacrolimus: aiming for trough level of 5 to 15 ng/ml for the first 3 months and then 5
to 10 ng/ml thereafter
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Outcomes Mortality, graft loss, acute rejection, treatment failure, recurrent hepatitis C, HCV-
RNA levels, Scheuer fibrosis, acute rejection requiring steroids, acute rejection requiring
multiple steroids, need for antiviral treatment (anti-HCV), diabetes mellitus, tacrolimus
levels
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: Astellas Pharma Italia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of randomisation sequence not
described
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and medical staff
not performed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding of outcome assessors not per-
formed
Incomplete outcome data (attrition bias) Low risk Missing data unlikely to affect outcome re-
sults
Selective reporting (reporting bias) Low risk All outcomes appear to be fully reported
Other bias High risk No sample size calculation reported; study
industry sponsored
Free of early stopping? Low risk Study not stopped early
Free of baseline imbalance? Low risk Study is free from baseline imbalance
ABO: blood group
ALT: alanine aminotransferase
AST: aspartate aminotransferase
BMI: body mass index
CMV: cytomegalovirus
GGT: gamma-glutamyl transferase
HBsAg: hepatitis B surface antigen
HBV: hepatitis B virus
HCC: hepatocellular carcinoma
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HCV: hepatitis C virus
HDL: high density lipoprotein
HSV: herpes simplex virus
IVC: inferior vena cava
LDL: low density lipoprotein
MELD: model for end-stage liver disease
MMF: mycophenolate mofetil
NAFLD: non-alcoholic fatty liver disease
RCT: randomised clinical trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Benitez 2010 Randomised clinical trial comparing RATG with glucocorticosteroids; no comment on glucocorticosteroid
avoidance or withdrawal possible
Boillot 2005 Randomised clinical trial comparing daclizumab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Cosimi 1987 Randomised clinical trial comparing muromonab CD3 with glucocorticosteroids for treatment of acute
rejection; no comment on glucocorticosteroid avoidance or withdrawal possible
Cuervas-Mons 2009 Randomised clinical trial comparing mycophenolate mofetil with glucocorticosteroids; no comment on glu-
cocorticosteroid avoidance or withdrawal possible
Day 2004 Randomised clinical trial comparing continuationof tacrolimusmonotherapywith tacrolimus discontinuation
and replacement with mycophenolate mofetil and glucocorticosteroids; no comment on glucocorticosteroid
avoidance or withdrawal possible
De Simone 2007 Randomised clinical trial comparing basiliximab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Filipponi 2004 Method reports study as a randomised clinical trial with ITT. Results are reported instead as a per-treatment
analysis with patients moved between arms for analysis as a result of a data-dependent process. This does
not appear to have been carried out using pre-specified criteria. Our inclusion criteria state that we are only
considering randomised clinical trials that present their data in an ITT analysis for this review. We made
attempts to contact the author to request the original data so that ITT analysis could be completed
Foroncewicz 2009 Randomised clinical trial comparing daclizumab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Ganschow 2007 Randomised clinical trial comparing high- and low-dose glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Jonas 2001 Randomised clinical trial comparing tacrolimus-based dual therapywith cyclosporine A-based quadruple ther-
apy in which glucocorticosteroid withdrawal was assessed as an outcome; no comment on glucocorticosteroid
avoidance or withdrawal possible
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Junge 2005 Randomised clinical trial comparing mycophenolate mofetil with glucocorticosteroids; no comment on glu-
cocorticosteroid avoidance or withdrawal possible
Kato 2007 Randomised clinical trial comparing daclizumab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Klintmalm 2011 Randomised clinical trial comparing daclizumab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Lupo 2008 Randomised clinical trial comparing basiliximab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Manousou 2009 Randomised clinical trial comparingmonotherapy of tacrolimuswith triple therapy of tacrolimus, azathioprine
and glucocorticosteroids; no comment on glucocorticosteroid avoidance or withdrawal possible
McDiarmid 1995 Randomised clinical trial comparing glucocorticosteroid continuation with glucocorticosteroid withdrawal
over 1 year post-transplant; investigation of alteration in an existing immunosuppression strategy rather than
a primary immunosuppression strategy
Nair 2006 Randomised clinical trial comparing RATG with glucocorticosteroids; no comment on glucocorticosteroid
avoidance or withdrawal possible
Nair 2008 Randomised clinical trial comparing PEG interferon alpha 2b, ribavirin and amantadine with PEG interferon
alpha 2b and ribavirin in 2 glucocorticosteroid-free arms; no comment on glucocorticosteroid avoidance or
withdrawal possible
Neumann 2012 Randomised clinical trial comparing daclizumab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Otero 2009 Randomised clinical trial comparing daclizumab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Saliba 2012 Randomised clinical trial comparing concentration-controlled mycophenolate mofetil with fixed-dose my-
cophenolate mofetil and glucocorticosteroids; differences in concomitant immunosuppression therefore no
comment on glucocorticosteroid avoidance or withdrawal possible
Spada 2006 Randomised clinical trial comparing basiliximab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Takada 2013 Randomised clinical trial comparing mycophenolate mofetil with glucocorticosteroids; no comment on glu-
cocorticosteroid avoidance or withdrawal possible
Teisseyre 2006 Randomised clinical trial comparing saline with methylprednisolone for prevention of ischaemia reperfusion
injury; no comment on glucocorticosteroid avoidance or withdrawal for post-transplantation immunosup-
pression possible
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Turner 2006 Randomised clinical trial comparing RATG with glucocorticosteroids; no comment on glucocorticosteroid
avoidance or withdrawal possible
Washburn 2001 Randomised clinical trial comparing daclizumab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
ITT: intention-to-treat
Muromonab CD3: muromonab cluster of differentiation 3
PEG: pegylated
RATG: rabbit antithymocyte globulin
Characteristics of ongoing studies [ordered by study ID]
Zhong 2010
Trial name or title Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without
Steroids
Methods Trial design: randomised, multicentre, double-blinded, placebo-controlled clinical trial
Mean follow-up: not reported
Study duration: not reported
Language: English
Type of information: abstract (abstract appears to present preliminary data for the first 182 participants
randomised)
Judgement on quality: unclear risk
Participants Setting: Shanghai First People’s Hospital
Allocation of participants: target enrolment of 300 participants, current participants not adequately reported
(study ongoing)
Sex ratio: total: not reported
Intervention A: not reported
Intervention B: not reported
Mean age: total: not reported
Intervention A: not reported
Intervention B: not reported
Indication (no. (%)): (hepatocellular carcinoma primary indication for all transplants)
Hepatocellular carcinoma: total: not reported (100%), Intervention A: not reported (100%), Intervention B:
not reported (100%)
Type of donor: not reported
Inclusion criteria: liver transplant recipients with hepatocellular carcinoma
Exclusion criteria: death within 3 months of transplantation, inability to provide written informed consent
prior to study entry
Interventions Intervention A: no intervention
Intervention B: methylprednisolone 10 mg/kg intraoperatively and a further 10 mg/kg given over 1 week
Concomitant immunosuppression:
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Tacrolimus/cyclosporine A: dose not reported (NOTE: published abstract reports use of cyclosporine A,
register on clinicaltrials.gov reports use of tacrolimus)
Basiliximab: 20 mg given twice (timings not reported)
Outcomes Mortality, graft loss, acute rejection, infection, bacterial infection, de novo diabetesmellitus, recurrent hepatitis
B, hypertension, neurological complications, tumour size, tumour differentiation, histological staging of
tumour, recurrence-free survival
Starting date 2005 (exact dates not provided)
Contact information Zhi-Hai Peng, Shanghai First People’s Hospital, Shanghai, China
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: Shanghai Jiao Tong University School of Medicine
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D A T A A N D A N A L Y S E S
Comparison 1. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 15 1323 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.93, 1.44]
1.1 Glucocorticosteroid
avoidance
9 758 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.84, 1.48]
1.2 Glucocorticosteroid
withdrawal
6 565 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.86, 1.72]
2 Graft loss including death 11 1002 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.91, 1.48]
2.1 Glucocorticosteroid
avoidance
8 671 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.78, 1.41]
2.2 Glucocorticosteroid
withdrawal
3 331 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.93, 2.24]
3 Acute rejection 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [1.08, 1.64]
3.1 Glucocorticosteroid
avoidance
10 782 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.04, 1.81]
3.2 Glucocorticosteroid
withdrawal
6 565 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.93, 1.76]
4 Infection 8 778 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.73, 1.05]
4.1 Glucocorticosteroid
avoidance
6 500 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.80, 1.15]
4.2 Glucocorticosteroid
withdrawal
2 278 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.19, 0.90]
5 Chronic rejection 9 974 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.52, 2.00]
5.1 Glucocorticosteroid
avoidance
6 586 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.27, 1.88]
5.2 Glucocorticosteroid
withdrawal
3 388 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.55, 3.78]
6 Glucocorticosteroid-resistant
rejection
10 1020 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [1.13, 4.02]
6.1 Glucocorticosteroid
avoidance
7 689 Risk Ratio (M-H, Fixed, 95% CI) 1.88 [0.89, 3.98]
6.2 Glucocorticosteroid
withdrawal
3 331 Risk Ratio (M-H, Fixed, 95% CI) 2.86 [0.86, 9.49]
7 Diabetes mellitus 12 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 0.99]
7.1 Glucocorticosteroid
avoidance
7 674 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.70, 1.17]
7.2 Glucocorticosteroid
withdrawal
5 511 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.50, 0.94]
8 CMV 7 786 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.16]
8.1 Glucocorticosteroid
avoidance
5 502 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.39, 1.49]
8.2 Glucocorticosteroid
withdrawal
2 284 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.41, 1.30]
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9 HCV recurrence 10 477 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.92, 1.15]
9.1 Glucocorticosteroid
avoidance
7 274 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.84, 1.08]
9.2 Glucocorticosteroid
withdrawal
3 203 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.96, 1.44]
10 Malignancy 3 528 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.16, 1.74]
10.1 Glucocorticosteroid
avoidance
2 354 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.13, 2.08]
10.2 Glucocorticosteroid
withdrawal
1 174 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.05, 5.80]
11 Post-transplant
lymphoproliferative disorder
2 330 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [0.36, 15.95]
11.1 Glucocorticosteroid
avoidance
1 156 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.61]
11.2 Glucocorticosteroid
withdrawal
1 174 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.13, 77.77]
12 Renal insufficiency 4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.19]
12.1 Glucocorticosteroid
avoidance
4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.19]
13 Creatinine 4 309 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.07, 0.16]
13.1 Glucocorticosteroid
avoidance
2 145 Mean Difference (IV, Fixed, 95% CI) 0.15 [0.10, 0.20]
13.2 Glucocorticosteroid
withdrawal
2 164 Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.16, 0.05]
14 Hypertension 10 1098 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.65, 0.90]
14.1 Glucocorticosteroid
avoidance
6 634 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 1.00]
14.2 Glucocorticosteroid
withdrawal
4 464 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.55, 0.91]
15 Hyperlipidaemia 4 400 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.38, 1.48]
15.1 Glucocorticosteroid
avoidance
2 150 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.45, 2.52]
15.2 Glucocorticosteroid
withdrawal
2 250 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.14, 1.41]
16 Cholesterol 6 611 Mean Difference (IV, Fixed, 95% CI) -18.49 [-22.02, -14.
96]
16.1 Glucocorticosteroid
avoidance
3 343 Mean Difference (IV, Fixed, 95% CI) -18.33 [-21.93, -14.
72]
16.2 Glucocorticosteroid
withdrawal
3 268 Mean Difference (IV, Fixed, 95% CI) -22.06 [-38.94, -5.
18]
17 Hypercholesterolaemia 2 266 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.32, 1.00]
17.1 Glucocorticosteroid
avoidance
1 156 Risk Ratio (M-H, Fixed, 95% CI) 1.2 [0.55, 2.61]
17.2 Glucocorticosteroid
withdrawal
1 110 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.08, 0.59]
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Comparison 2. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression (CNI subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 15 1323 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.93, 1.44]
1.1 Tacrolimus 11 802 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.92, 1.51]
1.2 Cyclosporine A 4 521 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.69, 1.74]
2 Graft loss including death 11 1002 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.91, 1.48]
2.1 Tacrolimus 8 585 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.86, 1.50]
2.2 Cyclosporine A 3 417 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.72, 2.09]
3 Acute rejection 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [1.08, 1.64]
3.1 Tacrolimus 11 802 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [1.02, 1.77]
3.2 Cyclosporine A 5 545 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.94, 1.80]
4 Infection 8 778 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.73, 1.05]
4.1 Tacrolimus 4 257 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.72, 1.27]
4.2 Cyclosporine A 4 521 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.66, 1.05]
5 Chronic rejection 9 974 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.52, 2.00]
5.1 Tacrolimus 4 429 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.38, 2.54]
5.2 Cyclosporine A 5 545 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.41, 2.76]
6 Glucocorticosteroid-resistant
rejection
10 1020 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [1.13, 4.02]
6.1 Tacrolimus 7 603 Risk Ratio (M-H, Fixed, 95% CI) 2.46 [1.01, 5.97]
6.2 Cyclosporine A 3 417 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [0.74, 4.55]
7 Diabetes mellitus 12 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 0.99]
7.1 Tacrolimus 9 709 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.72, 1.15]
7.2 Cyclosporine A 3 476 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.41, 0.90]
8 CMV infection 7 786 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.16]
8.1 Tacrolimus 4 369 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.46, 1.38]
8.2 Cyclosporine A 3 417 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.33, 1.40]
9 HCV recurrence 10 477 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.92, 1.15]
9.1 Tacrolimus 5 194 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.84, 1.16]
9.2 Cyclosporine A 5 283 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.92, 1.23]
10 Malignancy 3 528 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.16, 1.74]
10.1 Tacrolimus 1 156 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.24, 102.49]
10.2 Cyclosporine A 2 372 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.04, 1.22]
11 Post-transplant
lymphoproliferative disorder
2 330 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [0.36, 15.95]
11.1 Tacrolimus 1 156 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.61]
11.2 Cyclosporine A 1 174 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.13, 77.77]
12 Renal insufficiency 4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.19]
12.1 Tacrolimus 3 249 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.73, 1.64]
12.2 Cyclosporine A 1 198 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.63, 1.16]
13 Creatinine 4 309 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.07, 0.16]
13.1 Tacrolimus 3 264 Mean Difference (IV, Fixed, 95% CI) 0.17 [0.12, 0.22]
13.2 Cyclosporine A 1 45 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.19, -0.01]
14 Hypertension 10 1098 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.65, 0.90]
14.1 Tacrolimus 7 622 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.65, 1.06]
14.2 Cyclosporine A 3 476 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.58, 0.88]
15 Hyperlipidaemia 4 400 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.38, 1.48]
15.1 Tacrolimus 3 226 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.44, 2.02]
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15.2 Cyclosporine A 1 174 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.07, 1.72]
16 Cholesterol 6 611 Mean Difference (IV, Fixed, 95% CI) -18.49 [-22.02, -14.
96]
16.1 Tacrolimus 3 264 Mean Difference (IV, Fixed, 95% CI) -18.38 [-22.09, -14.
67]
16.2 Cyclosporine A 3 347 Mean Difference (IV, Fixed, 95% CI) -19.56 [-31.05, -8.
07]
Comparison 3. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression (antiproliferative subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 15 1323 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.93, 1.44]
1.1 No antiproliferative agent 8 928 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.92, 1.66]
1.2 Mycophenolate mofetil 6 350 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.75, 1.51]
1.3 Azathioprine 1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.40, 2.28]
2 Graft loss including death 11 1002 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.91, 1.48]
2.1 No antiproliferative agent 6 748 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.83, 1.55]
2.2 Mycophenolate mofetil 4 209 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.82, 1.96]
2.3 Azathioprine 1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.40, 2.28]
3 Acute rejection 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [1.08, 1.64]
3.1 No antiproliferative agent 9 952 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.97, 1.56]
3.2 Mycophenolate mofetil 6 350 Risk Ratio (M-H, Fixed, 95% CI) 1.87 [1.15, 3.04]
3.3 Azathioprine 1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.27, 3.36]
4 Infection 8 778 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.73, 1.05]
4.1 No antiproliferative agent 3 476 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.59, 1.02]
4.2 Mycophenolate mofetil 4 257 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.72, 1.27]
4.3 Azathioprine 1 45 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.75, 1.58]
5 Chronic rejection 9 974 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.52, 2.00]
5.1 No antiproliferative agent 7 829 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.61, 2.65]
5.2 Mycophenolate mofetil 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 2.16]
5.3 Azathioprine 1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Glucocorticosteroid-resistant
rejection
10 1020 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [1.13, 4.02]
6.1 No antiproliferative agent 6 748 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [1.13, 4.02]
6.2 Mycophenolate mofetil 3 227 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Azathioprine 1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Diabetes mellitus 12 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 0.99]
7.1 No antiproliferative agent 8 928 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.62, 1.00]
7.2 Mycophenolate mofetil 4 257 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.59, 1.25]
8 CMV infection 7 786 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.16]
8.1 No antiproliferative agent 5 701 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.45, 1.12]
8.2 Mycophenolate mofetil 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 Azathioprine 1 45 Risk Ratio (M-H, Fixed, 95% CI) 1.91 [0.19, 19.63]
9 HCV recurrence 10 477 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.92, 1.15]
9.1 No antiproliferative agent 7 386 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.98, 1.22]
9.2 Mycophenolate mofetil 2 76 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.55, 1.22]
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9.3 Azathioprine 1 15 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.03, 1.52]
10 Renal insufficiency 4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.19]
10.1 No antiproliferative
agent
3 417 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.72, 1.16]
10.2 Mycophenolate mofetil 1 30 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.30, 29.52]
11 Creatinine 4 309 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.07, 0.16]
11.1 No antiproliferative
agent
1 110 Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.47, 0.23]
11.2 Mycophenolate mofetil 2 154 Mean Difference (IV, Fixed, 95% CI) 0.18 [0.13, 0.23]
11.3 Azathioprine 1 45 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.19, -0.01]
12 Hypertension 10 1098 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.65, 0.90]
12.1 No antiproliferative
agent
7 881 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.62, 0.88]
12.2 Mycophenolate mofetil 3 217 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.61, 1.26]
13 Hyperlipidaemia 4 400 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.38, 1.48]
13.1 No antiproliferative
agent
3 313 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.32, 1.62]
13.2 Mycophenolate mofetil 1 87 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.24, 2.85]
14 Cholesterol 6 611 Mean Difference (IV, Fixed, 95% CI) -18.49 [-22.02, -14.
96]
14.1 No antiproliferative
agent
3 412 Mean Difference (IV, Fixed, 95% CI) -8.08 [-18.99, 2.82]
14.2 Mycophenolate mofetil 2 154 Mean Difference (IV, Fixed, 95% CI) -19.84 [-23.60, -16.
08]
14.3 Azathioprine 1 45 Mean Difference (IV, Fixed, 95% CI) -11.0 [-41.10, 19.
10]
Comparison 4. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression (induction therapy subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 15 1323 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.93, 1.44]
1.1 No induction therapy 8 581 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.85, 1.50]
1.2 Basiliximab 5 599 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.85, 1.81]
1.3 Rabbit antithymocyte
globulin
1 104 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.51, 2.50]
1.4 Daclizumab 1 39 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.35]
2 Graft loss including death 11 1002 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.91, 1.48]
2.1 No induction therapy 6 451 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.74, 1.41]
2.2 Basiliximab 4 512 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.99, 2.12]
2.3 Daclizumab 1 39 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 3.73]
3 Acute rejection 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [1.08, 1.64]
3.1 No induction therapy 8 581 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.94, 1.71]
3.2 Basiliximab 5 599 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [1.05, 2.05]
3.3 Rabbit antithymocyte
globulin
2 128 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.36, 1.67]
3.4 Daclizumab 1 39 Risk Ratio (M-H, Fixed, 95% CI) 2.22 [0.67, 7.34]
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4 Infection 8 778 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.73, 1.05]
4.1 No induction therapy 2 75 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.86, 1.77]
4.2 Basiliximab 5 599 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.71, 1.07]
4.3 Rabbit antithymocyte
globulin
1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.02, 0.89]
5 Chronic rejection 9 974 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.52, 2.00]
5.1 No induction therapy 4 374 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.51, 5.25]
5.2 Basiliximab 3 472 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.29, 1.89]
5.3 Rabbit antithymocyte
globulin
2 128 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.16, 6.72]
6 Glucocorticosteroid-resistant
rejection
10 1020 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [1.13, 4.02]
6.1 No induction therapy 5 421 Risk Ratio (M-H, Fixed, 95% CI) 2.46 [1.01, 5.97]
6.2 Basiliximab 5 599 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [0.74, 4.55]
7 Diabetes mellitus 12 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 0.99]
7.1 No induction therapy 6 482 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.69, 1.24]
7.2 Basiliximab 5 599 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.60, 1.06]
7.3 Rabbit antithymocyte
globulin
1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.07, 0.77]
8 CMV infection 7 786 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.16]
8.1 No induction therapy 4 374 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.50, 1.44]
8.2 Basiliximab 3 412 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.27, 1.30]
9 HCV recurrence 10 477 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.92, 1.15]
9.1 No induction therapy 4 133 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.84, 1.18]
9.2 Basiliximab 4 273 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.90, 1.18]
9.3 Rabbit antithymocyte
globulin
2 71 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.55, 3.11]
10 Malignancy 3 528 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.16, 1.74]
10.1 No induction therapy 1 156 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.24, 102.49]
10.2 Basiliximab 2 372 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.04, 1.22]
11 Post-transplant
lymphoproliferative disorder
2 330 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [0.36, 15.95]
11.1 No induction therapy 1 156 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.61]
11.2 Basiliximab 1 174 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.13, 77.77]
12 Renal insufficiency 4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.19]
12.1 No induction therapy 3 249 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.73, 1.64]
12.2 Basiliximab 1 198 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.63, 1.16]
13 Creatinine 4 309 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.07, 0.16]
13.1 No induction therapy 3 209 Mean Difference (IV, Fixed, 95% CI) -0.08 [-0.15, -0.01]
13.2 Basiliximab 1 100 Mean Difference (IV, Fixed, 95% CI) 0.25 [0.19, 0.31]
14 Hypertension 10 1098 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.65, 0.90]
14.1 No induction therapy 5 435 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.57, 1.08]
14.2 Basiliximab 4 559 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.72, 1.05]
14.3 Rabbit antithymocyte
globulin
1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.16, 0.57]
15 Hyperlipidaemia 4 400 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.38, 1.48]
15.1 No induction therapy 2 139 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.38, 2.72]
15.2 Basiliximab 2 261 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.22, 1.49]
16 Cholesterol 6 611 Mean Difference (IV, Fixed, 95% CI) -18.49 [-22.02, -14.
96]
16.1 No induction therapy 2 99 Mean Difference (IV, Fixed, 95% CI) -51.27 [-76.48, -26.
06]
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16.2 Basiliximab 3 408 Mean Difference (IV, Fixed, 95% CI) -17.10 [-20.69, -13.
51]
16.3 Rabbit antithymocyte
globulin
1 104 Mean Difference (IV, Fixed, 95% CI) -70.0 [-100.17, -39.
83]
Comparison 5. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression (co-interventions subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 15 1323 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.93, 1.44]
1.1 Monotherapy 5 452 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.90, 1.83]
1.2 Dual therapy 6 605 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.68, 1.42]
1.3 Triple therapy 4 266 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.79, 1.90]
2 Graft loss including death 11 1002 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.91, 1.48]
2.1 Monotherapy 4 376 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.75, 1.51]
2.2 Dual therapy 4 447 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.69, 1.93]
2.3 Triple therapy 3 179 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.86, 2.11]
3 Acute rejection 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [1.08, 1.64]
3.1 Monotherapy 5 452 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.81, 1.59]
3.2 Dual therapy 7 629 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [1.07, 1.95]
3.3 Triple therapy 4 266 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.84, 2.88]
4 Infection 8 778 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.73, 1.05]
4.1 Dual therapy 5 551 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.70, 1.09]
4.2 Triple therapy 3 227 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.65, 1.20]
5 Chronic rejection 9 974 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.52, 2.00]
5.1 Monotherapy 3 329 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.51, 5.25]
5.2 Dual therapy 5 545 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.41, 2.76]
5.3 Triple therapy 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 2.16]
6 Glucocorticosteroid-resistant
rejection
10 1020 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [1.13, 4.02]
6.1 Monotherapy 4 376 Risk Ratio (M-H, Fixed, 95% CI) 2.46 [1.01, 5.97]
6.2 Dual therapy 3 417 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [0.74, 4.55]
6.3 Triple therapy 3 227 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Diabetes mellitus 12 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 0.99]
7.1 Monotherapy 5 452 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.70, 1.28]
7.2 Dual therapy 4 506 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.41, 0.89]
7.3 Triple therapy 3 227 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.61, 1.31]
8 CMV infection 7 786 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.16]
8.1 Monotherapy 3 329 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.46, 1.38]
8.2 Dual therapy 3 417 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.33, 1.40]
8.3 Triple therapy 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 HCV recurrence 10 477 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.92, 1.15]
9.1 Monotherapy 3 118 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.91, 1.25]
9.2 Dual therapy 5 283 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.92, 1.23]
9.3 Triple therapy 2 76 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.55, 1.22]
10 Malignancy 3 528 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.16, 1.74]
10.1 Monotherapy 1 156 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.24, 102.49]
10.2 Dual therapy 2 372 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.04, 1.22]
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11 Post-transplant
lymphoproliferative disorder
2 330 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [0.36, 15.95]
11.1 Monotherapy 1 156 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.61]
11.2 Dual therapy 1 174 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.13, 77.77]
12 Renal insufficiency 4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.19]
12.1 Monotherapy 2 219 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.68, 1.56]
12.2 Dual therapy 2 228 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.66, 1.20]
13 Creatinine 4 309 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.07, 0.16]
13.1 Monotherapy 1 110 Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.47, 0.23]
13.2 Dual therapy 2 99 Mean Difference (IV, Fixed, 95% CI) -0.08 [-0.15, -0.01]
13.3 Triple therapy 1 100 Mean Difference (IV, Fixed, 95% CI) 0.25 [0.19, 0.31]
14 Hypertension 10 1098 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.65, 0.90]
14.1 Monotherapy 4 405 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.57, 1.10]
14.2 Dual therapy 4 506 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.57, 0.88]
14.3 Triple therapy 2 187 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.63, 1.32]
15 Hyperlipidaemia 4 400 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.38, 1.48]
15.1 Monotherapy 2 139 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.38, 2.72]
15.2 Dual therapy 1 174 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.07, 1.72]
15.3 Triple therapy 1 87 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.24, 2.85]
16 Cholesterol 6 611 Mean Difference (IV, Fixed, 95% CI) -18.49 [-22.02, -14.
96]
16.1 Monotherapy 1 110 Mean Difference (IV, Fixed, 95% CI) 35.0 [12.31, 57.69]
16.2 Dual therapy 4 401 Mean Difference (IV, Fixed, 95% CI) -26.94 [-38.10, -15.
79]
16.3 Triple therapy 1 100 Mean Difference (IV, Fixed, 95% CI) -19.0 [-22.77, -15.
23]
Comparison 6. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression (treatment duration subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 14 1149 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.87, 1.36]
1.1 2 to 3 months
glucocorticosteroid
7 655 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.70, 1.41]
1.2 > 3 to 6 months
glucocorticosteroids
3 250 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [1.00, 2.18]
1.3 > 6 months
glucocorticosteroids
4 244 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.55, 1.33]
2 Graft loss including death 10 828 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.84, 1.38]
2.1 2 to 3 months
glucocorticosteroid
5 492 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.60, 1.32]
2.2 > 3 to 6 months
glucocorticosteroids
3 250 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [1.01, 2.04]
2.3 > 6 months
glucocorticosteroids
2 86 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.25, 1.47]
3 Acute rejection 15 1173 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [1.01, 1.62]
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3.1 2 to 3 months
glucocorticosteroid
8 679 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.97, 1.75]
3.2 > 3 to 6 months
glucocorticosteroids
3 250 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.83, 2.15]
3.3 > 6 months
glucocorticosteroids
4 244 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.54, 2.12]
4 Infection 7 604 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.75, 1.08]
4.1 2 to 3 months
glucocorticosteroid
4 360 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.71, 1.11]
4.2 > 3 to 6 months
glucocorticosteroids
2 140 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.81, 1.54]
4.3 > 6 months
glucocorticosteroids
1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.02, 0.89]
5 Chronic rejection 8 800 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.54, 2.56]
5.1 2 to 3 months
glucocorticosteroid
5 486 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.33, 3.32]
5.2 > 3 to 6 months
glucocorticosteroids
2 210 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.51, 5.24]
5.3 > 6 months
glucocorticosteroids
1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.01, 7.42]
6 Glucocorticosteroid-resistant
rejection
9 846 Risk Ratio (M-H, Fixed, 95% CI) 1.93 [0.93, 4.01]
6.1 2 to 3 months
glucocorticosteroid
5 549 Risk Ratio (M-H, Fixed, 95% CI) 1.88 [0.89, 3.98]
6.2 > 3 to 6 months
glucocorticosteroids
3 250 Risk Ratio (M-H, Fixed, 95% CI) 2.89 [0.12, 69.55]
6.3 > 6 months
glucocorticosteroids
1 47 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Diabetes mellitus 11 1011 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.67, 1.03]
7.1 2 to 3 months
glucocorticosteroid
6 610 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.54, 1.01]
7.2 > 3 to 6 months
glucocorticosteroids
3 250 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.81, 1.66]
7.3 > 6 months
glucocorticosteroids
2 151 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.39, 1.03]
8 CMV infection 6 612 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.48, 1.18]
8.1 2 to 3 months
glucocorticosteroid
4 462 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.39, 1.49]
8.2 > 3 to 6 months
glucocorticosteroids
2 150 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.42, 1.35]
9 HCV recurrence 9 369 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.89, 1.15]
9.1 2 to 3 months
glucocorticosteroid
5 198 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.88, 1.12]
9.2 > 3 to 6 months
glucocorticosteroids
2 76 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.55, 1.22]
9.3 > 6 months
glucocorticosteroids
2 95 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [0.89, 2.09]
10 Creatinine 4 309 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.07, 0.16]
10.1 > 6 months
glucocorticosteroids
1 45 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.19, -0.01]
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10.2 2 to 3 months
glucocorticosteroid
2 210 Mean Difference (IV, Fixed, 95% CI) 0.24 [0.18, 0.30]
10.3 > 3 to 6 months
glucocorticosteroids
1 54 Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.16, 0.06]
11 Hypertension 9 924 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.63, 0.89]
11.1 2 to 3 months
glucocorticosteroid
6 610 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.57, 0.92]
11.2 > 3 to 6 months
glucocorticosteroids
2 210 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.80, 1.40]
11.3 > 6 months
glucocorticosteroids
1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.16, 0.57]
12 Cholesterol 6 611 Mean Difference (IV, Fixed, 95% CI) -18.49 [-22.02, -14.
96]
12.1 2 to 3 months
glucocorticosteroid
2 243 Mean Difference (IV, Fixed, 95% CI) -11.00 [-23.43, 1.
43]
12.2 > 3 to 6 months
glucocorticosteroids
2 210 Mean Difference (IV, Fixed, 95% CI) -17.55 [-21.27, -13.
83]
12.3 > 6 months
glucocorticosteroids
2 158 Mean Difference (IV, Fixed, 95% CI) -92.75 [-118.01, -
67.50]
13 Hypercholesterolaemia 2 266 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.32, 1.00]
13.1 2 to 3 months
glucocorticosteroid
1 156 Risk Ratio (M-H, Fixed, 95% CI) 1.2 [0.55, 2.61]
13.2 > 3 to 6 months
glucocorticosteroids
1 110 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.08, 0.59]
Comparison 7. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression (pre-2000 and post-2000 subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 15 1323 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.93, 1.44]
1.1 Pre-2000 4 386 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.90, 2.06]
1.2 Post-2000 11 937 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.83, 1.40]
2 Graft loss including death 11 1002 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.91, 1.48]
2.1 Pre-2000 3 282 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.65, 2.40]
2.2 Post-2000 8 720 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.88, 1.49]
3 Acute rejection 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [1.08, 1.64]
3.1 Pre-2000 5 410 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.91, 1.75]
3.2 Post-2000 11 937 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.05, 1.80]
4 Infection 8 778 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.73, 1.05]
4.1 Pre-2000 3 323 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.48, 1.04]
4.2 Post-2000 5 455 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.77, 1.15]
5 Chronic rejection 9 974 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.52, 2.00]
5.1 Pre-2000 5 410 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.25, 2.31]
5.2 Post-2000 4 564 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.52, 2.84]
6 Glucocorticosteroid-resistant
rejection
10 1020 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [1.13, 4.02]
6.1 Pre-2000 3 282 Risk Ratio (M-H, Fixed, 95% CI) 2.17 [0.84, 5.57]
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6.2 Post-2000 7 738 Risk Ratio (M-H, Fixed, 95% CI) 2.11 [0.90, 4.96]
7 Diabetes mellitus 12 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 0.99]
7.1 Pre-2000 3 341 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.36, 0.88]
7.2 Post-2000 9 844 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.72, 1.13]
8 CMV infection 7 786 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.16]
8.1 Pre-2000 3 282 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.20, 3.21]
8.2 Post-2000 4 504 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.46, 1.17]
9 HCV recurrence 10 477 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.92, 1.15]
9.1 Pre-2000 5 229 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.84, 1.22]
9.2 Post-2000 5 248 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.92, 1.19]
10 Malignancy 3 528 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.16, 1.74]
10.1 Pre-2000 1 174 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.05, 5.80]
10.2 Post-2000 2 354 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.13, 2.08]
11 Post-transplant
lymphoproliferative disorder
2 330 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [0.36, 15.95]
11.1 Pre-2000 1 174 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.13, 77.77]
11.2 Post-2000 1 156 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.61]
12 Renal insufficiency 4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.19]
12.1 Pre-2000 1 63 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.85, 1.96]
12.2 Post-2000 3 384 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.62, 1.12]
13 Creatinine 4 309 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.07, 0.16]
13.1 Pre-2000 1 45 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.19, -0.01]
13.2 Post-2000 3 264 Mean Difference (IV, Fixed, 95% CI) 0.17 [0.12, 0.22]
14 Hypertension 10 1098 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.65, 0.90]
14.1 Pre-2000 3 341 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.40, 0.79]
14.2 Post-2000 7 757 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.72, 1.03]
15 Hyperlipidaemia 4 400 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.38, 1.48]
15.1 Pre-2000 2 237 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.30, 1.91]
15.2 Post-2000 2 163 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.27, 2.01]
16 Cholesterol 6 611 Mean Difference (IV, Fixed, 95% CI) -18.49 [-22.02, -14.
96]
16.1 Pre-2000 2 149 Mean Difference (IV, Fixed, 95% CI) -40.42 [-61.73, -19.
11]
16.2 Post-2000 4 462 Mean Difference (IV, Fixed, 95% CI) -17.87 [-21.45, -14.
29]
Comparison 8. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression (best-worst analysis)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.80, 1.22]
1.1 Glucocorticosteroid
avoidance
10 782 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.87, 1.52]
1.2 Glucocorticosteroid
withdrawal
6 565 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.60, 1.12]
2 Graft loss including death 11 1002 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.79, 1.26]
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2.1 Glucocorticosteroid
avoidance
8 671 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.78, 1.41]
2.2 Glucocorticosteroid
withdrawal
3 331 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.61, 1.33]
3 Acute rejection 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.85, 1.26]
3.1 Glucocorticosteroid
avoidance
10 782 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.04, 1.81]
3.2 Glucocorticosteroid
withdrawal
6 565 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.59, 1.02]
4 Infection 8 778 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.67, 0.96]
4.1 Glucocorticosteroid
avoidance
6 500 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.80, 1.15]
4.2 Glucocorticosteroid
withdrawal
2 278 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.12, 0.50]
5 Chronic rejection 9 974 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.31, 1.00]
5.1 Glucocorticosteroid
avoidance
6 586 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.27, 1.88]
5.2 Glucocorticosteroid
withdrawal
3 388 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.23, 1.02]
6 Glucocorticosteroid-resistant
rejection
10 1020 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.61, 1.65]
6.1 Glucocorticosteroid
avoidance
7 689 Risk Ratio (M-H, Fixed, 95% CI) 1.88 [0.89, 3.98]
6.2 Glucocorticosteroid
withdrawal
3 331 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.27, 1.13]
7 Diabetes mellitus 12 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.58, 0.86]
7.1 Glucocorticosteroid
avoidance
7 674 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.70, 1.17]
7.2 Glucocorticosteroid
withdrawal
5 511 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.39, 0.70]
8 CMV infection 7 786 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.37, 0.87]
8.1 Glucocorticosteroid
avoidance
5 502 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.39, 1.49]
8.2 Glucocorticosteroid
withdrawal
2 284 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.27, 0.81]
9 Malignancy 3 528 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.07, 0.61]
9.1 Glucocorticosteroid
avoidance
2 354 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.13, 2.08]
9.2 Glucocorticosteroid
withdrawal
1 174 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.01, 0.57]
10 Post-transplant
lymphoproliferative disorder
2 330 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.07, 0.85]
10.1 Glucocorticosteroid
avoidance
1 156 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.61]
10.2 Glucocorticosteroid
withdrawal
1 174 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 0.67]
11 Hypertension 10 1098 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.60, 0.82]
11.1 Glucocorticosteroid
avoidance
6 634 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 1.00]
11.2 Glucocorticosteroid
withdrawal
4 464 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.47, 0.76]
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12 Hyperlipidaemia 4 400 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.21, 0.73]
12.1 Glucocorticosteroid
avoidance
2 150 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.45, 2.52]
12.2 Glucocorticosteroid
withdrawal
2 250 Risk Ratio (M-H, Fixed, 95% CI) 0.16 [0.06, 0.45]
Comparison 9. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression (worst-best analysis)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [1.10, 1.67]
1.1 Glucocorticosteroid
avoidance
10 782 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.86, 1.49]
1.2 Glucocorticosteroid
withdrawal
6 565 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [1.23, 2.38]
2 Graft loss including death 11 1002 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [1.10, 1.76]
2.1 Glucocorticosteroid
avoidance
8 671 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.79, 1.43]
2.2 Glucocorticosteroid
withdrawal
3 331 Risk Ratio (M-H, Fixed, 95% CI) 2.24 [1.47, 3.41]
3 Acute rejection 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [1.25, 1.88]
3.1 Glucocorticosteroid
avoidance
10 782 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [1.05, 1.83]
3.2 Glucocorticosteroid
withdrawal
6 565 Risk Ratio (M-H, Fixed, 95% CI) 1.73 [1.29, 2.31]
4 Infection 8 778 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.87, 1.23]
4.1 Glucocorticosteroid
avoidance
6 500 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.80, 1.15]
4.2 Glucocorticosteroid
withdrawal
2 278 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.89, 2.50]
5 Chronic rejection 9 974 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [1.36, 4.21]
5.1 Glucocorticosteroid
avoidance
6 586 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.27, 1.88]
5.2 Glucocorticosteroid
withdrawal
3 388 Risk Ratio (M-H, Fixed, 95% CI) 4.87 [2.16, 11.01]
6 Glucocorticosteroid-resistant
rejection
10 1020 Risk Ratio (M-H, Fixed, 95% CI) 3.71 [2.07, 6.66]
6.1 Glucocorticosteroid
avoidance
7 689 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [0.95, 4.17]
6.2 Glucocorticosteroid
withdrawal
3 331 Risk Ratio (M-H, Fixed, 95% CI) 8.63 [2.95, 25.28]
7 Diabetes mellitus 12 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.79, 1.15]
7.1 Glucocorticosteroid
avoidance
7 674 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.71, 1.19]
7.2 Glucocorticosteroid
withdrawal
5 511 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.76, 1.32]
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8 CMV infection 7 786 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.87, 1.90]
8.1 Glucocorticosteroid
avoidance
5 502 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.41, 1.59]
8.2 Glucocorticosteroid
withdrawal
2 284 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [1.04, 2.78]
9 Malignancy 3 528 Risk Ratio (M-H, Fixed, 95% CI) 3.05 [1.38, 6.73]
9.1 Glucocorticosteroid
avoidance
2 354 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.13, 2.08]
9.2 Glucocorticosteroid
withdrawal
1 174 Risk Ratio (M-H, Fixed, 95% CI) 10.71 [2.58, 44.45]
10 Post-transplant
lymphoproliferative disorder
2 330 Risk Ratio (M-H, Fixed, 95% CI) 15.64 [3.08, 79.56]
10.1 Glucocorticosteroid
avoidance
1 156 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.61]
10.2 Glucocorticosteroid
withdrawal
1 174 Risk Ratio (M-H, Fixed, 95% CI) 43.89 [2.70, 714.49]
11 Renal insufficiency 4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.75, 1.21]
11.1 Glucocorticosteroid
avoidance
4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.75, 1.21]
12 Hypertension 10 1098 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.75, 1.02]
12.1 Glucocorticosteroid
avoidance
6 634 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.67, 1.01]
12.2 Glucocorticosteroid
withdrawal
4 464 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.75, 1.18]
13 Hyperlipidaemia 4 400 Risk Ratio (M-H, Fixed, 95% CI) 1.92 [1.12, 3.28]
13.1 Glucocorticosteroid
avoidance
2 150 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.51, 2.73]
13.2 Glucocorticosteroid
withdrawal
2 250 Risk Ratio (M-H, Fixed, 95% CI) 2.64 [1.28, 5.44]
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Analysis 1.1. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 1 Mortality.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 1 Mortality
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Ju 2012 4/43 6/44 5.3 % 0.68 [ 0.21, 2.25 ]
Lerut 2008 17/78 13/78 11.7 % 1.31 [ 0.68, 2.51 ]
Llado 2006 5/96 11/102 9.6 % 0.48 [ 0.17, 1.34 ]
Margarit 2005 12/30 11/33 9.4 % 1.20 [ 0.63, 2.30 ]
Pelletier 2013 20/50 14/50 12.6 % 1.43 [ 0.82, 2.50 ]
Ramirez 2013 8/20 5/20 4.5 % 1.60 [ 0.63, 4.05 ]
Reggiani 2005 1/12 0/18 0.4 % 4.38 [ 0.19, 99.48 ]
Studenik 2005 0/20 1/19 1.4 % 0.32 [ 0.01, 7.35 ]
Tisone 1999 7/23 7/22 6.4 % 0.96 [ 0.40, 2.28 ]
Subtotal (95% CI) 372 386 61.1 % 1.11 [ 0.84, 1.48 ]
Total events: 74 (Gluc avoid), 68 (Gluc cont)
Heterogeneity: Chi2 = 6.33, df = 8 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
2 Glucocorticosteroid withdrawal
Belli 1998 11/54 9/50 8.4 % 1.13 [ 0.51, 2.50 ]
Chen 2007 10/28 14/26 13.0 % 0.66 [ 0.36, 1.22 ]
Hu 2008 1/40 1/36 0.9 % 0.90 [ 0.06, 13.87 ]
Moench 2007 17/56 11/54 10.0 % 1.49 [ 0.77, 2.88 ]
Pageaux 2004 9/84 2/90 1.7 % 4.82 [ 1.07, 21.67 ]
Vivarelli 2007 6/25 5/22 4.8 % 1.06 [ 0.37, 2.99 ]
Subtotal (95% CI) 287 278 38.9 % 1.22 [ 0.86, 1.72 ]
Total events: 54 (Gluc avoid), 42 (Gluc cont)
Heterogeneity: Chi2 = 7.52, df = 5 (P = 0.18); I2 =34%
Test for overall effect: Z = 1.11 (P = 0.27)
Total (95% CI) 659 664 100.0 % 1.15 [ 0.93, 1.44 ]
Total events: 128 (Gluc avoid), 110 (Gluc cont)
Heterogeneity: Chi2 = 13.54, df = 14 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
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Analysis 1.2. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 2 Graft loss including death.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 2 Graft loss including death
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Lerut 2008 20/78 17/78 19.0 % 1.18 [ 0.67, 2.07 ]
Llado 2006 9/96 12/102 13.0 % 0.80 [ 0.35, 1.81 ]
Margarit 2005 0/30 4/33 4.8 % 0.12 [ 0.01, 2.17 ]
Pelletier 2013 22/50 14/50 15.6 % 1.57 [ 0.91, 2.71 ]
Ramirez 2013 8/20 6/20 6.7 % 1.33 [ 0.57, 3.14 ]
Reggiani 2005 1/12 3/18 2.7 % 0.50 [ 0.06, 4.26 ]
Studenik 2005 0/20 2/19 2.9 % 0.19 [ 0.01, 3.73 ]
Tisone 1999 7/23 7/22 8.0 % 0.96 [ 0.40, 2.28 ]
Subtotal (95% CI) 329 342 72.5 % 1.05 [ 0.78, 1.41 ]
Total events: 67 (Gluc avoid), 65 (Gluc cont)
Heterogeneity: Chi2 = 6.92, df = 7 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
2 Glucocorticosteroid withdrawal
Moench 2007 21/56 15/54 17.0 % 1.35 [ 0.78, 2.33 ]
Pageaux 2004 9/84 2/90 2.2 % 4.82 [ 1.07, 21.67 ]
Vivarelli 2007 6/25 7/22 8.3 % 0.75 [ 0.30, 1.91 ]
Subtotal (95% CI) 165 166 27.5 % 1.44 [ 0.93, 2.24 ]
Total events: 36 (Gluc avoid), 24 (Gluc cont)
Heterogeneity: Chi2 = 4.41, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 1.62 (P = 0.10)
Total (95% CI) 494 508 100.0 % 1.16 [ 0.91, 1.48 ]
Total events: 103 (Gluc avoid), 89 (Gluc cont)
Heterogeneity: Chi2 = 11.24, df = 10 (P = 0.34); I2 =11%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Chi2 = 1.37, df = 1 (P = 0.24), I2 =27%
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Analysis 1.3. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 3 Acute rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 3 Acute rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Belli 2001 5/11 7/13 5.6 % 0.84 [ 0.37, 1.92 ]
Ju 2012 4/43 3/44 2.6 % 1.36 [ 0.32, 5.74 ]
Lerut 2008 18/78 16/78 13.9 % 1.13 [ 0.62, 2.04 ]
Llado 2006 17/96 13/102 10.9 % 1.39 [ 0.71, 2.70 ]
Margarit 2005 11/30 10/33 8.3 % 1.21 [ 0.60, 2.43 ]
Pelletier 2013 10/50 7/50 6.1 % 1.43 [ 0.59, 3.45 ]
Ramirez 2013 1/20 1/20 0.9 % 1.00 [ 0.07, 14.90 ]
Reggiani 2005 9/12 3/18 2.1 % 4.50 [ 1.52, 13.30 ]
Studenik 2005 7/20 3/19 2.7 % 2.22 [ 0.67, 7.34 ]
Tisone 1999 4/23 4/22 3.5 % 0.96 [ 0.27, 3.36 ]
Subtotal (95% CI) 383 399 56.5 % 1.37 [ 1.04, 1.81 ]
Total events: 86 (Gluc avoid), 67 (Gluc cont)
Heterogeneity: Chi2 = 7.50, df = 9 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.21 (P = 0.027)
2 Glucocorticosteroid withdrawal
Belli 1998 2/54 3/50 2.7 % 0.62 [ 0.11, 3.54 ]
Chen 2007 4/28 3/26 2.7 % 1.24 [ 0.31, 5.01 ]
Hu 2008 5/40 4/36 3.7 % 1.13 [ 0.33, 3.87 ]
Moench 2007 19/56 14/54 12.4 % 1.31 [ 0.73, 2.34 ]
Pageaux 2004 32/84 22/90 18.4 % 1.56 [ 0.99, 2.45 ]
Vivarelli 2007 2/25 4/22 3.7 % 0.44 [ 0.09, 2.17 ]
Subtotal (95% CI) 287 278 43.5 % 1.28 [ 0.93, 1.76 ]
Total events: 64 (Gluc avoid), 50 (Gluc cont)
Heterogeneity: Chi2 = 3.16, df = 5 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Total (95% CI) 670 677 100.0 % 1.33 [ 1.08, 1.64 ]
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 150 (Gluc avoid), 117 (Gluc cont)
Heterogeneity: Chi2 = 10.60, df = 15 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.66 (P = 0.0079)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
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Analysis 1.4. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 4 Infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 4 Infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Ju 2012 6/43 16/44 11.3 % 0.38 [ 0.17, 0.89 ]
Llado 2006 45/96 52/102 36.2 % 0.92 [ 0.69, 1.22 ]
Pelletier 2013 26/50 22/50 15.8 % 1.18 [ 0.78, 1.78 ]
Ramirez 2013 12/20 12/20 8.6 % 1.00 [ 0.60, 1.66 ]
Reggiani 2005 6/12 5/18 2.9 % 1.80 [ 0.71, 4.59 ]
Tisone 1999 17/23 15/22 11.0 % 1.08 [ 0.75, 1.58 ]
Subtotal (95% CI) 244 256 85.7 % 0.96 [ 0.80, 1.15 ]
Total events: 112 (Gluc avoid), 122 (Gluc cont)
Heterogeneity: Chi2 = 7.87, df = 5 (P = 0.16); I2 =36%
Test for overall effect: Z = 0.49 (P = 0.62)
2 Glucocorticosteroid withdrawal
Belli 1998 1/54 8/50 6.0 % 0.12 [ 0.02, 0.89 ]
Pageaux 2004 7/84 12/90 8.3 % 0.63 [ 0.26, 1.51 ]
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 138 140 14.3 % 0.41 [ 0.19, 0.90 ]
Total events: 8 (Gluc avoid), 20 (Gluc cont)
Heterogeneity: Chi2 = 2.34, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 2.23 (P = 0.026)
Total (95% CI) 382 396 100.0 % 0.88 [ 0.73, 1.05 ]
Total events: 120 (Gluc avoid), 142 (Gluc cont)
Heterogeneity: Chi2 = 13.93, df = 7 (P = 0.05); I2 =50%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 4.25, df = 1 (P = 0.04), I2 =76%
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Analysis 1.5. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 5 Chronic rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 5 Chronic rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Belli 2001 1/11 0/13 2.8 % 3.50 [ 0.16, 78.19 ]
Lerut 2008 1/78 4/78 24.5 % 0.25 [ 0.03, 2.19 ]
Llado 2006 3/96 1/102 5.9 % 3.19 [ 0.34, 30.12 ]
Margarit 2005 0/30 0/33 Not estimable
Pelletier 2013 1/50 4/50 24.5 % 0.25 [ 0.03, 2.16 ]
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 288 298 57.8 % 0.71 [ 0.27, 1.88 ]
Total events: 6 (Gluc avoid), 9 (Gluc cont)
Heterogeneity: Chi2 = 4.52, df = 3 (P = 0.21); I2 =34%
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.69 (P = 0.49)
2 Glucocorticosteroid withdrawal
Belli 1998 0/54 1/50 9.5 % 0.31 [ 0.01, 7.42 ]
Moench 2007 6/56 0/54 3.1 % 12.54 [ 0.72, 217.40 ]
Pageaux 2004 3/84 5/90 29.6 % 0.64 [ 0.16, 2.61 ]
Subtotal (95% CI) 194 194 42.2 % 1.45 [ 0.55, 3.78 ]
Total events: 9 (Gluc avoid), 6 (Gluc cont)
Heterogeneity: Chi2 = 4.40, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 0.75 (P = 0.45)
Total (95% CI) 482 492 100.0 % 1.02 [ 0.52, 2.00 ]
Total events: 15 (Gluc avoid), 15 (Gluc cont)
Heterogeneity: Chi2 = 8.78, df = 6 (P = 0.19); I2 =32%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 1.04, df = 1 (P = 0.31), I2 =4%
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Analysis 1.6. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 6 Glucocorticosteroid-resistant rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 6 Glucocorticosteroid-resistant rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Ju 2012 0/43 0/44 Not estimable
Lerut 2008 10/78 3/78 22.8 % 3.33 [ 0.95, 11.65 ]
Llado 2006 4/96 4/102 29.5 % 1.06 [ 0.27, 4.13 ]
Margarit 2005 4/30 3/33 21.7 % 1.47 [ 0.36, 6.03 ]
Pelletier 2013 0/50 0/50 Not estimable
Ramirez 2013 0/20 0/20 Not estimable
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 340 349 74.1 % 1.88 [ 0.89, 3.98 ]
Total events: 18 (Gluc avoid), 10 (Gluc cont)
Heterogeneity: Chi2 = 1.60, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.65 (P = 0.099)
2 Glucocorticosteroid withdrawal
Moench 2007 1/56 0/54 3.9 % 2.89 [ 0.12, 69.55 ]
Pageaux 2004 8/84 3/90 22.0 % 2.86 [ 0.78, 10.41 ]
Vivarelli 2007 0/25 0/22 Not estimable
Subtotal (95% CI) 165 166 25.9 % 2.86 [ 0.86, 9.49 ]
Total events: 9 (Gluc avoid), 3 (Gluc cont)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.085)
Total (95% CI) 505 515 100.0 % 2.14 [ 1.13, 4.02 ]
Total events: 27 (Gluc avoid), 13 (Gluc cont)
Heterogeneity: Chi2 = 2.00, df = 4 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Chi2 = 0.34, df = 1 (P = 0.56), I2 =0.0%
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Analysis 1.7. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 7 Diabetes mellitus.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 7 Diabetes mellitus
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Ju 2012 2/43 9/44 5.7 % 0.23 [ 0.05, 0.99 ]
Lerut 2008 18/78 14/78 9.0 % 1.29 [ 0.69, 2.40 ]
Llado 2006 17/96 23/102 14.4 % 0.79 [ 0.45, 1.38 ]
Margarit 2005 8/30 11/33 6.8 % 0.80 [ 0.37, 1.72 ]
Pelletier 2013 22/50 19/50 12.2 % 1.16 [ 0.72, 1.86 ]
Ramirez 2013 8/20 8/20 5.2 % 1.00 [ 0.47, 2.14 ]
Reggiani 2005 2/12 5/18 2.6 % 0.60 [ 0.14, 2.60 ]
Subtotal (95% CI) 329 345 55.9 % 0.90 [ 0.70, 1.17 ]
Total events: 77 (Gluc avoid), 89 (Gluc cont)
Heterogeneity: Chi2 = 6.36, df = 6 (P = 0.38); I2 =6%
Test for overall effect: Z = 0.76 (P = 0.45)
2 Glucocorticosteroid withdrawal
Belli 1998 3/54 12/50 8.0 % 0.23 [ 0.07, 0.77 ]
Hu 2008 7/40 14/36 9.5 % 0.45 [ 0.20, 0.99 ]
Moench 2007 12/56 9/54 5.9 % 1.29 [ 0.59, 2.80 ]
Pageaux 2004 12/84 20/90 12.4 % 0.64 [ 0.34, 1.23 ]
Vivarelli 2007 14/25 12/22 8.2 % 1.03 [ 0.61, 1.72 ]
Subtotal (95% CI) 259 252 44.1 % 0.68 [ 0.50, 0.94 ]
Total events: 48 (Gluc avoid), 67 (Gluc cont)
Heterogeneity: Chi2 = 9.12, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 2.34 (P = 0.019)
Total (95% CI) 588 597 100.0 % 0.81 [ 0.66, 0.99 ]
Total events: 125 (Gluc avoid), 156 (Gluc cont)
Heterogeneity: Chi2 = 16.61, df = 11 (P = 0.12); I2 =34%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Chi2 = 1.76, df = 1 (P = 0.19), I2 =43%
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Analysis 1.8. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 8 CMV.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 8 CMV
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Lerut 2008 3/78 2/78 5.2 % 1.50 [ 0.26, 8.73 ]
Llado 2006 8/96 14/102 35.5 % 0.61 [ 0.27, 1.38 ]
Margarit 2005 0/30 1/33 3.7 % 0.37 [ 0.02, 8.65 ]
Ramirez 2013 0/20 0/20 Not estimable
Tisone 1999 2/23 1/22 2.7 % 1.91 [ 0.19, 19.63 ]
Subtotal (95% CI) 247 255 47.1 % 0.76 [ 0.39, 1.49 ]
Total events: 13 (Gluc avoid), 18 (Gluc cont)
Heterogeneity: Chi2 = 1.67, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
2 Glucocorticosteroid withdrawal
Moench 2007 14/56 18/54 47.9 % 0.75 [ 0.42, 1.35 ]
Pageaux 2004 1/84 2/90 5.0 % 0.54 [ 0.05, 5.80 ]
Subtotal (95% CI) 140 144 52.9 % 0.73 [ 0.41, 1.30 ]
Total events: 15 (Gluc avoid), 20 (Gluc cont)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
Total (95% CI) 387 399 100.0 % 0.74 [ 0.48, 1.16 ]
Total events: 28 (Gluc avoid), 38 (Gluc cont)
Heterogeneity: Chi2 = 1.74, df = 5 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 1.9. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 9 HCV recurrence.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 9 HCV recurrence
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Belli 2001 4/11 4/13 2.3 % 1.18 [ 0.38, 3.66 ]
Lerut 2008 14/14 21/21 11.2 % 1.00 [ 0.89, 1.12 ]
Llado 2006 40/43 39/46 24.1 % 1.10 [ 0.95, 1.27 ]
Margarit 2005 17/20 14/15 10.2 % 0.91 [ 0.72, 1.14 ]
Pelletier 2013 6/20 15/31 7.5 % 0.62 [ 0.29, 1.33 ]
Ramirez 2013 12/14 9/11 6.4 % 1.05 [ 0.74, 1.49 ]
Tisone 1999 1/7 5/8 3.0 % 0.23 [ 0.03, 1.52 ]
Subtotal (95% CI) 129 145 64.8 % 0.95 [ 0.84, 1.08 ]
Total events: 94 (Gluc avoid), 107 (Gluc cont)
Heterogeneity: Chi2 = 8.14, df = 6 (P = 0.23); I2 =26%
Test for overall effect: Z = 0.75 (P = 0.45)
2 Glucocorticosteroid withdrawal
Belli 1998 5/25 3/22 2.0 % 1.47 [ 0.40, 5.44 ]
Pageaux 2004 41/53 39/55 24.5 % 1.09 [ 0.87, 1.36 ]
Vivarelli 2007 19/25 13/23 8.7 % 1.34 [ 0.88, 2.05 ]
Subtotal (95% CI) 103 100 35.2 % 1.18 [ 0.96, 1.44 ]
Total events: 65 (Gluc avoid), 55 (Gluc cont)
Heterogeneity: Chi2 = 0.93, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
Total (95% CI) 232 245 100.0 % 1.03 [ 0.92, 1.15 ]
Total events: 159 (Gluc avoid), 162 (Gluc cont)
Heterogeneity: Chi2 = 8.36, df = 9 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Chi2 = 2.92, df = 1 (P = 0.09), I2 =66%
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Analysis 1.10. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 10 Malignancy.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 10 Malignancy
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Lerut 2008 2/78 0/78 6.4 % 5.00 [ 0.24, 102.49 ]
Llado 2006 0/96 5/102 68.7 % 0.10 [ 0.01, 1.72 ]
Subtotal (95% CI) 174 180 75.1 % 0.52 [ 0.13, 2.08 ]
Total events: 2 (Gluc avoid), 5 (Gluc cont)
Heterogeneity: Chi2 = 3.47, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 0.93 (P = 0.35)
2 Glucocorticosteroid withdrawal
Pageaux 2004 1/84 2/90 24.9 % 0.54 [ 0.05, 5.80 ]
Subtotal (95% CI) 84 90 24.9 % 0.54 [ 0.05, 5.80 ]
Total events: 1 (Gluc avoid), 2 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Total (95% CI) 258 270 100.0 % 0.52 [ 0.16, 1.74 ]
Total events: 3 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 3.47, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
0.005 0.1 1 10 200
Favours gluc avoid Favours gluc cont
101Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.11. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 11 Post-transplant lymphoproliferative disorder.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 11 Post-transplant lymphoproliferative disorder
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Lerut 2008 2/78 1/78 67.4 % 2.00 [ 0.19, 21.61 ]
Subtotal (95% CI) 78 78 67.4 % 2.00 [ 0.19, 21.61 ]
Total events: 2 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 Glucocorticosteroid withdrawal
Pageaux 2004 1/84 0/90 32.6 % 3.21 [ 0.13, 77.77 ]
Subtotal (95% CI) 84 90 32.6 % 3.21 [ 0.13, 77.77 ]
Total events: 1 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 162 168 100.0 % 2.39 [ 0.36, 15.95 ]
Total events: 3 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 1.12. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 12 Renal insufficiency.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 12 Renal insufficiency
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Lerut 2008 4/78 8/78 10.7 % 0.50 [ 0.16, 1.59 ]
Llado 2006 41/96 51/102 66.4 % 0.85 [ 0.63, 1.16 ]
Margarit 2005 20/30 17/33 21.7 % 1.29 [ 0.85, 1.96 ]
Reggiani 2005 2/12 1/18 1.1 % 3.00 [ 0.30, 29.52 ]
Total (95% CI) 216 231 100.0 % 0.93 [ 0.73, 1.19 ]
Total events: 67 (Gluc avoid), 77 (Gluc cont)
Heterogeneity: Chi2 = 4.80, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 13 Creatinine.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 13 Creatinine
Study or subgroup Gluc avoid Gluc cont
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mg/dL] N Mean(SD)[mg/dL] IV,Fixed,95% CI IV,Fixed,95% CI
1 Glucocorticosteroid avoidance
Pelletier 2013 50 1.67 (0.15) 50 1.42 (0.15) 57.8 % 0.25 [ 0.19, 0.31 ]
Tisone 1999 23 1.8 (0.1) 22 1.9 (0.2) 23.1 % -0.10 [ -0.19, -0.01 ]
Subtotal (95% CI) 73 72 80.9 % 0.15 [ 0.10, 0.20 ]
Heterogeneity: Chi2 = 38.85, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 5.92 (P < 0.00001)
2 Glucocorticosteroid withdrawal
Chen 2007 28 0.75 (0.2) 26 0.8 (0.2) 17.5 % -0.05 [ -0.16, 0.06 ]
Moench 2007 56 1.14 (1.09) 54 1.26 (0.79) 1.6 % -0.12 [ -0.47, 0.23 ]
Subtotal (95% CI) 84 80 19.1 % -0.06 [ -0.16, 0.05 ]
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
Total (95% CI) 157 152 100.0 % 0.11 [ 0.07, 0.16 ]
Heterogeneity: Chi2 = 51.59, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 4.86 (P < 0.00001)
Test for subgroup differences: Chi2 = 12.60, df = 1 (P = 0.00), I2 =92%
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Analysis 1.14. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 14 Hypertension.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 14 Hypertension
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Ju 2012 2/43 9/44 4.3 % 0.23 [ 0.05, 0.99 ]
Lerut 2008 6/78 10/78 4.8 % 0.60 [ 0.23, 1.57 ]
Llado 2006 48/96 60/102 28.0 % 0.85 [ 0.66, 1.10 ]
Margarit 2005 4/30 9/33 4.1 % 0.49 [ 0.17, 1.42 ]
Pelletier 2013 28/50 24/50 11.6 % 1.17 [ 0.80, 1.70 ]
Reggiani 2005 2/12 5/18 1.9 % 0.60 [ 0.14, 2.60 ]
Subtotal (95% CI) 309 325 54.7 % 0.81 [ 0.66, 1.00 ]
Total events: 90 (Gluc avoid), 117 (Gluc cont)
Heterogeneity: Chi2 = 7.94, df = 5 (P = 0.16); I2 =37%
Test for overall effect: Z = 2.00 (P = 0.045)
2 Glucocorticosteroid withdrawal
Belli 1998 9/54 28/50 14.0 % 0.30 [ 0.16, 0.57 ]
Hu 2008 9/40 10/36 5.1 % 0.81 [ 0.37, 1.77 ]
Moench 2007 25/56 25/54 12.3 % 0.96 [ 0.64, 1.45 ]
Pageaux 2004 24/84 30/90 13.9 % 0.86 [ 0.55, 1.34 ]
Subtotal (95% CI) 234 230 45.3 % 0.71 [ 0.55, 0.91 ]
Total events: 67 (Gluc avoid), 93 (Gluc cont)
Heterogeneity: Chi2 = 9.94, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 2.65 (P = 0.0080)
Total (95% CI) 543 555 100.0 % 0.76 [ 0.65, 0.90 ]
Total events: 157 (Gluc avoid), 210 (Gluc cont)
Heterogeneity: Chi2 = 18.80, df = 9 (P = 0.03); I2 =52%
Test for overall effect: Z = 3.28 (P = 0.0010)
Test for subgroup differences: Chi2 = 0.65, df = 1 (P = 0.42), I2 =0.0%
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Analysis 1.15. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 15 Hyperlipidaemia.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 15 Hyperlipidaemia
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Ju 2012 4/43 5/44 27.9 % 0.82 [ 0.24, 2.85 ]
Margarit 2005 5/30 4/33 21.5 % 1.38 [ 0.41, 4.65 ]
Subtotal (95% CI) 73 77 49.4 % 1.06 [ 0.45, 2.52 ]
Total events: 9 (Gluc avoid), 9 (Gluc cont)
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.89)
2 Glucocorticosteroid withdrawal
Hu 2008 2/40 3/36 17.8 % 0.60 [ 0.11, 3.39 ]
Pageaux 2004 2/84 6/90 32.7 % 0.36 [ 0.07, 1.72 ]
Subtotal (95% CI) 124 126 50.6 % 0.44 [ 0.14, 1.41 ]
Total events: 4 (Gluc avoid), 9 (Gluc cont)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
Total (95% CI) 197 203 100.0 % 0.75 [ 0.38, 1.48 ]
Total events: 13 (Gluc avoid), 18 (Gluc cont)
Heterogeneity: Chi2 = 1.89, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 1.40, df = 1 (P = 0.24), I2 =29%
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Analysis 1.16. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 16 Cholesterol.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 16 Cholesterol
Study or subgroup Gluc avoid Gluc cont
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mg/dL] N Mean(SD)[mg/dL] IV,Fixed,95% CI IV,Fixed,95% CI
1 Glucocorticosteroid avoidance
Llado 2006 96 182 (54) 102 193 (43) 6.7 % -11.00 [ -24.65, 2.65 ]
Pelletier 2013 50 148 (8) 50 167 (11) 87.6 % -19.00 [ -22.77, -15.23 ]
Tisone 1999 23 117 (52) 22 128 (51) 1.4 % -11.00 [ -41.10, 19.10 ]
Subtotal (95% CI) 169 174 95.6 % -18.33 [ -21.93, -14.72 ]
Heterogeneity: Chi2 = 1.46, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 9.96 (P < 0.00001)
2 Glucocorticosteroid withdrawal
Belli 1998 54 183 (81) 50 253 (76) 1.4 % -70.00 [ -100.17, -39.83 ]
Chen 2007 28 151 (69) 26 297 (100) 0.6 % -146.00 [ -192.16, -99.84 ]
Moench 2007 56 207 (77) 54 172 (39) 2.4 % 35.00 [ 12.31, 57.69 ]
Subtotal (95% CI) 138 130 4.4 % -22.06 [ -38.94, -5.18 ]
Heterogeneity: Chi2 = 61.68, df = 2 (P<0.00001); I2 =97%
Test for overall effect: Z = 2.56 (P = 0.010)
Total (95% CI) 307 304 100.0 % -18.49 [ -22.02, -14.96 ]
Heterogeneity: Chi2 = 63.32, df = 5 (P<0.00001); I2 =92%
Test for overall effect: Z = 10.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.18, df = 1 (P = 0.67), I2 =0.0%
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Analysis 1.17. Comparison 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression, Outcome 17 Hypercholesterolaemia.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 1 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression
Outcome: 17 Hypercholesterolaemia
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Lerut 2008 12/78 10/78 35.3 % 1.20 [ 0.55, 2.61 ]
Subtotal (95% CI) 78 78 35.3 % 1.20 [ 0.55, 2.61 ]
Total events: 12 (Gluc avoid), 10 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
2 Glucocorticosteroid withdrawal
Moench 2007 4/56 18/54 64.7 % 0.21 [ 0.08, 0.59 ]
Subtotal (95% CI) 56 54 64.7 % 0.21 [ 0.08, 0.59 ]
Total events: 4 (Gluc avoid), 18 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0030)
Total (95% CI) 134 132 100.0 % 0.56 [ 0.32, 1.00 ]
Total events: 16 (Gluc avoid), 28 (Gluc cont)
Heterogeneity: Chi2 = 7.10, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Chi2 = 6.95, df = 1 (P = 0.01), I2 =86%
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Analysis 2.1. Comparison 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (CNI subgroups), Outcome 1 Mortality.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (CNI subgroups)
Outcome: 1 Mortality
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus
Chen 2007 10/28 14/26 13.0 % 0.66 [ 0.36, 1.22 ]
Hu 2008 1/40 1/36 0.9 % 0.90 [ 0.06, 13.87 ]
Ju 2012 4/43 6/44 5.3 % 0.68 [ 0.21, 2.25 ]
Lerut 2008 17/78 13/78 11.7 % 1.31 [ 0.68, 2.51 ]
Margarit 2005 12/30 11/33 9.4 % 1.20 [ 0.63, 2.30 ]
Moench 2007 17/56 11/54 10.0 % 1.49 [ 0.77, 2.88 ]
Pelletier 2013 20/50 14/50 12.6 % 1.43 [ 0.82, 2.50 ]
Ramirez 2013 8/20 5/20 4.5 % 1.60 [ 0.63, 4.05 ]
Reggiani 2005 1/12 0/18 0.4 % 4.38 [ 0.19, 99.48 ]
Studenik 2005 0/20 1/19 1.4 % 0.32 [ 0.01, 7.35 ]
Vivarelli 2007 6/25 5/22 4.8 % 1.06 [ 0.37, 2.99 ]
Subtotal (95% CI) 402 400 73.9 % 1.17 [ 0.92, 1.51 ]
Total events: 96 (Gluc avoid), 81 (Gluc cont)
Heterogeneity: Chi2 = 7.08, df = 10 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
2 Cyclosporine A
Belli 1998 11/54 9/50 8.4 % 1.13 [ 0.51, 2.50 ]
Llado 2006 5/96 11/102 9.6 % 0.48 [ 0.17, 1.34 ]
Pageaux 2004 9/84 2/90 1.7 % 4.82 [ 1.07, 21.67 ]
Tisone 1999 7/23 7/22 6.4 % 0.96 [ 0.40, 2.28 ]
Subtotal (95% CI) 257 264 26.1 % 1.10 [ 0.69, 1.74 ]
Total events: 32 (Gluc avoid), 29 (Gluc cont)
Heterogeneity: Chi2 = 6.31, df = 3 (P = 0.10); I2 =52%
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 659 664 100.0 % 1.15 [ 0.93, 1.44 ]
Total events: 128 (Gluc avoid), 110 (Gluc cont)
Heterogeneity: Chi2 = 13.54, df = 14 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.80), I2 =0.0%
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Analysis 2.2. Comparison 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (CNI subgroups), Outcome 2 Graft loss including death.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (CNI subgroups)
Outcome: 2 Graft loss including death
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus
Lerut 2008 20/78 17/78 19.0 % 1.18 [ 0.67, 2.07 ]
Margarit 2005 0/30 4/33 4.8 % 0.12 [ 0.01, 2.17 ]
Moench 2007 21/56 15/54 17.0 % 1.35 [ 0.78, 2.33 ]
Pelletier 2013 22/50 14/50 15.6 % 1.57 [ 0.91, 2.71 ]
Ramirez 2013 8/20 6/20 6.7 % 1.33 [ 0.57, 3.14 ]
Reggiani 2005 1/12 3/18 2.7 % 0.50 [ 0.06, 4.26 ]
Studenik 2005 0/20 2/19 2.9 % 0.19 [ 0.01, 3.73 ]
Vivarelli 2007 6/25 7/22 8.3 % 0.75 [ 0.30, 1.91 ]
Subtotal (95% CI) 291 294 76.9 % 1.14 [ 0.86, 1.50 ]
Total events: 78 (Gluc avoid), 68 (Gluc cont)
Heterogeneity: Chi2 = 6.90, df = 7 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
2 Cyclosporine A
Llado 2006 9/96 12/102 13.0 % 0.80 [ 0.35, 1.81 ]
Pageaux 2004 9/84 2/90 2.2 % 4.82 [ 1.07, 21.67 ]
Tisone 1999 7/23 7/22 8.0 % 0.96 [ 0.40, 2.28 ]
Subtotal (95% CI) 203 214 23.1 % 1.23 [ 0.72, 2.09 ]
Total events: 25 (Gluc avoid), 21 (Gluc cont)
Heterogeneity: Chi2 = 4.57, df = 2 (P = 0.10); I2 =56%
Test for overall effect: Z = 0.75 (P = 0.45)
Total (95% CI) 494 508 100.0 % 1.16 [ 0.91, 1.48 ]
Total events: 103 (Gluc avoid), 89 (Gluc cont)
Heterogeneity: Chi2 = 11.24, df = 10 (P = 0.34); I2 =11%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
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Analysis 2.3. Comparison 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (CNI subgroups), Outcome 3 Acute rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (CNI subgroups)
Outcome: 3 Acute rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus
Chen 2007 4/28 3/26 2.7 % 1.24 [ 0.31, 5.01 ]
Hu 2008 5/40 4/36 3.7 % 1.13 [ 0.33, 3.87 ]
Ju 2012 4/43 3/44 2.6 % 1.36 [ 0.32, 5.74 ]
Lerut 2008 18/78 16/78 13.9 % 1.13 [ 0.62, 2.04 ]
Margarit 2005 11/30 10/33 8.3 % 1.21 [ 0.60, 2.43 ]
Moench 2007 19/56 14/54 12.4 % 1.31 [ 0.73, 2.34 ]
Pelletier 2013 10/50 7/50 6.1 % 1.43 [ 0.59, 3.45 ]
Ramirez 2013 1/20 1/20 0.9 % 1.00 [ 0.07, 14.90 ]
Reggiani 2005 9/12 3/18 2.1 % 4.50 [ 1.52, 13.30 ]
Studenik 2005 7/20 3/19 2.7 % 2.22 [ 0.67, 7.34 ]
Vivarelli 2007 2/25 4/22 3.7 % 0.44 [ 0.09, 2.17 ]
Subtotal (95% CI) 402 400 58.8 % 1.35 [ 1.02, 1.77 ]
Total events: 90 (Gluc avoid), 68 (Gluc cont)
Heterogeneity: Chi2 = 7.92, df = 10 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
2 Cyclosporine A
Belli 1998 2/54 3/50 2.7 % 0.62 [ 0.11, 3.54 ]
Belli 2001 5/11 7/13 5.6 % 0.84 [ 0.37, 1.92 ]
Llado 2006 17/96 13/102 10.9 % 1.39 [ 0.71, 2.70 ]
Pageaux 2004 32/84 22/90 18.4 % 1.56 [ 0.99, 2.45 ]
Tisone 1999 4/23 4/22 3.5 % 0.96 [ 0.27, 3.36 ]
Subtotal (95% CI) 268 277 41.2 % 1.30 [ 0.94, 1.80 ]
Total events: 60 (Gluc avoid), 49 (Gluc cont)
Heterogeneity: Chi2 = 2.64, df = 4 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
Total (95% CI) 670 677 100.0 % 1.33 [ 1.08, 1.64 ]
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 150 (Gluc avoid), 117 (Gluc cont)
Heterogeneity: Chi2 = 10.60, df = 15 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.66 (P = 0.0079)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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Analysis 2.4. Comparison 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (CNI subgroups), Outcome 4 Infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (CNI subgroups)
Outcome: 4 Infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus
Ju 2012 6/43 16/44 11.3 % 0.38 [ 0.17, 0.89 ]
Pelletier 2013 26/50 22/50 15.8 % 1.18 [ 0.78, 1.78 ]
Ramirez 2013 12/20 12/20 8.6 % 1.00 [ 0.60, 1.66 ]
Reggiani 2005 6/12 5/18 2.9 % 1.80 [ 0.71, 4.59 ]
Subtotal (95% CI) 125 132 38.6 % 0.95 [ 0.72, 1.27 ]
Total events: 50 (Gluc avoid), 55 (Gluc cont)
Heterogeneity: Chi2 = 7.38, df = 3 (P = 0.06); I2 =59%
Test for overall effect: Z = 0.33 (P = 0.74)
2 Cyclosporine A
Belli 1998 1/54 8/50 6.0 % 0.12 [ 0.02, 0.89 ]
Llado 2006 45/96 52/102 36.2 % 0.92 [ 0.69, 1.22 ]
Pageaux 2004 7/84 12/90 8.3 % 0.63 [ 0.26, 1.51 ]
Tisone 1999 17/23 15/22 11.0 % 1.08 [ 0.75, 1.58 ]
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 257 264 61.4 % 0.83 [ 0.66, 1.05 ]
Total events: 70 (Gluc avoid), 87 (Gluc cont)
Heterogeneity: Chi2 = 6.39, df = 3 (P = 0.09); I2 =53%
Test for overall effect: Z = 1.57 (P = 0.12)
Total (95% CI) 382 396 100.0 % 0.88 [ 0.73, 1.05 ]
Total events: 120 (Gluc avoid), 142 (Gluc cont)
Heterogeneity: Chi2 = 13.93, df = 7 (P = 0.05); I2 =50%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 0.53, df = 1 (P = 0.47), I2 =0.0%
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Analysis 2.5. Comparison 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (CNI subgroups), Outcome 5 Chronic rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (CNI subgroups)
Outcome: 5 Chronic rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus
Lerut 2008 1/78 4/78 24.5 % 0.25 [ 0.03, 2.19 ]
Margarit 2005 0/30 0/33 Not estimable
Moench 2007 6/56 0/54 3.1 % 12.54 [ 0.72, 217.40 ]
Pelletier 2013 1/50 4/50 24.5 % 0.25 [ 0.03, 2.16 ]
Subtotal (95% CI) 214 215 52.1 % 0.99 [ 0.38, 2.54 ]
Total events: 8 (Gluc avoid), 8 (Gluc cont)
Heterogeneity: Chi2 = 6.15, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 0.03 (P = 0.98)
2 Cyclosporine A
Belli 1998 0/54 1/50 9.5 % 0.31 [ 0.01, 7.42 ]
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Belli 2001 1/11 0/13 2.8 % 3.50 [ 0.16, 78.19 ]
Llado 2006 3/96 1/102 5.9 % 3.19 [ 0.34, 30.12 ]
Pageaux 2004 3/84 5/90 29.6 % 0.64 [ 0.16, 2.61 ]
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 268 277 47.9 % 1.06 [ 0.41, 2.76 ]
Total events: 7 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 2.56, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
Total (95% CI) 482 492 100.0 % 1.02 [ 0.52, 2.00 ]
Total events: 15 (Gluc avoid), 15 (Gluc cont)
Heterogeneity: Chi2 = 8.78, df = 6 (P = 0.19); I2 =32%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
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Analysis 2.6. Comparison 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (CNI subgroups), Outcome 6 Glucocorticosteroid-resistant rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (CNI subgroups)
Outcome: 6 Glucocorticosteroid-resistant rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus
Ju 2012 0/43 0/44 Not estimable
Lerut 2008 10/78 3/78 22.8 % 3.33 [ 0.95, 11.65 ]
Margarit 2005 4/30 3/33 21.7 % 1.47 [ 0.36, 6.03 ]
Moench 2007 1/56 0/54 3.9 % 2.89 [ 0.12, 69.55 ]
Pelletier 2013 0/50 0/50 Not estimable
Ramirez 2013 0/20 0/20 Not estimable
Vivarelli 2007 0/25 0/22 Not estimable
Subtotal (95% CI) 302 301 48.4 % 2.46 [ 1.01, 5.97 ]
Total events: 15 (Gluc avoid), 6 (Gluc cont)
Heterogeneity: Chi2 = 0.75, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.99 (P = 0.047)
2 Cyclosporine A
Llado 2006 4/96 4/102 29.5 % 1.06 [ 0.27, 4.13 ]
Pageaux 2004 8/84 3/90 22.0 % 2.86 [ 0.78, 10.41 ]
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 203 214 51.6 % 1.83 [ 0.74, 4.55 ]
Total events: 12 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 1.07, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 1.30 (P = 0.19)
Total (95% CI) 505 515 100.0 % 2.14 [ 1.13, 4.02 ]
Total events: 27 (Gluc avoid), 13 (Gluc cont)
Heterogeneity: Chi2 = 2.00, df = 4 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.65), I2 =0.0%
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Analysis 2.7. Comparison 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (CNI subgroups), Outcome 7 Diabetes mellitus.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (CNI subgroups)
Outcome: 7 Diabetes mellitus
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus
Hu 2008 7/40 14/36 9.5 % 0.45 [ 0.20, 0.99 ]
Ju 2012 2/43 9/44 5.7 % 0.23 [ 0.05, 0.99 ]
Lerut 2008 18/78 14/78 9.0 % 1.29 [ 0.69, 2.40 ]
Margarit 2005 8/30 11/33 6.8 % 0.80 [ 0.37, 1.72 ]
Moench 2007 12/56 9/54 5.9 % 1.29 [ 0.59, 2.80 ]
Pelletier 2013 22/50 19/50 12.2 % 1.16 [ 0.72, 1.86 ]
Ramirez 2013 8/20 8/20 5.2 % 1.00 [ 0.47, 2.14 ]
Reggiani 2005 2/12 5/18 2.6 % 0.60 [ 0.14, 2.60 ]
Vivarelli 2007 14/25 12/22 8.2 % 1.03 [ 0.61, 1.72 ]
Subtotal (95% CI) 354 355 65.1 % 0.91 [ 0.72, 1.15 ]
Total events: 93 (Gluc avoid), 101 (Gluc cont)
Heterogeneity: Chi2 = 10.07, df = 8 (P = 0.26); I2 =21%
Test for overall effect: Z = 0.76 (P = 0.45)
2 Cyclosporine A
Belli 1998 3/54 12/50 8.0 % 0.23 [ 0.07, 0.77 ]
Llado 2006 17/96 23/102 14.4 % 0.79 [ 0.45, 1.38 ]
Pageaux 2004 12/84 20/90 12.4 % 0.64 [ 0.34, 1.23 ]
Subtotal (95% CI) 234 242 34.9 % 0.61 [ 0.41, 0.90 ]
Total events: 32 (Gluc avoid), 55 (Gluc cont)
Heterogeneity: Chi2 = 3.30, df = 2 (P = 0.19); I2 =39%
Test for overall effect: Z = 2.48 (P = 0.013)
Total (95% CI) 588 597 100.0 % 0.81 [ 0.66, 0.99 ]
Total events: 125 (Gluc avoid), 156 (Gluc cont)
Heterogeneity: Chi2 = 16.61, df = 11 (P = 0.12); I2 =34%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Chi2 = 3.05, df = 1 (P = 0.08), I2 =67%
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Analysis 2.8. Comparison 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (CNI subgroups), Outcome 8 CMV infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (CNI subgroups)
Outcome: 8 CMV infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus
Lerut 2008 3/78 2/78 5.2 % 1.50 [ 0.26, 8.73 ]
Margarit 2005 0/30 1/33 3.7 % 0.37 [ 0.02, 8.65 ]
Moench 2007 14/56 18/54 47.9 % 0.75 [ 0.42, 1.35 ]
Ramirez 2013 0/20 0/20 Not estimable
Subtotal (95% CI) 184 185 56.8 % 0.79 [ 0.46, 1.38 ]
Total events: 17 (Gluc avoid), 21 (Gluc cont)
Heterogeneity: Chi2 = 0.77, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
2 Cyclosporine A
Llado 2006 8/96 14/102 35.5 % 0.61 [ 0.27, 1.38 ]
Pageaux 2004 1/84 2/90 5.0 % 0.54 [ 0.05, 5.80 ]
Tisone 1999 2/23 1/22 2.7 % 1.91 [ 0.19, 19.63 ]
Subtotal (95% CI) 203 214 43.2 % 0.68 [ 0.33, 1.40 ]
Total events: 11 (Gluc avoid), 17 (Gluc cont)
Heterogeneity: Chi2 = 0.87, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Total (95% CI) 387 399 100.0 % 0.74 [ 0.48, 1.16 ]
Total events: 28 (Gluc avoid), 38 (Gluc cont)
Heterogeneity: Chi2 = 1.74, df = 5 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
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Analysis 2.9. Comparison 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (CNI subgroups), Outcome 9 HCV recurrence.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (CNI subgroups)
Outcome: 9 HCV recurrence
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus
Lerut 2008 14/14 21/21 11.2 % 1.00 [ 0.89, 1.12 ]
Margarit 2005 17/20 14/15 10.2 % 0.91 [ 0.72, 1.14 ]
Pelletier 2013 6/20 15/31 7.5 % 0.62 [ 0.29, 1.33 ]
Ramirez 2013 12/14 9/11 6.4 % 1.05 [ 0.74, 1.49 ]
Vivarelli 2007 19/25 13/23 8.7 % 1.34 [ 0.88, 2.05 ]
Subtotal (95% CI) 93 101 44.0 % 0.99 [ 0.84, 1.16 ]
Total events: 68 (Gluc avoid), 72 (Gluc cont)
Heterogeneity: Chi2 = 4.13, df = 4 (P = 0.39); I2 =3%
Test for overall effect: Z = 0.13 (P = 0.89)
2 Cyclosporine A
Belli 1998 5/25 3/22 2.0 % 1.47 [ 0.40, 5.44 ]
Belli 2001 4/11 4/13 2.3 % 1.18 [ 0.38, 3.66 ]
Llado 2006 40/43 39/46 24.1 % 1.10 [ 0.95, 1.27 ]
Pageaux 2004 41/53 39/55 24.5 % 1.09 [ 0.87, 1.36 ]
Tisone 1999 1/7 5/8 3.0 % 0.23 [ 0.03, 1.52 ]
Subtotal (95% CI) 139 144 56.0 % 1.07 [ 0.92, 1.23 ]
Total events: 91 (Gluc avoid), 90 (Gluc cont)
Heterogeneity: Chi2 = 3.00, df = 4 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Total (95% CI) 232 245 100.0 % 1.03 [ 0.92, 1.15 ]
Total events: 159 (Gluc avoid), 162 (Gluc cont)
Heterogeneity: Chi2 = 8.36, df = 9 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Chi2 = 0.44, df = 1 (P = 0.51), I2 =0.0%
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Analysis 2.10. Comparison 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (CNI subgroups), Outcome 10 Malignancy.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (CNI subgroups)
Outcome: 10 Malignancy
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus
Lerut 2008 2/78 0/78 6.4 % 5.00 [ 0.24, 102.49 ]
Subtotal (95% CI) 78 78 6.4 % 5.00 [ 0.24, 102.49 ]
Total events: 2 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
2 Cyclosporine A
Llado 2006 0/96 5/102 68.7 % 0.10 [ 0.01, 1.72 ]
Pageaux 2004 1/84 2/90 24.9 % 0.54 [ 0.05, 5.80 ]
Subtotal (95% CI) 180 192 93.6 % 0.21 [ 0.04, 1.22 ]
Total events: 1 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.082)
Total (95% CI) 258 270 100.0 % 0.52 [ 0.16, 1.74 ]
Total events: 3 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 3.47, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Chi2 = 3.15, df = 1 (P = 0.08), I2 =68%
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Analysis 2.11. Comparison 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (CNI subgroups), Outcome 11 Post-transplant lymphoproliferative disorder.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (CNI subgroups)
Outcome: 11 Post-transplant lymphoproliferative disorder
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus
Lerut 2008 2/78 1/78 67.4 % 2.00 [ 0.19, 21.61 ]
Subtotal (95% CI) 78 78 67.4 % 2.00 [ 0.19, 21.61 ]
Total events: 2 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 Cyclosporine A
Pageaux 2004 1/84 0/90 32.6 % 3.21 [ 0.13, 77.77 ]
Subtotal (95% CI) 84 90 32.6 % 3.21 [ 0.13, 77.77 ]
Total events: 1 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 162 168 100.0 % 2.39 [ 0.36, 15.95 ]
Total events: 3 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 2.12. Comparison 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (CNI subgroups), Outcome 12 Renal insufficiency.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (CNI subgroups)
Outcome: 12 Renal insufficiency
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus
Lerut 2008 4/78 8/78 10.7 % 0.50 [ 0.16, 1.59 ]
Margarit 2005 20/30 17/33 21.7 % 1.29 [ 0.85, 1.96 ]
Reggiani 2005 2/12 1/18 1.1 % 3.00 [ 0.30, 29.52 ]
Subtotal (95% CI) 120 129 33.6 % 1.09 [ 0.73, 1.64 ]
Total events: 26 (Gluc avoid), 26 (Gluc cont)
Heterogeneity: Chi2 = 3.12, df = 2 (P = 0.21); I2 =36%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Cyclosporine A
Llado 2006 41/96 51/102 66.4 % 0.85 [ 0.63, 1.16 ]
Subtotal (95% CI) 96 102 66.4 % 0.85 [ 0.63, 1.16 ]
Total events: 41 (Gluc avoid), 51 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 216 231 100.0 % 0.93 [ 0.73, 1.19 ]
Total events: 67 (Gluc avoid), 77 (Gluc cont)
Heterogeneity: Chi2 = 4.80, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 0.93, df = 1 (P = 0.34), I2 =0.0%
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Analysis 2.13. Comparison 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (CNI subgroups), Outcome 13 Creatinine.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (CNI subgroups)
Outcome: 13 Creatinine
Study or subgroup Gluc avoid Gluc cont
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mg/dL] N Mean(SD)[mg/dL] IV,Fixed,95% CI IV,Fixed,95% CI
1 Tacrolimus
Chen 2007 28 0.75 (0.2) 26 0.8 (0.2) 17.5 % -0.05 [ -0.16, 0.06 ]
Moench 2007 56 1.14 (1.09) 54 1.26 (0.79) 1.6 % -0.12 [ -0.47, 0.23 ]
Pelletier 2013 50 1.67 (0.15) 50 1.42 (0.15) 57.8 % 0.25 [ 0.19, 0.31 ]
Subtotal (95% CI) 134 130 76.9 % 0.17 [ 0.12, 0.22 ]
Heterogeneity: Chi2 = 25.97, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 6.69 (P < 0.00001)
2 Cyclosporine A
Tisone 1999 23 1.8 (0.1) 22 1.9 (0.2) 23.1 % -0.10 [ -0.19, -0.01 ]
Subtotal (95% CI) 23 22 23.1 % -0.10 [ -0.19, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
Total (95% CI) 157 152 100.0 % 0.11 [ 0.07, 0.16 ]
Heterogeneity: Chi2 = 51.59, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 4.86 (P < 0.00001)
Test for subgroup differences: Chi2 = 25.63, df = 1 (P = 0.00), I2 =96%
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Analysis 2.14. Comparison 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (CNI subgroups), Outcome 14 Hypertension.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (CNI subgroups)
Outcome: 14 Hypertension
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus
Hu 2008 9/40 10/36 5.1 % 0.81 [ 0.37, 1.77 ]
Ju 2012 2/43 9/44 4.3 % 0.23 [ 0.05, 0.99 ]
Lerut 2008 6/78 10/78 4.8 % 0.60 [ 0.23, 1.57 ]
Margarit 2005 4/30 9/33 4.1 % 0.49 [ 0.17, 1.42 ]
Moench 2007 25/56 25/54 12.3 % 0.96 [ 0.64, 1.45 ]
Pelletier 2013 28/50 24/50 11.6 % 1.17 [ 0.80, 1.70 ]
Reggiani 2005 2/12 5/18 1.9 % 0.60 [ 0.14, 2.60 ]
Subtotal (95% CI) 309 313 44.0 % 0.83 [ 0.65, 1.06 ]
Total events: 76 (Gluc avoid), 92 (Gluc cont)
Heterogeneity: Chi2 = 8.19, df = 6 (P = 0.22); I2 =27%
Test for overall effect: Z = 1.52 (P = 0.13)
2 Cyclosporine A
Belli 1998 9/54 28/50 14.0 % 0.30 [ 0.16, 0.57 ]
Llado 2006 48/96 60/102 28.0 % 0.85 [ 0.66, 1.10 ]
Pageaux 2004 24/84 30/90 13.9 % 0.86 [ 0.55, 1.34 ]
Subtotal (95% CI) 234 242 56.0 % 0.71 [ 0.58, 0.88 ]
Total events: 81 (Gluc avoid), 118 (Gluc cont)
Heterogeneity: Chi2 = 9.48, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 3.10 (P = 0.0019)
Total (95% CI) 543 555 100.0 % 0.76 [ 0.65, 0.90 ]
Total events: 157 (Gluc avoid), 210 (Gluc cont)
Heterogeneity: Chi2 = 18.80, df = 9 (P = 0.03); I2 =52%
Test for overall effect: Z = 3.28 (P = 0.0010)
Test for subgroup differences: Chi2 = 0.80, df = 1 (P = 0.37), I2 =0.0%
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Analysis 2.15. Comparison 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (CNI subgroups), Outcome 15 Hyperlipidaemia.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (CNI subgroups)
Outcome: 15 Hyperlipidaemia
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus
Hu 2008 2/40 3/36 17.8 % 0.60 [ 0.11, 3.39 ]
Ju 2012 4/43 5/44 27.9 % 0.82 [ 0.24, 2.85 ]
Margarit 2005 5/30 4/33 21.5 % 1.38 [ 0.41, 4.65 ]
Subtotal (95% CI) 113 113 67.3 % 0.94 [ 0.44, 2.02 ]
Total events: 11 (Gluc avoid), 12 (Gluc cont)
Heterogeneity: Chi2 = 0.68, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
2 Cyclosporine A
Pageaux 2004 2/84 6/90 32.7 % 0.36 [ 0.07, 1.72 ]
Subtotal (95% CI) 84 90 32.7 % 0.36 [ 0.07, 1.72 ]
Total events: 2 (Gluc avoid), 6 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Total (95% CI) 197 203 100.0 % 0.75 [ 0.38, 1.48 ]
Total events: 13 (Gluc avoid), 18 (Gluc cont)
Heterogeneity: Chi2 = 1.89, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 1.17, df = 1 (P = 0.28), I2 =15%
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Analysis 2.16. Comparison 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (CNI subgroups), Outcome 16 Cholesterol.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 2 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (CNI subgroups)
Outcome: 16 Cholesterol
Study or subgroup Gluc avoid Gluc cont
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mg/dL] N Mean(SD)[mg/dL] IV,Fixed,95% CI IV,Fixed,95% CI
1 Tacrolimus
Chen 2007 28 151 (69) 26 297 (100) 0.6 % -146.00 [ -192.16, -99.84 ]
Moench 2007 56 207 (77) 54 172 (39) 2.4 % 35.00 [ 12.31, 57.69 ]
Pelletier 2013 50 148 (8) 50 167 (11) 87.6 % -19.00 [ -22.77, -15.23 ]
Subtotal (95% CI) 134 130 90.6 % -18.38 [ -22.09, -14.67 ]
Heterogeneity: Chi2 = 50.73, df = 2 (P<0.00001); I2 =96%
Test for overall effect: Z = 9.72 (P < 0.00001)
2 Cyclosporine A
Belli 1998 54 183 (81) 50 253 (76) 1.4 % -70.00 [ -100.17, -39.83 ]
Llado 2006 96 182 (54) 102 193 (43) 6.7 % -11.00 [ -24.65, 2.65 ]
Tisone 1999 23 117 (52) 22 128 (51) 1.4 % -11.00 [ -41.10, 19.10 ]
Subtotal (95% CI) 173 174 9.4 % -19.56 [ -31.05, -8.07 ]
Heterogeneity: Chi2 = 12.56, df = 2 (P = 0.002); I2 =84%
Test for overall effect: Z = 3.34 (P = 0.00085)
Total (95% CI) 307 304 100.0 % -18.49 [ -22.02, -14.96 ]
Heterogeneity: Chi2 = 63.32, df = 5 (P<0.00001); I2 =92%
Test for overall effect: Z = 10.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
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Analysis 3.1. Comparison 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (antiproliferative subgroups), Outcome 1 Mortality.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (antiproliferative subgroups)
Outcome: 1 Mortality
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No antiproliferative agent
Belli 1998 11/54 9/50 8.4 % 1.13 [ 0.51, 2.50 ]
Hu 2008 1/40 1/36 0.9 % 0.90 [ 0.06, 13.87 ]
Lerut 2008 17/78 13/78 11.7 % 1.31 [ 0.68, 2.51 ]
Llado 2006 5/96 11/102 9.6 % 0.48 [ 0.17, 1.34 ]
Margarit 2005 12/30 11/33 9.4 % 1.20 [ 0.63, 2.30 ]
Moench 2007 17/56 11/54 10.0 % 1.49 [ 0.77, 2.88 ]
Pageaux 2004 9/84 2/90 1.7 % 4.82 [ 1.07, 21.67 ]
Vivarelli 2007 6/25 5/22 4.8 % 1.06 [ 0.37, 2.99 ]
Subtotal (95% CI) 463 465 56.5 % 1.24 [ 0.92, 1.66 ]
Total events: 78 (Gluc avoid), 63 (Gluc cont)
Heterogeneity: Chi2 = 6.95, df = 7 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
2 Mycophenolate mofetil
Chen 2007 10/28 14/26 13.0 % 0.66 [ 0.36, 1.22 ]
Ju 2012 4/43 6/44 5.3 % 0.68 [ 0.21, 2.25 ]
Pelletier 2013 20/50 14/50 12.6 % 1.43 [ 0.82, 2.50 ]
Ramirez 2013 8/20 5/20 4.5 % 1.60 [ 0.63, 4.05 ]
Reggiani 2005 1/12 0/18 0.4 % 4.38 [ 0.19, 99.48 ]
Studenik 2005 0/20 1/19 1.4 % 0.32 [ 0.01, 7.35 ]
Subtotal (95% CI) 173 177 37.1 % 1.06 [ 0.75, 1.51 ]
Total events: 43 (Gluc avoid), 40 (Gluc cont)
Heterogeneity: Chi2 = 5.99, df = 5 (P = 0.31); I2 =17%
Test for overall effect: Z = 0.33 (P = 0.74)
3 Azathioprine
Tisone 1999 7/23 7/22 6.4 % 0.96 [ 0.40, 2.28 ]
Subtotal (95% CI) 23 22 6.4 % 0.96 [ 0.40, 2.28 ]
Total events: 7 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.10 (P = 0.92)
Total (95% CI) 659 664 100.0 % 1.15 [ 0.93, 1.44 ]
Total events: 128 (Gluc avoid), 110 (Gluc cont)
Heterogeneity: Chi2 = 13.54, df = 14 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Chi2 = 0.60, df = 2 (P = 0.74), I2 =0.0%
0.01 0.1 1 10 100
Favours gluc avoid Favours gluc cont
Analysis 3.2. Comparison 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (antiproliferative subgroups), Outcome 2 Graft loss including death.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (antiproliferative subgroups)
Outcome: 2 Graft loss including death
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No antiproliferative agent
Lerut 2008 20/78 17/78 19.0 % 1.18 [ 0.67, 2.07 ]
Llado 2006 9/96 12/102 13.0 % 0.80 [ 0.35, 1.81 ]
Margarit 2005 0/30 4/33 4.8 % 0.12 [ 0.01, 2.17 ]
Moench 2007 21/56 15/54 17.0 % 1.35 [ 0.78, 2.33 ]
Pageaux 2004 9/84 2/90 2.2 % 4.82 [ 1.07, 21.67 ]
Vivarelli 2007 6/25 7/22 8.3 % 0.75 [ 0.30, 1.91 ]
Subtotal (95% CI) 369 379 64.2 % 1.13 [ 0.83, 1.55 ]
Total events: 65 (Gluc avoid), 57 (Gluc cont)
Heterogeneity: Chi2 = 7.73, df = 5 (P = 0.17); I2 =35%
Test for overall effect: Z = 0.79 (P = 0.43)
2 Mycophenolate mofetil
Pelletier 2013 22/50 14/50 15.6 % 1.57 [ 0.91, 2.71 ]
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ramirez 2013 8/20 6/20 6.7 % 1.33 [ 0.57, 3.14 ]
Reggiani 2005 1/12 3/18 2.7 % 0.50 [ 0.06, 4.26 ]
Studenik 2005 0/20 2/19 2.9 % 0.19 [ 0.01, 3.73 ]
Subtotal (95% CI) 102 107 27.8 % 1.27 [ 0.82, 1.96 ]
Total events: 31 (Gluc avoid), 25 (Gluc cont)
Heterogeneity: Chi2 = 2.89, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
3 Azathioprine
Tisone 1999 7/23 7/22 8.0 % 0.96 [ 0.40, 2.28 ]
Subtotal (95% CI) 23 22 8.0 % 0.96 [ 0.40, 2.28 ]
Total events: 7 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
Total (95% CI) 494 508 100.0 % 1.16 [ 0.91, 1.48 ]
Total events: 103 (Gluc avoid), 89 (Gluc cont)
Heterogeneity: Chi2 = 11.24, df = 10 (P = 0.34); I2 =11%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Chi2 = 0.37, df = 2 (P = 0.83), I2 =0.0%
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Analysis 3.3. Comparison 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (antiproliferative subgroups), Outcome 3 Acute rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (antiproliferative subgroups)
Outcome: 3 Acute rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No antiproliferative agent
Belli 1998 2/54 3/50 2.7 % 0.62 [ 0.11, 3.54 ]
Belli 2001 5/11 7/13 5.6 % 0.84 [ 0.37, 1.92 ]
Hu 2008 5/40 4/36 3.7 % 1.13 [ 0.33, 3.87 ]
Lerut 2008 18/78 16/78 13.9 % 1.13 [ 0.62, 2.04 ]
Llado 2006 17/96 13/102 10.9 % 1.39 [ 0.71, 2.70 ]
Margarit 2005 11/30 10/33 8.3 % 1.21 [ 0.60, 2.43 ]
Moench 2007 19/56 14/54 12.4 % 1.31 [ 0.73, 2.34 ]
Pageaux 2004 32/84 22/90 18.4 % 1.56 [ 0.99, 2.45 ]
Vivarelli 2007 2/25 4/22 3.7 % 0.44 [ 0.09, 2.17 ]
Subtotal (95% CI) 474 478 79.5 % 1.23 [ 0.97, 1.56 ]
Total events: 111 (Gluc avoid), 93 (Gluc cont)
Heterogeneity: Chi2 = 4.32, df = 8 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.086)
2 Mycophenolate mofetil
Chen 2007 4/28 3/26 2.7 % 1.24 [ 0.31, 5.01 ]
Ju 2012 4/43 3/44 2.6 % 1.36 [ 0.32, 5.74 ]
Pelletier 2013 10/50 7/50 6.1 % 1.43 [ 0.59, 3.45 ]
Ramirez 2013 1/20 1/20 0.9 % 1.00 [ 0.07, 14.90 ]
Reggiani 2005 9/12 3/18 2.1 % 4.50 [ 1.52, 13.30 ]
Studenik 2005 7/20 3/19 2.7 % 2.22 [ 0.67, 7.34 ]
Subtotal (95% CI) 173 177 17.0 % 1.87 [ 1.15, 3.04 ]
Total events: 35 (Gluc avoid), 20 (Gluc cont)
Heterogeneity: Chi2 = 3.68, df = 5 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.50 (P = 0.012)
3 Azathioprine
Tisone 1999 4/23 4/22 3.5 % 0.96 [ 0.27, 3.36 ]
Subtotal (95% CI) 23 22 3.5 % 0.96 [ 0.27, 3.36 ]
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 4 (Gluc avoid), 4 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
Total (95% CI) 670 677 100.0 % 1.33 [ 1.08, 1.64 ]
Total events: 150 (Gluc avoid), 117 (Gluc cont)
Heterogeneity: Chi2 = 10.60, df = 15 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.66 (P = 0.0079)
Test for subgroup differences: Chi2 = 2.53, df = 2 (P = 0.28), I2 =21%
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Analysis 3.4. Comparison 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (antiproliferative subgroups), Outcome 4 Infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (antiproliferative subgroups)
Outcome: 4 Infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No antiproliferative agent
Belli 1998 1/54 8/50 6.0 % 0.12 [ 0.02, 0.89 ]
Llado 2006 45/96 52/102 36.2 % 0.92 [ 0.69, 1.22 ]
Pageaux 2004 7/84 12/90 8.3 % 0.63 [ 0.26, 1.51 ]
Subtotal (95% CI) 234 242 50.4 % 0.78 [ 0.59, 1.02 ]
Total events: 53 (Gluc avoid), 72 (Gluc cont)
Heterogeneity: Chi2 = 4.92, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 1.81 (P = 0.070)
2 Mycophenolate mofetil
Ju 2012 6/43 16/44 11.3 % 0.38 [ 0.17, 0.89 ]
Pelletier 2013 26/50 22/50 15.8 % 1.18 [ 0.78, 1.78 ]
Ramirez 2013 12/20 12/20 8.6 % 1.00 [ 0.60, 1.66 ]
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Reggiani 2005 6/12 5/18 2.9 % 1.80 [ 0.71, 4.59 ]
Subtotal (95% CI) 125 132 38.6 % 0.95 [ 0.72, 1.27 ]
Total events: 50 (Gluc avoid), 55 (Gluc cont)
Heterogeneity: Chi2 = 7.38, df = 3 (P = 0.06); I2 =59%
Test for overall effect: Z = 0.33 (P = 0.74)
3 Azathioprine
Tisone 1999 17/23 15/22 11.0 % 1.08 [ 0.75, 1.58 ]
Subtotal (95% CI) 23 22 11.0 % 1.08 [ 0.75, 1.58 ]
Total events: 17 (Gluc avoid), 15 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
Total (95% CI) 382 396 100.0 % 0.88 [ 0.73, 1.05 ]
Total events: 120 (Gluc avoid), 142 (Gluc cont)
Heterogeneity: Chi2 = 13.93, df = 7 (P = 0.05); I2 =50%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 2.22, df = 2 (P = 0.33), I2 =10%
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Analysis 3.5. Comparison 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (antiproliferative subgroups), Outcome 5 Chronic rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (antiproliferative subgroups)
Outcome: 5 Chronic rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No antiproliferative agent
Belli 1998 0/54 1/50 9.5 % 0.31 [ 0.01, 7.42 ]
Belli 2001 1/11 0/13 2.8 % 3.50 [ 0.16, 78.19 ]
Lerut 2008 1/78 4/78 24.5 % 0.25 [ 0.03, 2.19 ]
Llado 2006 3/96 1/102 5.9 % 3.19 [ 0.34, 30.12 ]
Margarit 2005 0/30 0/33 Not estimable
Moench 2007 6/56 0/54 3.1 % 12.54 [ 0.72, 217.40 ]
Pageaux 2004 3/84 5/90 29.6 % 0.64 [ 0.16, 2.61 ]
Subtotal (95% CI) 409 420 75.5 % 1.27 [ 0.61, 2.65 ]
Total events: 14 (Gluc avoid), 11 (Gluc cont)
Heterogeneity: Chi2 = 7.36, df = 5 (P = 0.20); I2 =32%
Test for overall effect: Z = 0.64 (P = 0.52)
2 Mycophenolate mofetil
Pelletier 2013 1/50 4/50 24.5 % 0.25 [ 0.03, 2.16 ]
Subtotal (95% CI) 50 50 24.5 % 0.25 [ 0.03, 2.16 ]
Total events: 1 (Gluc avoid), 4 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
3 Azathioprine
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 23 22 Not estimable
Total events: 0 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 482 492 100.0 % 1.02 [ 0.52, 2.00 ]
Total events: 15 (Gluc avoid), 15 (Gluc cont)
Heterogeneity: Chi2 = 8.78, df = 6 (P = 0.19); I2 =32%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 1.96, df = 1 (P = 0.16), I2 =49%
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Analysis 3.6. Comparison 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (antiproliferative subgroups), Outcome 6 Glucocorticosteroid-resistant
rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (antiproliferative subgroups)
Outcome: 6 Glucocorticosteroid-resistant rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No antiproliferative agent
Lerut 2008 10/78 3/78 22.8 % 3.33 [ 0.95, 11.65 ]
Llado 2006 4/96 4/102 29.5 % 1.06 [ 0.27, 4.13 ]
Margarit 2005 4/30 3/33 21.7 % 1.47 [ 0.36, 6.03 ]
Moench 2007 1/56 0/54 3.9 % 2.89 [ 0.12, 69.55 ]
Pageaux 2004 8/84 3/90 22.0 % 2.86 [ 0.78, 10.41 ]
Vivarelli 2007 0/25 0/22 Not estimable
Subtotal (95% CI) 369 379 100.0 % 2.14 [ 1.13, 4.02 ]
Total events: 27 (Gluc avoid), 13 (Gluc cont)
Heterogeneity: Chi2 = 2.00, df = 4 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
2 Mycophenolate mofetil
Ju 2012 0/43 0/44 Not estimable
Pelletier 2013 0/50 0/50 Not estimable
Ramirez 2013 0/20 0/20 Not estimable
Subtotal (95% CI) 113 114 Not estimable
Total events: 0 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Azathioprine
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 23 22 Not estimable
Total events: 0 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 505 515 100.0 % 2.14 [ 1.13, 4.02 ]
Total events: 27 (Gluc avoid), 13 (Gluc cont)
Heterogeneity: Chi2 = 2.00, df = 4 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (antiproliferative subgroups), Outcome 7 Diabetes mellitus.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (antiproliferative subgroups)
Outcome: 7 Diabetes mellitus
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No antiproliferative agent
Belli 1998 3/54 12/50 8.0 % 0.23 [ 0.07, 0.77 ]
Hu 2008 7/40 14/36 9.5 % 0.45 [ 0.20, 0.99 ]
Lerut 2008 18/78 14/78 9.0 % 1.29 [ 0.69, 2.40 ]
Llado 2006 17/96 23/102 14.4 % 0.79 [ 0.45, 1.38 ]
Margarit 2005 8/30 11/33 6.8 % 0.80 [ 0.37, 1.72 ]
Moench 2007 12/56 9/54 5.9 % 1.29 [ 0.59, 2.80 ]
Pageaux 2004 12/84 20/90 12.4 % 0.64 [ 0.34, 1.23 ]
Vivarelli 2007 14/25 12/22 8.2 % 1.03 [ 0.61, 1.72 ]
Subtotal (95% CI) 463 465 74.3 % 0.79 [ 0.62, 1.00 ]
Total events: 91 (Gluc avoid), 115 (Gluc cont)
Heterogeneity: Chi2 = 11.19, df = 7 (P = 0.13); I2 =37%
Test for overall effect: Z = 1.96 (P = 0.050)
2 Mycophenolate mofetil
Ju 2012 2/43 9/44 5.7 % 0.23 [ 0.05, 0.99 ]
Pelletier 2013 22/50 19/50 12.2 % 1.16 [ 0.72, 1.86 ]
Ramirez 2013 8/20 8/20 5.2 % 1.00 [ 0.47, 2.14 ]
Reggiani 2005 2/12 5/18 2.6 % 0.60 [ 0.14, 2.60 ]
Subtotal (95% CI) 125 132 25.7 % 0.86 [ 0.59, 1.25 ]
Total events: 34 (Gluc avoid), 41 (Gluc cont)
Heterogeneity: Chi2 = 5.02, df = 3 (P = 0.17); I2 =40%
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI) 588 597 100.0 % 0.81 [ 0.66, 0.99 ]
Total events: 125 (Gluc avoid), 156 (Gluc cont)
Heterogeneity: Chi2 = 16.61, df = 11 (P = 0.12); I2 =34%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.68), I2 =0.0%
0.05 0.2 1 5 20
Favours gluc avoid Favours gluc cont
134Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.8. Comparison 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (antiproliferative subgroups), Outcome 8 CMV infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (antiproliferative subgroups)
Outcome: 8 CMV infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No antiproliferative agent
Lerut 2008 3/78 2/78 5.2 % 1.50 [ 0.26, 8.73 ]
Llado 2006 8/96 14/102 35.5 % 0.61 [ 0.27, 1.38 ]
Margarit 2005 0/30 1/33 3.7 % 0.37 [ 0.02, 8.65 ]
Moench 2007 14/56 18/54 47.9 % 0.75 [ 0.42, 1.35 ]
Pageaux 2004 1/84 2/90 5.0 % 0.54 [ 0.05, 5.80 ]
Subtotal (95% CI) 344 357 97.3 % 0.71 [ 0.45, 1.12 ]
Total events: 26 (Gluc avoid), 37 (Gluc cont)
Heterogeneity: Chi2 = 1.09, df = 4 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
2 Mycophenolate mofetil
Ramirez 2013 0/20 0/20 Not estimable
Subtotal (95% CI) 20 20 Not estimable
Total events: 0 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Azathioprine
Tisone 1999 2/23 1/22 2.7 % 1.91 [ 0.19, 19.63 ]
Subtotal (95% CI) 23 22 2.7 % 1.91 [ 0.19, 19.63 ]
Total events: 2 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.59)
Total (95% CI) 387 399 100.0 % 0.74 [ 0.48, 1.16 ]
Total events: 28 (Gluc avoid), 38 (Gluc cont)
Heterogeneity: Chi2 = 1.74, df = 5 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 0.67, df = 1 (P = 0.41), I2 =0.0%
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Analysis 3.9. Comparison 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (antiproliferative subgroups), Outcome 9 HCV recurrence.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (antiproliferative subgroups)
Outcome: 9 HCV recurrence
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No antiproliferative agent
Belli 1998 5/25 3/22 2.0 % 1.47 [ 0.40, 5.44 ]
Belli 2001 4/11 4/13 2.3 % 1.18 [ 0.38, 3.66 ]
Lerut 2008 14/14 21/21 11.2 % 1.00 [ 0.89, 1.12 ]
Llado 2006 40/43 39/46 24.1 % 1.10 [ 0.95, 1.27 ]
Margarit 2005 17/20 14/15 10.2 % 0.91 [ 0.72, 1.14 ]
Pageaux 2004 41/53 39/55 24.5 % 1.09 [ 0.87, 1.36 ]
Vivarelli 2007 19/25 13/23 8.7 % 1.34 [ 0.88, 2.05 ]
Subtotal (95% CI) 191 195 83.0 % 1.10 [ 0.98, 1.22 ]
Total events: 140 (Gluc avoid), 133 (Gluc cont)
Heterogeneity: Chi2 = 6.18, df = 6 (P = 0.40); I2 =3%
Test for overall effect: Z = 1.66 (P = 0.097)
2 Mycophenolate mofetil
Pelletier 2013 6/20 15/31 7.5 % 0.62 [ 0.29, 1.33 ]
Ramirez 2013 12/14 9/11 6.4 % 1.05 [ 0.74, 1.49 ]
Subtotal (95% CI) 34 42 14.0 % 0.82 [ 0.55, 1.22 ]
Total events: 18 (Gluc avoid), 24 (Gluc cont)
Heterogeneity: Chi2 = 2.42, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.98 (P = 0.32)
3 Azathioprine
Tisone 1999 1/7 5/8 3.0 % 0.23 [ 0.03, 1.52 ]
Subtotal (95% CI) 7 8 3.0 % 0.23 [ 0.03, 1.52 ]
Total events: 1 (Gluc avoid), 5 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
Total (95% CI) 232 245 100.0 % 1.03 [ 0.92, 1.15 ]
Total events: 159 (Gluc avoid), 162 (Gluc cont)
Heterogeneity: Chi2 = 8.36, df = 9 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Chi2 = 4.48, df = 2 (P = 0.11), I2 =55%
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Analysis 3.10. Comparison 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (antiproliferative subgroups), Outcome 10 Renal insufficiency.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (antiproliferative subgroups)
Outcome: 10 Renal insufficiency
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No antiproliferative agent
Lerut 2008 4/78 8/78 10.7 % 0.50 [ 0.16, 1.59 ]
Llado 2006 41/96 51/102 66.4 % 0.85 [ 0.63, 1.16 ]
Margarit 2005 20/30 17/33 21.7 % 1.29 [ 0.85, 1.96 ]
Subtotal (95% CI) 204 213 98.9 % 0.91 [ 0.72, 1.16 ]
Total events: 65 (Gluc avoid), 76 (Gluc cont)
Heterogeneity: Chi2 = 3.92, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 0.74 (P = 0.46)
2 Mycophenolate mofetil
Reggiani 2005 2/12 1/18 1.1 % 3.00 [ 0.30, 29.52 ]
Subtotal (95% CI) 12 18 1.1 % 3.00 [ 0.30, 29.52 ]
Total events: 2 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Total (95% CI) 216 231 100.0 % 0.93 [ 0.73, 1.19 ]
Total events: 67 (Gluc avoid), 77 (Gluc cont)
Heterogeneity: Chi2 = 4.80, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 1.03, df = 1 (P = 0.31), I2 =3%
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Analysis 3.11. Comparison 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (antiproliferative subgroups), Outcome 11 Creatinine.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (antiproliferative subgroups)
Outcome: 11 Creatinine
Study or subgroup Gluc avoid Gluc cont
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mg/dL] N Mean(SD)[mg/dL] IV,Fixed,95% CI IV,Fixed,95% CI
1 No antiproliferative agent
Moench 2007 56 1.14 (1.09) 54 1.26 (0.79) 1.6 % -0.12 [ -0.47, 0.23 ]
Subtotal (95% CI) 56 54 1.6 % -0.12 [ -0.47, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Mycophenolate mofetil
Chen 2007 28 0.75 (0.2) 26 0.8 (0.2) 17.5 % -0.05 [ -0.16, 0.06 ]
Pelletier 2013 50 1.67 (0.15) 50 1.42 (0.15) 57.8 % 0.25 [ 0.19, 0.31 ]
Subtotal (95% CI) 78 76 75.3 % 0.18 [ 0.13, 0.23 ]
Heterogeneity: Chi2 = 23.27, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 6.86 (P < 0.00001)
3 Azathioprine
Tisone 1999 23 1.8 (0.1) 22 1.9 (0.2) 23.1 % -0.10 [ -0.19, -0.01 ]
Subtotal (95% CI) 23 22 23.1 % -0.10 [ -0.19, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
Total (95% CI) 157 152 100.0 % 0.11 [ 0.07, 0.16 ]
Heterogeneity: Chi2 = 51.59, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 4.86 (P < 0.00001)
Test for subgroup differences: Chi2 = 28.32, df = 2 (P = 0.00), I2 =93%
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Analysis 3.12. Comparison 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (antiproliferative subgroups), Outcome 12 Hypertension.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (antiproliferative subgroups)
Outcome: 12 Hypertension
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No antiproliferative agent
Belli 1998 9/54 28/50 14.0 % 0.30 [ 0.16, 0.57 ]
Hu 2008 9/40 10/36 5.1 % 0.81 [ 0.37, 1.77 ]
Lerut 2008 6/78 10/78 4.8 % 0.60 [ 0.23, 1.57 ]
Llado 2006 48/96 60/102 28.0 % 0.85 [ 0.66, 1.10 ]
Margarit 2005 4/30 9/33 4.1 % 0.49 [ 0.17, 1.42 ]
Moench 2007 25/56 25/54 12.3 % 0.96 [ 0.64, 1.45 ]
Pageaux 2004 24/84 30/90 13.9 % 0.86 [ 0.55, 1.34 ]
Subtotal (95% CI) 438 443 82.2 % 0.74 [ 0.62, 0.88 ]
Total events: 125 (Gluc avoid), 172 (Gluc cont)
Heterogeneity: Chi2 = 11.62, df = 6 (P = 0.07); I2 =48%
Test for overall effect: Z = 3.30 (P = 0.00096)
2 Mycophenolate mofetil
Ju 2012 2/43 9/44 4.3 % 0.23 [ 0.05, 0.99 ]
Pelletier 2013 28/50 24/50 11.6 % 1.17 [ 0.80, 1.70 ]
Reggiani 2005 2/12 5/18 1.9 % 0.60 [ 0.14, 2.60 ]
Subtotal (95% CI) 105 112 17.8 % 0.88 [ 0.61, 1.26 ]
Total events: 32 (Gluc avoid), 38 (Gluc cont)
Heterogeneity: Chi2 = 5.64, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 543 555 100.0 % 0.76 [ 0.65, 0.90 ]
Total events: 157 (Gluc avoid), 210 (Gluc cont)
Heterogeneity: Chi2 = 18.80, df = 9 (P = 0.03); I2 =52%
Test for overall effect: Z = 3.28 (P = 0.0010)
Test for subgroup differences: Chi2 = 0.71, df = 1 (P = 0.40), I2 =0.0%
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Analysis 3.13. Comparison 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (antiproliferative subgroups), Outcome 13 Hyperlipidaemia.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (antiproliferative subgroups)
Outcome: 13 Hyperlipidaemia
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No antiproliferative agent
Hu 2008 2/40 3/36 17.8 % 0.60 [ 0.11, 3.39 ]
Margarit 2005 5/30 4/33 21.5 % 1.38 [ 0.41, 4.65 ]
Pageaux 2004 2/84 6/90 32.7 % 0.36 [ 0.07, 1.72 ]
Subtotal (95% CI) 154 159 72.1 % 0.72 [ 0.32, 1.62 ]
Total events: 9 (Gluc avoid), 13 (Gluc cont)
Heterogeneity: Chi2 = 1.89, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
2 Mycophenolate mofetil
Ju 2012 4/43 5/44 27.9 % 0.82 [ 0.24, 2.85 ]
Subtotal (95% CI) 43 44 27.9 % 0.82 [ 0.24, 2.85 ]
Total events: 4 (Gluc avoid), 5 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
Total (95% CI) 197 203 100.0 % 0.75 [ 0.38, 1.48 ]
Total events: 13 (Gluc avoid), 18 (Gluc cont)
Heterogeneity: Chi2 = 1.89, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 3.14. Comparison 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (antiproliferative subgroups), Outcome 14 Cholesterol.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 3 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (antiproliferative subgroups)
Outcome: 14 Cholesterol
Study or subgroup Gluc avoid Gluc cont
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mg/dL] N Mean(SD)[mg/dL] IV,Fixed,95% CI IV,Fixed,95% CI
1 No antiproliferative agent
Belli 1998 54 183 (81) 50 253 (76) 1.4 % -70.00 [ -100.17, -39.83 ]
Llado 2006 96 182 (54) 102 193 (43) 6.7 % -11.00 [ -24.65, 2.65 ]
Moench 2007 56 207 (77) 54 172 (39) 2.4 % 35.00 [ 12.31, 57.69 ]
Subtotal (95% CI) 206 206 10.5 % -8.08 [ -18.99, 2.82 ]
Heterogeneity: Chi2 = 30.20, df = 2 (P<0.00001); I2 =93%
Test for overall effect: Z = 1.45 (P = 0.15)
2 Mycophenolate mofetil
Chen 2007 28 151 (69) 26 297 (100) 0.6 % -146.00 [ -192.16, -99.84 ]
Pelletier 2013 50 148 (8) 50 167 (11) 87.6 % -19.00 [ -22.77, -15.23 ]
Subtotal (95% CI) 78 76 88.2 % -19.84 [ -23.60, -16.08 ]
Heterogeneity: Chi2 = 28.89, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 10.35 (P < 0.00001)
3 Azathioprine
Tisone 1999 23 117 (52) 22 128 (51) 1.4 % -11.00 [ -41.10, 19.10 ]
Subtotal (95% CI) 23 22 1.4 % -11.00 [ -41.10, 19.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 307 304 100.0 % -18.49 [ -22.02, -14.96 ]
Heterogeneity: Chi2 = 63.32, df = 5 (P<0.00001); I2 =92%
Test for overall effect: Z = 10.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.23, df = 2 (P = 0.12), I2 =53%
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Analysis 4.1. Comparison 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (induction therapy subgroups), Outcome 1 Mortality.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (induction therapy subgroups)
Outcome: 1 Mortality
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No induction therapy
Chen 2007 10/28 14/26 13.0 % 0.66 [ 0.36, 1.22 ]
Hu 2008 1/40 1/36 0.9 % 0.90 [ 0.06, 13.87 ]
Lerut 2008 17/78 13/78 11.7 % 1.31 [ 0.68, 2.51 ]
Margarit 2005 12/30 11/33 9.4 % 1.20 [ 0.63, 2.30 ]
Moench 2007 17/56 11/54 10.0 % 1.49 [ 0.77, 2.88 ]
Reggiani 2005 1/12 0/18 0.4 % 4.38 [ 0.19, 99.48 ]
Tisone 1999 7/23 7/22 6.4 % 0.96 [ 0.40, 2.28 ]
Vivarelli 2007 6/25 5/22 4.8 % 1.06 [ 0.37, 2.99 ]
Subtotal (95% CI) 292 289 56.6 % 1.13 [ 0.85, 1.50 ]
Total events: 71 (Gluc avoid), 62 (Gluc cont)
Heterogeneity: Chi2 = 4.72, df = 7 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
2 Basiliximab
Ju 2012 4/43 6/44 5.3 % 0.68 [ 0.21, 2.25 ]
Llado 2006 5/96 11/102 9.6 % 0.48 [ 0.17, 1.34 ]
Pageaux 2004 9/84 2/90 1.7 % 4.82 [ 1.07, 21.67 ]
Pelletier 2013 20/50 14/50 12.6 % 1.43 [ 0.82, 2.50 ]
Ramirez 2013 8/20 5/20 4.5 % 1.60 [ 0.63, 4.05 ]
Subtotal (95% CI) 293 306 33.6 % 1.24 [ 0.85, 1.81 ]
Total events: 46 (Gluc avoid), 38 (Gluc cont)
Heterogeneity: Chi2 = 7.92, df = 4 (P = 0.09); I2 =49%
Test for overall effect: Z = 1.10 (P = 0.27)
3 Rabbit antithymocyte globulin
Belli 1998 11/54 9/50 8.4 % 1.13 [ 0.51, 2.50 ]
Subtotal (95% CI) 54 50 8.4 % 1.13 [ 0.51, 2.50 ]
Total events: 11 (Gluc avoid), 9 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
4 Daclizumab
Studenik 2005 0/20 1/19 1.4 % 0.32 [ 0.01, 7.35 ]
Subtotal (95% CI) 20 19 1.4 % 0.32 [ 0.01, 7.35 ]
Total events: 0 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 659 664 100.0 % 1.15 [ 0.93, 1.44 ]
Total events: 128 (Gluc avoid), 110 (Gluc cont)
Heterogeneity: Chi2 = 13.54, df = 14 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Chi2 = 0.81, df = 3 (P = 0.85), I2 =0.0%
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Analysis 4.2. Comparison 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (induction therapy subgroups), Outcome 2 Graft loss including death.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (induction therapy subgroups)
Outcome: 2 Graft loss including death
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No induction therapy
Lerut 2008 20/78 17/78 19.0 % 1.18 [ 0.67, 2.07 ]
Margarit 2005 0/30 4/33 4.8 % 0.12 [ 0.01, 2.17 ]
Moench 2007 21/56 15/54 17.0 % 1.35 [ 0.78, 2.33 ]
Reggiani 2005 1/12 3/18 2.7 % 0.50 [ 0.06, 4.26 ]
Tisone 1999 7/23 7/22 8.0 % 0.96 [ 0.40, 2.28 ]
Vivarelli 2007 6/25 7/22 8.3 % 0.75 [ 0.30, 1.91 ]
Subtotal (95% CI) 224 227 59.7 % 1.02 [ 0.74, 1.41 ]
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 55 (Gluc avoid), 53 (Gluc cont)
Heterogeneity: Chi2 = 4.18, df = 5 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
2 Basiliximab
Llado 2006 9/96 12/102 13.0 % 0.80 [ 0.35, 1.81 ]
Pageaux 2004 9/84 2/90 2.2 % 4.82 [ 1.07, 21.67 ]
Pelletier 2013 22/50 14/50 15.6 % 1.57 [ 0.91, 2.71 ]
Ramirez 2013 8/20 6/20 6.7 % 1.33 [ 0.57, 3.14 ]
Subtotal (95% CI) 250 262 37.4 % 1.45 [ 0.99, 2.12 ]
Total events: 48 (Gluc avoid), 34 (Gluc cont)
Heterogeneity: Chi2 = 4.63, df = 3 (P = 0.20); I2 =35%
Test for overall effect: Z = 1.89 (P = 0.058)
3 Daclizumab
Studenik 2005 0/20 2/19 2.9 % 0.19 [ 0.01, 3.73 ]
Subtotal (95% CI) 20 19 2.9 % 0.19 [ 0.01, 3.73 ]
Total events: 0 (Gluc avoid), 2 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
Total (95% CI) 494 508 100.0 % 1.16 [ 0.91, 1.48 ]
Total events: 103 (Gluc avoid), 89 (Gluc cont)
Heterogeneity: Chi2 = 11.24, df = 10 (P = 0.34); I2 =11%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Chi2 = 3.28, df = 2 (P = 0.19), I2 =39%
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Analysis 4.3. Comparison 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (induction therapy subgroups), Outcome 3 Acute rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (induction therapy subgroups)
Outcome: 3 Acute rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No induction therapy
Chen 2007 4/28 3/26 2.7 % 1.24 [ 0.31, 5.01 ]
Hu 2008 5/40 4/36 3.7 % 1.13 [ 0.33, 3.87 ]
Lerut 2008 18/78 16/78 13.9 % 1.13 [ 0.62, 2.04 ]
Margarit 2005 11/30 10/33 8.3 % 1.21 [ 0.60, 2.43 ]
Moench 2007 19/56 14/54 12.4 % 1.31 [ 0.73, 2.34 ]
Reggiani 2005 9/12 3/18 2.1 % 4.50 [ 1.52, 13.30 ]
Tisone 1999 4/23 4/22 3.5 % 0.96 [ 0.27, 3.36 ]
Vivarelli 2007 2/25 4/22 3.7 % 0.44 [ 0.09, 2.17 ]
Subtotal (95% CI) 292 289 50.2 % 1.27 [ 0.94, 1.71 ]
Total events: 72 (Gluc avoid), 58 (Gluc cont)
Heterogeneity: Chi2 = 7.35, df = 7 (P = 0.39); I2 =5%
Test for overall effect: Z = 1.56 (P = 0.12)
2 Basiliximab
Ju 2012 4/43 3/44 2.6 % 1.36 [ 0.32, 5.74 ]
Llado 2006 17/96 13/102 10.9 % 1.39 [ 0.71, 2.70 ]
Pageaux 2004 32/84 22/90 18.4 % 1.56 [ 0.99, 2.45 ]
Pelletier 2013 10/50 7/50 6.1 % 1.43 [ 0.59, 3.45 ]
Ramirez 2013 1/20 1/20 0.9 % 1.00 [ 0.07, 14.90 ]
Subtotal (95% CI) 293 306 38.9 % 1.47 [ 1.05, 2.05 ]
Total events: 64 (Gluc avoid), 46 (Gluc cont)
Heterogeneity: Chi2 = 0.18, df = 4 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.24 (P = 0.025)
3 Rabbit antithymocyte globulin
Belli 1998 2/54 3/50 2.7 % 0.62 [ 0.11, 3.54 ]
Belli 2001 5/11 7/13 5.6 % 0.84 [ 0.37, 1.92 ]
Subtotal (95% CI) 65 63 8.3 % 0.77 [ 0.36, 1.67 ]
Total events: 7 (Gluc avoid), 10 (Gluc cont)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.66 (P = 0.51)
4 Daclizumab
Studenik 2005 7/20 3/19 2.7 % 2.22 [ 0.67, 7.34 ]
Subtotal (95% CI) 20 19 2.7 % 2.22 [ 0.67, 7.34 ]
Total events: 7 (Gluc avoid), 3 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Total (95% CI) 670 677 100.0 % 1.33 [ 1.08, 1.64 ]
Total events: 150 (Gluc avoid), 117 (Gluc cont)
Heterogeneity: Chi2 = 10.60, df = 15 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.66 (P = 0.0079)
Test for subgroup differences: Chi2 = 3.04, df = 3 (P = 0.39), I2 =1%
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Analysis 4.4. Comparison 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (induction therapy subgroups), Outcome 4 Infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (induction therapy subgroups)
Outcome: 4 Infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No induction therapy
Reggiani 2005 6/12 5/18 2.9 % 1.80 [ 0.71, 4.59 ]
Tisone 1999 17/23 15/22 11.0 % 1.08 [ 0.75, 1.58 ]
Subtotal (95% CI) 35 40 13.9 % 1.23 [ 0.86, 1.77 ]
Total events: 23 (Gluc avoid), 20 (Gluc cont)
Heterogeneity: Chi2 = 1.08, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 1.12 (P = 0.26)
2 Basiliximab
Ju 2012 6/43 16/44 11.3 % 0.38 [ 0.17, 0.89 ]
Llado 2006 45/96 52/102 36.2 % 0.92 [ 0.69, 1.22 ]
Pageaux 2004 7/84 12/90 8.3 % 0.63 [ 0.26, 1.51 ]
Pelletier 2013 26/50 22/50 15.8 % 1.18 [ 0.78, 1.78 ]
Ramirez 2013 12/20 12/20 8.6 % 1.00 [ 0.60, 1.66 ]
Subtotal (95% CI) 293 306 80.2 % 0.87 [ 0.71, 1.07 ]
Total events: 96 (Gluc avoid), 114 (Gluc cont)
Heterogeneity: Chi2 = 6.73, df = 4 (P = 0.15); I2 =41%
Test for overall effect: Z = 1.30 (P = 0.19)
3 Rabbit antithymocyte globulin
Belli 1998 1/54 8/50 6.0 % 0.12 [ 0.02, 0.89 ]
Subtotal (95% CI) 54 50 6.0 % 0.12 [ 0.02, 0.89 ]
Total events: 1 (Gluc avoid), 8 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.039)
Total (95% CI) 382 396 100.0 % 0.88 [ 0.73, 1.05 ]
Total events: 120 (Gluc avoid), 142 (Gluc cont)
Heterogeneity: Chi2 = 13.93, df = 7 (P = 0.05); I2 =50%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 6.65, df = 2 (P = 0.04), I2 =70%
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Analysis 4.5. Comparison 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (induction therapy subgroups), Outcome 5 Chronic rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (induction therapy subgroups)
Outcome: 5 Chronic rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No induction therapy
Lerut 2008 1/78 4/78 24.5 % 0.25 [ 0.03, 2.19 ]
Margarit 2005 0/30 0/33 Not estimable
Moench 2007 6/56 0/54 3.1 % 12.54 [ 0.72, 217.40 ]
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 187 187 27.6 % 1.64 [ 0.51, 5.25 ]
Total events: 7 (Gluc avoid), 4 (Gluc cont)
Heterogeneity: Chi2 = 4.84, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.83 (P = 0.41)
2 Basiliximab
Llado 2006 3/96 1/102 5.9 % 3.19 [ 0.34, 30.12 ]
Pageaux 2004 3/84 5/90 29.6 % 0.64 [ 0.16, 2.61 ]
Pelletier 2013 1/50 4/50 24.5 % 0.25 [ 0.03, 2.16 ]
Subtotal (95% CI) 230 242 60.0 % 0.73 [ 0.29, 1.89 ]
Total events: 7 (Gluc avoid), 10 (Gluc cont)
Heterogeneity: Chi2 = 2.64, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 0.64 (P = 0.52)
3 Rabbit antithymocyte globulin
Belli 1998 0/54 1/50 9.5 % 0.31 [ 0.01, 7.42 ]
Belli 2001 1/11 0/13 2.8 % 3.50 [ 0.16, 78.19 ]
Subtotal (95% CI) 65 63 12.4 % 1.04 [ 0.16, 6.72 ]
Total events: 1 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 482 492 100.0 % 1.02 [ 0.52, 2.00 ]
Total events: 15 (Gluc avoid), 15 (Gluc cont)
Heterogeneity: Chi2 = 8.78, df = 6 (P = 0.19); I2 =32%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 1.10, df = 2 (P = 0.58), I2 =0.0%
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Analysis 4.6. Comparison 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (induction therapy subgroups), Outcome 6 Glucocorticosteroid-resistant
rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (induction therapy subgroups)
Outcome: 6 Glucocorticosteroid-resistant rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No induction therapy
Lerut 2008 10/78 3/78 22.8 % 3.33 [ 0.95, 11.65 ]
Margarit 2005 4/30 3/33 21.7 % 1.47 [ 0.36, 6.03 ]
Moench 2007 1/56 0/54 3.9 % 2.89 [ 0.12, 69.55 ]
Tisone 1999 0/23 0/22 Not estimable
Vivarelli 2007 0/25 0/22 Not estimable
Subtotal (95% CI) 212 209 48.4 % 2.46 [ 1.01, 5.97 ]
Total events: 15 (Gluc avoid), 6 (Gluc cont)
Heterogeneity: Chi2 = 0.75, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.99 (P = 0.047)
2 Basiliximab
Ju 2012 0/43 0/44 Not estimable
Llado 2006 4/96 4/102 29.5 % 1.06 [ 0.27, 4.13 ]
Pageaux 2004 8/84 3/90 22.0 % 2.86 [ 0.78, 10.41 ]
Pelletier 2013 0/50 0/50 Not estimable
Ramirez 2013 0/20 0/20 Not estimable
Subtotal (95% CI) 293 306 51.6 % 1.83 [ 0.74, 4.55 ]
Total events: 12 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 1.07, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 1.30 (P = 0.19)
Total (95% CI) 505 515 100.0 % 2.14 [ 1.13, 4.02 ]
Total events: 27 (Gluc avoid), 13 (Gluc cont)
Heterogeneity: Chi2 = 2.00, df = 4 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.65), I2 =0.0%
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Analysis 4.7. Comparison 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (induction therapy subgroups), Outcome 7 Diabetes mellitus.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (induction therapy subgroups)
Outcome: 7 Diabetes mellitus
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No induction therapy
Hu 2008 7/40 14/36 9.5 % 0.45 [ 0.20, 0.99 ]
Lerut 2008 18/78 14/78 9.0 % 1.29 [ 0.69, 2.40 ]
Margarit 2005 8/30 11/33 6.8 % 0.80 [ 0.37, 1.72 ]
Moench 2007 12/56 9/54 5.9 % 1.29 [ 0.59, 2.80 ]
Reggiani 2005 2/12 5/18 2.6 % 0.60 [ 0.14, 2.60 ]
Vivarelli 2007 14/25 12/22 8.2 % 1.03 [ 0.61, 1.72 ]
Subtotal (95% CI) 241 241 42.0 % 0.93 [ 0.69, 1.24 ]
Total events: 61 (Gluc avoid), 65 (Gluc cont)
Heterogeneity: Chi2 = 5.60, df = 5 (P = 0.35); I2 =11%
Test for overall effect: Z = 0.51 (P = 0.61)
2 Basiliximab
Ju 2012 2/43 9/44 5.7 % 0.23 [ 0.05, 0.99 ]
Llado 2006 17/96 23/102 14.4 % 0.79 [ 0.45, 1.38 ]
Pageaux 2004 12/84 20/90 12.4 % 0.64 [ 0.34, 1.23 ]
Pelletier 2013 22/50 19/50 12.2 % 1.16 [ 0.72, 1.86 ]
Ramirez 2013 8/20 8/20 5.2 % 1.00 [ 0.47, 2.14 ]
Subtotal (95% CI) 293 306 50.0 % 0.80 [ 0.60, 1.06 ]
Total events: 61 (Gluc avoid), 79 (Gluc cont)
Heterogeneity: Chi2 = 5.93, df = 4 (P = 0.20); I2 =33%
Test for overall effect: Z = 1.53 (P = 0.13)
3 Rabbit antithymocyte globulin
Belli 1998 3/54 12/50 8.0 % 0.23 [ 0.07, 0.77 ]
Subtotal (95% CI) 54 50 8.0 % 0.23 [ 0.07, 0.77 ]
Total events: 3 (Gluc avoid), 12 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 2.38 (P = 0.017)
Total (95% CI) 588 597 100.0 % 0.81 [ 0.66, 0.99 ]
Total events: 125 (Gluc avoid), 156 (Gluc cont)
Heterogeneity: Chi2 = 16.61, df = 11 (P = 0.12); I2 =34%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Chi2 = 4.90, df = 2 (P = 0.09), I2 =59%
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Analysis 4.8. Comparison 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (induction therapy subgroups), Outcome 8 CMV infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (induction therapy subgroups)
Outcome: 8 CMV infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No induction therapy
Lerut 2008 3/78 2/78 5.2 % 1.50 [ 0.26, 8.73 ]
Margarit 2005 0/30 1/33 3.7 % 0.37 [ 0.02, 8.65 ]
Moench 2007 14/56 18/54 47.9 % 0.75 [ 0.42, 1.35 ]
Tisone 1999 2/23 1/22 2.7 % 1.91 [ 0.19, 19.63 ]
Subtotal (95% CI) 187 187 59.5 % 0.84 [ 0.50, 1.44 ]
Total events: 19 (Gluc avoid), 22 (Gluc cont)
Heterogeneity: Chi2 = 1.31, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
2 Basiliximab
Llado 2006 8/96 14/102 35.5 % 0.61 [ 0.27, 1.38 ]
Pageaux 2004 1/84 2/90 5.0 % 0.54 [ 0.05, 5.80 ]
Ramirez 2013 0/20 0/20 Not estimable
Subtotal (95% CI) 200 212 40.5 % 0.60 [ 0.27, 1.30 ]
Total events: 9 (Gluc avoid), 16 (Gluc cont)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
Total (95% CI) 387 399 100.0 % 0.74 [ 0.48, 1.16 ]
Total events: 28 (Gluc avoid), 38 (Gluc cont)
Heterogeneity: Chi2 = 1.74, df = 5 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 0.51, df = 1 (P = 0.47), I2 =0.0%
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Analysis 4.9. Comparison 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (induction therapy subgroups), Outcome 9 HCV recurrence.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (induction therapy subgroups)
Outcome: 9 HCV recurrence
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No induction therapy
Lerut 2008 14/14 21/21 11.2 % 1.00 [ 0.89, 1.12 ]
Margarit 2005 17/20 14/15 10.2 % 0.91 [ 0.72, 1.14 ]
Tisone 1999 1/7 5/8 3.0 % 0.23 [ 0.03, 1.52 ]
Vivarelli 2007 19/25 13/23 8.7 % 1.34 [ 0.88, 2.05 ]
Subtotal (95% CI) 66 67 33.0 % 0.99 [ 0.84, 1.18 ]
Total events: 51 (Gluc avoid), 53 (Gluc cont)
Heterogeneity: Chi2 = 4.87, df = 3 (P = 0.18); I2 =38%
Test for overall effect: Z = 0.08 (P = 0.94)
2 Basiliximab
Llado 2006 40/43 39/46 24.1 % 1.10 [ 0.95, 1.27 ]
Pageaux 2004 41/53 39/55 24.5 % 1.09 [ 0.87, 1.36 ]
Pelletier 2013 6/20 15/31 7.5 % 0.62 [ 0.29, 1.33 ]
Ramirez 2013 12/14 9/11 6.4 % 1.05 [ 0.74, 1.49 ]
Subtotal (95% CI) 130 143 62.6 % 1.03 [ 0.90, 1.18 ]
Total events: 99 (Gluc avoid), 102 (Gluc cont)
Heterogeneity: Chi2 = 2.62, df = 3 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
3 Rabbit antithymocyte globulin
Belli 1998 5/25 3/22 2.0 % 1.47 [ 0.40, 5.44 ]
Belli 2001 4/11 4/13 2.3 % 1.18 [ 0.38, 3.66 ]
Subtotal (95% CI) 36 35 4.4 % 1.31 [ 0.55, 3.11 ]
Total events: 9 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
Total (95% CI) 232 245 100.0 % 1.03 [ 0.92, 1.15 ]
Total events: 159 (Gluc avoid), 162 (Gluc cont)
Heterogeneity: Chi2 = 8.36, df = 9 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Chi2 = 0.46, df = 2 (P = 0.80), I2 =0.0%
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Analysis 4.10. Comparison 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (induction therapy subgroups), Outcome 10 Malignancy.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (induction therapy subgroups)
Outcome: 10 Malignancy
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No induction therapy
Lerut 2008 2/78 0/78 6.4 % 5.00 [ 0.24, 102.49 ]
Subtotal (95% CI) 78 78 6.4 % 5.00 [ 0.24, 102.49 ]
Total events: 2 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
2 Basiliximab
Llado 2006 0/96 5/102 68.7 % 0.10 [ 0.01, 1.72 ]
Pageaux 2004 1/84 2/90 24.9 % 0.54 [ 0.05, 5.80 ]
Subtotal (95% CI) 180 192 93.6 % 0.21 [ 0.04, 1.22 ]
Total events: 1 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.082)
Total (95% CI) 258 270 100.0 % 0.52 [ 0.16, 1.74 ]
Total events: 3 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 3.47, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Chi2 = 3.15, df = 1 (P = 0.08), I2 =68%
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Analysis 4.11. Comparison 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (induction therapy subgroups), Outcome 11 Post-transplant
lymphoproliferative disorder.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (induction therapy subgroups)
Outcome: 11 Post-transplant lymphoproliferative disorder
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No induction therapy
Lerut 2008 2/78 1/78 67.4 % 2.00 [ 0.19, 21.61 ]
Subtotal (95% CI) 78 78 67.4 % 2.00 [ 0.19, 21.61 ]
Total events: 2 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 Basiliximab
Pageaux 2004 1/84 0/90 32.6 % 3.21 [ 0.13, 77.77 ]
Subtotal (95% CI) 84 90 32.6 % 3.21 [ 0.13, 77.77 ]
Total events: 1 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 162 168 100.0 % 2.39 [ 0.36, 15.95 ]
Total events: 3 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 4.12. Comparison 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (induction therapy subgroups), Outcome 12 Renal insufficiency.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (induction therapy subgroups)
Outcome: 12 Renal insufficiency
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No induction therapy
Lerut 2008 4/78 8/78 10.7 % 0.50 [ 0.16, 1.59 ]
Margarit 2005 20/30 17/33 21.7 % 1.29 [ 0.85, 1.96 ]
Reggiani 2005 2/12 1/18 1.1 % 3.00 [ 0.30, 29.52 ]
Subtotal (95% CI) 120 129 33.6 % 1.09 [ 0.73, 1.64 ]
Total events: 26 (Gluc avoid), 26 (Gluc cont)
Heterogeneity: Chi2 = 3.12, df = 2 (P = 0.21); I2 =36%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Basiliximab
Llado 2006 41/96 51/102 66.4 % 0.85 [ 0.63, 1.16 ]
Subtotal (95% CI) 96 102 66.4 % 0.85 [ 0.63, 1.16 ]
Total events: 41 (Gluc avoid), 51 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 216 231 100.0 % 0.93 [ 0.73, 1.19 ]
Total events: 67 (Gluc avoid), 77 (Gluc cont)
Heterogeneity: Chi2 = 4.80, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 0.93, df = 1 (P = 0.34), I2 =0.0%
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Analysis 4.13. Comparison 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (induction therapy subgroups), Outcome 13 Creatinine.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (induction therapy subgroups)
Outcome: 13 Creatinine
Study or subgroup Gluc avoid Gluc cont
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mg/dL] N Mean(SD)[mg/dL] IV,Fixed,95% CI IV,Fixed,95% CI
1 No induction therapy
Chen 2007 28 0.75 (0.2) 26 0.8 (0.2) 17.5 % -0.05 [ -0.16, 0.06 ]
Moench 2007 56 1.14 (1.09) 54 1.26 (0.79) 1.6 % -0.12 [ -0.47, 0.23 ]
Tisone 1999 23 1.8 (0.1) 22 1.9 (0.2) 23.1 % -0.10 [ -0.19, -0.01 ]
Subtotal (95% CI) 107 102 42.2 % -0.08 [ -0.15, -0.01 ]
Heterogeneity: Chi2 = 0.53, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.28 (P = 0.023)
2 Basiliximab
Pelletier 2013 50 1.67 (0.15) 50 1.42 (0.15) 57.8 % 0.25 [ 0.19, 0.31 ]
Subtotal (95% CI) 50 50 57.8 % 0.25 [ 0.19, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.33 (P < 0.00001)
Total (95% CI) 157 152 100.0 % 0.11 [ 0.07, 0.16 ]
Heterogeneity: Chi2 = 51.59, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 4.86 (P < 0.00001)
Test for subgroup differences: Chi2 = 51.06, df = 1 (P = 0.00), I2 =98%
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Analysis 4.14. Comparison 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (induction therapy subgroups), Outcome 14 Hypertension.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (induction therapy subgroups)
Outcome: 14 Hypertension
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No induction therapy
Hu 2008 9/40 10/36 5.1 % 0.81 [ 0.37, 1.77 ]
Lerut 2008 6/78 10/78 4.8 % 0.60 [ 0.23, 1.57 ]
Margarit 2005 4/30 9/33 4.1 % 0.49 [ 0.17, 1.42 ]
Moench 2007 25/56 25/54 12.3 % 0.96 [ 0.64, 1.45 ]
Reggiani 2005 2/12 5/18 1.9 % 0.60 [ 0.14, 2.60 ]
Subtotal (95% CI) 216 219 28.2 % 0.78 [ 0.57, 1.08 ]
Total events: 46 (Gluc avoid), 59 (Gluc cont)
Heterogeneity: Chi2 = 2.18, df = 4 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
2 Basiliximab
Ju 2012 2/43 9/44 4.3 % 0.23 [ 0.05, 0.99 ]
Llado 2006 48/96 60/102 28.0 % 0.85 [ 0.66, 1.10 ]
Pageaux 2004 24/84 30/90 13.9 % 0.86 [ 0.55, 1.34 ]
Pelletier 2013 28/50 24/50 11.6 % 1.17 [ 0.80, 1.70 ]
Subtotal (95% CI) 273 286 57.8 % 0.87 [ 0.72, 1.05 ]
Total events: 102 (Gluc avoid), 123 (Gluc cont)
Heterogeneity: Chi2 = 5.53, df = 3 (P = 0.14); I2 =46%
Test for overall effect: Z = 1.42 (P = 0.16)
3 Rabbit antithymocyte globulin
Belli 1998 9/54 28/50 14.0 % 0.30 [ 0.16, 0.57 ]
Subtotal (95% CI) 54 50 14.0 % 0.30 [ 0.16, 0.57 ]
Total events: 9 (Gluc avoid), 28 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 3.68 (P = 0.00023)
Total (95% CI) 543 555 100.0 % 0.76 [ 0.65, 0.90 ]
Total events: 157 (Gluc avoid), 210 (Gluc cont)
Heterogeneity: Chi2 = 18.80, df = 9 (P = 0.03); I2 =52%
Test for overall effect: Z = 3.28 (P = 0.0010)
Test for subgroup differences: Chi2 = 9.73, df = 2 (P = 0.01), I2 =79%
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Analysis 4.15. Comparison 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (induction therapy subgroups), Outcome 15 Hyperlipidaemia.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (induction therapy subgroups)
Outcome: 15 Hyperlipidaemia
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No induction therapy
Hu 2008 2/40 3/36 17.8 % 0.60 [ 0.11, 3.39 ]
Margarit 2005 5/30 4/33 21.5 % 1.38 [ 0.41, 4.65 ]
Subtotal (95% CI) 70 69 39.4 % 1.02 [ 0.38, 2.72 ]
Total events: 7 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
2 Basiliximab
Ju 2012 4/43 5/44 27.9 % 0.82 [ 0.24, 2.85 ]
Pageaux 2004 2/84 6/90 32.7 % 0.36 [ 0.07, 1.72 ]
Subtotal (95% CI) 127 134 60.6 % 0.57 [ 0.22, 1.49 ]
Total events: 6 (Gluc avoid), 11 (Gluc cont)
Heterogeneity: Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Total (95% CI) 197 203 100.0 % 0.75 [ 0.38, 1.48 ]
Total events: 13 (Gluc avoid), 18 (Gluc cont)
Heterogeneity: Chi2 = 1.89, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 0.70, df = 1 (P = 0.40), I2 =0.0%
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Analysis 4.16. Comparison 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (induction therapy subgroups), Outcome 16 Cholesterol.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 4 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (induction therapy subgroups)
Outcome: 16 Cholesterol
Study or subgroup Gluc avoid Gluc cont
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mg/dL] N Mean(SD)[mg/dL] IV,Fixed,95% CI IV,Fixed,95% CI
1 No induction therapy
Chen 2007 28 151 (69) 26 297 (100) 0.6 % -146.00 [ -192.16, -99.84 ]
Tisone 1999 23 117 (52) 22 128 (51) 1.4 % -11.00 [ -41.10, 19.10 ]
Subtotal (95% CI) 51 48 2.0 % -51.27 [ -76.48, -26.06 ]
Heterogeneity: Chi2 = 23.06, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 3.99 (P = 0.000067)
2 Basiliximab
Llado 2006 96 182 (54) 102 193 (43) 6.7 % -11.00 [ -24.65, 2.65 ]
Moench 2007 56 207 (77) 54 172 (39) 2.4 % 35.00 [ 12.31, 57.69 ]
Pelletier 2013 50 148 (8) 50 167 (11) 87.6 % -19.00 [ -22.77, -15.23 ]
Subtotal (95% CI) 202 206 96.7 % -17.10 [ -20.69, -13.51 ]
Heterogeneity: Chi2 = 21.99, df = 2 (P = 0.00002); I2 =91%
Test for overall effect: Z = 9.34 (P < 0.00001)
3 Rabbit antithymocyte globulin
Belli 1998 54 183 (81) 50 253 (76) 1.4 % -70.00 [ -100.17, -39.83 ]
Subtotal (95% CI) 54 50 1.4 % -70.00 [ -100.17, -39.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.55 (P < 0.00001)
Total (95% CI) 307 304 100.0 % -18.49 [ -22.02, -14.96 ]
Heterogeneity: Chi2 = 63.32, df = 5 (P<0.00001); I2 =92%
Test for overall effect: Z = 10.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 18.27, df = 2 (P = 0.00), I2 =89%
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Analysis 5.1. Comparison 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (co-interventions subgroups), Outcome 1 Mortality.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (co-interventions subgroups)
Outcome: 1 Mortality
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Monotherapy
Hu 2008 1/40 1/36 0.9 % 0.90 [ 0.06, 13.87 ]
Lerut 2008 17/78 13/78 11.7 % 1.31 [ 0.68, 2.51 ]
Margarit 2005 12/30 11/33 9.4 % 1.20 [ 0.63, 2.30 ]
Moench 2007 17/56 11/54 10.0 % 1.49 [ 0.77, 2.88 ]
Vivarelli 2007 6/25 5/22 4.8 % 1.06 [ 0.37, 2.99 ]
Subtotal (95% CI) 229 223 36.8 % 1.29 [ 0.90, 1.83 ]
Total events: 53 (Gluc avoid), 41 (Gluc cont)
Heterogeneity: Chi2 = 0.44, df = 4 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
2 Dual therapy
Belli 1998 11/54 9/50 8.4 % 1.13 [ 0.51, 2.50 ]
Chen 2007 10/28 14/26 13.0 % 0.66 [ 0.36, 1.22 ]
Llado 2006 5/96 11/102 9.6 % 0.48 [ 0.17, 1.34 ]
Pageaux 2004 9/84 2/90 1.7 % 4.82 [ 1.07, 21.67 ]
Reggiani 2005 1/12 0/18 0.4 % 4.38 [ 0.19, 99.48 ]
Tisone 1999 7/23 7/22 6.4 % 0.96 [ 0.40, 2.28 ]
Subtotal (95% CI) 297 308 39.5 % 0.98 [ 0.68, 1.42 ]
Total events: 43 (Gluc avoid), 43 (Gluc cont)
Heterogeneity: Chi2 = 8.77, df = 5 (P = 0.12); I2 =43%
Test for overall effect: Z = 0.09 (P = 0.93)
3 Triple therapy
Ju 2012 4/43 6/44 5.3 % 0.68 [ 0.21, 2.25 ]
Pelletier 2013 20/50 14/50 12.6 % 1.43 [ 0.82, 2.50 ]
Ramirez 2013 8/20 5/20 4.5 % 1.60 [ 0.63, 4.05 ]
Studenik 2005 0/20 1/19 1.4 % 0.32 [ 0.01, 7.35 ]
Subtotal (95% CI) 133 133 23.7 % 1.23 [ 0.79, 1.90 ]
Total events: 32 (Gluc avoid), 26 (Gluc cont)
Heterogeneity: Chi2 = 2.24, df = 3 (P = 0.53); I2 =0.0%
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 659 664 100.0 % 1.15 [ 0.93, 1.44 ]
Total events: 128 (Gluc avoid), 110 (Gluc cont)
Heterogeneity: Chi2 = 13.54, df = 14 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Chi2 = 1.18, df = 2 (P = 0.55), I2 =0.0%
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Analysis 5.2. Comparison 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (co-interventions subgroups), Outcome 2 Graft loss including death.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (co-interventions subgroups)
Outcome: 2 Graft loss including death
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Monotherapy
Lerut 2008 20/78 17/78 19.0 % 1.18 [ 0.67, 2.07 ]
Margarit 2005 0/30 4/33 4.8 % 0.12 [ 0.01, 2.17 ]
Moench 2007 21/56 15/54 17.0 % 1.35 [ 0.78, 2.33 ]
Vivarelli 2007 6/25 7/22 8.3 % 0.75 [ 0.30, 1.91 ]
Subtotal (95% CI) 189 187 49.1 % 1.06 [ 0.75, 1.51 ]
Total events: 47 (Gluc avoid), 43 (Gluc cont)
Heterogeneity: Chi2 = 3.56, df = 3 (P = 0.31); I2 =16%
Test for overall effect: Z = 0.34 (P = 0.74)
2 Dual therapy
Llado 2006 9/96 12/102 13.0 % 0.80 [ 0.35, 1.81 ]
Pageaux 2004 9/84 2/90 2.2 % 4.82 [ 1.07, 21.67 ]
Reggiani 2005 1/12 3/18 2.7 % 0.50 [ 0.06, 4.26 ]
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Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tisone 1999 7/23 7/22 8.0 % 0.96 [ 0.40, 2.28 ]
Subtotal (95% CI) 215 232 25.8 % 1.15 [ 0.69, 1.93 ]
Total events: 26 (Gluc avoid), 24 (Gluc cont)
Heterogeneity: Chi2 = 5.02, df = 3 (P = 0.17); I2 =40%
Test for overall effect: Z = 0.54 (P = 0.59)
3 Triple therapy
Pelletier 2013 22/50 14/50 15.6 % 1.57 [ 0.91, 2.71 ]
Ramirez 2013 8/20 6/20 6.7 % 1.33 [ 0.57, 3.14 ]
Studenik 2005 0/20 2/19 2.9 % 0.19 [ 0.01, 3.73 ]
Subtotal (95% CI) 90 89 25.2 % 1.35 [ 0.86, 2.11 ]
Total events: 30 (Gluc avoid), 22 (Gluc cont)
Heterogeneity: Chi2 = 1.96, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
Total (95% CI) 494 508 100.0 % 1.16 [ 0.91, 1.48 ]
Total events: 103 (Gluc avoid), 89 (Gluc cont)
Heterogeneity: Chi2 = 11.24, df = 10 (P = 0.34); I2 =11%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Chi2 = 0.69, df = 2 (P = 0.71), I2 =0.0%
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Analysis 5.3. Comparison 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (co-interventions subgroups), Outcome 3 Acute rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (co-interventions subgroups)
Outcome: 3 Acute rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Monotherapy
Hu 2008 5/40 4/36 3.7 % 1.13 [ 0.33, 3.87 ]
Lerut 2008 18/78 16/78 13.9 % 1.13 [ 0.62, 2.04 ]
Margarit 2005 11/30 10/33 8.3 % 1.21 [ 0.60, 2.43 ]
Moench 2007 19/56 14/54 12.4 % 1.31 [ 0.73, 2.34 ]
Vivarelli 2007 2/25 4/22 3.7 % 0.44 [ 0.09, 2.17 ]
Subtotal (95% CI) 229 223 41.9 % 1.14 [ 0.81, 1.59 ]
Total events: 55 (Gluc avoid), 48 (Gluc cont)
Heterogeneity: Chi2 = 1.62, df = 4 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
2 Dual therapy
Belli 1998 2/54 3/50 2.7 % 0.62 [ 0.11, 3.54 ]
Belli 2001 5/11 7/13 5.6 % 0.84 [ 0.37, 1.92 ]
Chen 2007 4/28 3/26 2.7 % 1.24 [ 0.31, 5.01 ]
Llado 2006 17/96 13/102 10.9 % 1.39 [ 0.71, 2.70 ]
Pageaux 2004 32/84 22/90 18.4 % 1.56 [ 0.99, 2.45 ]
Reggiani 2005 9/12 3/18 2.1 % 4.50 [ 1.52, 13.30 ]
Tisone 1999 4/23 4/22 3.5 % 0.96 [ 0.27, 3.36 ]
Subtotal (95% CI) 308 321 46.0 % 1.44 [ 1.07, 1.95 ]
Total events: 73 (Gluc avoid), 55 (Gluc cont)
Heterogeneity: Chi2 = 7.36, df = 6 (P = 0.29); I2 =19%
Test for overall effect: Z = 2.41 (P = 0.016)
3 Triple therapy
Ju 2012 4/43 3/44 2.6 % 1.36 [ 0.32, 5.74 ]
Pelletier 2013 10/50 7/50 6.1 % 1.43 [ 0.59, 3.45 ]
Ramirez 2013 1/20 1/20 0.9 % 1.00 [ 0.07, 14.90 ]
Studenik 2005 7/20 3/19 2.7 % 2.22 [ 0.67, 7.34 ]
Subtotal (95% CI) 133 133 12.2 % 1.56 [ 0.84, 2.88 ]
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Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 22 (Gluc avoid), 14 (Gluc cont)
Heterogeneity: Chi2 = 0.51, df = 3 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI) 670 677 100.0 % 1.33 [ 1.08, 1.64 ]
Total events: 150 (Gluc avoid), 117 (Gluc cont)
Heterogeneity: Chi2 = 10.60, df = 15 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.66 (P = 0.0079)
Test for subgroup differences: Chi2 = 1.40, df = 2 (P = 0.50), I2 =0.0%
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Analysis 5.4. Comparison 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (co-interventions subgroups), Outcome 4 Infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (co-interventions subgroups)
Outcome: 4 Infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Dual therapy
Belli 1998 1/54 8/50 6.0 % 0.12 [ 0.02, 0.89 ]
Llado 2006 45/96 52/102 36.2 % 0.92 [ 0.69, 1.22 ]
Pageaux 2004 7/84 12/90 8.3 % 0.63 [ 0.26, 1.51 ]
Reggiani 2005 6/12 5/18 2.9 % 1.80 [ 0.71, 4.59 ]
Tisone 1999 17/23 15/22 11.0 % 1.08 [ 0.75, 1.58 ]
Subtotal (95% CI) 269 282 64.3 % 0.87 [ 0.70, 1.09 ]
Total events: 76 (Gluc avoid), 92 (Gluc cont)
Heterogeneity: Chi2 = 7.99, df = 4 (P = 0.09); I2 =50%
Test for overall effect: Z = 1.18 (P = 0.24)
2 Triple therapy
Ju 2012 6/43 16/44 11.3 % 0.38 [ 0.17, 0.89 ]
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Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pelletier 2013 26/50 22/50 15.8 % 1.18 [ 0.78, 1.78 ]
Ramirez 2013 12/20 12/20 8.6 % 1.00 [ 0.60, 1.66 ]
Subtotal (95% CI) 113 114 35.7 % 0.88 [ 0.65, 1.20 ]
Total events: 44 (Gluc avoid), 50 (Gluc cont)
Heterogeneity: Chi2 = 5.94, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 0.79 (P = 0.43)
Total (95% CI) 382 396 100.0 % 0.88 [ 0.73, 1.05 ]
Total events: 120 (Gluc avoid), 142 (Gluc cont)
Heterogeneity: Chi2 = 13.93, df = 7 (P = 0.05); I2 =50%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
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Analysis 5.5. Comparison 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (co-interventions subgroups), Outcome 5 Chronic rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (co-interventions subgroups)
Outcome: 5 Chronic rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Monotherapy
Lerut 2008 1/78 4/78 24.5 % 0.25 [ 0.03, 2.19 ]
Margarit 2005 0/30 0/33 Not estimable
Moench 2007 6/56 0/54 3.1 % 12.54 [ 0.72, 217.40 ]
Subtotal (95% CI) 164 165 27.6 % 1.64 [ 0.51, 5.25 ]
Total events: 7 (Gluc avoid), 4 (Gluc cont)
Heterogeneity: Chi2 = 4.84, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.83 (P = 0.41)
2 Dual therapy
Belli 1998 0/54 1/50 9.5 % 0.31 [ 0.01, 7.42 ]
Belli 2001 1/11 0/13 2.8 % 3.50 [ 0.16, 78.19 ]
Llado 2006 3/96 1/102 5.9 % 3.19 [ 0.34, 30.12 ]
Pageaux 2004 3/84 5/90 29.6 % 0.64 [ 0.16, 2.61 ]
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 268 277 47.9 % 1.06 [ 0.41, 2.76 ]
Total events: 7 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 2.56, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
3 Triple therapy
Pelletier 2013 1/50 4/50 24.5 % 0.25 [ 0.03, 2.16 ]
Subtotal (95% CI) 50 50 24.5 % 0.25 [ 0.03, 2.16 ]
Total events: 1 (Gluc avoid), 4 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
Total (95% CI) 482 492 100.0 % 1.02 [ 0.52, 2.00 ]
Total events: 15 (Gluc avoid), 15 (Gluc cont)
Heterogeneity: Chi2 = 8.78, df = 6 (P = 0.19); I2 =32%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 2.26, df = 2 (P = 0.32), I2 =11%
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Analysis 5.6. Comparison 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (co-interventions subgroups), Outcome 6 Glucocorticosteroid-resistant
rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (co-interventions subgroups)
Outcome: 6 Glucocorticosteroid-resistant rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Monotherapy
Lerut 2008 10/78 3/78 22.8 % 3.33 [ 0.95, 11.65 ]
Margarit 2005 4/30 3/33 21.7 % 1.47 [ 0.36, 6.03 ]
Moench 2007 1/56 0/54 3.9 % 2.89 [ 0.12, 69.55 ]
Vivarelli 2007 0/25 0/22 Not estimable
Subtotal (95% CI) 189 187 48.4 % 2.46 [ 1.01, 5.97 ]
Total events: 15 (Gluc avoid), 6 (Gluc cont)
Heterogeneity: Chi2 = 0.75, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.99 (P = 0.047)
2 Dual therapy
Llado 2006 4/96 4/102 29.5 % 1.06 [ 0.27, 4.13 ]
Pageaux 2004 8/84 3/90 22.0 % 2.86 [ 0.78, 10.41 ]
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 203 214 51.6 % 1.83 [ 0.74, 4.55 ]
Total events: 12 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 1.07, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 1.30 (P = 0.19)
3 Triple therapy
Ju 2012 0/43 0/44 Not estimable
Pelletier 2013 0/50 0/50 Not estimable
Ramirez 2013 0/20 0/20 Not estimable
Subtotal (95% CI) 113 114 Not estimable
Total events: 0 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 505 515 100.0 % 2.14 [ 1.13, 4.02 ]
Total events: 27 (Gluc avoid), 13 (Gluc cont)
Heterogeneity: Chi2 = 2.00, df = 4 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.65), I2 =0.0%
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Analysis 5.7. Comparison 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (co-interventions subgroups), Outcome 7 Diabetes mellitus.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (co-interventions subgroups)
Outcome: 7 Diabetes mellitus
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Monotherapy
Hu 2008 7/40 14/36 9.5 % 0.45 [ 0.20, 0.99 ]
Lerut 2008 18/78 14/78 9.0 % 1.29 [ 0.69, 2.40 ]
Margarit 2005 8/30 11/33 6.8 % 0.80 [ 0.37, 1.72 ]
Moench 2007 12/56 9/54 5.9 % 1.29 [ 0.59, 2.80 ]
Vivarelli 2007 14/25 12/22 8.2 % 1.03 [ 0.61, 1.72 ]
Subtotal (95% CI) 229 223 39.4 % 0.95 [ 0.70, 1.28 ]
Total events: 59 (Gluc avoid), 60 (Gluc cont)
Heterogeneity: Chi2 = 5.22, df = 4 (P = 0.27); I2 =23%
Test for overall effect: Z = 0.36 (P = 0.72)
2 Dual therapy
Belli 1998 3/54 12/50 8.0 % 0.23 [ 0.07, 0.77 ]
Llado 2006 17/96 23/102 14.4 % 0.79 [ 0.45, 1.38 ]
Pageaux 2004 12/84 20/90 12.4 % 0.64 [ 0.34, 1.23 ]
Reggiani 2005 2/12 5/18 2.6 % 0.60 [ 0.14, 2.60 ]
Subtotal (95% CI) 246 260 37.4 % 0.61 [ 0.41, 0.89 ]
Total events: 34 (Gluc avoid), 60 (Gluc cont)
Heterogeneity: Chi2 = 3.30, df = 3 (P = 0.35); I2 =9%
Test for overall effect: Z = 2.57 (P = 0.010)
3 Triple therapy
Ju 2012 2/43 9/44 5.7 % 0.23 [ 0.05, 0.99 ]
Pelletier 2013 22/50 19/50 12.2 % 1.16 [ 0.72, 1.86 ]
Ramirez 2013 8/20 8/20 5.2 % 1.00 [ 0.47, 2.14 ]
Subtotal (95% CI) 113 114 23.1 % 0.89 [ 0.61, 1.31 ]
Total events: 32 (Gluc avoid), 36 (Gluc cont)
Heterogeneity: Chi2 = 4.56, df = 2 (P = 0.10); I2 =56%
Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% CI) 588 597 100.0 % 0.81 [ 0.66, 0.99 ]
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Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 125 (Gluc avoid), 156 (Gluc cont)
Heterogeneity: Chi2 = 16.61, df = 11 (P = 0.12); I2 =34%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Chi2 = 3.47, df = 2 (P = 0.18), I2 =42%
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Analysis 5.8. Comparison 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (co-interventions subgroups), Outcome 8 CMV infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (co-interventions subgroups)
Outcome: 8 CMV infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Monotherapy
Lerut 2008 3/78 2/78 5.2 % 1.50 [ 0.26, 8.73 ]
Margarit 2005 0/30 1/33 3.7 % 0.37 [ 0.02, 8.65 ]
Moench 2007 14/56 18/54 47.9 % 0.75 [ 0.42, 1.35 ]
Subtotal (95% CI) 164 165 56.8 % 0.79 [ 0.46, 1.38 ]
Total events: 17 (Gluc avoid), 21 (Gluc cont)
Heterogeneity: Chi2 = 0.77, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
2 Dual therapy
Llado 2006 8/96 14/102 35.5 % 0.61 [ 0.27, 1.38 ]
Pageaux 2004 1/84 2/90 5.0 % 0.54 [ 0.05, 5.80 ]
Tisone 1999 2/23 1/22 2.7 % 1.91 [ 0.19, 19.63 ]
Subtotal (95% CI) 203 214 43.2 % 0.68 [ 0.33, 1.40 ]
Total events: 11 (Gluc avoid), 17 (Gluc cont)
Heterogeneity: Chi2 = 0.87, df = 2 (P = 0.65); I2 =0.0%
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Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 1.04 (P = 0.30)
3 Triple therapy
Ramirez 2013 0/20 0/20 Not estimable
Subtotal (95% CI) 20 20 Not estimable
Total events: 0 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 387 399 100.0 % 0.74 [ 0.48, 1.16 ]
Total events: 28 (Gluc avoid), 38 (Gluc cont)
Heterogeneity: Chi2 = 1.74, df = 5 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
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Analysis 5.9. Comparison 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (co-interventions subgroups), Outcome 9 HCV recurrence.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (co-interventions subgroups)
Outcome: 9 HCV recurrence
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Monotherapy
Lerut 2008 14/14 21/21 11.2 % 1.00 [ 0.89, 1.12 ]
Margarit 2005 17/20 14/15 10.2 % 0.91 [ 0.72, 1.14 ]
Vivarelli 2007 19/25 13/23 8.7 % 1.34 [ 0.88, 2.05 ]
Subtotal (95% CI) 59 59 30.1 % 1.07 [ 0.91, 1.25 ]
Total events: 50 (Gluc avoid), 48 (Gluc cont)
Heterogeneity: Chi2 = 4.36, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 0.82 (P = 0.41)
2 Dual therapy
Belli 1998 5/25 3/22 2.0 % 1.47 [ 0.40, 5.44 ]
Belli 2001 4/11 4/13 2.3 % 1.18 [ 0.38, 3.66 ]
Llado 2006 40/43 39/46 24.1 % 1.10 [ 0.95, 1.27 ]
Pageaux 2004 41/53 39/55 24.5 % 1.09 [ 0.87, 1.36 ]
Tisone 1999 1/7 5/8 3.0 % 0.23 [ 0.03, 1.52 ]
Subtotal (95% CI) 139 144 56.0 % 1.07 [ 0.92, 1.23 ]
Total events: 91 (Gluc avoid), 90 (Gluc cont)
Heterogeneity: Chi2 = 3.00, df = 4 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
3 Triple therapy
Pelletier 2013 6/20 15/31 7.5 % 0.62 [ 0.29, 1.33 ]
Ramirez 2013 12/14 9/11 6.4 % 1.05 [ 0.74, 1.49 ]
Subtotal (95% CI) 34 42 14.0 % 0.82 [ 0.55, 1.22 ]
Total events: 18 (Gluc avoid), 24 (Gluc cont)
Heterogeneity: Chi2 = 2.42, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.98 (P = 0.32)
Total (95% CI) 232 245 100.0 % 1.03 [ 0.92, 1.15 ]
Total events: 159 (Gluc avoid), 162 (Gluc cont)
Heterogeneity: Chi2 = 8.36, df = 9 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Chi2 = 1.58, df = 2 (P = 0.45), I2 =0.0%
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Analysis 5.10. Comparison 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (co-interventions subgroups), Outcome 10 Malignancy.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (co-interventions subgroups)
Outcome: 10 Malignancy
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Monotherapy
Lerut 2008 2/78 0/78 6.4 % 5.00 [ 0.24, 102.49 ]
Subtotal (95% CI) 78 78 6.4 % 5.00 [ 0.24, 102.49 ]
Total events: 2 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
2 Dual therapy
Llado 2006 0/96 5/102 68.7 % 0.10 [ 0.01, 1.72 ]
Pageaux 2004 1/84 2/90 24.9 % 0.54 [ 0.05, 5.80 ]
Subtotal (95% CI) 180 192 93.6 % 0.21 [ 0.04, 1.22 ]
Total events: 1 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.082)
Total (95% CI) 258 270 100.0 % 0.52 [ 0.16, 1.74 ]
Total events: 3 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 3.47, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Chi2 = 3.15, df = 1 (P = 0.08), I2 =68%
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Analysis 5.11. Comparison 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (co-interventions subgroups), Outcome 11 Post-transplant
lymphoproliferative disorder.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (co-interventions subgroups)
Outcome: 11 Post-transplant lymphoproliferative disorder
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Monotherapy
Lerut 2008 2/78 1/78 67.4 % 2.00 [ 0.19, 21.61 ]
Subtotal (95% CI) 78 78 67.4 % 2.00 [ 0.19, 21.61 ]
Total events: 2 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 Dual therapy
Pageaux 2004 1/84 0/90 32.6 % 3.21 [ 0.13, 77.77 ]
Subtotal (95% CI) 84 90 32.6 % 3.21 [ 0.13, 77.77 ]
Total events: 1 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 162 168 100.0 % 2.39 [ 0.36, 15.95 ]
Total events: 3 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 5.12. Comparison 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (co-interventions subgroups), Outcome 12 Renal insufficiency.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (co-interventions subgroups)
Outcome: 12 Renal insufficiency
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Monotherapy
Lerut 2008 4/78 8/78 10.7 % 0.50 [ 0.16, 1.59 ]
Margarit 2005 20/30 17/33 21.7 % 1.29 [ 0.85, 1.96 ]
Subtotal (95% CI) 108 111 32.5 % 1.03 [ 0.68, 1.56 ]
Total events: 24 (Gluc avoid), 25 (Gluc cont)
Heterogeneity: Chi2 = 2.64, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.15 (P = 0.88)
2 Dual therapy
Llado 2006 41/96 51/102 66.4 % 0.85 [ 0.63, 1.16 ]
Reggiani 2005 2/12 1/18 1.1 % 3.00 [ 0.30, 29.52 ]
Subtotal (95% CI) 108 120 67.5 % 0.89 [ 0.66, 1.20 ]
Total events: 43 (Gluc avoid), 52 (Gluc cont)
Heterogeneity: Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI) 216 231 100.0 % 0.93 [ 0.73, 1.19 ]
Total events: 67 (Gluc avoid), 77 (Gluc cont)
Heterogeneity: Chi2 = 4.80, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 0.33, df = 1 (P = 0.56), I2 =0.0%
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Analysis 5.13. Comparison 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (co-interventions subgroups), Outcome 13 Creatinine.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (co-interventions subgroups)
Outcome: 13 Creatinine
Study or subgroup Gluc avoid Gluc cont
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mg/dL] N Mean(SD)[mg/dL] IV,Fixed,95% CI IV,Fixed,95% CI
1 Monotherapy
Moench 2007 56 1.14 (1.09) 54 1.26 (0.79) 1.6 % -0.12 [ -0.47, 0.23 ]
Subtotal (95% CI) 56 54 1.6 % -0.12 [ -0.47, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Dual therapy
Chen 2007 28 0.75 (0.2) 26 0.8 (0.2) 17.5 % -0.05 [ -0.16, 0.06 ]
Tisone 1999 23 1.8 (0.1) 22 1.9 (0.2) 23.1 % -0.10 [ -0.19, -0.01 ]
Subtotal (95% CI) 51 48 40.6 % -0.08 [ -0.15, -0.01 ]
Heterogeneity: Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.028)
3 Triple therapy
Pelletier 2013 50 1.67 (0.15) 50 1.42 (0.15) 57.8 % 0.25 [ 0.19, 0.31 ]
Subtotal (95% CI) 50 50 57.8 % 0.25 [ 0.19, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.33 (P < 0.00001)
Total (95% CI) 157 152 100.0 % 0.11 [ 0.07, 0.16 ]
Heterogeneity: Chi2 = 51.59, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 4.86 (P < 0.00001)
Test for subgroup differences: Chi2 = 51.11, df = 2 (P = 0.00), I2 =96%
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Analysis 5.14. Comparison 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (co-interventions subgroups), Outcome 14 Hypertension.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (co-interventions subgroups)
Outcome: 14 Hypertension
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Monotherapy
Hu 2008 9/40 10/36 5.1 % 0.81 [ 0.37, 1.77 ]
Lerut 2008 6/78 10/78 4.8 % 0.60 [ 0.23, 1.57 ]
Margarit 2005 4/30 9/33 4.1 % 0.49 [ 0.17, 1.42 ]
Moench 2007 25/56 25/54 12.3 % 0.96 [ 0.64, 1.45 ]
Subtotal (95% CI) 204 201 26.3 % 0.79 [ 0.57, 1.10 ]
Total events: 44 (Gluc avoid), 54 (Gluc cont)
Heterogeneity: Chi2 = 1.99, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
2 Dual therapy
Belli 1998 9/54 28/50 14.0 % 0.30 [ 0.16, 0.57 ]
Llado 2006 48/96 60/102 28.0 % 0.85 [ 0.66, 1.10 ]
Pageaux 2004 24/84 30/90 13.9 % 0.86 [ 0.55, 1.34 ]
Reggiani 2005 2/12 5/18 1.9 % 0.60 [ 0.14, 2.60 ]
Subtotal (95% CI) 246 260 57.9 % 0.71 [ 0.57, 0.88 ]
Total events: 83 (Gluc avoid), 123 (Gluc cont)
Heterogeneity: Chi2 = 9.59, df = 3 (P = 0.02); I2 =69%
Test for overall effect: Z = 3.17 (P = 0.0015)
3 Triple therapy
Ju 2012 2/43 9/44 4.3 % 0.23 [ 0.05, 0.99 ]
Pelletier 2013 28/50 24/50 11.6 % 1.17 [ 0.80, 1.70 ]
Subtotal (95% CI) 93 94 15.8 % 0.91 [ 0.63, 1.32 ]
Total events: 30 (Gluc avoid), 33 (Gluc cont)
Heterogeneity: Chi2 = 5.03, df = 1 (P = 0.02); I2 =80%
Test for overall effect: Z = 0.48 (P = 0.63)
Total (95% CI) 543 555 100.0 % 0.76 [ 0.65, 0.90 ]
Total events: 157 (Gluc avoid), 210 (Gluc cont)
Heterogeneity: Chi2 = 18.80, df = 9 (P = 0.03); I2 =52%
Test for overall effect: Z = 3.28 (P = 0.0010)
Test for subgroup differences: Chi2 = 1.40, df = 2 (P = 0.50), I2 =0.0%
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Analysis 5.15. Comparison 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (co-interventions subgroups), Outcome 15 Hyperlipidaemia.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (co-interventions subgroups)
Outcome: 15 Hyperlipidaemia
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Monotherapy
Hu 2008 2/40 3/36 17.8 % 0.60 [ 0.11, 3.39 ]
Margarit 2005 5/30 4/33 21.5 % 1.38 [ 0.41, 4.65 ]
Subtotal (95% CI) 70 69 39.4 % 1.02 [ 0.38, 2.72 ]
Total events: 7 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
2 Dual therapy
Pageaux 2004 2/84 6/90 32.7 % 0.36 [ 0.07, 1.72 ]
Subtotal (95% CI) 84 90 32.7 % 0.36 [ 0.07, 1.72 ]
Total events: 2 (Gluc avoid), 6 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
3 Triple therapy
Ju 2012 4/43 5/44 27.9 % 0.82 [ 0.24, 2.85 ]
Subtotal (95% CI) 43 44 27.9 % 0.82 [ 0.24, 2.85 ]
Total events: 4 (Gluc avoid), 5 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
Total (95% CI) 197 203 100.0 % 0.75 [ 0.38, 1.48 ]
Total events: 13 (Gluc avoid), 18 (Gluc cont)
Heterogeneity: Chi2 = 1.89, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 1.25, df = 2 (P = 0.54), I2 =0.0%
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Analysis 5.16. Comparison 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (co-interventions subgroups), Outcome 16 Cholesterol.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 5 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (co-interventions subgroups)
Outcome: 16 Cholesterol
Study or subgroup Gluc avoid Gluc cont
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mg/dL] N Mean(SD)[mg/dL] IV,Fixed,95% CI IV,Fixed,95% CI
1 Monotherapy
Moench 2007 56 207 (77) 54 172 (39) 2.4 % 35.00 [ 12.31, 57.69 ]
Subtotal (95% CI) 56 54 2.4 % 35.00 [ 12.31, 57.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
2 Dual therapy
Belli 1998 54 183 (81) 50 253 (76) 1.4 % -70.00 [ -100.17, -39.83 ]
Chen 2007 28 151 (69) 26 297 (100) 0.6 % -146.00 [ -192.16, -99.84 ]
Llado 2006 96 182 (54) 102 193 (43) 6.7 % -11.00 [ -24.65, 2.65 ]
Tisone 1999 23 117 (52) 22 128 (51) 1.4 % -11.00 [ -41.10, 19.10 ]
Subtotal (95% CI) 201 200 10.0 % -26.94 [ -38.10, -15.79 ]
Heterogeneity: Chi2 = 39.70, df = 3 (P<0.00001); I2 =92%
Test for overall effect: Z = 4.73 (P < 0.00001)
3 Triple therapy
Pelletier 2013 50 148 (8) 50 167 (11) 87.6 % -19.00 [ -22.77, -15.23 ]
Subtotal (95% CI) 50 50 87.6 % -19.00 [ -22.77, -15.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.88 (P < 0.00001)
Total (95% CI) 307 304 100.0 % -18.49 [ -22.02, -14.96 ]
Heterogeneity: Chi2 = 63.32, df = 5 (P<0.00001); I2 =92%
Test for overall effect: Z = 10.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 23.62, df = 2 (P = 0.00), I2 =92%
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Analysis 6.1. Comparison 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (treatment duration subgroups), Outcome 1 Mortality.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (treatment duration subgroups)
Outcome: 1 Mortality
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2 to 3 months glucocorticosteroid
Hu 2008 1/40 1/36 1.0 % 0.90 [ 0.06, 13.87 ]
Ju 2012 4/43 6/44 5.4 % 0.68 [ 0.21, 2.25 ]
Lerut 2008 17/78 13/78 11.9 % 1.31 [ 0.68, 2.51 ]
Llado 2006 5/96 11/102 9.7 % 0.48 [ 0.17, 1.34 ]
Margarit 2005 12/30 11/33 9.6 % 1.20 [ 0.63, 2.30 ]
Reggiani 2005 1/12 0/18 0.4 % 4.38 [ 0.19, 99.48 ]
Tisone 1999 7/23 7/22 6.5 % 0.96 [ 0.40, 2.28 ]
Subtotal (95% CI) 322 333 44.4 % 0.99 [ 0.70, 1.41 ]
Total events: 47 (Gluc avoid), 49 (Gluc cont)
Heterogeneity: Chi2 = 4.19, df = 6 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
2 > 3 to 6 months glucocorticosteroids
Moench 2007 17/56 11/54 10.2 % 1.49 [ 0.77, 2.88 ]
Pelletier 2013 20/50 14/50 12.8 % 1.43 [ 0.82, 2.50 ]
Ramirez 2013 8/20 5/20 4.6 % 1.60 [ 0.63, 4.05 ]
Subtotal (95% CI) 126 124 27.6 % 1.48 [ 1.00, 2.18 ]
Total events: 45 (Gluc avoid), 30 (Gluc cont)
Heterogeneity: Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.98 (P = 0.048)
3 > 6 months glucocorticosteroids
Belli 1998 11/54 9/50 8.5 % 1.13 [ 0.51, 2.50 ]
Chen 2007 10/28 14/26 13.2 % 0.66 [ 0.36, 1.22 ]
Studenik 2005 0/20 1/19 1.4 % 0.32 [ 0.01, 7.35 ]
Vivarelli 2007 6/25 5/22 4.9 % 1.06 [ 0.37, 2.99 ]
Subtotal (95% CI) 127 117 28.0 % 0.86 [ 0.55, 1.33 ]
Total events: 27 (Gluc avoid), 29 (Gluc cont)
Heterogeneity: Chi2 = 1.69, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.49)
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total (95% CI) 575 574 100.0 % 1.09 [ 0.87, 1.36 ]
Total events: 119 (Gluc avoid), 108 (Gluc cont)
Heterogeneity: Chi2 = 9.85, df = 13 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Chi2 = 3.82, df = 2 (P = 0.15), I2 =48%
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Analysis 6.2. Comparison 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (treatment duration subgroups), Outcome 2 Graft loss including death.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (treatment duration subgroups)
Outcome: 2 Graft loss including death
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2 to 3 months glucocorticosteroid
Lerut 2008 20/78 17/78 19.4 % 1.18 [ 0.67, 2.07 ]
Llado 2006 9/96 12/102 13.3 % 0.80 [ 0.35, 1.81 ]
Margarit 2005 0/30 4/33 4.9 % 0.12 [ 0.01, 2.17 ]
Reggiani 2005 1/12 3/18 2.7 % 0.50 [ 0.06, 4.26 ]
Tisone 1999 7/23 7/22 8.2 % 0.96 [ 0.40, 2.28 ]
Subtotal (95% CI) 239 253 48.4 % 0.89 [ 0.60, 1.32 ]
Total events: 37 (Gluc avoid), 43 (Gluc cont)
Heterogeneity: Chi2 = 3.14, df = 4 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
2 > 3 to 6 months glucocorticosteroids
Moench 2007 21/56 15/54 17.4 % 1.35 [ 0.78, 2.33 ]
Pelletier 2013 22/50 14/50 16.0 % 1.57 [ 0.91, 2.71 ]
Ramirez 2013 8/20 6/20 6.8 % 1.33 [ 0.57, 3.14 ]
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 126 124 40.2 % 1.44 [ 1.01, 2.04 ]
Total events: 51 (Gluc avoid), 35 (Gluc cont)
Heterogeneity: Chi2 = 0.18, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.044)
3 > 6 months glucocorticosteroids
Studenik 2005 0/20 2/19 2.9 % 0.19 [ 0.01, 3.73 ]
Vivarelli 2007 6/25 7/22 8.5 % 0.75 [ 0.30, 1.91 ]
Subtotal (95% CI) 45 41 11.4 % 0.61 [ 0.25, 1.47 ]
Total events: 6 (Gluc avoid), 9 (Gluc cont)
Heterogeneity: Chi2 = 0.79, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 410 418 100.0 % 1.08 [ 0.84, 1.38 ]
Total events: 94 (Gluc avoid), 87 (Gluc cont)
Heterogeneity: Chi2 = 7.99, df = 9 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Chi2 = 5.03, df = 2 (P = 0.08), I2 =60%
0.01 0.1 1 10 100
Favours gluc avoid Favours gluc cont
181Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.3. Comparison 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (treatment duration subgroups), Outcome 3 Acute rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (treatment duration subgroups)
Outcome: 3 Acute rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2 to 3 months glucocorticosteroid
Belli 2001 5/11 7/13 6.8 % 0.84 [ 0.37, 1.92 ]
Hu 2008 5/40 4/36 4.5 % 1.13 [ 0.33, 3.87 ]
Ju 2012 4/43 3/44 3.2 % 1.36 [ 0.32, 5.74 ]
Lerut 2008 18/78 16/78 17.0 % 1.13 [ 0.62, 2.04 ]
Llado 2006 17/96 13/102 13.4 % 1.39 [ 0.71, 2.70 ]
Margarit 2005 11/30 10/33 10.1 % 1.21 [ 0.60, 2.43 ]
Reggiani 2005 9/12 3/18 2.6 % 4.50 [ 1.52, 13.30 ]
Tisone 1999 4/23 4/22 4.3 % 0.96 [ 0.27, 3.36 ]
Subtotal (95% CI) 333 346 61.9 % 1.30 [ 0.97, 1.75 ]
Total events: 73 (Gluc avoid), 60 (Gluc cont)
Heterogeneity: Chi2 = 6.71, df = 7 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.078)
2 > 3 to 6 months glucocorticosteroids
Moench 2007 19/56 14/54 15.2 % 1.31 [ 0.73, 2.34 ]
Pelletier 2013 10/50 7/50 7.4 % 1.43 [ 0.59, 3.45 ]
Ramirez 2013 1/20 1/20 1.1 % 1.00 [ 0.07, 14.90 ]
Subtotal (95% CI) 126 124 23.7 % 1.33 [ 0.83, 2.15 ]
Total events: 30 (Gluc avoid), 22 (Gluc cont)
Heterogeneity: Chi2 = 0.07, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
3 > 6 months glucocorticosteroids
Belli 1998 2/54 3/50 3.3 % 0.62 [ 0.11, 3.54 ]
Chen 2007 4/28 3/26 3.3 % 1.24 [ 0.31, 5.01 ]
Studenik 2005 7/20 3/19 3.3 % 2.22 [ 0.67, 7.34 ]
Vivarelli 2007 2/25 4/22 4.5 % 0.44 [ 0.09, 2.17 ]
Subtotal (95% CI) 127 117 14.4 % 1.07 [ 0.54, 2.12 ]
Total events: 15 (Gluc avoid), 13 (Gluc cont)
Heterogeneity: Chi2 = 3.03, df = 3 (P = 0.39); I2 =1%
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.19 (P = 0.85)
Total (95% CI) 586 587 100.0 % 1.28 [ 1.01, 1.62 ]
Total events: 118 (Gluc avoid), 95 (Gluc cont)
Heterogeneity: Chi2 = 9.97, df = 14 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.043)
Test for subgroup differences: Chi2 = 0.31, df = 2 (P = 0.85), I2 =0.0%
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Analysis 6.4. Comparison 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (treatment duration subgroups), Outcome 4 Infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (treatment duration subgroups)
Outcome: 4 Infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2 to 3 months glucocorticosteroid
Ju 2012 6/43 16/44 12.4 % 0.38 [ 0.17, 0.89 ]
Llado 2006 45/96 52/102 39.4 % 0.92 [ 0.69, 1.22 ]
Reggiani 2005 6/12 5/18 3.1 % 1.80 [ 0.71, 4.59 ]
Tisone 1999 17/23 15/22 12.0 % 1.08 [ 0.75, 1.58 ]
Subtotal (95% CI) 174 186 66.9 % 0.89 [ 0.71, 1.11 ]
Total events: 74 (Gluc avoid), 88 (Gluc cont)
Heterogeneity: Chi2 = 7.14, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 1.02 (P = 0.31)
2 > 3 to 6 months glucocorticosteroids
Pelletier 2013 26/50 22/50 17.2 % 1.18 [ 0.78, 1.78 ]
Ramirez 2013 12/20 12/20 9.4 % 1.00 [ 0.60, 1.66 ]
Subtotal (95% CI) 70 70 26.6 % 1.12 [ 0.81, 1.54 ]
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 38 (Gluc avoid), 34 (Gluc cont)
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
3 > 6 months glucocorticosteroids
Belli 1998 1/54 8/50 6.5 % 0.12 [ 0.02, 0.89 ]
Subtotal (95% CI) 54 50 6.5 % 0.12 [ 0.02, 0.89 ]
Total events: 1 (Gluc avoid), 8 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.039)
Total (95% CI) 298 306 100.0 % 0.90 [ 0.75, 1.08 ]
Total events: 113 (Gluc avoid), 130 (Gluc cont)
Heterogeneity: Chi2 = 12.75, df = 6 (P = 0.05); I2 =53%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Chi2 = 5.38, df = 2 (P = 0.07), I2 =63%
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Analysis 6.5. Comparison 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (treatment duration subgroups), Outcome 5 Chronic rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (treatment duration subgroups)
Outcome: 5 Chronic rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2 to 3 months glucocorticosteroid
Belli 2001 1/11 0/13 4.0 % 3.50 [ 0.16, 78.19 ]
Lerut 2008 1/78 4/78 34.8 % 0.25 [ 0.03, 2.19 ]
Llado 2006 3/96 1/102 8.4 % 3.19 [ 0.34, 30.12 ]
Margarit 2005 0/30 0/33 Not estimable
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 238 248 47.2 % 1.05 [ 0.33, 3.32 ]
Total events: 5 (Gluc avoid), 5 (Gluc cont)
Heterogeneity: Chi2 = 3.20, df = 2 (P = 0.20); I2 =37%
Test for overall effect: Z = 0.08 (P = 0.93)
2 > 3 to 6 months glucocorticosteroids
Moench 2007 6/56 0/54 4.4 % 12.54 [ 0.72, 217.40 ]
Pelletier 2013 1/50 4/50 34.8 % 0.25 [ 0.03, 2.16 ]
Subtotal (95% CI) 106 104 39.2 % 1.64 [ 0.51, 5.24 ]
Total events: 7 (Gluc avoid), 4 (Gluc cont)
Heterogeneity: Chi2 = 4.88, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.83 (P = 0.41)
3 > 6 months glucocorticosteroids
Belli 1998 0/54 1/50 13.5 % 0.31 [ 0.01, 7.42 ]
Subtotal (95% CI) 54 50 13.5 % 0.31 [ 0.01, 7.42 ]
Total events: 0 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 398 402 100.0 % 1.18 [ 0.54, 2.56 ]
Total events: 12 (Gluc avoid), 10 (Gluc cont)
Heterogeneity: Chi2 = 8.50, df = 5 (P = 0.13); I2 =41%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Chi2 = 1.03, df = 2 (P = 0.60), I2 =0.0%
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Analysis 6.6. Comparison 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (treatment duration subgroups), Outcome 6 Glucocorticosteroid-resistant
rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (treatment duration subgroups)
Outcome: 6 Glucocorticosteroid-resistant rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2 to 3 months glucocorticosteroid
Ju 2012 0/43 0/44 Not estimable
Lerut 2008 10/78 3/78 29.3 % 3.33 [ 0.95, 11.65 ]
Llado 2006 4/96 4/102 37.9 % 1.06 [ 0.27, 4.13 ]
Margarit 2005 4/30 3/33 27.9 % 1.47 [ 0.36, 6.03 ]
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 270 279 95.0 % 1.88 [ 0.89, 3.98 ]
Total events: 18 (Gluc avoid), 10 (Gluc cont)
Heterogeneity: Chi2 = 1.60, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.65 (P = 0.099)
2 > 3 to 6 months glucocorticosteroids
Moench 2007 1/56 0/54 5.0 % 2.89 [ 0.12, 69.55 ]
Pelletier 2013 0/50 0/50 Not estimable
Ramirez 2013 0/20 0/20 Not estimable
Subtotal (95% CI) 126 124 5.0 % 2.89 [ 0.12, 69.55 ]
Total events: 1 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
3 > 6 months glucocorticosteroids
Vivarelli 2007 0/25 0/22 Not estimable
Subtotal (95% CI) 25 22 Not estimable
Total events: 0 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 421 425 100.0 % 1.93 [ 0.93, 4.01 ]
Total events: 19 (Gluc avoid), 10 (Gluc cont)
Heterogeneity: Chi2 = 1.68, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.80), I2 =0.0%
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Analysis 6.7. Comparison 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (treatment duration subgroups), Outcome 7 Diabetes mellitus.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (treatment duration subgroups)
Outcome: 7 Diabetes mellitus
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2 to 3 months glucocorticosteroid
Hu 2008 7/40 14/36 10.9 % 0.45 [ 0.20, 0.99 ]
Ju 2012 2/43 9/44 6.6 % 0.23 [ 0.05, 0.99 ]
Lerut 2008 18/78 14/78 10.3 % 1.29 [ 0.69, 2.40 ]
Llado 2006 17/96 23/102 16.4 % 0.79 [ 0.45, 1.38 ]
Margarit 2005 8/30 11/33 7.7 % 0.80 [ 0.37, 1.72 ]
Reggiani 2005 2/12 5/18 2.9 % 0.60 [ 0.14, 2.60 ]
Subtotal (95% CI) 299 311 54.8 % 0.74 [ 0.54, 1.01 ]
Total events: 54 (Gluc avoid), 76 (Gluc cont)
Heterogeneity: Chi2 = 7.17, df = 5 (P = 0.21); I2 =30%
Test for overall effect: Z = 1.92 (P = 0.055)
2 > 3 to 6 months glucocorticosteroids
Moench 2007 12/56 9/54 6.7 % 1.29 [ 0.59, 2.80 ]
Pelletier 2013 22/50 19/50 14.0 % 1.16 [ 0.72, 1.86 ]
Ramirez 2013 8/20 8/20 5.9 % 1.00 [ 0.47, 2.14 ]
Subtotal (95% CI) 126 124 26.6 % 1.16 [ 0.81, 1.66 ]
Total events: 42 (Gluc avoid), 36 (Gluc cont)
Heterogeneity: Chi2 = 0.21, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
3 > 6 months glucocorticosteroids
Belli 1998 3/54 12/50 9.2 % 0.23 [ 0.07, 0.77 ]
Vivarelli 2007 14/25 12/22 9.4 % 1.03 [ 0.61, 1.72 ]
Subtotal (95% CI) 79 72 18.6 % 0.63 [ 0.39, 1.03 ]
Total events: 17 (Gluc avoid), 24 (Gluc cont)
Heterogeneity: Chi2 = 6.04, df = 1 (P = 0.01); I2 =83%
Test for overall effect: Z = 1.82 (P = 0.068)
Total (95% CI) 504 507 100.0 % 0.83 [ 0.67, 1.03 ]
Total events: 113 (Gluc avoid), 136 (Gluc cont)
Heterogeneity: Chi2 = 15.73, df = 10 (P = 0.11); I2 =36%
Test for overall effect: Z = 1.73 (P = 0.084)
Test for subgroup differences: Chi2 = 4.95, df = 2 (P = 0.08), I2 =60%
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Analysis 6.8. Comparison 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (treatment duration subgroups), Outcome 8 CMV infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (treatment duration subgroups)
Outcome: 8 CMV infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2 to 3 months glucocorticosteroid
Lerut 2008 3/78 2/78 5.5 % 1.50 [ 0.26, 8.73 ]
Llado 2006 8/96 14/102 37.3 % 0.61 [ 0.27, 1.38 ]
Margarit 2005 0/30 1/33 3.9 % 0.37 [ 0.02, 8.65 ]
Tisone 1999 2/23 1/22 2.8 % 1.91 [ 0.19, 19.63 ]
Subtotal (95% CI) 227 235 49.6 % 0.76 [ 0.39, 1.49 ]
Total events: 13 (Gluc avoid), 18 (Gluc cont)
Heterogeneity: Chi2 = 1.67, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
2 > 3 to 6 months glucocorticosteroids
Moench 2007 14/56 18/54 50.4 % 0.75 [ 0.42, 1.35 ]
Ramirez 2013 0/20 0/20 Not estimable
Subtotal (95% CI) 76 74 50.4 % 0.75 [ 0.42, 1.35 ]
Total events: 14 (Gluc avoid), 18 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 303 309 100.0 % 0.76 [ 0.48, 1.18 ]
Total events: 27 (Gluc avoid), 36 (Gluc cont)
Heterogeneity: Chi2 = 1.67, df = 4 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 6.9. Comparison 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (treatment duration subgroups), Outcome 9 HCV recurrence.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (treatment duration subgroups)
Outcome: 9 HCV recurrence
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2 to 3 months glucocorticosteroid
Belli 2001 4/11 4/13 3.1 % 1.18 [ 0.38, 3.66 ]
Lerut 2008 14/14 21/21 14.8 % 1.00 [ 0.89, 1.12 ]
Llado 2006 40/43 39/46 31.9 % 1.10 [ 0.95, 1.27 ]
Margarit 2005 17/20 14/15 13.6 % 0.91 [ 0.72, 1.14 ]
Tisone 1999 1/7 5/8 4.0 % 0.23 [ 0.03, 1.52 ]
Subtotal (95% CI) 95 103 67.3 % 0.99 [ 0.88, 1.12 ]
Total events: 76 (Gluc avoid), 83 (Gluc cont)
Heterogeneity: Chi2 = 4.78, df = 4 (P = 0.31); I2 =16%
Test for overall effect: Z = 0.15 (P = 0.88)
2 > 3 to 6 months glucocorticosteroids
Pelletier 2013 6/20 15/31 10.0 % 0.62 [ 0.29, 1.33 ]
Ramirez 2013 12/14 9/11 8.5 % 1.05 [ 0.74, 1.49 ]
Subtotal (95% CI) 34 42 18.5 % 0.82 [ 0.55, 1.22 ]
Total events: 18 (Gluc avoid), 24 (Gluc cont)
Heterogeneity: Chi2 = 2.42, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.98 (P = 0.32)
3 > 6 months glucocorticosteroids
Belli 1998 5/25 3/22 2.7 % 1.47 [ 0.40, 5.44 ]
Vivarelli 2007 19/25 13/23 11.5 % 1.34 [ 0.88, 2.05 ]
Subtotal (95% CI) 50 45 14.2 % 1.37 [ 0.89, 2.09 ]
Total events: 24 (Gluc avoid), 16 (Gluc cont)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
Total (95% CI) 179 190 100.0 % 1.01 [ 0.89, 1.15 ]
Total events: 118 (Gluc avoid), 123 (Gluc cont)
Heterogeneity: Chi2 = 8.15, df = 8 (P = 0.42); I2 =2%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Chi2 = 3.07, df = 2 (P = 0.22), I2 =35%
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Analysis 6.10. Comparison 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (treatment duration subgroups), Outcome 10 Creatinine.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (treatment duration subgroups)
Outcome: 10 Creatinine
Study or subgroup Gluc avoid Gluc cont
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mg/dL] N Mean(SD)[mg/dL] IV,Fixed,95% CI IV,Fixed,95% CI
1 > 6 months glucocorticosteroids
Tisone 1999 23 1.8 (0.1) 22 1.9 (0.2) 23.1 % -0.10 [ -0.19, -0.01 ]
Subtotal (95% CI) 23 22 23.1 % -0.10 [ -0.19, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
2 2 to 3 months glucocorticosteroid
Moench 2007 56 1.14 (1.09) 54 1.26 (0.79) 1.6 % -0.12 [ -0.47, 0.23 ]
Pelletier 2013 50 1.67 (0.15) 50 1.42 (0.15) 57.8 % 0.25 [ 0.19, 0.31 ]
Subtotal (95% CI) 106 104 59.4 % 0.24 [ 0.18, 0.30 ]
Heterogeneity: Chi2 = 4.07, df = 1 (P = 0.04); I2 =75%
Test for overall effect: Z = 8.11 (P < 0.00001)
3 > 3 to 6 months glucocorticosteroids
Chen 2007 28 0.75 (0.2) 26 0.8 (0.2) 17.5 % -0.05 [ -0.16, 0.06 ]
Subtotal (95% CI) 28 26 17.5 % -0.05 [ -0.16, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Total (95% CI) 157 152 100.0 % 0.11 [ 0.07, 0.16 ]
Heterogeneity: Chi2 = 51.59, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 4.86 (P < 0.00001)
Test for subgroup differences: Chi2 = 47.53, df = 2 (P = 0.00), I2 =96%
-0.5 -0.25 0 0.25 0.5
Favours gluc avoid Favours gluc cont
190Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.11. Comparison 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (treatment duration subgroups), Outcome 11 Hypertension.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (treatment duration subgroups)
Outcome: 11 Hypertension
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2 to 3 months glucocorticosteroid
Hu 2008 9/40 10/36 5.9 % 0.81 [ 0.37, 1.77 ]
Ju 2012 2/43 9/44 5.0 % 0.23 [ 0.05, 0.99 ]
Lerut 2008 6/78 10/78 5.6 % 0.60 [ 0.23, 1.57 ]
Llado 2006 48/96 60/102 32.6 % 0.85 [ 0.66, 1.10 ]
Margarit 2005 4/30 9/33 4.8 % 0.49 [ 0.17, 1.42 ]
Reggiani 2005 2/12 5/18 2.2 % 0.60 [ 0.14, 2.60 ]
Subtotal (95% CI) 299 311 56.1 % 0.72 [ 0.57, 0.92 ]
Total events: 71 (Gluc avoid), 103 (Gluc cont)
Heterogeneity: Chi2 = 4.66, df = 5 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.68 (P = 0.0073)
2 > 3 to 6 months glucocorticosteroids
Moench 2007 25/56 25/54 14.2 % 0.96 [ 0.64, 1.45 ]
Pelletier 2013 28/50 24/50 13.4 % 1.17 [ 0.80, 1.70 ]
Subtotal (95% CI) 106 104 27.7 % 1.06 [ 0.80, 1.40 ]
Total events: 53 (Gluc avoid), 49 (Gluc cont)
Heterogeneity: Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
3 > 6 months glucocorticosteroids
Belli 1998 9/54 28/50 16.3 % 0.30 [ 0.16, 0.57 ]
Subtotal (95% CI) 54 50 16.3 % 0.30 [ 0.16, 0.57 ]
Total events: 9 (Gluc avoid), 28 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 3.68 (P = 0.00023)
Total (95% CI) 459 465 100.0 % 0.75 [ 0.63, 0.89 ]
Total events: 133 (Gluc avoid), 180 (Gluc cont)
Heterogeneity: Chi2 = 18.98, df = 8 (P = 0.01); I2 =58%
Test for overall effect: Z = 3.30 (P = 0.00098)
Test for subgroup differences: Chi2 = 13.67, df = 2 (P = 0.00), I2 =85%
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Analysis 6.12. Comparison 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (treatment duration subgroups), Outcome 12 Cholesterol.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (treatment duration subgroups)
Outcome: 12 Cholesterol
Study or subgroup Gluc avoid Gluc cont
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mg/dL] N Mean(SD)[mg/dL] IV,Fixed,95% CI IV,Fixed,95% CI
1 2 to 3 months glucocorticosteroid
Llado 2006 96 182 (54) 102 193 (43) 6.7 % -11.00 [ -24.65, 2.65 ]
Tisone 1999 23 117 (52) 22 128 (51) 1.4 % -11.00 [ -41.10, 19.10 ]
Subtotal (95% CI) 119 124 8.1 % -11.00 [ -23.43, 1.43 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.083)
2 > 3 to 6 months glucocorticosteroids
Moench 2007 56 207 (77) 54 172 (39) 2.4 % 35.00 [ 12.31, 57.69 ]
Pelletier 2013 50 148 (8) 50 167 (11) 87.6 % -19.00 [ -22.77, -15.23 ]
Subtotal (95% CI) 106 104 90.0 % -17.55 [ -21.27, -13.83 ]
Heterogeneity: Chi2 = 21.17, df = 1 (P<0.00001); I2 =95%
Test for overall effect: Z = 9.25 (P < 0.00001)
3 > 6 months glucocorticosteroids
Belli 1998 54 183 (81) 50 253 (76) 1.4 % -70.00 [ -100.17, -39.83 ]
Chen 2007 28 151 (69) 26 297 (100) 0.6 % -146.00 [ -192.16, -99.84 ]
Subtotal (95% CI) 82 76 2.0 % -92.75 [ -118.01, -67.50 ]
Heterogeneity: Chi2 = 7.30, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 7.20 (P < 0.00001)
Total (95% CI) 307 304 100.0 % -18.49 [ -22.02, -14.96 ]
Heterogeneity: Chi2 = 63.32, df = 5 (P<0.00001); I2 =92%
Test for overall effect: Z = 10.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 34.85, df = 2 (P = 0.00), I2 =94%
-200 -100 0 100 200
Favours gluc avoid Favours gluc cont
192Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.13. Comparison 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (treatment duration subgroups), Outcome 13 Hypercholesterolaemia.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 6 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (treatment duration subgroups)
Outcome: 13 Hypercholesterolaemia
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2 to 3 months glucocorticosteroid
Lerut 2008 12/78 10/78 35.3 % 1.20 [ 0.55, 2.61 ]
Subtotal (95% CI) 78 78 35.3 % 1.20 [ 0.55, 2.61 ]
Total events: 12 (Gluc avoid), 10 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
2 > 3 to 6 months glucocorticosteroids
Moench 2007 4/56 18/54 64.7 % 0.21 [ 0.08, 0.59 ]
Subtotal (95% CI) 56 54 64.7 % 0.21 [ 0.08, 0.59 ]
Total events: 4 (Gluc avoid), 18 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0030)
Total (95% CI) 134 132 100.0 % 0.56 [ 0.32, 1.00 ]
Total events: 16 (Gluc avoid), 28 (Gluc cont)
Heterogeneity: Chi2 = 7.10, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Chi2 = 6.95, df = 1 (P = 0.01), I2 =86%
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Analysis 7.1. Comparison 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (pre-2000 and post-2000 subgroups), Outcome 1 Mortality.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (pre-2000 and post-2000 subgroups)
Outcome: 1 Mortality
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-2000
Belli 1998 11/54 9/50 8.4 % 1.13 [ 0.51, 2.50 ]
Margarit 2005 12/30 11/33 9.4 % 1.20 [ 0.63, 2.30 ]
Pageaux 2004 9/84 2/90 1.7 % 4.82 [ 1.07, 21.67 ]
Tisone 1999 7/23 7/22 6.4 % 0.96 [ 0.40, 2.28 ]
Subtotal (95% CI) 191 195 25.9 % 1.36 [ 0.90, 2.06 ]
Total events: 39 (Gluc avoid), 29 (Gluc cont)
Heterogeneity: Chi2 = 3.70, df = 3 (P = 0.30); I2 =19%
Test for overall effect: Z = 1.45 (P = 0.15)
2 Post-2000
Chen 2007 10/28 14/26 13.0 % 0.66 [ 0.36, 1.22 ]
Hu 2008 1/40 1/36 0.9 % 0.90 [ 0.06, 13.87 ]
Ju 2012 4/43 6/44 5.3 % 0.68 [ 0.21, 2.25 ]
Lerut 2008 17/78 13/78 11.7 % 1.31 [ 0.68, 2.51 ]
Llado 2006 5/96 11/102 9.6 % 0.48 [ 0.17, 1.34 ]
Moench 2007 17/56 11/54 10.0 % 1.49 [ 0.77, 2.88 ]
Pelletier 2013 20/50 14/50 12.6 % 1.43 [ 0.82, 2.50 ]
Ramirez 2013 8/20 5/20 4.5 % 1.60 [ 0.63, 4.05 ]
Reggiani 2005 1/12 0/18 0.4 % 4.38 [ 0.19, 99.48 ]
Studenik 2005 0/20 1/19 1.4 % 0.32 [ 0.01, 7.35 ]
Vivarelli 2007 6/25 5/22 4.8 % 1.06 [ 0.37, 2.99 ]
Subtotal (95% CI) 468 469 74.1 % 1.08 [ 0.83, 1.40 ]
Total events: 89 (Gluc avoid), 81 (Gluc cont)
Heterogeneity: Chi2 = 9.68, df = 10 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.55)
Total (95% CI) 659 664 100.0 % 1.15 [ 0.93, 1.44 ]
Total events: 128 (Gluc avoid), 110 (Gluc cont)
Heterogeneity: Chi2 = 13.54, df = 14 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Chi2 = 0.84, df = 1 (P = 0.36), I2 =0.0%
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Analysis 7.2. Comparison 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (pre-2000 and post-2000 subgroups), Outcome 2 Graft loss including death.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (pre-2000 and post-2000 subgroups)
Outcome: 2 Graft loss including death
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-2000
Margarit 2005 0/30 4/33 4.8 % 0.12 [ 0.01, 2.17 ]
Pageaux 2004 9/84 2/90 2.2 % 4.82 [ 1.07, 21.67 ]
Tisone 1999 7/23 7/22 8.0 % 0.96 [ 0.40, 2.28 ]
Subtotal (95% CI) 137 145 14.9 % 1.25 [ 0.65, 2.40 ]
Total events: 16 (Gluc avoid), 13 (Gluc cont)
Heterogeneity: Chi2 = 5.97, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 0.66 (P = 0.51)
2 Post-2000
Lerut 2008 20/78 17/78 19.0 % 1.18 [ 0.67, 2.07 ]
Llado 2006 9/96 12/102 13.0 % 0.80 [ 0.35, 1.81 ]
Moench 2007 21/56 15/54 17.0 % 1.35 [ 0.78, 2.33 ]
Pelletier 2013 22/50 14/50 15.6 % 1.57 [ 0.91, 2.71 ]
Ramirez 2013 8/20 6/20 6.7 % 1.33 [ 0.57, 3.14 ]
Reggiani 2005 1/12 3/18 2.7 % 0.50 [ 0.06, 4.26 ]
Studenik 2005 0/20 2/19 2.9 % 0.19 [ 0.01, 3.73 ]
Vivarelli 2007 6/25 7/22 8.3 % 0.75 [ 0.30, 1.91 ]
Subtotal (95% CI) 357 363 85.1 % 1.14 [ 0.88, 1.49 ]
Total events: 87 (Gluc avoid), 76 (Gluc cont)
Heterogeneity: Chi2 = 5.29, df = 7 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
Total (95% CI) 494 508 100.0 % 1.16 [ 0.91, 1.48 ]
Total events: 103 (Gluc avoid), 89 (Gluc cont)
Heterogeneity: Chi2 = 11.24, df = 10 (P = 0.34); I2 =11%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 7.3. Comparison 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (pre-2000 and post-2000 subgroups), Outcome 3 Acute rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (pre-2000 and post-2000 subgroups)
Outcome: 3 Acute rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-2000
Belli 1998 2/54 3/50 2.7 % 0.62 [ 0.11, 3.54 ]
Belli 2001 5/11 7/13 5.6 % 0.84 [ 0.37, 1.92 ]
Margarit 2005 11/30 10/33 8.3 % 1.21 [ 0.60, 2.43 ]
Pageaux 2004 32/84 22/90 18.4 % 1.56 [ 0.99, 2.45 ]
Tisone 1999 4/23 4/22 3.5 % 0.96 [ 0.27, 3.36 ]
Subtotal (95% CI) 202 208 38.5 % 1.26 [ 0.91, 1.75 ]
Total events: 54 (Gluc avoid), 46 (Gluc cont)
Heterogeneity: Chi2 = 2.60, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
2 Post-2000
Chen 2007 4/28 3/26 2.7 % 1.24 [ 0.31, 5.01 ]
Hu 2008 5/40 4/36 3.7 % 1.13 [ 0.33, 3.87 ]
Ju 2012 4/43 3/44 2.6 % 1.36 [ 0.32, 5.74 ]
Lerut 2008 18/78 16/78 13.9 % 1.13 [ 0.62, 2.04 ]
Llado 2006 17/96 13/102 10.9 % 1.39 [ 0.71, 2.70 ]
Moench 2007 19/56 14/54 12.4 % 1.31 [ 0.73, 2.34 ]
Pelletier 2013 10/50 7/50 6.1 % 1.43 [ 0.59, 3.45 ]
Ramirez 2013 1/20 1/20 0.9 % 1.00 [ 0.07, 14.90 ]
Reggiani 2005 9/12 3/18 2.1 % 4.50 [ 1.52, 13.30 ]
Studenik 2005 7/20 3/19 2.7 % 2.22 [ 0.67, 7.34 ]
Vivarelli 2007 2/25 4/22 3.7 % 0.44 [ 0.09, 2.17 ]
Subtotal (95% CI) 468 469 61.5 % 1.37 [ 1.05, 1.80 ]
Total events: 96 (Gluc avoid), 71 (Gluc cont)
Heterogeneity: Chi2 = 7.81, df = 10 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.28 (P = 0.023)
Total (95% CI) 670 677 100.0 % 1.33 [ 1.08, 1.64 ]
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 150 (Gluc avoid), 117 (Gluc cont)
Heterogeneity: Chi2 = 10.60, df = 15 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.66 (P = 0.0079)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
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Analysis 7.4. Comparison 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (pre-2000 and post-2000 subgroups), Outcome 4 Infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (pre-2000 and post-2000 subgroups)
Outcome: 4 Infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-2000
Belli 1998 1/54 8/50 6.0 % 0.12 [ 0.02, 0.89 ]
Pageaux 2004 7/84 12/90 8.3 % 0.63 [ 0.26, 1.51 ]
Tisone 1999 17/23 15/22 11.0 % 1.08 [ 0.75, 1.58 ]
Subtotal (95% CI) 161 162 25.3 % 0.70 [ 0.48, 1.04 ]
Total events: 25 (Gluc avoid), 35 (Gluc cont)
Heterogeneity: Chi2 = 8.15, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 1.75 (P = 0.080)
2 Post-2000
Ju 2012 6/43 16/44 11.3 % 0.38 [ 0.17, 0.89 ]
Llado 2006 45/96 52/102 36.2 % 0.92 [ 0.69, 1.22 ]
Pelletier 2013 26/50 22/50 15.8 % 1.18 [ 0.78, 1.78 ]
Ramirez 2013 12/20 12/20 8.6 % 1.00 [ 0.60, 1.66 ]
Reggiani 2005 6/12 5/18 2.9 % 1.80 [ 0.71, 4.59 ]
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 221 234 74.7 % 0.94 [ 0.77, 1.15 ]
Total events: 95 (Gluc avoid), 107 (Gluc cont)
Heterogeneity: Chi2 = 7.53, df = 4 (P = 0.11); I2 =47%
Test for overall effect: Z = 0.63 (P = 0.53)
Total (95% CI) 382 396 100.0 % 0.88 [ 0.73, 1.05 ]
Total events: 120 (Gluc avoid), 142 (Gluc cont)
Heterogeneity: Chi2 = 13.93, df = 7 (P = 0.05); I2 =50%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 1.60, df = 1 (P = 0.21), I2 =37%
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Analysis 7.5. Comparison 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (pre-2000 and post-2000 subgroups), Outcome 5 Chronic rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (pre-2000 and post-2000 subgroups)
Outcome: 5 Chronic rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-2000
Belli 1998 0/54 1/50 9.5 % 0.31 [ 0.01, 7.42 ]
Belli 2001 1/11 0/13 2.8 % 3.50 [ 0.16, 78.19 ]
Margarit 2005 0/30 0/33 Not estimable
Pageaux 2004 3/84 5/90 29.6 % 0.64 [ 0.16, 2.61 ]
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 202 208 41.9 % 0.76 [ 0.25, 2.31 ]
Total events: 4 (Gluc avoid), 6 (Gluc cont)
Heterogeneity: Chi2 = 1.29, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
2 Post-2000
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Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lerut 2008 1/78 4/78 24.5 % 0.25 [ 0.03, 2.19 ]
Llado 2006 3/96 1/102 5.9 % 3.19 [ 0.34, 30.12 ]
Moench 2007 6/56 0/54 3.1 % 12.54 [ 0.72, 217.40 ]
Pelletier 2013 1/50 4/50 24.5 % 0.25 [ 0.03, 2.16 ]
Subtotal (95% CI) 280 284 58.1 % 1.21 [ 0.52, 2.84 ]
Total events: 11 (Gluc avoid), 9 (Gluc cont)
Heterogeneity: Chi2 = 7.38, df = 3 (P = 0.06); I2 =59%
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 482 492 100.0 % 1.02 [ 0.52, 2.00 ]
Total events: 15 (Gluc avoid), 15 (Gluc cont)
Heterogeneity: Chi2 = 8.78, df = 6 (P = 0.19); I2 =32%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 0.42, df = 1 (P = 0.51), I2 =0.0%
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Analysis 7.6. Comparison 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (pre-2000 and post-2000 subgroups), Outcome 6 Glucocorticosteroid-resistant
rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (pre-2000 and post-2000 subgroups)
Outcome: 6 Glucocorticosteroid-resistant rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-2000
Margarit 2005 4/30 3/33 21.7 % 1.47 [ 0.36, 6.03 ]
Pageaux 2004 8/84 3/90 22.0 % 2.86 [ 0.78, 10.41 ]
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 137 145 43.8 % 2.17 [ 0.84, 5.57 ]
Total events: 12 (Gluc avoid), 6 (Gluc cont)
Heterogeneity: Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
2 Post-2000
Ju 2012 0/43 0/44 Not estimable
Lerut 2008 10/78 3/78 22.8 % 3.33 [ 0.95, 11.65 ]
Llado 2006 4/96 4/102 29.5 % 1.06 [ 0.27, 4.13 ]
Moench 2007 1/56 0/54 3.9 % 2.89 [ 0.12, 69.55 ]
Pelletier 2013 0/50 0/50 Not estimable
Ramirez 2013 0/20 0/20 Not estimable
Vivarelli 2007 0/25 0/22 Not estimable
Subtotal (95% CI) 368 370 56.2 % 2.11 [ 0.90, 4.96 ]
Total events: 15 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 1.53, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.086)
Total (95% CI) 505 515 100.0 % 2.14 [ 1.13, 4.02 ]
Total events: 27 (Gluc avoid), 13 (Gluc cont)
Heterogeneity: Chi2 = 2.00, df = 4 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 7.7. Comparison 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (pre-2000 and post-2000 subgroups), Outcome 7 Diabetes mellitus.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (pre-2000 and post-2000 subgroups)
Outcome: 7 Diabetes mellitus
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-2000
Belli 1998 3/54 12/50 8.0 % 0.23 [ 0.07, 0.77 ]
Margarit 2005 8/30 11/33 6.8 % 0.80 [ 0.37, 1.72 ]
Pageaux 2004 12/84 20/90 12.4 % 0.64 [ 0.34, 1.23 ]
Subtotal (95% CI) 168 173 27.2 % 0.56 [ 0.36, 0.88 ]
Total events: 23 (Gluc avoid), 43 (Gluc cont)
Heterogeneity: Chi2 = 3.07, df = 2 (P = 0.22); I2 =35%
Test for overall effect: Z = 2.51 (P = 0.012)
2 Post-2000
Hu 2008 7/40 14/36 9.5 % 0.45 [ 0.20, 0.99 ]
Ju 2012 2/43 9/44 5.7 % 0.23 [ 0.05, 0.99 ]
Lerut 2008 18/78 14/78 9.0 % 1.29 [ 0.69, 2.40 ]
Llado 2006 17/96 23/102 14.4 % 0.79 [ 0.45, 1.38 ]
Moench 2007 12/56 9/54 5.9 % 1.29 [ 0.59, 2.80 ]
Pelletier 2013 22/50 19/50 12.2 % 1.16 [ 0.72, 1.86 ]
Ramirez 2013 8/20 8/20 5.2 % 1.00 [ 0.47, 2.14 ]
Reggiani 2005 2/12 5/18 2.6 % 0.60 [ 0.14, 2.60 ]
Vivarelli 2007 14/25 12/22 8.2 % 1.03 [ 0.61, 1.72 ]
Subtotal (95% CI) 420 424 72.8 % 0.90 [ 0.72, 1.13 ]
Total events: 102 (Gluc avoid), 113 (Gluc cont)
Heterogeneity: Chi2 = 10.33, df = 8 (P = 0.24); I2 =23%
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 588 597 100.0 % 0.81 [ 0.66, 0.99 ]
Total events: 125 (Gluc avoid), 156 (Gluc cont)
Heterogeneity: Chi2 = 16.61, df = 11 (P = 0.12); I2 =34%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Chi2 = 3.35, df = 1 (P = 0.07), I2 =70%
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Analysis 7.8. Comparison 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (pre-2000 and post-2000 subgroups), Outcome 8 CMV infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (pre-2000 and post-2000 subgroups)
Outcome: 8 CMV infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-2000
Margarit 2005 0/30 1/33 3.7 % 0.37 [ 0.02, 8.65 ]
Pageaux 2004 1/84 2/90 5.0 % 0.54 [ 0.05, 5.80 ]
Tisone 1999 2/23 1/22 2.7 % 1.91 [ 0.19, 19.63 ]
Subtotal (95% CI) 137 145 11.5 % 0.80 [ 0.20, 3.21 ]
Total events: 3 (Gluc avoid), 4 (Gluc cont)
Heterogeneity: Chi2 = 0.88, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.75)
2 Post-2000
Lerut 2008 3/78 2/78 5.2 % 1.50 [ 0.26, 8.73 ]
Llado 2006 8/96 14/102 35.5 % 0.61 [ 0.27, 1.38 ]
Moench 2007 14/56 18/54 47.9 % 0.75 [ 0.42, 1.35 ]
Ramirez 2013 0/20 0/20 Not estimable
Subtotal (95% CI) 250 254 88.5 % 0.74 [ 0.46, 1.17 ]
Total events: 25 (Gluc avoid), 34 (Gluc cont)
Heterogeneity: Chi2 = 0.84, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
Total (95% CI) 387 399 100.0 % 0.74 [ 0.48, 1.16 ]
Total events: 28 (Gluc avoid), 38 (Gluc cont)
Heterogeneity: Chi2 = 1.74, df = 5 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
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Analysis 7.9. Comparison 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (pre-2000 and post-2000 subgroups), Outcome 9 HCV recurrence.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (pre-2000 and post-2000 subgroups)
Outcome: 9 HCV recurrence
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-2000
Belli 1998 5/25 3/22 2.0 % 1.47 [ 0.40, 5.44 ]
Belli 2001 4/11 4/13 2.3 % 1.18 [ 0.38, 3.66 ]
Margarit 2005 17/20 14/15 10.2 % 0.91 [ 0.72, 1.14 ]
Pageaux 2004 41/53 39/55 24.5 % 1.09 [ 0.87, 1.36 ]
Tisone 1999 1/7 5/8 3.0 % 0.23 [ 0.03, 1.52 ]
Subtotal (95% CI) 116 113 42.1 % 1.01 [ 0.84, 1.22 ]
Total events: 68 (Gluc avoid), 65 (Gluc cont)
Heterogeneity: Chi2 = 4.00, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
2 Post-2000
Lerut 2008 14/14 21/21 11.2 % 1.00 [ 0.89, 1.12 ]
Llado 2006 40/43 39/46 24.1 % 1.10 [ 0.95, 1.27 ]
Pelletier 2013 6/20 15/31 7.5 % 0.62 [ 0.29, 1.33 ]
Ramirez 2013 12/14 9/11 6.4 % 1.05 [ 0.74, 1.49 ]
Vivarelli 2007 19/25 13/23 8.7 % 1.34 [ 0.88, 2.05 ]
Subtotal (95% CI) 116 132 57.9 % 1.05 [ 0.92, 1.19 ]
Total events: 91 (Gluc avoid), 97 (Gluc cont)
Heterogeneity: Chi2 = 4.20, df = 4 (P = 0.38); I2 =5%
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 232 245 100.0 % 1.03 [ 0.92, 1.15 ]
Total events: 159 (Gluc avoid), 162 (Gluc cont)
Heterogeneity: Chi2 = 8.36, df = 9 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
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Analysis 7.10. Comparison 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (pre-2000 and post-2000 subgroups), Outcome 10 Malignancy.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (pre-2000 and post-2000 subgroups)
Outcome: 10 Malignancy
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-2000
Pageaux 2004 1/84 2/90 24.9 % 0.54 [ 0.05, 5.80 ]
Subtotal (95% CI) 84 90 24.9 % 0.54 [ 0.05, 5.80 ]
Total events: 1 (Gluc avoid), 2 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
2 Post-2000
Lerut 2008 2/78 0/78 6.4 % 5.00 [ 0.24, 102.49 ]
Llado 2006 0/96 5/102 68.7 % 0.10 [ 0.01, 1.72 ]
Subtotal (95% CI) 174 180 75.1 % 0.52 [ 0.13, 2.08 ]
Total events: 2 (Gluc avoid), 5 (Gluc cont)
Heterogeneity: Chi2 = 3.47, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 258 270 100.0 % 0.52 [ 0.16, 1.74 ]
Total events: 3 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 3.47, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
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Analysis 7.11. Comparison 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (pre-2000 and post-2000 subgroups), Outcome 11 Post-transplant
lymphoproliferative disorder.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (pre-2000 and post-2000 subgroups)
Outcome: 11 Post-transplant lymphoproliferative disorder
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-2000
Pageaux 2004 1/84 0/90 32.6 % 3.21 [ 0.13, 77.77 ]
Subtotal (95% CI) 84 90 32.6 % 3.21 [ 0.13, 77.77 ]
Total events: 1 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
2 Post-2000
Lerut 2008 2/78 1/78 67.4 % 2.00 [ 0.19, 21.61 ]
Subtotal (95% CI) 78 78 67.4 % 2.00 [ 0.19, 21.61 ]
Total events: 2 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 162 168 100.0 % 2.39 [ 0.36, 15.95 ]
Total events: 3 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 7.12. Comparison 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (pre-2000 and post-2000 subgroups), Outcome 12 Renal insufficiency.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (pre-2000 and post-2000 subgroups)
Outcome: 12 Renal insufficiency
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-2000
Margarit 2005 20/30 17/33 21.7 % 1.29 [ 0.85, 1.96 ]
Subtotal (95% CI) 30 33 21.7 % 1.29 [ 0.85, 1.96 ]
Total events: 20 (Gluc avoid), 17 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
2 Post-2000
Lerut 2008 4/78 8/78 10.7 % 0.50 [ 0.16, 1.59 ]
Llado 2006 41/96 51/102 66.4 % 0.85 [ 0.63, 1.16 ]
Reggiani 2005 2/12 1/18 1.1 % 3.00 [ 0.30, 29.52 ]
Subtotal (95% CI) 186 198 78.3 % 0.83 [ 0.62, 1.12 ]
Total events: 47 (Gluc avoid), 60 (Gluc cont)
Heterogeneity: Chi2 = 1.98, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
Total (95% CI) 216 231 100.0 % 0.93 [ 0.73, 1.19 ]
Total events: 67 (Gluc avoid), 77 (Gluc cont)
Heterogeneity: Chi2 = 4.80, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 2.84, df = 1 (P = 0.09), I2 =65%
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Analysis 7.13. Comparison 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (pre-2000 and post-2000 subgroups), Outcome 13 Creatinine.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (pre-2000 and post-2000 subgroups)
Outcome: 13 Creatinine
Study or subgroup Gluc avoid Gluc cont
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mg/dL] N Mean(SD)[mg/dL] IV,Fixed,95% CI IV,Fixed,95% CI
1 Pre-2000
Tisone 1999 23 1.8 (0.1) 22 1.9 (0.2) 23.1 % -0.10 [ -0.19, -0.01 ]
Subtotal (95% CI) 23 22 23.1 % -0.10 [ -0.19, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
2 Post-2000
Chen 2007 28 0.75 (0.2) 26 0.8 (0.2) 17.5 % -0.05 [ -0.16, 0.06 ]
Moench 2007 56 1.14 (1.09) 54 1.26 (0.79) 1.6 % -0.12 [ -0.47, 0.23 ]
Pelletier 2013 50 1.67 (0.15) 50 1.42 (0.15) 57.8 % 0.25 [ 0.19, 0.31 ]
Subtotal (95% CI) 134 130 76.9 % 0.17 [ 0.12, 0.22 ]
Heterogeneity: Chi2 = 25.97, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 6.69 (P < 0.00001)
Total (95% CI) 157 152 100.0 % 0.11 [ 0.07, 0.16 ]
Heterogeneity: Chi2 = 51.59, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 4.86 (P < 0.00001)
Test for subgroup differences: Chi2 = 25.63, df = 1 (P = 0.00), I2 =96%
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Analysis 7.14. Comparison 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (pre-2000 and post-2000 subgroups), Outcome 14 Hypertension.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (pre-2000 and post-2000 subgroups)
Outcome: 14 Hypertension
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-2000
Belli 1998 9/54 28/50 14.0 % 0.30 [ 0.16, 0.57 ]
Margarit 2005 4/30 9/33 4.1 % 0.49 [ 0.17, 1.42 ]
Pageaux 2004 24/84 30/90 13.9 % 0.86 [ 0.55, 1.34 ]
Subtotal (95% CI) 168 173 32.1 % 0.57 [ 0.40, 0.79 ]
Total events: 37 (Gluc avoid), 67 (Gluc cont)
Heterogeneity: Chi2 = 7.20, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 3.29 (P = 0.0010)
2 Post-2000
Hu 2008 9/40 10/36 5.1 % 0.81 [ 0.37, 1.77 ]
Ju 2012 2/43 9/44 4.3 % 0.23 [ 0.05, 0.99 ]
Lerut 2008 6/78 10/78 4.8 % 0.60 [ 0.23, 1.57 ]
Llado 2006 48/96 60/102 28.0 % 0.85 [ 0.66, 1.10 ]
Moench 2007 25/56 25/54 12.3 % 0.96 [ 0.64, 1.45 ]
Pelletier 2013 28/50 24/50 11.6 % 1.17 [ 0.80, 1.70 ]
Reggiani 2005 2/12 5/18 1.9 % 0.60 [ 0.14, 2.60 ]
Subtotal (95% CI) 375 382 67.9 % 0.86 [ 0.72, 1.03 ]
Total events: 120 (Gluc avoid), 143 (Gluc cont)
Heterogeneity: Chi2 = 6.75, df = 6 (P = 0.34); I2 =11%
Test for overall effect: Z = 1.66 (P = 0.097)
Total (95% CI) 543 555 100.0 % 0.76 [ 0.65, 0.90 ]
Total events: 157 (Gluc avoid), 210 (Gluc cont)
Heterogeneity: Chi2 = 18.80, df = 9 (P = 0.03); I2 =52%
Test for overall effect: Z = 3.28 (P = 0.0010)
Test for subgroup differences: Chi2 = 4.49, df = 1 (P = 0.03), I2 =78%
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Analysis 7.15. Comparison 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (pre-2000 and post-2000 subgroups), Outcome 15 Hyperlipidaemia.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (pre-2000 and post-2000 subgroups)
Outcome: 15 Hyperlipidaemia
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-2000
Margarit 2005 5/30 4/33 21.5 % 1.38 [ 0.41, 4.65 ]
Pageaux 2004 2/84 6/90 32.7 % 0.36 [ 0.07, 1.72 ]
Subtotal (95% CI) 114 123 54.2 % 0.76 [ 0.30, 1.91 ]
Total events: 7 (Gluc avoid), 10 (Gluc cont)
Heterogeneity: Chi2 = 1.79, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 0.58 (P = 0.56)
2 Post-2000
Hu 2008 2/40 3/36 17.8 % 0.60 [ 0.11, 3.39 ]
Ju 2012 4/43 5/44 27.9 % 0.82 [ 0.24, 2.85 ]
Subtotal (95% CI) 83 80 45.8 % 0.73 [ 0.27, 2.01 ]
Total events: 6 (Gluc avoid), 8 (Gluc cont)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 197 203 100.0 % 0.75 [ 0.38, 1.48 ]
Total events: 13 (Gluc avoid), 18 (Gluc cont)
Heterogeneity: Chi2 = 1.89, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
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Analysis 7.16. Comparison 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (pre-2000 and post-2000 subgroups), Outcome 16 Cholesterol.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 7 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (pre-2000 and post-2000 subgroups)
Outcome: 16 Cholesterol
Study or subgroup Gluc avoid Gluc cont
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mg/dL] N Mean(SD)[mg/dL] IV,Fixed,95% CI IV,Fixed,95% CI
1 Pre-2000
Belli 1998 54 183 (81) 50 253 (76) 1.4 % -70.00 [ -100.17, -39.83 ]
Tisone 1999 23 117 (52) 22 128 (51) 1.4 % -11.00 [ -41.10, 19.10 ]
Subtotal (95% CI) 77 72 2.7 % -40.42 [ -61.73, -19.11 ]
Heterogeneity: Chi2 = 7.36, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 3.72 (P = 0.00020)
2 Post-2000
Chen 2007 28 151 (69) 26 297 (100) 0.6 % -146.00 [ -192.16, -99.84 ]
Llado 2006 96 182 (54) 102 193 (43) 6.7 % -11.00 [ -24.65, 2.65 ]
Moench 2007 56 207 (77) 54 172 (39) 2.4 % 35.00 [ 12.31, 57.69 ]
Pelletier 2013 50 148 (8) 50 167 (11) 87.6 % -19.00 [ -22.77, -15.23 ]
Subtotal (95% CI) 230 232 97.3 % -17.87 [ -21.45, -14.29 ]
Heterogeneity: Chi2 = 51.77, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 9.79 (P < 0.00001)
Total (95% CI) 307 304 100.0 % -18.49 [ -22.02, -14.96 ]
Heterogeneity: Chi2 = 63.32, df = 5 (P<0.00001); I2 =92%
Test for overall effect: Z = 10.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.18, df = 1 (P = 0.04), I2 =76%
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Analysis 8.1. Comparison 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (best-worst analysis), Outcome 1 Mortality.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (best-worst analysis)
Outcome: 1 Mortality
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Belli 2001 3/11 1/13 0.7 % 3.55 [ 0.43, 29.42 ]
Ju 2012 4/43 6/44 4.4 % 0.68 [ 0.21, 2.25 ]
Lerut 2008 17/78 13/78 9.7 % 1.31 [ 0.68, 2.51 ]
Llado 2006 5/96 11/102 8.0 % 0.48 [ 0.17, 1.34 ]
Margarit 2005 12/30 11/33 7.8 % 1.20 [ 0.63, 2.30 ]
Pelletier 2013 20/50 14/50 10.5 % 1.43 [ 0.82, 2.50 ]
Ramirez 2013 8/20 5/20 3.7 % 1.60 [ 0.63, 4.05 ]
Reggiani 2005 1/12 0/18 0.3 % 4.38 [ 0.19, 99.48 ]
Studenik 2005 0/20 1/19 1.2 % 0.32 [ 0.01, 7.35 ]
Tisone 1999 7/23 7/22 5.4 % 0.96 [ 0.40, 2.28 ]
Subtotal (95% CI) 383 399 51.7 % 1.15 [ 0.87, 1.52 ]
Total events: 77 (Gluc avoid), 69 (Gluc cont)
Heterogeneity: Chi2 = 7.37, df = 9 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
2 Glucocorticosteroid withdrawal
Belli 1998 11/54 11/50 8.6 % 0.93 [ 0.44, 1.94 ]
Chen 2007 10/28 14/26 10.9 % 0.66 [ 0.36, 1.22 ]
Hu 2008 1/40 5/36 3.9 % 0.18 [ 0.02, 1.47 ]
Moench 2007 17/56 11/54 8.4 % 1.49 [ 0.77, 2.88 ]
Pageaux 2004 9/84 14/90 10.1 % 0.69 [ 0.31, 1.51 ]
Vivarelli 2007 6/25 8/22 6.4 % 0.66 [ 0.27, 1.61 ]
Subtotal (95% CI) 287 278 48.3 % 0.82 [ 0.60, 1.12 ]
Total events: 54 (Gluc avoid), 63 (Gluc cont)
Heterogeneity: Chi2 = 6.14, df = 5 (P = 0.29); I2 =19%
Test for overall effect: Z = 1.24 (P = 0.21)
Total (95% CI) 670 677 100.0 % 0.99 [ 0.80, 1.22 ]
Total events: 131 (Gluc avoid), 132 (Gluc cont)
Heterogeneity: Chi2 = 16.09, df = 15 (P = 0.38); I2 =7%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Chi2 = 2.44, df = 1 (P = 0.12), I2 =59%
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Analysis 8.2. Comparison 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (best-worst analysis), Outcome 2 Graft loss including death.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (best-worst analysis)
Outcome: 2 Graft loss including death
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Lerut 2008 20/78 17/78 16.3 % 1.18 [ 0.67, 2.07 ]
Llado 2006 9/96 12/102 11.1 % 0.80 [ 0.35, 1.81 ]
Margarit 2005 0/30 4/33 4.1 % 0.12 [ 0.01, 2.17 ]
Pelletier 2013 22/50 14/50 13.4 % 1.57 [ 0.91, 2.71 ]
Ramirez 2013 8/20 6/20 5.7 % 1.33 [ 0.57, 3.14 ]
Reggiani 2005 1/12 3/18 2.3 % 0.50 [ 0.06, 4.26 ]
Studenik 2005 0/20 2/19 2.5 % 0.19 [ 0.01, 3.73 ]
Tisone 1999 7/23 7/22 6.8 % 0.96 [ 0.40, 2.28 ]
Subtotal (95% CI) 329 342 62.3 % 1.05 [ 0.78, 1.41 ]
Total events: 67 (Gluc avoid), 65 (Gluc cont)
Heterogeneity: Chi2 = 6.92, df = 7 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
2 Glucocorticosteroid withdrawal
Moench 2007 21/56 15/54 14.6 % 1.35 [ 0.78, 2.33 ]
Pageaux 2004 9/84 14/90 12.9 % 0.69 [ 0.31, 1.51 ]
Vivarelli 2007 6/25 10/22 10.2 % 0.53 [ 0.23, 1.22 ]
Subtotal (95% CI) 165 166 37.7 % 0.90 [ 0.61, 1.33 ]
Total events: 36 (Gluc avoid), 39 (Gluc cont)
Heterogeneity: Chi2 = 4.13, df = 2 (P = 0.13); I2 =52%
Test for overall effect: Z = 0.52 (P = 0.60)
Total (95% CI) 494 508 100.0 % 0.99 [ 0.79, 1.26 ]
Total events: 103 (Gluc avoid), 104 (Gluc cont)
Heterogeneity: Chi2 = 11.68, df = 10 (P = 0.31); I2 =14%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 0.38, df = 1 (P = 0.54), I2 =0.0%
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Analysis 8.3. Comparison 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (best-worst analysis), Outcome 3 Acute rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (best-worst analysis)
Outcome: 3 Acute rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Belli 2001 5/11 7/13 4.3 % 0.84 [ 0.37, 1.92 ]
Ju 2012 4/43 3/44 2.0 % 1.36 [ 0.32, 5.74 ]
Lerut 2008 18/78 16/78 10.8 % 1.13 [ 0.62, 2.04 ]
Llado 2006 17/96 13/102 8.5 % 1.39 [ 0.71, 2.70 ]
Margarit 2005 11/30 10/33 6.4 % 1.21 [ 0.60, 2.43 ]
Pelletier 2013 10/50 7/50 4.7 % 1.43 [ 0.59, 3.45 ]
Ramirez 2013 1/20 1/20 0.7 % 1.00 [ 0.07, 14.90 ]
Reggiani 2005 9/12 3/18 1.6 % 4.50 [ 1.52, 13.30 ]
Studenik 2005 7/20 3/19 2.1 % 2.22 [ 0.67, 7.34 ]
Tisone 1999 4/23 4/22 2.8 % 0.96 [ 0.27, 3.36 ]
Subtotal (95% CI) 383 399 44.0 % 1.37 [ 1.04, 1.81 ]
Total events: 86 (Gluc avoid), 67 (Gluc cont)
Heterogeneity: Chi2 = 7.50, df = 9 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.21 (P = 0.027)
2 Glucocorticosteroid withdrawal
Belli 1998 2/54 16/50 11.2 % 0.12 [ 0.03, 0.48 ]
Chen 2007 4/28 3/26 2.1 % 1.24 [ 0.31, 5.01 ]
Hu 2008 5/40 8/36 5.7 % 0.56 [ 0.20, 1.56 ]
Moench 2007 19/56 14/54 9.6 % 1.31 [ 0.73, 2.34 ]
Pageaux 2004 32/84 34/90 22.2 % 1.01 [ 0.69, 1.47 ]
Vivarelli 2007 2/25 7/22 5.0 % 0.25 [ 0.06, 1.09 ]
Subtotal (95% CI) 287 278 56.0 % 0.78 [ 0.59, 1.02 ]
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 64 (Gluc avoid), 82 (Gluc cont)
Heterogeneity: Chi2 = 14.94, df = 5 (P = 0.01); I2 =67%
Test for overall effect: Z = 1.80 (P = 0.072)
Total (95% CI) 670 677 100.0 % 1.04 [ 0.85, 1.26 ]
Total events: 150 (Gluc avoid), 149 (Gluc cont)
Heterogeneity: Chi2 = 25.35, df = 15 (P = 0.05); I2 =41%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 8.02, df = 1 (P = 0.00), I2 =88%
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Analysis 8.4. Comparison 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (best-worst analysis), Outcome 4 Infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (best-worst analysis)
Outcome: 4 Infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Ju 2012 6/43 16/44 10.3 % 0.38 [ 0.17, 0.89 ]
Llado 2006 45/96 52/102 32.9 % 0.92 [ 0.69, 1.22 ]
Pelletier 2013 26/50 22/50 14.4 % 1.18 [ 0.78, 1.78 ]
Ramirez 2013 12/20 12/20 7.8 % 1.00 [ 0.60, 1.66 ]
Reggiani 2005 6/12 5/18 2.6 % 1.80 [ 0.71, 4.59 ]
Tisone 1999 17/23 15/22 10.0 % 1.08 [ 0.75, 1.58 ]
Subtotal (95% CI) 244 256 78.1 % 0.96 [ 0.80, 1.15 ]
Total events: 112 (Gluc avoid), 122 (Gluc cont)
Heterogeneity: Chi2 = 7.87, df = 5 (P = 0.16); I2 =36%
Test for overall effect: Z = 0.49 (P = 0.62)
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
2 Glucocorticosteroid withdrawal
Belli 1998 1/54 10/50 6.8 % 0.09 [ 0.01, 0.70 ]
Pageaux 2004 7/84 24/90 15.1 % 0.31 [ 0.14, 0.69 ]
Subtotal (95% CI) 138 140 21.9 % 0.24 [ 0.12, 0.50 ]
Total events: 8 (Gluc avoid), 34 (Gluc cont)
Heterogeneity: Chi2 = 1.26, df = 1 (P = 0.26); I2 =21%
Test for overall effect: Z = 3.81 (P = 0.00014)
Total (95% CI) 382 396 100.0 % 0.80 [ 0.67, 0.96 ]
Total events: 120 (Gluc avoid), 156 (Gluc cont)
Heterogeneity: Chi2 = 23.35, df = 7 (P = 0.001); I2 =70%
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Chi2 = 12.77, df = 1 (P = 0.00), I2 =92%
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Analysis 8.5. Comparison 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (best-worst analysis), Outcome 5 Chronic rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (best-worst analysis)
Outcome: 5 Chronic rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Belli 2001 1/11 0/13 1.5 % 3.50 [ 0.16, 78.19 ]
Lerut 2008 1/78 4/78 13.3 % 0.25 [ 0.03, 2.19 ]
Llado 2006 3/96 1/102 3.2 % 3.19 [ 0.34, 30.12 ]
Margarit 2005 0/30 0/33 Not estimable
Pelletier 2013 1/50 4/50 13.3 % 0.25 [ 0.03, 2.16 ]
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 288 298 31.5 % 0.71 [ 0.27, 1.88 ]
Total events: 6 (Gluc avoid), 9 (Gluc cont)
Heterogeneity: Chi2 = 4.52, df = 3 (P = 0.21); I2 =34%
Test for overall effect: Z = 0.69 (P = 0.49)
2 Glucocorticosteroid withdrawal
Belli 1998 0/54 3/50 12.1 % 0.13 [ 0.01, 2.50 ]
Moench 2007 6/56 0/54 1.7 % 12.54 [ 0.72, 217.40 ]
Pageaux 2004 3/84 17/90 54.7 % 0.19 [ 0.06, 0.62 ]
Subtotal (95% CI) 194 194 68.5 % 0.48 [ 0.23, 1.02 ]
Total events: 9 (Gluc avoid), 20 (Gluc cont)
Heterogeneity: Chi2 = 8.15, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 1.90 (P = 0.057)
Total (95% CI) 482 492 100.0 % 0.56 [ 0.31, 1.00 ]
Total events: 15 (Gluc avoid), 29 (Gluc cont)
Heterogeneity: Chi2 = 13.37, df = 6 (P = 0.04); I2 =55%
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Chi2 = 0.38, df = 1 (P = 0.54), I2 =0.0%
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Analysis 8.6. Comparison 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (best-worst analysis), Outcome 6 Glucocorticosteroid-resistant rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (best-worst analysis)
Outcome: 6 Glucocorticosteroid-resistant rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Ju 2012 0/43 0/44 Not estimable
Lerut 2008 10/78 3/78 10.5 % 3.33 [ 0.95, 11.65 ]
Llado 2006 4/96 4/102 13.6 % 1.06 [ 0.27, 4.13 ]
Margarit 2005 4/30 3/33 10.0 % 1.47 [ 0.36, 6.03 ]
Pelletier 2013 0/50 0/50 Not estimable
Ramirez 2013 0/20 0/20 Not estimable
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 340 349 34.2 % 1.88 [ 0.89, 3.98 ]
Total events: 18 (Gluc avoid), 10 (Gluc cont)
Heterogeneity: Chi2 = 1.60, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.65 (P = 0.099)
2 Glucocorticosteroid withdrawal
Moench 2007 1/56 0/54 1.8 % 2.89 [ 0.12, 69.55 ]
Pageaux 2004 8/84 15/90 50.9 % 0.57 [ 0.26, 1.28 ]
Vivarelli 2007 0/25 3/22 13.1 % 0.13 [ 0.01, 2.32 ]
Subtotal (95% CI) 165 166 65.8 % 0.55 [ 0.27, 1.13 ]
Total events: 9 (Gluc avoid), 18 (Gluc cont)
Heterogeneity: Chi2 = 2.04, df = 2 (P = 0.36); I2 =2%
Test for overall effect: Z = 1.64 (P = 0.10)
Total (95% CI) 505 515 100.0 % 1.00 [ 0.61, 1.65 ]
Total events: 27 (Gluc avoid), 28 (Gluc cont)
Heterogeneity: Chi2 = 8.07, df = 5 (P = 0.15); I2 =38%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi2 = 5.41, df = 1 (P = 0.02), I2 =82%
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Analysis 8.7. Comparison 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (best-worst analysis), Outcome 7 Diabetes mellitus.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (best-worst analysis)
Outcome: 7 Diabetes mellitus
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Ju 2012 2/43 9/44 5.0 % 0.23 [ 0.05, 0.99 ]
Lerut 2008 18/78 14/78 7.9 % 1.29 [ 0.69, 2.40 ]
Llado 2006 17/96 23/102 12.7 % 0.79 [ 0.45, 1.38 ]
Margarit 2005 8/30 11/33 5.9 % 0.80 [ 0.37, 1.72 ]
Pelletier 2013 22/50 19/50 10.8 % 1.16 [ 0.72, 1.86 ]
Ramirez 2013 8/20 8/20 4.5 % 1.00 [ 0.47, 2.14 ]
Reggiani 2005 2/12 5/18 2.3 % 0.60 [ 0.14, 2.60 ]
Subtotal (95% CI) 329 345 49.2 % 0.90 [ 0.70, 1.17 ]
Total events: 77 (Gluc avoid), 89 (Gluc cont)
Heterogeneity: Chi2 = 6.36, df = 6 (P = 0.38); I2 =6%
Test for overall effect: Z = 0.76 (P = 0.45)
2 Glucocorticosteroid withdrawal
Belli 1998 3/54 14/50 8.3 % 0.20 [ 0.06, 0.65 ]
Hu 2008 7/40 18/36 10.8 % 0.35 [ 0.17, 0.74 ]
Moench 2007 12/56 9/54 5.2 % 1.29 [ 0.59, 2.80 ]
Pageaux 2004 12/84 32/90 17.5 % 0.40 [ 0.22, 0.73 ]
Vivarelli 2007 14/25 15/22 9.1 % 0.82 [ 0.52, 1.29 ]
Subtotal (95% CI) 259 252 50.8 % 0.52 [ 0.39, 0.70 ]
Total events: 48 (Gluc avoid), 88 (Gluc cont)
Heterogeneity: Chi2 = 13.42, df = 4 (P = 0.01); I2 =70%
Test for overall effect: Z = 4.26 (P = 0.000020)
Total (95% CI) 588 597 100.0 % 0.71 [ 0.58, 0.86 ]
Total events: 125 (Gluc avoid), 177 (Gluc cont)
Heterogeneity: Chi2 = 24.98, df = 11 (P = 0.01); I2 =56%
Test for overall effect: Z = 3.45 (P = 0.00057)
Test for subgroup differences: Chi2 = 7.31, df = 1 (P = 0.01), I2 =86%
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Analysis 8.8. Comparison 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (best-worst analysis), Outcome 8 CMV infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (best-worst analysis)
Outcome: 8 CMV infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Lerut 2008 3/78 2/78 4.0 % 1.50 [ 0.26, 8.73 ]
Llado 2006 8/96 14/102 27.2 % 0.61 [ 0.27, 1.38 ]
Margarit 2005 0/30 1/33 2.9 % 0.37 [ 0.02, 8.65 ]
Ramirez 2013 0/20 0/20 Not estimable
Tisone 1999 2/23 1/22 2.0 % 1.91 [ 0.19, 19.63 ]
Subtotal (95% CI) 247 255 36.1 % 0.76 [ 0.39, 1.49 ]
Total events: 13 (Gluc avoid), 18 (Gluc cont)
Heterogeneity: Chi2 = 1.67, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
2 Glucocorticosteroid withdrawal
Moench 2007 14/56 18/54 36.7 % 0.75 [ 0.42, 1.35 ]
Pageaux 2004 1/84 14/90 27.1 % 0.08 [ 0.01, 0.57 ]
Subtotal (95% CI) 140 144 63.9 % 0.46 [ 0.27, 0.81 ]
Total events: 15 (Gluc avoid), 32 (Gluc cont)
Heterogeneity: Chi2 = 5.64, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 2.72 (P = 0.0065)
Total (95% CI) 387 399 100.0 % 0.57 [ 0.37, 0.87 ]
Total events: 28 (Gluc avoid), 50 (Gluc cont)
Heterogeneity: Chi2 = 6.96, df = 5 (P = 0.22); I2 =28%
Test for overall effect: Z = 2.58 (P = 0.0099)
Test for subgroup differences: Chi2 = 1.23, df = 1 (P = 0.27), I2 =19%
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Analysis 8.9. Comparison 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (best-worst analysis), Outcome 9 Malignancy.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (best-worst analysis)
Outcome: 9 Malignancy
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Lerut 2008 2/78 0/78 2.6 % 5.00 [ 0.24, 102.49 ]
Llado 2006 0/96 5/102 27.6 % 0.10 [ 0.01, 1.72 ]
Subtotal (95% CI) 174 180 30.2 % 0.52 [ 0.13, 2.08 ]
Total events: 2 (Gluc avoid), 5 (Gluc cont)
Heterogeneity: Chi2 = 3.47, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 0.93 (P = 0.35)
2 Glucocorticosteroid withdrawal
Pageaux 2004 1/84 14/90 69.8 % 0.08 [ 0.01, 0.57 ]
Subtotal (95% CI) 84 90 69.8 % 0.08 [ 0.01, 0.57 ]
Total events: 1 (Gluc avoid), 14 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 2.51 (P = 0.012)
Total (95% CI) 258 270 100.0 % 0.21 [ 0.07, 0.61 ]
Total events: 3 (Gluc avoid), 19 (Gluc cont)
Heterogeneity: Chi2 = 5.48, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 2.85 (P = 0.0043)
Test for subgroup differences: Chi2 = 2.35, df = 1 (P = 0.13), I2 =57%
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Analysis 8.10. Comparison 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (best-worst analysis), Outcome 10 Post-transplant lymphoproliferative
disorder.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (best-worst analysis)
Outcome: 10 Post-transplant lymphoproliferative disorder
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Lerut 2008 2/78 1/78 7.9 % 2.00 [ 0.19, 21.61 ]
Subtotal (95% CI) 78 78 7.9 % 2.00 [ 0.19, 21.61 ]
Total events: 2 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 Glucocorticosteroid withdrawal
Pageaux 2004 1/84 12/90 92.1 % 0.09 [ 0.01, 0.67 ]
Subtotal (95% CI) 84 90 92.1 % 0.09 [ 0.01, 0.67 ]
Total events: 1 (Gluc avoid), 12 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
Total (95% CI) 162 168 100.0 % 0.24 [ 0.07, 0.85 ]
Total events: 3 (Gluc avoid), 13 (Gluc cont)
Heterogeneity: Chi2 = 3.97, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 2.22 (P = 0.026)
Test for subgroup differences: Chi2 = 3.81, df = 1 (P = 0.05), I2 =74%
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Analysis 8.11. Comparison 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (best-worst analysis), Outcome 11 Hypertension.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (best-worst analysis)
Outcome: 11 Hypertension
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Ju 2012 2/43 9/44 3.9 % 0.23 [ 0.05, 0.99 ]
Lerut 2008 6/78 10/78 4.4 % 0.60 [ 0.23, 1.57 ]
Llado 2006 48/96 60/102 25.8 % 0.85 [ 0.66, 1.10 ]
Margarit 2005 4/30 9/33 3.8 % 0.49 [ 0.17, 1.42 ]
Pelletier 2013 28/50 24/50 10.6 % 1.17 [ 0.80, 1.70 ]
Reggiani 2005 2/12 5/18 1.8 % 0.60 [ 0.14, 2.60 ]
Subtotal (95% CI) 309 325 50.4 % 0.81 [ 0.66, 1.00 ]
Total events: 90 (Gluc avoid), 117 (Gluc cont)
Heterogeneity: Chi2 = 7.94, df = 5 (P = 0.16); I2 =37%
Test for overall effect: Z = 2.00 (P = 0.045)
2 Glucocorticosteroid withdrawal
Belli 1998 9/54 30/50 13.8 % 0.28 [ 0.15, 0.53 ]
Hu 2008 9/40 14/36 6.5 % 0.58 [ 0.29, 1.17 ]
Moench 2007 25/56 25/54 11.3 % 0.96 [ 0.64, 1.45 ]
Pageaux 2004 24/84 42/90 18.0 % 0.61 [ 0.41, 0.92 ]
Subtotal (95% CI) 234 230 49.6 % 0.59 [ 0.47, 0.76 ]
Total events: 67 (Gluc avoid), 111 (Gluc cont)
Heterogeneity: Chi2 = 10.85, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 4.18 (P = 0.000029)
Total (95% CI) 543 555 100.0 % 0.70 [ 0.60, 0.82 ]
Total events: 157 (Gluc avoid), 228 (Gluc cont)
Heterogeneity: Chi2 = 22.96, df = 9 (P = 0.01); I2 =61%
Test for overall effect: Z = 4.39 (P = 0.000012)
Test for subgroup differences: Chi2 = 3.61, df = 1 (P = 0.06), I2 =72%
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Analysis 8.12. Comparison 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (best-worst analysis), Outcome 12 Hyperlipidaemia.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 8 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (best-worst analysis)
Outcome: 12 Hyperlipidaemia
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Ju 2012 4/43 5/44 14.8 % 0.82 [ 0.24, 2.85 ]
Margarit 2005 5/30 4/33 11.4 % 1.38 [ 0.41, 4.65 ]
Subtotal (95% CI) 73 77 26.1 % 1.06 [ 0.45, 2.52 ]
Total events: 9 (Gluc avoid), 9 (Gluc cont)
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.89)
2 Glucocorticosteroid withdrawal
Hu 2008 2/40 7/36 22.0 % 0.26 [ 0.06, 1.16 ]
Pageaux 2004 2/84 18/90 51.9 % 0.12 [ 0.03, 0.50 ]
Subtotal (95% CI) 124 126 73.9 % 0.16 [ 0.06, 0.45 ]
Total events: 4 (Gluc avoid), 25 (Gluc cont)
Heterogeneity: Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 3.47 (P = 0.00053)
Total (95% CI) 197 203 100.0 % 0.40 [ 0.21, 0.73 ]
Total events: 13 (Gluc avoid), 34 (Gluc cont)
Heterogeneity: Chi2 = 8.35, df = 3 (P = 0.04); I2 =64%
Test for overall effect: Z = 2.97 (P = 0.0029)
Test for subgroup differences: Chi2 = 7.55, df = 1 (P = 0.01), I2 =87%
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Analysis 9.1. Comparison 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (worst-best analysis), Outcome 1 Mortality.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (worst-best analysis)
Outcome: 1 Mortality
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Belli 2001 2/11 2/13 1.6 % 1.18 [ 0.20, 7.06 ]
Ju 2012 4/43 6/44 5.2 % 0.68 [ 0.21, 2.25 ]
Lerut 2008 17/78 13/78 11.5 % 1.31 [ 0.68, 2.51 ]
Llado 2006 5/96 11/102 9.4 % 0.48 [ 0.17, 1.34 ]
Margarit 2005 13/30 11/33 9.2 % 1.30 [ 0.69, 2.45 ]
Pelletier 2013 20/50 14/50 12.3 % 1.43 [ 0.82, 2.50 ]
Ramirez 2013 8/20 5/20 4.4 % 1.60 [ 0.63, 4.05 ]
Reggiani 2005 1/12 0/18 0.4 % 4.38 [ 0.19, 99.48 ]
Studenik 2005 0/20 1/19 1.4 % 0.32 [ 0.01, 7.35 ]
Tisone 1999 7/23 7/22 6.3 % 0.96 [ 0.40, 2.28 ]
Subtotal (95% CI) 383 399 61.7 % 1.13 [ 0.86, 1.49 ]
Total events: 77 (Gluc avoid), 70 (Gluc cont)
Heterogeneity: Chi2 = 6.45, df = 9 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
2 Glucocorticosteroid withdrawal
Belli 1998 13/54 9/50 8.2 % 1.34 [ 0.63, 2.85 ]
Chen 2007 10/28 14/26 12.8 % 0.66 [ 0.36, 1.22 ]
Hu 2008 1/40 1/36 0.9 % 0.90 [ 0.06, 13.87 ]
Moench 2007 17/56 11/54 9.9 % 1.49 [ 0.77, 2.88 ]
Pageaux 2004 28/84 2/90 1.7 % 15.00 [ 3.69, 61.03 ]
Vivarelli 2007 6/25 5/22 4.7 % 1.06 [ 0.37, 2.99 ]
Subtotal (95% CI) 287 278 38.3 % 1.71 [ 1.23, 2.38 ]
Total events: 75 (Gluc avoid), 42 (Gluc cont)
Heterogeneity: Chi2 = 20.08, df = 5 (P = 0.001); I2 =75%
Test for overall effect: Z = 3.20 (P = 0.0014)
Total (95% CI) 670 677 100.0 % 1.35 [ 1.10, 1.67 ]
Total events: 152 (Gluc avoid), 112 (Gluc cont)
Heterogeneity: Chi2 = 24.28, df = 15 (P = 0.06); I2 =38%
Test for overall effect: Z = 2.80 (P = 0.0051)
Test for subgroup differences: Chi2 = 3.59, df = 1 (P = 0.06), I2 =72%
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Analysis 9.2. Comparison 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (worst-best analysis), Outcome 2 Graft loss including death.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (worst-best analysis)
Outcome: 2 Graft loss including death
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Lerut 2008 20/78 17/78 19.1 % 1.18 [ 0.67, 2.07 ]
Llado 2006 9/96 12/102 13.0 % 0.80 [ 0.35, 1.81 ]
Margarit 2005 1/30 4/33 4.3 % 0.28 [ 0.03, 2.33 ]
Pelletier 2013 22/50 14/50 15.7 % 1.57 [ 0.91, 2.71 ]
Ramirez 2013 8/20 6/20 6.7 % 1.33 [ 0.57, 3.14 ]
Reggiani 2005 1/12 3/18 2.7 % 0.50 [ 0.06, 4.26 ]
Studenik 2005 0/20 2/19 2.9 % 0.19 [ 0.01, 3.73 ]
Tisone 1999 7/23 7/22 8.0 % 0.96 [ 0.40, 2.28 ]
Subtotal (95% CI) 329 342 72.4 % 1.07 [ 0.79, 1.43 ]
Total events: 68 (Gluc avoid), 65 (Gluc cont)
Heterogeneity: Chi2 = 6.20, df = 7 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
2 Glucocorticosteroid withdrawal
Moench 2007 21/56 15/54 17.1 % 1.35 [ 0.78, 2.33 ]
Pageaux 2004 28/84 2/90 2.2 % 15.00 [ 3.69, 61.03 ]
Vivarelli 2007 6/25 7/22 8.3 % 0.75 [ 0.30, 1.91 ]
Subtotal (95% CI) 165 166 27.6 % 2.24 [ 1.47, 3.41 ]
Total events: 55 (Gluc avoid), 24 (Gluc cont)
Heterogeneity: Chi2 = 15.63, df = 2 (P = 0.00040); I2 =87%
Test for overall effect: Z = 3.76 (P = 0.00017)
Total (95% CI) 494 508 100.0 % 1.39 [ 1.10, 1.76 ]
Total events: 123 (Gluc avoid), 89 (Gluc cont)
Heterogeneity: Chi2 = 20.55, df = 10 (P = 0.02); I2 =51%
Test for overall effect: Z = 2.71 (P = 0.0066)
Test for subgroup differences: Chi2 = 8.02, df = 1 (P = 0.00), I2 =88%
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Analysis 9.3. Comparison 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (worst-best analysis), Outcome 3 Acute rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (worst-best analysis)
Outcome: 3 Acute rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Belli 2001 5/11 7/13 5.6 % 0.84 [ 0.37, 1.92 ]
Ju 2012 4/43 3/44 2.6 % 1.36 [ 0.32, 5.74 ]
Lerut 2008 18/78 16/78 13.9 % 1.13 [ 0.62, 2.04 ]
Llado 2006 17/96 13/102 10.9 % 1.39 [ 0.71, 2.70 ]
Margarit 2005 12/30 10/33 8.3 % 1.32 [ 0.67, 2.60 ]
Pelletier 2013 10/50 7/50 6.1 % 1.43 [ 0.59, 3.45 ]
Ramirez 2013 1/20 1/20 0.9 % 1.00 [ 0.07, 14.90 ]
Reggiani 2005 9/12 3/18 2.1 % 4.50 [ 1.52, 13.30 ]
Studenik 2005 7/20 3/19 2.7 % 2.22 [ 0.67, 7.34 ]
Tisone 1999 4/23 4/22 3.5 % 0.96 [ 0.27, 3.36 ]
Subtotal (95% CI) 383 399 56.5 % 1.38 [ 1.05, 1.83 ]
Total events: 87 (Gluc avoid), 67 (Gluc cont)
Heterogeneity: Chi2 = 7.42, df = 9 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.30 (P = 0.022)
2 Glucocorticosteroid withdrawal
Belli 1998 5/54 3/50 2.7 % 1.54 [ 0.39, 6.13 ]
Chen 2007 4/28 3/26 2.7 % 1.24 [ 0.31, 5.01 ]
Hu 2008 5/40 4/36 3.7 % 1.13 [ 0.33, 3.87 ]
Moench 2007 19/56 14/54 12.4 % 1.31 [ 0.73, 2.34 ]
Pageaux 2004 51/84 22/90 18.4 % 2.48 [ 1.66, 3.71 ]
Vivarelli 2007 2/25 4/22 3.7 % 0.44 [ 0.09, 2.17 ]
Subtotal (95% CI) 287 278 43.5 % 1.73 [ 1.29, 2.31 ]
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 86 (Gluc avoid), 50 (Gluc cont)
Heterogeneity: Chi2 = 7.54, df = 5 (P = 0.18); I2 =34%
Test for overall effect: Z = 3.66 (P = 0.00026)
Total (95% CI) 670 677 100.0 % 1.53 [ 1.25, 1.88 ]
Total events: 173 (Gluc avoid), 117 (Gluc cont)
Heterogeneity: Chi2 = 16.69, df = 15 (P = 0.34); I2 =10%
Test for overall effect: Z = 4.17 (P = 0.000031)
Test for subgroup differences: Chi2 = 1.16, df = 1 (P = 0.28), I2 =14%
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Analysis 9.4. Comparison 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (worst-best analysis), Outcome 4 Infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (worst-best analysis)
Outcome: 4 Infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Ju 2012 6/43 16/44 11.3 % 0.38 [ 0.17, 0.89 ]
Llado 2006 45/96 52/102 36.2 % 0.92 [ 0.69, 1.22 ]
Pelletier 2013 26/50 22/50 15.8 % 1.18 [ 0.78, 1.78 ]
Ramirez 2013 12/20 12/20 8.6 % 1.00 [ 0.60, 1.66 ]
Reggiani 2005 6/12 5/18 2.9 % 1.80 [ 0.71, 4.59 ]
Tisone 1999 17/23 15/22 11.0 % 1.08 [ 0.75, 1.58 ]
Subtotal (95% CI) 244 256 85.7 % 0.96 [ 0.80, 1.15 ]
Total events: 112 (Gluc avoid), 122 (Gluc cont)
Heterogeneity: Chi2 = 7.87, df = 5 (P = 0.16); I2 =36%
Test for overall effect: Z = 0.49 (P = 0.62)
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(. . . Continued)
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
2 Glucocorticosteroid withdrawal
Belli 1998 3/54 8/50 6.0 % 0.35 [ 0.10, 1.24 ]
Pageaux 2004 26/84 12/90 8.3 % 2.32 [ 1.25, 4.30 ]
Subtotal (95% CI) 138 140 14.3 % 1.50 [ 0.89, 2.50 ]
Total events: 29 (Gluc avoid), 20 (Gluc cont)
Heterogeneity: Chi2 = 7.03, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.54 (P = 0.12)
Total (95% CI) 382 396 100.0 % 1.03 [ 0.87, 1.23 ]
Total events: 141 (Gluc avoid), 142 (Gluc cont)
Heterogeneity: Chi2 = 17.31, df = 7 (P = 0.02); I2 =60%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 2.60, df = 1 (P = 0.11), I2 =62%
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Analysis 9.5. Comparison 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (worst-best analysis), Outcome 5 Chronic rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (worst-best analysis)
Outcome: 5 Chronic rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Belli 2001 1/11 0/13 2.9 % 3.50 [ 0.16, 78.19 ]
Lerut 2008 1/78 4/78 25.3 % 0.25 [ 0.03, 2.19 ]
Llado 2006 3/96 1/102 6.1 % 3.19 [ 0.34, 30.12 ]
Margarit 2005 0/30 0/33 Not estimable
Pelletier 2013 1/50 4/50 25.3 % 0.25 [ 0.03, 2.16 ]
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 288 298 59.7 % 0.71 [ 0.27, 1.88 ]
Total events: 6 (Gluc avoid), 9 (Gluc cont)
Heterogeneity: Chi2 = 4.52, df = 3 (P = 0.21); I2 =34%
Test for overall effect: Z = 0.69 (P = 0.49)
2 Glucocorticosteroid withdrawal
Belli 1998 2/54 1/50 6.6 % 1.85 [ 0.17, 19.80 ]
Moench 2007 6/56 0/54 3.2 % 12.54 [ 0.72, 217.40 ]
Pageaux 2004 22/84 5/90 30.5 % 4.71 [ 1.87, 11.88 ]
Subtotal (95% CI) 194 194 40.3 % 4.87 [ 2.16, 11.01 ]
Total events: 30 (Gluc avoid), 6 (Gluc cont)
Heterogeneity: Chi2 = 1.07, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 3.81 (P = 0.00014)
Total (95% CI) 482 492 100.0 % 2.39 [ 1.36, 4.21 ]
Total events: 36 (Gluc avoid), 15 (Gluc cont)
Heterogeneity: Chi2 = 11.91, df = 6 (P = 0.06); I2 =50%
Test for overall effect: Z = 3.02 (P = 0.0026)
Test for subgroup differences: Chi2 = 8.85, df = 1 (P = 0.00), I2 =89%
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Analysis 9.6. Comparison 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (worst-best analysis), Outcome 6 Glucocorticosteroid-resistant rejection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (worst-best analysis)
Outcome: 6 Glucocorticosteroid-resistant rejection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Ju 2012 0/43 0/44 Not estimable
Lerut 2008 10/78 3/78 22.8 % 3.33 [ 0.95, 11.65 ]
Llado 2006 4/96 4/102 29.5 % 1.06 [ 0.27, 4.13 ]
Margarit 2005 5/30 3/33 21.7 % 1.83 [ 0.48, 7.02 ]
Pelletier 2013 0/50 0/50 Not estimable
Ramirez 2013 0/20 0/20 Not estimable
Tisone 1999 0/23 0/22 Not estimable
Subtotal (95% CI) 340 349 74.1 % 1.99 [ 0.95, 4.17 ]
Total events: 19 (Gluc avoid), 10 (Gluc cont)
Heterogeneity: Chi2 = 1.49, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
2 Glucocorticosteroid withdrawal
Moench 2007 1/56 0/54 3.9 % 2.89 [ 0.12, 69.55 ]
Pageaux 2004 27/84 3/90 22.0 % 9.64 [ 3.04, 30.61 ]
Vivarelli 2007 0/25 0/22 Not estimable
Subtotal (95% CI) 165 166 25.9 % 8.63 [ 2.95, 25.28 ]
Total events: 28 (Gluc avoid), 3 (Gluc cont)
Heterogeneity: Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 3.93 (P = 0.000084)
Total (95% CI) 505 515 100.0 % 3.71 [ 2.07, 6.66 ]
Total events: 47 (Gluc avoid), 13 (Gluc cont)
Heterogeneity: Chi2 = 7.00, df = 4 (P = 0.14); I2 =43%
Test for overall effect: Z = 4.40 (P = 0.000011)
Test for subgroup differences: Chi2 = 4.86, df = 1 (P = 0.03), I2 =79%
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Analysis 9.7. Comparison 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (worst-best analysis), Outcome 7 Diabetes mellitus.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (worst-best analysis)
Outcome: 7 Diabetes mellitus
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Ju 2012 2/43 9/44 5.7 % 0.23 [ 0.05, 0.99 ]
Lerut 2008 18/78 14/78 9.0 % 1.29 [ 0.69, 2.40 ]
Llado 2006 17/96 23/102 14.4 % 0.79 [ 0.45, 1.38 ]
Margarit 2005 9/30 11/33 6.8 % 0.90 [ 0.43, 1.87 ]
Pelletier 2013 22/50 19/50 12.2 % 1.16 [ 0.72, 1.86 ]
Ramirez 2013 8/20 8/20 5.2 % 1.00 [ 0.47, 2.14 ]
Reggiani 2005 2/12 5/18 2.6 % 0.60 [ 0.14, 2.60 ]
Subtotal (95% CI) 329 345 55.9 % 0.92 [ 0.71, 1.19 ]
Total events: 78 (Gluc avoid), 89 (Gluc cont)
Heterogeneity: Chi2 = 6.18, df = 6 (P = 0.40); I2 =3%
Test for overall effect: Z = 0.67 (P = 0.51)
2 Glucocorticosteroid withdrawal
Belli 1998 5/54 12/50 8.0 % 0.39 [ 0.15, 1.02 ]
Hu 2008 7/40 14/36 9.5 % 0.45 [ 0.20, 0.99 ]
Moench 2007 12/56 9/54 5.9 % 1.29 [ 0.59, 2.80 ]
Pageaux 2004 31/84 20/90 12.4 % 1.66 [ 1.03, 2.68 ]
Vivarelli 2007 14/25 12/22 8.2 % 1.03 [ 0.61, 1.72 ]
Subtotal (95% CI) 259 252 44.1 % 1.00 [ 0.76, 1.32 ]
Total events: 69 (Gluc avoid), 67 (Gluc cont)
Heterogeneity: Chi2 = 12.41, df = 4 (P = 0.01); I2 =68%
Test for overall effect: Z = 0.00 (P = 1.0)
Total (95% CI) 588 597 100.0 % 0.95 [ 0.79, 1.15 ]
Total events: 147 (Gluc avoid), 156 (Gluc cont)
Heterogeneity: Chi2 = 18.73, df = 11 (P = 0.07); I2 =41%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.65), I2 =0.0%
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Analysis 9.8. Comparison 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (worst-best analysis), Outcome 8 CMV infection.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (worst-best analysis)
Outcome: 8 CMV infection
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Lerut 2008 3/78 2/78 5.3 % 1.50 [ 0.26, 8.73 ]
Llado 2006 8/96 14/102 35.9 % 0.61 [ 0.27, 1.38 ]
Margarit 2005 1/30 1/33 2.5 % 1.10 [ 0.07, 16.82 ]
Ramirez 2013 0/20 0/20 Not estimable
Tisone 1999 2/23 1/22 2.7 % 1.91 [ 0.19, 19.63 ]
Subtotal (95% CI) 247 255 46.4 % 0.81 [ 0.41, 1.59 ]
Total events: 14 (Gluc avoid), 18 (Gluc cont)
Heterogeneity: Chi2 = 1.51, df = 3 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
2 Glucocorticosteroid withdrawal
Moench 2007 14/56 18/54 48.5 % 0.75 [ 0.42, 1.35 ]
Pageaux 2004 20/84 2/90 5.1 % 10.71 [ 2.58, 44.45 ]
Subtotal (95% CI) 140 144 53.6 % 1.70 [ 1.04, 2.78 ]
Total events: 34 (Gluc avoid), 20 (Gluc cont)
Heterogeneity: Chi2 = 13.82, df = 1 (P = 0.00020); I2 =93%
Test for overall effect: Z = 2.12 (P = 0.034)
Total (95% CI) 387 399 100.0 % 1.29 [ 0.87, 1.90 ]
Total events: 48 (Gluc avoid), 38 (Gluc cont)
Heterogeneity: Chi2 = 15.10, df = 5 (P = 0.01); I2 =67%
Test for overall effect: Z = 1.27 (P = 0.21)
Test for subgroup differences: Chi2 = 3.03, df = 1 (P = 0.08), I2 =67%
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Analysis 9.9. Comparison 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (worst-best analysis), Outcome 9 Malignancy.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (worst-best analysis)
Outcome: 9 Malignancy
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Lerut 2008 2/78 0/78 6.4 % 5.00 [ 0.24, 102.49 ]
Llado 2006 0/96 5/102 68.7 % 0.10 [ 0.01, 1.72 ]
Subtotal (95% CI) 174 180 75.1 % 0.52 [ 0.13, 2.08 ]
Total events: 2 (Gluc avoid), 5 (Gluc cont)
Heterogeneity: Chi2 = 3.47, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 0.93 (P = 0.35)
2 Glucocorticosteroid withdrawal
Pageaux 2004 20/84 2/90 24.9 % 10.71 [ 2.58, 44.45 ]
Subtotal (95% CI) 84 90 24.9 % 10.71 [ 2.58, 44.45 ]
Total events: 20 (Gluc avoid), 2 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 3.27 (P = 0.0011)
Total (95% CI) 258 270 100.0 % 3.05 [ 1.38, 6.73 ]
Total events: 22 (Gluc avoid), 7 (Gluc cont)
Heterogeneity: Chi2 = 8.61, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 2.77 (P = 0.0057)
Test for subgroup differences: Chi2 = 8.90, df = 1 (P = 0.00), I2 =89%
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Analysis 9.10. Comparison 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (worst-best analysis), Outcome 10 Post-transplant lymphoproliferative
disorder.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (worst-best analysis)
Outcome: 10 Post-transplant lymphoproliferative disorder
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Lerut 2008 2/78 1/78 67.4 % 2.00 [ 0.19, 21.61 ]
Subtotal (95% CI) 78 78 67.4 % 2.00 [ 0.19, 21.61 ]
Total events: 2 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 Glucocorticosteroid withdrawal
Pageaux 2004 20/84 0/90 32.6 % 43.89 [ 2.70, 714.49 ]
Subtotal (95% CI) 84 90 32.6 % 43.89 [ 2.70, 714.49 ]
Total events: 20 (Gluc avoid), 0 (Gluc cont)
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0079)
Total (95% CI) 162 168 100.0 % 15.64 [ 3.08, 79.56 ]
Total events: 22 (Gluc avoid), 1 (Gluc cont)
Heterogeneity: Chi2 = 3.40, df = 1 (P = 0.07); I2 =71%
Test for overall effect: Z = 3.31 (P = 0.00092)
Test for subgroup differences: Chi2 = 2.73, df = 1 (P = 0.10), I2 =63%
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Analysis 9.11. Comparison 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (worst-best analysis), Outcome 11 Renal insufficiency.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (worst-best analysis)
Outcome: 11 Renal insufficiency
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Lerut 2008 4/78 8/78 10.7 % 0.50 [ 0.16, 1.59 ]
Llado 2006 41/96 51/102 66.4 % 0.85 [ 0.63, 1.16 ]
Margarit 2005 21/30 17/33 21.7 % 1.36 [ 0.91, 2.04 ]
Reggiani 2005 2/12 1/18 1.1 % 3.00 [ 0.30, 29.52 ]
Total (95% CI) 216 231 100.0 % 0.95 [ 0.75, 1.21 ]
Total events: 68 (Gluc avoid), 77 (Gluc cont)
Heterogeneity: Chi2 = 5.63, df = 3 (P = 0.13); I2 =47%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 9.12. Comparison 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (worst-best analysis), Outcome 12 Hypertension.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (worst-best analysis)
Outcome: 12 Hypertension
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Ju 2012 2/43 9/44 4.3 % 0.23 [ 0.05, 0.99 ]
Lerut 2008 6/78 10/78 4.8 % 0.60 [ 0.23, 1.57 ]
Llado 2006 48/96 60/102 28.0 % 0.85 [ 0.66, 1.10 ]
Margarit 2005 5/30 9/33 4.1 % 0.61 [ 0.23, 1.62 ]
Pelletier 2013 28/50 24/50 11.6 % 1.17 [ 0.80, 1.70 ]
Reggiani 2005 2/12 5/18 1.9 % 0.60 [ 0.14, 2.60 ]
Subtotal (95% CI) 309 325 54.7 % 0.82 [ 0.67, 1.01 ]
Total events: 91 (Gluc avoid), 117 (Gluc cont)
Heterogeneity: Chi2 = 7.25, df = 5 (P = 0.20); I2 =31%
Test for overall effect: Z = 1.90 (P = 0.057)
2 Glucocorticosteroid withdrawal
Belli 1998 11/54 28/50 14.0 % 0.36 [ 0.20, 0.65 ]
Hu 2008 9/40 10/36 5.1 % 0.81 [ 0.37, 1.77 ]
Moench 2007 25/56 25/54 12.3 % 0.96 [ 0.64, 1.45 ]
Pageaux 2004 43/84 30/90 13.9 % 1.54 [ 1.07, 2.20 ]
Subtotal (95% CI) 234 230 45.3 % 0.94 [ 0.75, 1.18 ]
Total events: 88 (Gluc avoid), 93 (Gluc cont)
Heterogeneity: Chi2 = 17.58, df = 3 (P = 0.00054); I2 =83%
Test for overall effect: Z = 0.56 (P = 0.58)
Total (95% CI) 543 555 100.0 % 0.87 [ 0.75, 1.02 ]
Total events: 179 (Gluc avoid), 210 (Gluc cont)
Heterogeneity: Chi2 = 25.31, df = 9 (P = 0.003); I2 =64%
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Chi2 = 0.74, df = 1 (P = 0.39), I2 =0.0%
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Analysis 9.13. Comparison 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-
containing immunosuppression (worst-best analysis), Outcome 13 Hyperlipidaemia.
Review: Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Comparison: 9 Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression (worst-best analysis)
Outcome: 13 Hyperlipidaemia
Study or subgroup Gluc avoid Gluc cont Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Glucocorticosteroid avoidance
Ju 2012 4/43 5/44 27.9 % 0.82 [ 0.24, 2.85 ]
Margarit 2005 6/30 4/33 21.5 % 1.65 [ 0.51, 5.29 ]
Subtotal (95% CI) 73 77 49.4 % 1.18 [ 0.51, 2.73 ]
Total events: 10 (Gluc avoid), 9 (Gluc cont)
Heterogeneity: Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
2 Glucocorticosteroid withdrawal
Hu 2008 2/40 3/36 17.8 % 0.60 [ 0.11, 3.39 ]
Pageaux 2004 21/84 6/90 32.7 % 3.75 [ 1.59, 8.84 ]
Subtotal (95% CI) 124 126 50.6 % 2.64 [ 1.28, 5.44 ]
Total events: 23 (Gluc avoid), 9 (Gluc cont)
Heterogeneity: Chi2 = 3.46, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 2.63 (P = 0.0085)
Total (95% CI) 197 203 100.0 % 1.92 [ 1.12, 3.28 ]
Total events: 33 (Gluc avoid), 18 (Gluc cont)
Heterogeneity: Chi2 = 5.94, df = 3 (P = 0.11); I2 =49%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Chi2 = 2.03, df = 1 (P = 0.15), I2 =51%
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A P P E N D I C E S
Appendix 1. Search strategies
Database Time span Search strategy
TheCochraneHepato-BiliaryGroupCon-
trolled Trials Register
September 2014 ((liver OR hepat*) AND (transplant* OR graft*)) AND
(glucocorticosteroid* OR corticosteroid* OR steroid* OR
gluco-corticoid* OR cortico-steroid* OR methylpredniso*
ORmethyl-predniso* OR predniso* OR dexamethaso* OR
dexa-methaso* or monotherapy*) AND (immunosuppres*
or tacrolimus* or mycopheno* or MMF* or (monoclonal
adj3 antibod*) or mab* or daclizumab* or basiliximab* or
cyclosporin* or ciclosporin* or calcineurin inhibitor* or
calcineurin antagonist* or purine inhibitor* or purine an-
tagonist* or sirolimus* or rapamycin* or everolimus* or
methotrexate* or azathioprine* or muromonab* or ortho-
clon* or OKT3* or anti-CD3* or antithymocyte* or ATG*
or anti-IL2* or anti-CD52* or campath* or FK506* or
steroid-free* or corticosteroid-free* or glucocorticoid-free*
or glucocorticosteroid-free* or steroid-sparing* or corticos-
teroid-sparing* or glucocorticoid-sparing* or glucocorticos-
teroid-sparing* or steroid-avoid* or corticosteroid-avoid*
or glucocorticoid-avoid* or glucocorticosteroid-avoid* or
steroid-taper* or corticosteroid-taper* or glucocorticoid-
taper* or glucocorticosteroid-taper* or steroid-withdraw*
or corticosteroid-withdraw* or glucocorticoid-withdraw* or
glucocorticosteroid-withdraw* or steroid-eliminat* or corti-
costeroid-eliminat* or glucocorticoid-eliminat* or glucocor-
ticosteroid-eliminat* or steroid-minimi* or corticosteroid-
minimi* or glucocorticoid-minimi* or glucocorticosteroid-
minimi*)
Cochrane Central Register of Controlled
Trials (CENTRAL) (Wiley)
Issue 8 of 12, 2014 #1 MeSH descriptor: [Liver Transplantation] explode all
trees
#2 ((liver or hepat*) and (transplant* or graft*))
#3 #1 or #2
#4 MeSH descriptor: [Steroids] explode all trees
#5 MeSH descriptor: [Adrenal Cortex Hormones] explode
all trees
#6MeSHdescriptor: [Methylprednisolone] explode all trees
#7 MeSH descriptor: [Prednisone] explode all trees
#8 MeSH descriptor: [Glucocorticoids] explode all trees
#9 MeSH descriptor: [Dexamethasone] explode all trees
#10 glucocorticosteroid* or corticosteroid* or steroid* or
gluco-corticoid* or cortico-steroid* or methylpredniso* or
methyl-predniso* or predniso* or dexamethaso* or dexa-
methaso* or monotherapy*
#11 #4 or #5 or #6 or #7 or #8 or #9 or #10
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(Continued)
#12 MeSH descriptor: [Immunosuppression] explode all
trees
#13 MeSH descriptor: [Immunosuppressive Agents] ex-
plode all trees
#14 MeSH descriptor: [Antibodies, Monoclonal] explode
all trees
#15 MeSH descriptor: [Mycophenolic Acid] explode all
trees
#16 MeSH descriptor: [Antilymphocyte Serum] explode all
trees
#17 MeSH descriptor: [Tacrolimus] explode all trees
#18 MeSH descriptor: [Cyclosporine] explode all trees
#19 MeSH descriptor: [Sirolimus] explode all trees
#20MeSH descriptor: [Muromonab-CD3] explode all trees
#21 immunosuppres* or tacrolimus* or mycopheno* or
MMF* or (monoclonal adj3 antibod*) or mab* or da-
clizumab* or basiliximab* or cyclosporin* or ciclosporin*
or calcineurin inhibitor* or calcineurin antagonist* or
purine inhibitor* or purine antagonist* or sirolimus* or ra-
pamycin* or everolimus* or methotrexate* or azathioprine*
or muromonab* or orthoclon* or OKT3* or anti-CD3*
or antithymocyte* or ATG* or anti-IL2* or anti-CD52* or
campath* or FK506*
#22 steroid-free* or corticosteroid-free* or glucocorticoid-
free* or glucocorticosteroid-free* or steroid-sparing* or cor-
ticosteroid-sparing* or glucocorticoid-sparing* or gluco-
corticosteroid-sparing* or steroid-avoid* or corticosteroid-
avoid* or glucocorticoid-avoid* or glucocorticosteroid-
avoid* or steroid-taper* or corticosteroid-taper* or glucocor-
ticoid-taper* or glucocorticosteroid-taper* or steroid-with-
draw* or corticosteroid-withdraw* or glucocorticoid-with-
draw* or glucocorticosteroid-withdraw* or steroid-elimi-
nat* or corticosteroid-eliminat* or glucocorticoid-eliminat*
or glucocorticosteroid-eliminat* or steroid-minimi* or cor-
ticosteroid-minimi* or glucocorticoid-minimi* or glucocor-
ticosteroid-minimi*
#23 #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #
18 OR #19 OR #20 OR #21 OR #22
#24 #3 AND #11 AND #23
MEDLINE (Ovid SP) 1946 to September 2014 #1 exp Liver Transplantation/
#2 ((liver or hepat*) and (transplant* or graft*)).mp. [mp=
title, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplemen-
tary concept, rare disease supplementary concept, unique
identifier]
#3 1 or 2
#4 exp Steroids/
#5 exp Glucocorticoids/
239Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
#6 exp Adrenal Cortex Hormones/
#7 exp Methylprednisolone/
#8 exp Prednisone/
#9 exp Dexamethasone/
#10 (glucocorticosteroid* or corticosteroid* or steroid* or
gluco-corticoid* or cortico-steroid* or methylpredniso* or
methyl-predniso* or predniso* or dexamethaso* or dexa-
methaso* or monotherapy*).mp. [mp=title, abstract, orig-
inal title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept,
rare disease supplementary concept, unique identifier]
#11 4 or 5 or 6 or 7 or 8 or 9 or 10
#12 exp Immunosuppressive Agents/
#13 exp Antibodies, Monoclonal/
#14 exp Tacrolimus/
#15 exp Mycophenolic Acid/
#16 exp Cyclosporine/
#17 exp Sirolimus/
#18 exp Muromonab-CD3/
#19 exp Antilymphocyte Serum/
#20 (immunosuppres* or tacrolimus* or FK506* or my-
copheno* or MMF* or (monoclonal adj3 antibod*) or
mab* or daclizumab* or basiliximab* or cyclosporin* or ci-
closporin* or calcineurin inhibitor* or calcineurin antago-
nist* or purine inhibitor* or purine antagonist* or sirolimus*
or rapamycin* or everolimus* or methotrexate* or azathio-
prine* or muromonab* or orthoclon* or OKT3* or anti-
CD3* or antithymocyte* or ATG* or anti-IL2* or anti-
CD52* or campath*).mp. [mp=title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept, rare disease
supplementary concept, unique identifier]
#21 (steroid-free* or corticosteroid-free* or glucocorticoid-
free* or glucocorticosteroid-free* or steroid-sparing* or cor-
ticosteroid-sparing* or glucocorticoid-sparing* or gluco-
corticosteroid-sparing* or steroid-avoid* or corticosteroid-
avoid* or glucocorticoid-avoid* or glucocorticosteroid-
avoid* or steroid-taper* or corticosteroid-taper* or glucocor-
ticoid-taper* or glucocorticosteroid-taper* or steroid-with-
draw* or corticosteroid-withdraw* or glucocorticoid-with-
draw* or glucocorticosteroid-withdraw* or steroid-elimi-
nat* or corticosteroid-eliminat* or glucocorticoid-eliminat*
or glucocorticosteroid-eliminat* or steroid-minimi* or cor-
ticosteroid-minimi* or glucocorticoid-minimi* or glucocor-
ticosteroid-minimi* or ((steroid* or corticosteroid* or glu-
cocorticoid* or glucocorticosteroid*) adj3 (free* or spar* or
avoid* or taper* or withdraw* or eliminat* or minimi* or
without*))).mp. [mp=title, abstract, original title, name of
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substance word, subject heading word, keyword heading
word, protocol supplementary concept, rare disease supple-
mentary concept, unique identifier]
#22 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or
21
#23 (random* or blind* or placebo* or meta-analys*).mp.
[mp=title, abstract, original title, name of substance word,
subject heading word, keyword heading word, protocol sup-
plementary concept, rare disease supplementary concept,
unique identifier]
#24 3 and 11 and 22 and 23
Embase (Ovid SP) 1974 to September 2014 #1 exp Liver Transplantation/
#2 ((liver or hepat*) and (transplant* or graft*)).mp. [mp=
title, abstract, subject headings, heading word, drug trade
name, original title, device manufacturer, drug manufac-
turer, device trade name, keyword]
#3 1 or 2
#4 exp Steroids/
#5 exp Glucocorticoids/
#6 exp Adrenal Cortex Hormones/
#7 exp Methylprednisolone/
#8 exp Prednisone/
#9 exp Dexamethasone/
#10 (glucocorticosteroid* or corticosteroid* or steroid* or
gluco-corticoid* or cortico-steroid* or methylpredniso* or
methyl-predniso* or predniso* or dexamethaso* or dexa-
methaso* ormonotherapy*).mp. [mp=title, abstract, subject
headings, heading word, drug trade name, original title, de-
vice manufacturer, drug manufacturer, device trade name,
keyword]
#11 4 or 5 or 6 or 7 or 8 or 9 or 10
#12 exp Immunosuppressive Agents/
#13 exp Antibodies, Monoclonal/
#14 exp Tacrolimus/
#15 exp Mycophenolic Acid/
#16 exp Cyclosporine/
#17 exp Sirolimus/
#18 exp Muromonab-CD3/
#19 exp Antilymphocyte Serum/
#20 (immunosuppres* or tacrolimus* or FK506* or my-
copheno* or MMF* or (monoclonal adj3 antibod*) or
mab* or daclizumab* or basiliximab* or cyclosporin* or ci-
closporin* or calcineurin inhibitor* or calcineurin antago-
nist* or purine inhibitor* or purine antagonist* or sirolimus*
or rapamycin* or everolimus* or methotrexate* or azathio-
prine* or muromonab* or orthoclon* or OKT3* or anti-
CD3* or antithymocyte* or ATG* or anti-IL2* or anti-
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CD52* or campath*).mp. [mp=title, abstract, subject head-
ings, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, key-
word]
#21 (steroid-free* or corticosteroid-free* or glucocorticoid-
free* or glucocorticosteroid-free* or steroid-sparing* or cor-
ticosteroid-sparing* or glucocorticoid-sparing* or gluco-
corticosteroid-sparing* or steroid-avoid* or corticosteroid-
avoid* or glucocorticoid-avoid* or glucocorticosteroid-
avoid* or steroid-taper* or corticosteroid-taper* or glucocor-
ticoid-taper* or glucocorticosteroid-taper* or steroid-with-
draw* or corticosteroid-withdraw* or glucocorticoid-with-
draw* or glucocorticosteroid-withdraw* or steroid-elimi-
nat* or corticosteroid-eliminat* or glucocorticoid-eliminat*
or glucocorticosteroid-eliminat* or steroid-minimi* or cor-
ticosteroid-minimi* or glucocorticoid-minimi* or glucocor-
ticosteroid-minimi* or ((steroid* or corticosteroid* or glu-
cocorticoid* or glucocorticosteroid*) adj3 (free* or spar* or
avoid* or taper* or withdraw* or eliminat* or minimi* or
without*))).mp. [mp=title, abstract, subject headings, head-
ing word, drug trade name, original title, device manufac-
turer, drug manufacturer, device trade name, keyword]
#22 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or
21
#23 (random* or blind* or placebo* or meta-analys*).mp.
[mp=title, abstract, subject headings, heading word, drug
trade name, original title, device manufacturer, drug manu-
facturer, device trade name, keyword]
#24 3 and 11 and 22 and 23
Science Citation Index EXPANDED 1900 to September 2014 #6 #5 AND #4
#5 TS=(random* or blind* or placebo* or meta-analys*)
#4 #3 AND #2 AND #1
#3 TS=(immunosuppres* or tacrolimus* or mycopheno*
or MMF* or (monoclonal adj3 antibod*) or mab* or da-
clizumab* or basiliximab* or cyclosporin* or ciclosporin*
or calcineurin inhibitor* or calcineurin antagonist* or
purine inhibitor* or purine antagonist* or sirolimus* or
rapamycin* or everolimus* or methotrexate* or azathio-
prine* or muromonab* or orthoclon* or OKT3* or anti-
CD3* or antithymocyte* or ATG* or anti-IL2* or anti-
CD52* or campath* or FK506* or steroid-free* or cor-
ticosteroid-free* or glucocorticoid-free* or glucocorticos-
teroid-free* or steroid-sparing* or corticosteroid-sparing*
or glucocorticoid-sparing* or glucocorticosteroid-sparing*
or steroid-avoid* or corticosteroid-avoid* or glucocorti-
coid-avoid* or glucocorticosteroid-avoid* or steroid-taper*
or corticosteroid-taper* or glucocorticoid-taper* or glu-
cocorticosteroid-taper* or steroid-withdraw* or corticos-
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teroid-withdraw* or glucocorticoid-withdraw* or gluco-
corticosteroid-withdraw* or steroid-eliminat* or corticos-
teroid-eliminat* or glucocorticoid-eliminat* or glucocor-
ticosteroid-eliminat* or steroid-minimi* or corticosteroid-
minimi* or glucocorticoid-minimi* or glucocorticosteroid-
minimi*)
#2 TS=(glucocorticosteroid* or corticosteroid* or steroid*
or gluco-corticoid* or cortico-steroid* ormethylpredniso*
or methyl-predniso* or predniso* or dexamethaso* or dexa-
methaso* or monotherapy*)
#1 TS=((liver or hepat*) and (transplant* or graft*))
H I S T O R Y
Protocol first published: Issue 1, 2009
Review first published: Issue 12, 2015
Date Event Description
2 May 2014 New citation required and major changes Methods and analysis sections updated. Outcomes altered. Back-
ground updated. References added. Search strategies updated
19 October 2013 Amended A new team of review authors.
C O N T R I B U T I O N S O F A U T H O R S
CF prepared a draft protocol.
LP and CF wrote the final version of the protocol published previously.
SW, EH, and JP commented on the draft and approved of the final version of the protocol.
CF ran the searches.
CF contacted pharmaceutical companies and experts in the field.
CF, JP, SW, and EH selected studies for inclusion.
CF, JP, SW, and EH extracted data.
CF contacted authors to request additional information.
CF, JP, SW, and EH made assessments of bias.
CF entered trial data and performed analyses.
EH and CF worked on the code for empirical continuity correction for zero event trials and the linear regression test for funnel plot
asymmetry.
LP completed the trial sequential analyses.
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CF completed the results section and the discussion.
CF, LP, EH, JP, and SW wrote the author’s conclusions.
LP, JP, EH, and SW made comments on the draft and approved the final version of the review.
D E C L A R A T I O N S O F I N T E R E S T
Cameron Fairfield: none known.
Luit Penninga: none known.
James Powell: none known.
Ewen M Harrison: none known.
Stephen J Wigmore: none known.
S O U R C E S O F S U P P O R T
Internal sources
• University of Edinburgh, College of Medicine and Veterinary Medicine, UK.
• Royal Infirmary Edinburgh, Hepatobiliary-Pancreatic Surgical Services and Edinburgh Transplant Unit, UK.
• Royal Infirmary Edinburgh, Clinical Surgery, UK.
• National University Hospital Rigshospitalet, Copenhagen, Denmark.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• Cholesterol and hypercholesterolaemia added to secondary outcomes.
• Renal function outcome modified.
• Number of sub-analyses reduced.
• Definition of the sub-analysis of ’co-interventions’ changed.
• Per-treatment analyses added to exclusion criteria.
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